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Ithaca 
“When you set out on your journey to Ithaca, 
pray that the road is long, 
full of adventure, full of knowledge. 
The Lestrygonians and the Cyclops, 
the angry Poseidon, do not fear them. 
You will never find such as these on your path, 
if your thoughts remain lofty, if a fine 
emotion touches your spirit and your body. 
The Lestrygonians and the Cyclops, 
the fierce Poseidon you will never encounter, 
if you do not carry them within your soul, 
if your soul does not set them up before you. 
 
Pray that the road is long. 
That the summer mornings are many, when, 
with such pleasure, with such joy 
you will enter ports seen for the first time; 
stop at Phoenician markets, 
and purchase fine merchandise, 
mother-of-pearl and coral, amber and ebony, 
and sensual perfumes of all kinds, 
as many sensual perfumes as you can; 
visit many Egyptian cities, 
to learn and learn from scholars. 
 
Always keep Ithaca in your mind. 
To arrive there is your ultimate goal. 
But do not hurry the voyage at all. 
It is better to let it last for many years; 
and to anchor at the island when you are old, 
rich with all you have gained on the way, 
not expecting that Ithaca will offer you riches. 
 
Ithaca has given you the beautiful voyage. 
Without her you would have never set out on the road. 
She has nothing more to give you. 
 
And if you find her poor, Ithaca has not deceived you. 
Wise as you have become, with so much experience, 
you must already have understood what Ithacas mean. 
 
Konstantinos P. Cavafy (1911) 
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SUMMARY 
As Crohn’s disease (CD) is a disease of the gastrointestinal tract, nutrition is very important 
and is implicated in several aspects of the disease, from aetiology, management, and the 
long-term health of the patient. Nutritional therapy with EEN is the mainstream approach in 
the management of active paediatric CD and has a dual effect, inducing clinical remission 
and providing nutritional support and rehabilitation. Although its efficacy is well established 
by human trials and clinical experience, the mode of action remains unknown. Initial 
speculations for a mechanism of action mediated through gut rest, and protein/energy 
reconstitution have not been established. On the other hand the strong evidence for the role 
of the indigenous microbiota and micronutrients in disease aetiology and mucosal injury, 
challenged the researcher to explore whether the action of EEN is mediated through 
changes in these parameters.  
This study aimed to assess aspects of the nutritional status of paediatric patients with 
inflammatory bowel disease (IBD), to appraise the use of nutritional remedies in the same 
population, and to explore putative mechanisms of action of EEN, the nutritional therapy, with 
the most robust evidence of clinically efficacy. 
The first of these studies was a questionnaire survey which assessed the use of 
special diets, nutritional supplements, herbals, and alternative medicine in a representative 
sample of paediatric patients with IBD. Use of these treatments was declared by two thirds of 
the patients with probiotic use and dairy free diet being the commonest forms used.  
Prevalence of anaemia and predictors of its progress at six and 12 months were 
assessed in a large retrospective case review study. Anaemia was as high as 73% of 
patients at diagnosis and haemoglobin concentration improvement at six and 12 post 
diagnosis was associated with the use of oral iron supplementation, improvement of 
nutritional status markers, growth, and systemic markers of disease activity.  
In a mechanistic study the validity of a bedside method, used to assess the body 
composition of children with CD, was compared against a reference method. The agreement 
of the two methods was low and the inter-individual bias between them was substantial.     
The aim of this thesis was to study the effect of EEN on gut microbiota diversity, 
bacterial metabolic activity, inflammatory response and nutritional status in paediatric 
patients with active CD.   
Newly diagnosed children with active CD, and patients with longstanding disease, on 
clinical relapse, who started treatment with EEN as part of their standard clinical 
management, were recruited. Four stool samples were collected while on treatment with 
EEN and one when the patient returned to their normal diet. Bacterial diversity was assessed 
with molecular microbiology techniques, and bacterial metabolites were measured in serial 
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stool samples and correlated with faecal calprotectin levels, systemic inflammatory markers 
and clinical activity. A single stool sample was collected from their first-degree relatives and 
two serial samples from healthy children with no family history of IBD. 
Significant changes were observed for the metabolic activity of the commensal 
microbiota during the course of treatment. In particular, faecal butyrate significantly 
decreased by more than 100%, faecal pH moved into the alkaline range, and a five-fold 
increase was observed in total sulphide but only in those patients who achieved clinical 
remission, or in whom faecal calprotectin levels decreased at the end of treatment. No such 
changes were observed in children who did not achieve complete clinical remission or when 
the treatment failed. Gut bacterial diversity did not change significantly during treatment, but 
was significantly lower than in healthy children, who also presented a higher degree of 
similarity between the two serial samples. Interestingly the gut microbiota of the healthy first 
degree relatives of CD children had significantly lower bacterial diversity compared with the 
healthy children but no such difference was observed compared with their CD relatives. The 
majority of the healthy relatives had also significantly high levels of calprotectin suggesting 
intestinal inflammation but no clinical presentation of gastrointestinal disease.    
A secondary outcome of this study was to measure changes in the systemic and gut 
specific markers of disease activity during treatment. Although systemic markers of disease 
activity improved to normal levels in the majority of the patients, intestinal inflammation was 
still ongoing and only one of the 16 children had normal calprotectin levels at the end of EEN. 
Moreover, only in those patients who achieved clinically complete remission, did calprotectin 
levels decrease significantly at the end of treatment. 
From the same cohort of patients three blood samples were also collected before, at 
the end of treatment and on normal diet. Changes in the concentration of 19 different 
micronutrients were measured in the serum and some in erythrocytes and correlated with 
systemic markers of disease activity. Serial changes in anthropometry and body composition 
were assessed during EEN and correlated with disease activity markers. 
Body weight increased in all patients at the end of treatment but fat free mass 
significantly increased only in those patients who entered in clinical remission. Several 
micronutrients and mainly antioxidants were below the reference range for the majority of 
patients at the time of treatment initiation. Most of them improved by the end of treatment but 
the serum concentration of carotenoids further deteriorated with more than 90% of the 
patients presenting concentration lower than the lower sensitivity level of the assay. A strong 
association was found between systemic markers of disease activity and antioxidant 
vitamins, but not with intestinal inflammation. 
In conclusion, paediatric patients with IBD, and mainly those with CD present with 
suboptimal protein/energy status, anaemia, and low circulating levels for many antioxidants. 
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Treatment with EEN corrected the majority of these markers of nutritional status but the 
carotenoid levels deteriorated. Although the improvement in the serum levels of some 
micronutrients can be an epiphenomenon of the acute phase response, it does not explain 
the depleted levels of carotenoids at the end of EEN. This may be attributed to the lack of 
carotenoids in the feeds used in conjunction with excessive utilisation during the active 
course of the disease.  
On the other hand, the unhealthy intestinal microenvironment observed, in only those 
patients who clinically improved at the end of treatment; do not support a prebiotic mode of 
EEN action, as was proposed by a recent Italian study. These changes may be a secondary 
phenomenon, associated with changes in gut motility, better absorption of butyrate with 
disease improvement, or changes in the availability of colonic bacterial substrates. 
Alternatively these changes may be associated with changes in the microbiota composition 
and production of so far unknown bacterial bioproducts which may have a causative 
association with the onset and propagation of intestinal inflammation in CD.  
These results may have significant implications in manufacturers of clinical nutrition 
products. Addition of carotenoids may improve the provision of antioxidant micronutrients 
and a dual nutritional therapy combining EEN with prebiotics, butyrate supplementation, or 
probiotics may increase the efficacy of the existing formulae. This should be addressed in 
future studies.       
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1.1. Inflammatory bowel disease 
 
rohn’s disease (CD) and ulcerative colitis (UC), collectively known as 
inflammatory bowel disease (IBD) are idiopathic, lifelong, inflammatory, 
destructive conditions of the gastrointestinal (GI) tract. The disease relapses 
and remits throughout its course (1-4). 
Crohn’s disease and UC, although part of the same constellation present distinct clinical, 
extraintestinal and pathological characteristics that constitute the basis for their differential 
diagnosis (Table 1.1). Ulcerative colitis is characterized by continuous diffuse mucosal 
inflammation limited to the colon and rectum whereas CD is characterized by patchy, 
transmural inflammation, which may affect any part of the GI tract from the mouth to the anus 
(1-4).  
 
Table 1.1: Differential diagnosis of UC and CD (adapted from  (Baumgart & Sandborn 2007 (5)) 
 UC CD 
Clinical features 
  
Haematochezia Common Uncommon 
Passage of mucus or pus Common Rare 
Small bowel disease No Yes 
Can affect upper GI tract No (except backwash 
ileitis) 
Yes 
Abdominal mass Rare Sometimes on right side 
Extraintestinal manifestations Common Common 
Small bowel obstruction Rarely Common 
Colonic obstruction Rarely Common 
Fistulae and perianal disease No Common 
Biochemical features 
  
Anti-neutrophil cytoplasmic 
antibodies 
Common Rarely 
Anti-saccharomyces cerevisiae 
antibodies 
Rarely Common 
Pathological features 
  
Transmural mucosal 
inflammation 
No Yes 
Distorted crypt architecture Yes Uncommon 
Cryptitis and crypt abscesses Yes Yes 
Granulomas No Yes but rarely in mucosal 
biopsies 
Fissures and skip lesions Rarely Common 
 
A small proportion of patients with chronic inflammatory colitis that cannot be classified 
into either of the two types of disease by endoscopic and histology findings are characterized 
as indeterminate colitis (IC) or IBD unspecified (IBDU) using new phenotypic classification 
systems (6). The disease is more extreme in children with IBD but there is no difference in 
the spatial distribution (7). Recently a new consensus classification system has been 
proposed to characterise the diverse phenotypic presentation of IBD considering a) age of 
C 
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disease onset b) disease location and c) disease behavior as the predominant phenotypic 
elements (Table 1.2) (6).  
 
Table 1.2: Montreal phenotypic classification of IBD 
Phenotype Classification Clinical features 
Crohn’s disease 
  
Age at diagnosis A1 Below 16 y 
 A2 Between 17 and 40 y 
 A3 Above 40 y 
Location L1 Ileal 
 L2 Colonic 
 L3 Ileocolonic 
 L4 Isolated upper disease 
Behaviour B1 Non structuring, non penetrating 
 B2 Stricturing 
 B3 Penetrating 
  *p perianal disease modifier 
   
Ulcerative colitis 
Ulcerative proctitis E1 Involvement limited to the rectum 
(rectosigmoid junction) 
Left side colitis E2 Involvement limited to a proportion 
of the colorectum distal to the 
splenic flexure 
Extensive colitis E3 Involvement extends proximal to the 
splenic flexure 
 
Inflammatory bowel disease unspecified IBDU IBD affecting the colon without small 
bowel involvement and no definitive 
histology or other evidence to 
suggest CD or UC 
 
1.1.1. Epidemiology of IBD 
Understanding the epidemiology of IBD may offer clues to the aetiology and pathogenesis of 
IBD and identify areas for further research (8). However defining the exact epidemiology of 
IBD is difficult mainly due to the insidious onset of the disease, the frequent marked delay in 
diagnosis, and the occasional misclassification of patients. In paediatrics the small number of 
cases hampers this further. 
Ulcerative colitis incidence varies from 1-5/105 cases per year for Latin America, 
Africa and Asia to values up to 10-20/105 for the Northern America and Northern Europe. For 
CD the respective values are 5-10/105 for Northern America and Europe and 0.5-4/105 for 
Asia, Africa, Latin America and Southern Europe (9). CD and UC are most commonly 
diagnosed in early adulthood but the diagnosis may occur at any age (9) with approximately 
15%-25% of IBD being diagnosed during childhood or adolescence (10).  
Juvenile UC and CD occur with an average incidence of 5.2/105 cases per year in the 
UK and Republic of Ireland (11). Scotland presents the highest prevalence for CD and is 
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second after Ireland for UC (Table 1.3). The highest incidence occurs between 12-16 years 
(11;12) with almost 2/3 of the patients diagnosed with CD.  
Epidemiology in IBD is a dynamic process and recent data show that IBD incidence 
and prevalence is increasing with time (8;11-15) in both developing and developed countries 
(9). Armitage and her colleagues (16) using the Scottish hospital discharge linked database, 
showed an increasing trend of both juvenile-onset (< 16 y old) CD and UC in Scotland. 
Combining their results with those of Barton et al (17) they estimated a steady increase for 
the crude incidence of CD from 1 per 105 between 1971-1975 to 3.1 per 105 for 1991-1995. 
In UC the results from Barton’s study showed a marginal fall that reversed according to the 
results of Armitage (16). A higher incidence for juvenile CD but not UC onset was observed 
in the northern regions compared with the southern regions of Scotland (12). 
 
Table 1.3: Incidence (x105/y) of IBD by country (adapted from Sawczenko, 2001 (11)) 
 All IBD CD UC IC 
UK 5.2 3.1 1.4 0.6 
England 5.2 3.1 1.4 0.7 
Scotland 6.5 4.2 1.8 0.6 
Wales 5.2 3.2 1.7 0.3 
Northern Ireland 3.6 2.4 1.0 0.2 
Republic of Ireland 4.4 2.3 2.0 - 
 
1.1.2. Pathogenesis of IBD 
While IBD has been studied for decades it remains mysterious in its pathogenesis (18). 
Various factors keep researchers guessing why some individuals develop IBD while others 
are never afflicted. It is now speculated that a single and simple cause and effect relation 
probably does not account for most cases of IBD.  
The most consensual model of disease pathogenesis suggests that disease occurrence 
is an interaction of four elements: genetic susceptibility, environment, abnormal immune host 
response and commensal gut microbiota (18) as discussed later in this thesis (Section 1.7) 
Although the exact interaction of these elements remains unknown, IBD pathogenesis is 
believed to occur from errors in the interpretation or regulation of immune perception and 
responsiveness to endogenous microbiota, and thus disruption in the mucosal homeostasis, 
with initiation of immune response in genetically predisposed individuals (18). 
 
1.1.2.1. Genetic factors 
Clinical observations suggest that genetic factors are implicated in the pathogenesis of IBD. 
Family aggregation has long been recognized. First-degree relatives of an affected patient 
have an increased risk of IBD (13;14;19;20) whereas a substantially higher rate of disease 
concordance has been observed in monozygotic twins than in dizygotic ones, especially in 
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those with CD (21-24). Over the past 20 years a wide variety of candidate genes have been 
implicated in the pathogenesis of IBD (21). Many of these putative associations have not 
been reproducible whereas there is substantial consensus evidence for others (21). The 
region on chromosome 16 known as (IBD1) was first identified in 1996 by French 
researchers (25). Detailed mapping of this chromosome, resulted in the identification of the 
NOD2/CARD15 gene that encodes a cytoplasmic protein designated NOD2 or CARD15 
which serves as a pattern recognition receptor for bacterial lipopolysaccharide, and regulates 
activation of nuclear factor-kβ and secretion of a-defensins by ileal paneth cells (26). People 
who are homozygous for variant NOD2 may have 20-fold or more increased susceptibility to 
CD (27;28). However fewer than 20% of patients with CD are homozygous for NOD2 
variants so it does not fully explain the disease pathogenesis. Since these first observations 
a number of other candidate genes have been identified with the strongest evidence for the 
HLA region, MDR-1, as well as the recently implicated IL23R and ATG16L1 genes (29). 
 
1.1.2.2. Environmental factors 
Despite the strong evidence implicating genetic factors in IBD, environmental factors may 
also be important.  Approximately 40%-50% of individuals with identical genetic makeup are 
discordant for CD, indicating that environmental influences play an important role particularly 
when the rapid increase in the incidence of IBD cannot be fully explained by slow long-term 
changes in the human genome.  
Several epidemiological studies have implicated diet, anti-inflammatory drugs, 
vaccination history, smoking, seasonal variation, appedicectomy, use of swimming pools, 
and water supply to the occurrence and increasing incidence of IBD (9).   
 
1.1.2.3. Gut microbiota  
There is substantial evidence to incriminate the commensal gut microbiota in the 
pathogenesis of IBD (30). This is discussed in detail in Section 1.7.2. 
 
1.1.3. Symptoms and clinical manifestations of IBD 
For many patients, IBD imposes a substantial personal burden, with unpredictable fluctuating 
symptoms, time off work, intestinal and extra-intestinal complications (31) (Table 1.4), need 
for drugs with substantial side effects, possible surgical resection of part of the gut, and 
reduced quality of life (32). 
There is no feature, characteristic of disease presentation, which can differentiate IBD 
from other diseases. Furthermore intestinal symptoms of IBD can be insidious and subtle 
delaying early diagnosis. Common presenting symptoms and clinical manifestations are 
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abdominal pain, diarrhoea, perirectal bleeding, lethargy, anaemia, and weight loss that are 
often misdiagnosed as infectious gastroenteritis, iron deficiency anaemia (IDA), thyroid 
disorders and eating disorders (15;33). In a British and Irish collaboration (33) 25% of CD 
children presented with the triad of abdominal pain, diarrhea and weight loss (Table 1.4). The 
variability in symptoms reflects and correlates with the different sites of GI involvement (34).  
Common extra-intestinal manifestations in IBD patients are orofacial granulomatosis, 
angular stomatitis, erythema nodosum, hepatobiliary complications, anaemia, weight loss 
and, particularly in children, growth retardation and sexual immaturity (31). The impact of IBD 
on nutritional status and body composition of the patients is presented in detail in Section 
1.3.2. Beyond the health related consequences of IBD, acute active disease may necessitate 
frequent hospital admittance, causing major disruptions in social, family life, professional 
career, and academic attendance in children that subsequently lead to low quality of life (32) 
and psychological concerns (35). Psychological support is now considered an integral part of 
the multidisciplinary approach to IBD management.   
 
Table 1.4: Presenting symptoms and signs of paediatric IBD in UK (adapted from Sawzcenko & 
Sandhu 2003 (33)) 
 CD (n=379) IC (n=72) UC (n=172) 
Common symptoms 
   
Abdominal pain  274  (72%)  54  (75%)  106  (62%) 
Diarrhoea  214  (56%)  56  (78%)  127  (74%) 
Bleeding  84  (22%)  49  (68%)  145  (84%) 
Weight loss  220  (58%)  25  (35%)  53  (31%) 
Lethargy  103  (27%)  10  (14%)  20  (12%) 
Anorexia  94  (25%)  9  (13%)  11  (6%) 
    
Other symptoms 
   
Arthropathy 28 3 11 
Nausea vomiting 22 1 1 
Constipation/soiling 4   
Psychiatric symptoms 3   
Secondary amenorrhoea 1  1 
    
Signs 
   
Anal fistula 17   
Growth failure/delayed 
puberty 
14 1  
Anal abscess, ulcer 8   
Erythema nodosum/rash 6  1 
Liver disease 3 2 5 
Appendicectomy 2   
Toxic megacolon   1 
 
1.1.4. Management of IBD 
Despite the progress in overall management of IBD over recent decades (36), no innovative 
curative treatment has been developed and contemporary treatment achieves mainly 
symptom control. Recent therapeutic goals for pediatric patients with IBD were established 
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and were described in the workgroup report of the First World Congress of Pediatric 
Gastroenterology, Hepatology and Nutrition (37). 
The conventional treatment strategies in IBD are classified into inductive, to achieve 
disease remission, and maintenance, to prolong disease remission and prevent a 
subsequent flare up. In paediatric patients in particular, linear growth and pubertal 
development are two distinct characteristics that differentiate the options, and choice of 
management compared to adults. 
Due to the chronicity of the disease and the lack of effective curative treatment 
patients with IBD are committed to stay on daily lifelong treatment. The choice of medication 
is determined by the type of disease (CD or UC), the severity, and the extent of disease 
involvement (Table 1.5) and therefore it is important to tailor treatment according to the 
particular individual needs of each patient (36;38-40). 
The medical therapy of IBD has improved considerably in recent years (36;38-40). 
Recently the British Society of Gastroenterology (41) published practice guidelines for the 
management of IBD in adults, with however, negligible reference to paediatric patients. 
Medical treatment in paediatric IBD is extensively reviewed elsewhere (38) and the 
mainstream options are presented in Table 1.5. 
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Table 1.5: Common medical treatment options and indications of use in paediatric IBD (compiled from (36;38;39;41-44)) 
Drug Disease Role in IBD Action Examples Side effects 
Aminosalicylates 
 (5-ASA) 
Mild/moderate UC 
& CD 
Induction and maintenance of 
remission 
Control the release of 
lipid mediators, 
cytokines and oxygen 
species 
Mesalazine 
Sulfasalazine 
Nephritis 
Nephropathy 
Hepatotoxicity 
Pancreatitis, 
Pulmonitis 
Pericarditis 
Corticosteroids Moderate/severe 
UC & CD 
Induction of remission Potent immunologic and 
anti-inflammatory agents 
Prednisolone 
Prednisone 
Hydrocortisone 
Budesonide 
Infection 
Hypertension 
Weight gain 
Acne 
Myopathy 
Fluid retention  
Bone 
demineralization 
Immunosuppresants UC & CD Maintenance of remission Inducing T cell apoptosis 
by modulating cell 
signaling 
Azathioprine (AZA) 
6-mercaptopurine 
Pancreatitis 
Fever 
Leukopenia, 
Hepatotoxicity 
Nausea 
Antibiotics CD Induction of remission in 
mild/moderate peri-anal disease 
Alteration of the bacterial 
flora 
Metronidazole 
Ciprofloxacin 
Nausea,  
Headache 
Glossitis  
Peripheral neuropathy 
Methotrexate CD Induction of remission in 
moderate/severe, refractory, 
intolerant of standard therapies 
Immunosuppression Methotrexate Myelosuppression 
Hepatotoxicity 
Biological agents CD & UC Induction of remission in moderate/ 
severe, alternative induction therapy 
to steroids or as a first-line agent for 
severe perianal fistulizing disease 
Antibody against 
proinflammatory 
cytokines 
Infliximab Nausea 
Headache 
Upper respiratory 
infections 
Fatigue 
Fever 
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With the treatment approach described in Table 1.5, most patients with active IBD will 
enter into a remission phase. However those who fail to respond to medical therapy can 
usually be operated and enter surgically induced remission. It is estimated that between 30% 
to 40% of patients with UC will need surgical intervention in the course of their disease, 
whereas between 70% and 80% of CD patients will have resection of a part of their GI tract 
(45). Indications for surgery include perforation, strictures, fistulae and toxic megacolon. 
In a retrospective study in Scotland by Watson et al (15) 48% of paediatric patients 
with CD underwent surgery compared with 23% of patients with UC. It is noteworthy that the 
same study reports that the incidence of surgical intervention appeared to be decreasing. 
Fifty-four percent of paediatric IBD patients underwent surgery in the 1980 to 1989 cohort 
compared with 34% in the 1990 to 1999 group although the mean length of follow-up in the 
latter group was shorter, and this figure may have risen with time. 
The use of nutritional therapy is a promising field in the treatment of IBD. A number of 
studies using in-vitro models, experimental animal models of colitis and human trials support 
the use of a range of potential nutritional remedies in the management of IBD including 
exclusive enteral nutrition (EEN), administration of probiotics and/or prebiotics, butyrate 
enemas or oral supplements, and the use of omega 3 fatty acids. These approaches are 
quite new and the evidence so far is controversial and inconclusive. The mostly studied and 
well established nutritional remedy in clinical practice is the administration of EEN in adult 
and paediatric patients with CD. This is described below (Section 1.5) 
When conventional treatment fails to cure, the use of unconventional treatment 
purchased over the counter and provided by alternative health professionals are often used. 
This is discussed below in Chapter 1.2. 
 
1.2. Complementary and alternative medicine in IBD 
It is probably due to the serious and relapsing nature of the symptoms of the disease that 
there is increasing interest in the use of unconventional remedies by IBD patients. 
Complementary and alternative medicine (CAM) encompass a group of diverse medical and 
health systems, therapies, and products that are not presently considered to be part of 
conventional medicine. Within this definition, there is no firm description which specific 
methods and remedies comprise CAM and which do not (Table 1.2.1) particularly as new 
branches of established disciplines are continually being developed. Thus some studies have 
considered prayer and exercise as a form of CAM (46) whereas others restricted definition 
solely to consultations with alternative therapists (47). Moreover therapies that are included 
in the definition of CAM in some countries are part of integrated conventional medicine in 
others (i.e. traditional Chinese medicine in China).  
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Table 1.2.1: Common types of CAM  
Special diets Nutritional 
supplements 
Herbals Alternative 
therapists 
Dairy/Milk free Probiotics Aloe Acupuncture 
Gluten/Wheat free Prebiotics Cat’s Claw Chiropractic 
Low residue/Fibre Fish/Omega 3 oils Evening primrose Hypnosis 
Low carbohydrate Glutamine Echinacea Massage 
Gottschall diet Vitamin/Minerals Garlic Relaxation therapy 
Vegeterian/Vegan  Ginseng Chinese therapies 
  Grapeseed extract Aromatherapy 
  Milk thistle Reflexology 
  Slippery elm Yoga 
  Gingko biloba Homeopathy 
  Chinese herbs  
 
1.2.1. Prevalence of CAM in the general population 
The use of CAM is common in the general population (48;49) and has increased 
substantially over time (50;51). Data from the National Health Interview Survey in 2002, in 
31044 adults, showed that 62% of adults in the USA used some form of CAM therapy over 
the past two months (52). CAM is also becoming popular in the UK general adult and 
paediatric population (53;54). Results from the National Omnibus survey in Great Britain 
estimated that 10% of the general population had received some form of 23 named 
unconventional therapies from a CAM practitioner in the last year without assessing the 
usage of self-prescribed CAM therapies (55). Estimates of CAM use were similar in England, 
Scotland and Wales. Likewise a paediatric survey in Bath, England, estimated that 17.9% of 
children in the general population had used CAM at least once, and 6.9% had a consultation 
with a complementary medicine practitioner (53).  
In parallel to that, the proportion of patients that are recommended to access a 
complementary practitioner through their primary care health providers is increasing. Thomas 
et al (53;56) interviewed general practitioners in England throughout 1995-2001 and 
observed that the proportion of practitioners that provided some access to CAM increased 
from 39% in 1995 to 49.4% in 2001. 
The most common factor associated with the use of CAM is poor health esteem and 
increased morbidity (55). Ong et al (57) using a postal questionnaire in four English counties 
found that 60% of CAM users reported having a chronic illness or disability. Patients with 
increased mortality and morbidity risk, like cancer (58) and HIV infection (59) were among 
the common users of CAM. Use of CAM is similarly high in patients with functional and 
organic GI disorders. Ganguli and his colleagues (60) estimated use of CAM, over the last 
year to be as high as 52.5% in gastroenterology patients and Kong et al (61) in a study of 
932 subjects from a gastroenterology clinic and 477 healthy controls found the incidence of 
 33 
CAM use to be 49.5% for IBD patients, 50.9% for irritable bowel disease, 20% for general GI 
disorders and 27% for the healthy control group.  
 
1.2.2. Literature review of studies on CAM use in IBD patients 
An extensive electronic literature search was conducted to retrieve relevant studies on the 
use of CAM in IBD using subject specific keywords. Nineteen adult and four paediatric 
studies were identified. As it is outside the scope of this thesis to describe each of these 
studies separately, only well-designed studies with adequate sample size, reports from the 
UK, and all those conducted in pediatric IBD patients will be presented (Table 1.2.2).  
Overall the studies were heterogeneous in design, responding populations, definitions 
of CAM (Table 1.2.2) and did not allow direct comparison or to draw conclusive results. 
Some studies were restricted to the use of CAM provided by specialized therapists (47;62), 
whereas others included oral remedies and nutritional supplements (multivitamins, 
probiotics) (61;63) bought over the counter. Dietary manipulations and special diets were 
included in most studies (63;64) but not all (65). Some studies assessed current use of CAM 
(66), whereas others looked into the overall past use since IBD diagnosis (67) or defined use 
within a specific timeframe (64). Methodology also varied between studies. Most studies 
used postal surveys (64;65), others used personal interviews or questionnaires administered 
at the patients’ routine clinical appointments (61;67) and others a combination (62;65). The 
average prevalence of CAM use varied considerably between studies from as low as 4% (62) 
to up 72% of the responding population (66) subject to the CAM definition used (Table 1.2.2).  
Disease onset seemed to be the main trigger of CAM use, as the latter was significantly 
lower prior to disease diagnosis (63;68). Moreover the use of CAM in IBD is significantly 
higher compared with healthy people (61;67) or patients with other clinical conditions (47).  
Herbal medicine, nutritional remedies and homeopathy were reported among the 
common types of CAM. Probiotics were used predominantly by IBD patients in some studies 
(64;66;69) but were uncommon in others (65). Differences in the prevalence and 
predominant types of CAM among studies could be attributed to the different study design 
and responding populations (Table 1.2.2). In particular patients recruited from tertiary 
hospitals may be patients with severe IBD or perhaps those that have benefited more from 
the conventional medicine. On the other hand geographical differences in the type of CAM 
may denote cultural differences and beliefs in the utility of CAM as well as different 
approaches to CAM by the medical staff and different promotion of CAM in countries that are 
traditional users of them.  
Disease severity (63), high education level (68), high socio-economic status, female 
gender (61), young age (68), internet usage (64), prior or parental CAM usage, longterm use 
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of steroids (68) low quality of life and increased psychological stress (70),  have all been 
reported as predictors of CAM use by IBD patients (65;68).   
The main reasons given by IBD patients for use of CAM included the need for an 
optimum treatment (68), the wish to be actively involved in and personally responsible for 
their disease management (68), wish for a holistic therapeutic approach and, frustration with 
the ineffectiveness and side effects of conventional medicine (66;68). Common sources of 
information on CAM were magazines, internet search, friends, family and their medical 
doctors (66). Many patients did not reveal the use of CAM to their primary health providers 
and actually a few CAM users discontinued or reduced their conventional treatment on their 
own or were advised to do so by their CAM practitioners (47). In a German survey, 31% IBD 
participants reported reduction or discontinuation of conventional medicine on CAM use (68). 
This is of great concern as some of these therapies exert only a placebo effect, or may 
interfere with the action of conventional treatments. In the study by Hilsden et al (63) 53% of 
the patients who tried CAM reported some form of harm ascribed to CAM use.  
Whatever the true action of CAM, many patients found CAM at least effective (68;70) 
and the majority of them would consider CAM use in the future (66;68).  
 
1.2.3. CAM effectiveness in IBD. How good is the evidence? 
Unlike CAM conventional medical treatment in IBD is supported by randomized control trials 
(RCT) evidence of their efficacy. On the contrary use of CAM is based mostly on theoretical 
foundations with a lack of well-designed clinical trials. The few studies that are reported in 
the literature are usually open label studies of poor design, although recent lines of evidence 
support the use of some of them (71). Probiotics, prebiotics, SCFA and omega 3 fatty acids 
have demonstrated some clinical efficacy in some studies in IBD whereas for other remedies 
such as acupuncture, wheat grass juice, aloe vera, and special diets more evidence is 
accumulating (72-74).  
Ben Arye et al (72) in a double blind RCT showed that wheat grass juice appeared 
effective and safe as a single or adjuvant treatment of active distal UC. Treatment with wheat 
grass juice was associated with significant reduction in the overall disease activity and 
severity of rectal bleeding. Recently Joos et al (73) in a single blind RCT showed that 
patients with mild to moderate active CD treated with acupuncture for four weeks, 
experienced a decrease in their clinical activity index, inflammatory markers, and a better 
general well being compared with a control group. Finally, Langmead et al (74) found that 
oral aloe vera taken for four weeks produced a clinical response more often than placebo 
treatment and it also reduced the histological disease activity without presenting side effects. 
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1.2.4. Conclusion 
In conclusion the use of CAM in adult IBD patients is well studied, but in children there is a 
lack of substantial evidence. Most of the paediatric surveys have been conducted in the US 
(64) and Australia (66) with only one multinational study which included only a small sample 
of UK patients from a single hospital in London, UK (65).  
Extrapolation of the results of adult studies is inappropriate and can be misleading as 
there are considerable differences in disease management regimes between adult and 
paediatric patients (34). Furthermore, the use of CAM by paediatric patients reflects the 
choice of their guardians and how they cope with their child’s disease.   
Further studies should be undertaken to address the use of new non-medicinal 
products, like probiotics and prebiotics, with emerging evidence of efficacy in IBD (75;76). 
Characteristics of patients who may be more amenable to CAM use should be identified with 
a study. On the other hand health professionals that care for IBD children should be aware of 
CAM use by their patients as the latter can interfere with conventional medical treatment or 
may have serious health related side effects (77).  This was explored in the study described 
in Chapter 2 of this thesis. 
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Table 1.2.2: Major studies on the prevalence of use of CAM in adult and paediatric patients with IBD  
Study Country; Setting Sample; 
Methodology 
CAM definition Prevalence of 
CAM use  
Predominant 
CAM 
Predictors of 
CAM use 
Comments 
ADULT STUDIES 
Langhorst et 
al 2005 (68) 
Germany; 
National IBD 
database 
N:864; Mailed 
questionnaire 
Self 
prescribed & 
CAM 
therapists 
51.3% overall; 
26.8% current 
users 
Homeopathy, 
herbals, ayurvedic 
medicine; 
traditional Chinese 
medicine; 
probiotics used by 
54.2% 
More UC users 
than CD; high 
education; young 
age; steroids 
intake more than 
10 g was the 
strongest 
predictor 
6.8% used 
exclusive CAM 
permanently; 
11.5% 
experienced side 
effects 
Kong et al 
2005 (61) 
Sheffield UK; 
Outpatient GI 
clinic 
N:1409:(311 IBD), 
healthy control group; 
Doctor-administered 
questionnaire  
Oral 
supplements 
49.5% IBD; 51% 
IBS; 20% general 
GI; 27% healthy 
controls 
Multivitamins More women 
than men 
Most participants 
did not find CAM 
beneficial 
Hilsden et al 
2003 (63) 
Calgary 
Canada; 
National IBD 
database 
N:2847; Mailed 
questionnaire 
Vitamins 
were not 
included; 
Prayers and 
exercise 
excluded 
47.2%; 23.6% 
current users 
Herbals; 27.5% 
used dietary 
modifications  
Severe disease 15% used CAM 
before IBD 
diagnosis; 
Median number 
of therapies 
currently used:3; 
53% reported 
harm of CAM use 
Langmead 
et al 2002 
(70) 
London, UK; GI 
& general 
medicine 
outpatient clinic 
N:239; Questionnaire 
completed in the clinic 
 28%  Herbals Low quality of life 
scores for the 
emotional and 
social factors; 
Fatigue 
No difference in 
use with non IBD 
patients; over 
50% found it 
beneficial 
Moody et al 
1998 (47) 
Leicestershire, 
UK; Database 
of chronic GI 
disorders 
N:572 (219 IBD, 145 
coeliac); Mailed 
questionnaire 
CAM 
therapists  
23% of Asians & 
18% of 
Europeans; 8% 
for coeliac  
Herbalists; 
homeopathists 
No difference 
between 
ethnicities 
Some patients 
were advised to 
reduce or stop 
conventional 
medication  
Smart et al 
1986 (62) 
Nottingham, 
UK; Outpatient 
GI clinic 
N=461 (96 IBS, 222 CD, 
143 general GI); 
Questionnaire completed 
in the clinic; postal survey 
for CD patients 
CAM 
Therapists  
16% of IBS, 6% 
of CD, 2% of 
general GI; 11% 
of IBS and 4% of 
CD current users 
Herbalists; 
homeopathists 
Failure of 
conventional 
therapy 
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PAEDIATRIC STUDIES 
McCann et 
al 2006 (67) 
Leeds, UK; 
Outpatient 
clinic 
N=75 with chronic 
illnesses (25 IBD) & 
25 healthy control; 
Face to face 
Interviews 
All types of CAM; 
Ever use of CAM 
 Only summary results 
for all GI patients 
  
Day et al 
2004 (66)  
Sydney, 
Australia; 
Outpatient GI 
clinic 
N=46; Mailed 
questionnaire 
All types of CAM; 
Ever use of CAM 
72% current 
users; 2.4 
agents in 
average 
Probiotics, fish oil, 
herbals 
 Reasons of use: 
To avoid 
medication side 
effects, 
dissatisfaction 
with medication, 
experience by 
others; 12% found 
CAM partially 
effective; 4% 
found it 
expensive; the 
majority would 
use CAM again  
Markowitz et 
al 2004 (64) 
Greater 
Philadelphia 
area, US; IBD 
database 
N=335; Mailed 
questionnaire 
CAM use last 12 
mth; No 
multivitamin only 
megavitamins  
50.8% Nutritional therapies 
(22% probiotics, 
16.4% fish oils, 
megavitamins), 
special diets (dairy 
free diet) 
Internet use, 
caloric 
supplementation, 
IBD surgery, 
school absences, 
low quality of life 
 
Heuschkel 
et al 2002 
(65)  
Multinational; 
Boston, Detroit 
US, London 
UK; Outpatient 
clinic & 
database 
N=208 (51 from 
London); 
Questionnaire 
completed in the 
clinic or mailed  
CAM use last 12 
mth; No dietary 
modifications 
41% 
excluding 
dietary 
modifications; 
35% dietary 
modifications 
19% megavitamins, 
17% dietary 
supplements, 9% 
herbals, 6% 
homeopathy only 2% 
probiotics in London 
and 6% in total 
No of adverse 
effects from 
conventional 
medicine, 
parental use 
 Reasons of use: 
feel better, hoping 
for a cure, 
disappointment 
with conventional 
treatment 
IBS: Irritable bowel syndrome
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1.3. Nutrition considerations in IBD 
Beyond the GI manifestations of IBD, extraintestinal complications accompany the natural 
history of the disease and often appear before diagnosis. Amongst these, nutritional 
complications are present in the majority of patients with IBD and comprise an additional 
burden for the health professionals and the patients. Intervention through dietary counseling, 
nutritional supplements, EN or parenteral nutrition may become necessary at some point to 
reconstitute nutritional balance (35;78). In 2004 the North American Society for Paediatric 
Gastroenterology, Hepatology and Nutrition, published a consensus report on nutrition 
support for paediatric patients with IBD, highlighting the major nutritional problems, and 
proposing guidelines for assessment and monitoring of the nutritional status (35).  
In IBD malnutrition can occur with all its different facets and can affect clinical 
outcomes, immune system function, gut mucosa barrier (79), antioxidant mechanisms, body 
growth, bone health and quality of life (35). Protein-energy undernutrition, micronutrient 
deficiencies and poor bone health are commonly reported in IBD, whereas in paediatric 
patients growth failure, and pubertal delay are additional features. Multiple factors are 
involved in the manifestation of malnutrition in IBD with suboptimal dietary intake and 
excessive losses being the main contributors (Table 1.3.1).  
 
Table 1.3.1: Causes of malnutrition in IBD 
Factor Reason 
Suboptimal intake Reduced appetite 
 Food aversions-fear of worsening symptoms 
Malabsorption Intestinal inflammation 
 Intestinal resection 
Excessive losses Protein loosing enteropathy 
 GI bleeding 
 Excessive GI mucosa sloughing  
 Fistula output 
 Diarrhoea-steatorrhoea 
Increased requirements Increased metabolic needs 
 Increased GI mucosa turnover 
 Increased consumption of antioxidants 
 Altered lipid and muscle oxidation  
 Fever 
Disease activity Pro-inflammatory cytokines-growth 
Drug nutrient interactions Steroids-Inhibition of IGF-1 
 Steroids-Poor bone mineralization 
 Steroids-Impair fat and muscle metabolism 
 Methotrexate-Impair folate metabolism 
 Sulfasalazine-Inhibits folate absorption 
 
1.3.1. Protein-energy malnutrition 
IBD patients often suffer from protein energy malnutrition by the time of diagnosis, and their 
status fluctuates during the disease course (80;81). Recent weight loss is a common feature 
in the newly presented IBD patient, particularly in CD, and accompanies almost every 
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relapse (82;83). Around 60% of newly diagnosed children with CD, compared to 35% in UC, 
present at diagnosis with a history of recent weight loss (33;82). 
As a subsequent result of excessive weight loss and undernutrition, basic 
anthropometry is affected. IBD patients and particularly those with CD, present with low BMI 
and are underweight compared with the national reference range or their healthy peers 
(33;84-88). Recent data, however, suggest that fewer patients at risk of undernutrition are 
now seen compared with previous studies. In fact a large proportion of patients are 
overweight at diagnosis, particularly UC patients, and this has been linked to the obesity 
epidemic observed in the general population (82;87). In a North American study of 783 newly 
diagnosed IBD children, low BMI was seen in 22%-24% of the children with CD, and 7%-9% 
of children with UC. Ten percent of the CD children and 20%-30% of the UC had high BMI 
consistent with the definition of overnutrition (82). Low risk of undernutrition has been 
described recently (87) in a cross-sectional study of adult IBD patients, and an alternative 
explanation suggested was the progress in medical treatment with the evolution of new drugs 
that spare the use of steroids, and achieve not only symptomatic relief but also mucosal 
healing (89;90).  
Other than differences between the two types of IBD there is no consistent evidence 
to link specific disease characteristics with undernutrition. Some studies found an association 
with small bowel disease and risk of underweight (91) but others did not (82). A higher 
prevalence of undernutrition was also reported in patients with active (60%) compared with 
inactive disease (13.7%) in a recent study using the Subjective Global Assessment to screen 
for undernutrition (80).  
 
1.3.2. Body composition 
Body size dimensions and BMI should best be seen as an index of nutritional status and 
body composition (92). Although BMI correlates well with obesity (93) and defines risk of 
undernutrition (94) in the general population, its diagnostic accuracy to distinguish between 
fat and muscle stores in chronic illness, like IBD, is unknown. 
There are several reasons that body composition in IBD may differ from that of 
healthy people. Inflammation and the secretion of pro-inflammatory cytokines may alter 
energy metabolism, protein turnover and substrate utilization (91), whereas the use of 
corticosteroids increases body fat and exerts negative catabolic effects on lean mass (95). 
Physical activity on the other hand was reported to be low in IBD patients and correlated 
inversely with fat mass (FM) in one recent report (87).  
Several studies assessed the body composition of IBD patients and compared it with 
reference norms or healthy subjects, but results were inconsistent. A lower FFM compared 
 40 
with healthy subjects and preservation of FM was found in some adult studies (85;87;91;96) 
but not all(97;98). A series of studies in newly diagnosed adult IBD patients (99) and other 
patients with longstanding disease in remission (100), failed to identify an overall difference 
in body composition between the two types of IBD and healthy control subjects, although 
gender specific differences were evident (101).  
 Strong associations between body composition and disease characteristics, like 
phenotypic characterization, duration of disease (85), and history of small bowel resection 
(87;96) have not been described extensively in adult studies. Sex differences have been 
reported occasionally in some adult studies (85;101) but not others (87) and one study found 
an inverse association between disease activity and body fat (100).  
There are only a few studies that assessed body composition in IBD children. Among 
these studies, body lean mass is reported as significantly lower than healthy control groups 
(84;88;100;102;103) whereas gender specific associations with FM were observed in some 
(84;88;100;103). Sentogo et al., in a cross-sectional study (103), found that boys and girls 
presented lower FFM by 3.5 and 2.9 kg respectively, compared with the control sample, 
whereas FM, although not different from the control group in CD boys was 3.7 kg higher in 
CD girls. Similarly Burnham et al. in a cross-sectional study (84) found that children with 
longstanding CD had a 6% reduction in lean mass compared with healthy children after 
correcting for stature, age, pubertal stage and race (84). No similar deficits were found for 
FM that conforms to the definition of nutritional cachexia. Recently Thayu et al. in a well-
designed study (88) of a cohort of newly diagnosed children with CD, also reported gender 
associated differences with body composition. Fat mass and lean mass for height (adjusted 
for age, race and pubertal stage) were lower in female than in male patients. Compared with 
a cohort of healthy controls, body composition in girls was more consistent with the definition 
of wasting (low lean and FM) whereas in boys there was mostly preservation of FM and 
deficits in lean mass consistent with the definition of cachexia. No associations were 
observed between body composition, clinical activity, disease location or delay of diagnosis.   
Different characteristics of patients, and the recruitment of new (88) compared with 
longstanding patients (84), may explain some of the discrepancies found in adult and 
paediatric studies. Although many authors compared the body composition of IBD patients 
with a cohort of healthy controls, of similar age and gender, they did not to match for body 
weight, height or BMI and this might explain differences found in the absolute fat or lean 
mass but not in their relative body proportions (85;87;96;99). In IBD children in particular, 
impaired growth and pubertal delay are frequently seen and a proper comparison of body 
composition between CD and healthy children needs to account for these confounders 
(84;85;87;88;96;99).   
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On the other hand as there is no method to measure body composition accurately 
(92), the use of different techniques makes a direct comparison between studies difficult. 
Indeed the results of each study are inherent to the limitations and theoretical assumptions of 
the method used, that may additionally not be valid in illness (92). Most in vivo body 
composition methods have been tested and validated in healthy individuals or animal 
cadavers and their applicability in chronic illness is questionable given the changes that 
occur in the hydration level and distribution of water fluids in the body compartments (104). 
Using IBD as a prime example, studies showed that the hydration level of lean mass is not 
the same as with healthy subjects (104) and in fact depends on gender (101). Therefore 
application of body composition methods that consider a constant hydration of FFM (DXA, 
bioimpedance, double labelled water) is inaccurate and may produce erroneous results. 
Comparison and validation of the commonly used body composition methods in disease are 
needed. This thesis is presenting a relevant study between bioimpedance measurements of 
body composition and DXA in Chapter 4.  
 
1.3.3. Growth  
Faltering linear growth is commonly encountered in children with IBD, and often precedes 
disease diagnosis (102;103;105-107). Approximately 23%-25% of the children present 
deviations from their growth velocity and height for age centiles and are significantly shorter 
than their healthy peers (103). Sentogo et al. (103) found significant growth deficits in 
children with CD, compared with healthy children, and failure to attain their genetic potential 
for linear growth when their heights deficits were compared with their estimated mid-parental 
target height. This effect was more profound in boys. Girls did not differ from the healthy 
controls. Nevertheless most children with IBD will eventually achieve final heights within the 
normal range for the general population or close or their genetic potential (108-110). 
The exact mechanisms by which growth impairment occurs in IBD are unclear. 
Undernutrition, the effect of circulating proinflammatory cytokines on growth promoting 
factors and growth plate (111), long-term use of steroids (84;111-113) and genetic make up 
(114) are all implicated (115). On the other hand skeletal or bone age is negatively affected 
in CD particularly in boys, and may explain to some extent the degree of growth deficits seen 
in IBD (103). This coincides with the fact that most of the patients will eventually achieve final 
adult heights within their normal or slightly lower than their genetic potential (110;112).  
 
1.3.4. Bone health 
Bone mineralization is another important aspect in the care of the growing child with IBD, 
particularly as peak bone mass, attained during adolescence, is the most important 
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determinant of lifelong skeletal health (116;117). Osteopenia and osteoporosis are important 
extraintestinal manifestations in IBD that may be related to increased risk of fractures 
(116;118-120) although adequate evidence in children is missing. Semeao et al (121) 
reported five cases of vertebral compression fractures in paediatric patients with CD, but 
Persad et al. (122) found no difference in the prevalence of long bone fractures between 
paediatric IBD patients and their siblings.  
A large number of studies reported osteopenia and osteoporosis in adult and 
paediatric patients with IBD (85;96;102;113;123-127). Total body or femoral neck and lumbar 
spine bone mineral content or density were significantly lower than the reference cut offs or 
compared with healthy individuals (101-103;117;128). A disease associated effect has been 
reported with poor bone health seen more often in CD than UC (85;102;129;130). Disease 
location, disease duration, and history of disease activity were risk factors in some studies 
but not others (103;120;131-133). In a study by Burnham (113) the difference in bone 
mineral content between CD children and healthy control was eliminated when the authors 
accounted for the differences in lean mass in a regression model. This suggests that 
decreased mechanical stress is an important factor for reduced bone health in children with 
CD (117) and opens the window of opportunity to improve bone mass by optimising lean 
tissue gain with nutrition and weight bearing exercise in patients with IBD. 
Poor nutrition and nutritional status, vitamin D deficiency, the effect of pro-
inflammatory cytokines on bone resorption, and the longterm use of high steroid doses 
(85;102;132;134-139) are the main contributors that can negatively affect bone 
mineralization in IBD. 
 
1.3.5. Delayed puberty 
Delayed puberty frequently complicates the clinical course of young patients with IBD, more 
often in CD than UC and in boys than in girls (84;102;103). In a study of young patients with 
CD, menarche occurred at age 16 years or later in 73% of female patients in whom disease 
onset preceded puberty. In a few patients, menarche was delayed until the early twenties. In 
contrast, menarche occurred at 14 years or younger in all patients with juvenile-onset UC 
(108). Likewise Boot et al. (102) found a mean delay of puberty of 0.7 y in Dutch children 
with IBD and Burnham (84) 1.5 y in CD children in the USA.  
Delayed pubertal onset may influence linear growth and final adult height. Moreover 
delayed puberty can affect quality of life and self-esteem although this has not been 
addressed in a study to date. Undernutrition has always been thought to be the main reason 
for delayed puberty in IBD patients. However, puberty may be delayed despite a normal 
nutritional status. Observations in animal models of experimental colitis suggest that 
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inflammatory mediators may have a direct adverse influence, independent of undernutrition, 
on the onset and progression of puberty (140).  
 
1.3.6. Micronutrient status in IBD 
Vitamins, minerals and trace elements, collectively known as micronutrients, are essential for 
the normal function and development of the human body (Table 1.3.2). In IBD some 
micronutrients may have additional importance or play additional roles in the pathogenesis 
and clinical course of the disease (Table 1.3.2). Micronutrient deficiencies can influence 
clinical outcomes and disease progression in IBD, by affecting the immune system, tissue 
repair, antioxidant defence system, body growth and bone mineralization. A consensus 
report of the North American Society of Paediatric Gastroenterology, Hepatology and 
Nutrition suggested routine screening for micronutrients status in paediatric patients with IBD 
(35).  
Of particular interest is the evidence that supports an association between the body’s 
antioxidant defense system, and the pathogenesis and gut injury of IBD (141;142). IBD is 
characterised by aggravation of inflammatory cells (granulocytes, monocytes and 
neutrophils) at the site of the intestinal lesion and production of reactive oxygen species 
(ROS) as part of the normal immune properties of these cells. Reactive oxygen species are 
free radicals which include superoxide anion, hydrogen peroxide, nitric oxide, and 
hypochloride. In the human body the oxidative action of the free radicals is counteracted by 
antioxidant micronutrients and uncontrolled production coupled with reduced removal from 
an impaired endogenous antioxidant mechanism may cause tissue damage (143;144). 
There is good evidence to suggest that IBD patients are oxidatively stressed 
(145;146). This is believed to be the result of an imbalance between increased ROS 
production (142) and a suppressed antioxidant defence mechanism to compensate 
adequately, causing damage to biological macromolecules (142;146-148) and possibly 
intestinal lesions. Wenland et al (146) found that lipid peroxidation, a marker of ROS 
production, was higher in CD patients, compared with healthy controls. Indeed the plasma 
antioxidant vitamins were low despite no profound differences in the dietary intake of 
antioxidants between CD patients and healthy controls. A putative association between ROS 
and gut injury in IBD is also supported by the use of the aminosalicylates in IBD which are 
believed to work through an antioxidant property and scavenging of oxidative radicals (149).    
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Table 1.3.2: Micronutrient basic body functions and importance in IBD 
Micronutrient Main functions Main deficiency disease Importance in IBD 
Retinol/b-carotene (A) Visual pigments in the retina; 
antioxidant; normal development; 
differentiation of tissues 
Night blindness; xerophthalmia; 
keratinization;  
1. Antioxidant 
2. Deficiency exacerbates colitis (150) 
Calciferol (D) Calcium balance Rickets, osteomalakia; osteoporosis 3. Bone health (151) 
4. Fracture 
5. Deficiency in IBD (136;152)  
6. Antiinflammatory properties (153) 
Tocopherol/tocotrienols (E) Antioxidant Neurological dysfunction 1. Antioxidant 
2. Treatment of colitis (154) 
Phylloquinone/Manaquinones (K) Blood clotting; bone formation Impaired blood clotting; haemorrhagic 
disease 
1. Bone health (155;156) 
Thiamin (B1) Enzyme co-factors; carbohydrate 
alcohol metabolism 
Peripheral nerve damage (Beri-Beri); 
central nerve lesions (Wernicke-
Korsakoff syndrome) 
No data 
Riboflavin (B2) Enzyme co-factors in oxidation and 
reduction reactions; nutrient 
metabolism 
Lesions of corner mouth, lips, tongue; 
seborrhoeic skin lesions 
No data 
Nicotinic acid/Nicotinamide 
(Niacin) 
Enzyme co-factors in oxidation and 
reduction reactions; part of NAD 
and NADP 
Pellagra: photosensitive dermatitis, 
depressive psychosis 
No data 
Pyridoxine/Pyridoxal/Pyridoxamine 
(B6) 
Coenzyme in transamination, 
decarboxylation of amino acids, 
glycogen metabolism; role in 
steroid hormone 
Disorders of amino acid metabolism, 
convulsions 
1. Hyperhomocysteinemia more common in IBD 
(157) 
2. Thromboembolic Complications (158) 
Folic Acid Coenzyme in transfer of one 
carbon fragments; nucleic acids 
synthesis 
Megaloblastic anaemia 1. Risk of deficiency in methotrexate & 
sulphasalazine users 
2. Colorectal cancer (159-161) 
3. Megalobastic anaemia 
Hyperhomocysteinemia (162) 
Cobalamin (B12) Coenzyme in transfer of one 
carbon fragments; nucleic acids 
Percinious anaemia (megaloblastic 
anaemia with degeneration of the 
1. Megalobalstic anaemia 
2. Malabsorption in patients with ileal disease or 
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synthesis; folate metabolism spinal cord)  resection (163) 
3. Hyperhomocysteinemia; Thrombosis risk (164) 
Pantothenic Functional part of coenzyme A and 
acyl carrier protein 
Peripheral nerve damage (burning foot 
syndrome) 
No data 
Biotin (H) Coenzyme in carboxylation 
reactions in gluconeogenesis and 
fatty acid synthesis 
Impaired fat carbohydrate metabolism, 
dermatitis 
No data 
Ascorbic Acid  Coenzyme in hydroxylation of 
proline and lysine in collagen 
synthesis; antioxidant, iron 
absorption 
Scurvy; impaired wound healing; loss 
of dental cement; subcutaneous 
hemorrhage 
1. Antioxidant 
Carotenoids Antioxidant system  1. Decrease oxidative stress (150)  
2. Deficient in CD (165) 
Calcium (Ca) Growth and skeleton formation; 
muscle function; blood clotting 
Poor bone health; Osteoporosis; 
Fractures 
1. Bone health (166) 
2. Fractures  
Magnesium (Mg) ATP stabilization Abnormal muscle function; disruption 
of Ca metabolism 
1. Malabsorption 
Phosphorus (P) Growth and skeleton formation; 
blood buffering capacity; energy 
production 
Anorexia, bone pain, rickets; 
osteomalacia; muscle weakness, 
ataxia, susceptibility to infections 
No data 
Sodium (Na) Osmotic and electrolyte 
homeostasis; water balance; nerve 
conduction; active cellular 
transportation; mineral bone of the 
apatite 
 1. Electrolyte disturbances in severe diarrhoea 
Chloride (Cl) Osmotic and electrolyte 
homeostasis; hydrochloric acid in 
the stomach 
 No data 
Potassium (P) Osmotic and electrolyte 
homeostasis; enzyme cofactor in 
energy metabolism and cellular 
growth and division, nerve and 
muscle function 
Muscle and neural dysfunction; 
cardiac arrest;  
1. Electrolyte disturbances in severe diarrhoea 
Iron (Fe) Reaction catalyst, blood synthesis; 
oxygen transportation; energy 
production;  
Anaemia, fatigue, restlessness; 
impaired work performance; abnormal 
thermoregulation; suppressed immune 
system; adverse effect on 
psychomotor and mental development 
1. Impaired absorption in IBD (167) 
2. Anaemia 
3. Oral iron exacerbate colitis and increase 
oxidative stress (159) 
Zinc (Zn) Enzyme cofactor; antioxidant Growth retardation; sexual and 1. Decreased absorption (168) 
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skeletal immaturity; neuropsychiatric 
disturbances; dermatitis, alopecia; 
diarrhea; loss of appetite; susceptibility 
to infections  
2. Mucosal permeability (144;169)  
3. Antiinflammatory properties (170)  
4. Antioxidant 
Copper (Cu) Enzyme cofactor; function of 
immune, nervous and 
cardiovascular system; bone 
health; iron metabolism; 
haemopoiesis; mitochondrial 
function; energy production; 
antioxidant  
Anaemia; neutropaenia; bone 
fractures; hypopigmentatio; impaired 
growth; abnormalities of glucose and 
cholesterol metabolism 
1. Antioxidant 
 
Selenium (Se) Enzyme cofactor; antioxidant; 
catalyst 
Keshan disease; immune system 
dysfunction;  
1. Deficient in IBD (171;172) 
2. Antioxidant  
Iodine (I) Thyroid hormone synthesis Goiter; cretinism;  No data 
Manganese (Mn) Enzyme co factor Impaired growth; skeletal 
abnormalities; impaired reproduction; 
nutrient metabolism; weight loss; 
dermatitis 
No data 
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Following these observations clinical trials found a reduction of markers of oxidative 
stress and improved antioxidant status on supplementation with antioxidant micronutrients 
(171;173;174). Nevertheless a positive association between improvement of disease activity 
and restoration of oxidative status has not been shown (174).  
Although clinical presentation of frank micronutrient deficiencies in IBD is very rare 
(175)  and largely limited to case reports (176), suboptimal circulating levels for virtually 
every vitamin, mineral and trace element have been reported previously primarily in adult 
patients and a few paediatric IBD patients (Table 1.3.3). Antioxidant trace elements (eg. Zn, 
Se, Cu) and vitamins (vitamins A, E, C, carotenoids) were the main nutrients consistently 
reported in lower circulating concentrations in IBD patients compared with healthy controls or 
the normal reference range (Table 1.3.3).  
Suboptimal dietary intake, increased utilization, malabsorption and increased enteric 
losses have all been postulated. Some studies have linked nutritional deficiencies with 
clinical disease activity and inflammatory markers (Table 1.3.3) but whether micronutrient 
depletion plays an important role in the pathogenesis and perpetuation of the mucosal 
lesions or is the result of it needs to be studied further.  
On the other hand the changes in the serum levels of many antioxidants and their 
association with systemic and clinical activity indexes (175-177) can be an epiphenomenon 
of the acute phase response that accompanies chronic inflammatory conditions, malignancy 
and infection. Reduced serum levels of micronutrients are often used to define deficiency 
states, but these levels may correlate better with markers of disease activity and 
inflammation rather than being reflective of body tissue stores or functional deficits (178). A 
prime example of this is the perturbation in trace elements and vitamin concentrations in 
patients with cancer of the colon which can be partially reversed by anti-inflammatory 
treatment, without supplementation (179). 
 
1.3.7. Principal causes of malnutrition in IBD 
The aetiology of malnutrition in IBD is multifactorial as are its manifestations. Poor diet, 
increased energy needs, altered metabolism, malabsorption, excessive GI losses and 
nutrient-drug interactions are among the major causes (Table 1.3.1).   
 48 
 
Table 1.3.3: Major studies assessed systemic levels of micronutrients in patients with IBD.  
Study Age Micronutrients  Results Comments 
ADULTS STUDIES 
Hengstermann 
et al 2008 (80) 
132 quiescent IBD; 35 
active; 45 controls 
Vit C, Vit E, carotenoids, Se, Zn, Cu, Low to control: Vit C, carotenoids No major differences with disease 
activity 
Filippi et al 
2006 (97) 
54 CD remission Vit C, Vit A, Vit D, Vit E, Vit B1, Vit B6, Vit 
B12, Vit E, Folate, Niacin, β-carotene, Fe, 
Cu, Ca, P, Mg, Zn,  
Low to reference: Vit C, Cu, Niacin, Zn, 
Fe, B6, B1, B12, Folate, b-carotene, Vit E 
 
D’Odorico et al 
2001 (147)  
83 IBD; 386 controls Vit A, Vit E, carotenoids Low to control: Vit A, Vit E, some 
carotenoids, no disease type effect, 
Difference between active & inactive; 
disease activity was negatively 
associated with carotenoids 
Oxidative DNA damage was 
increased in IBD; no association 
between impaired oxidative status & 
disease activity; Malnourished lower 
antioxidants than well nourished 
Wendland et 
al 2001 (146) 
37 CD; 37 controls Vit C, Vit E, carotenoids, GSHPx, Se Low to control: Vit C, Carotenoids No association with disease activity; 
Some inversely correlated with 
inflammatory markers; lipid 
peroxidation markers did not 
correlated with disease activity; 
Some carotenoids associated with 
lipid peroxidation  
Geerling et al 
2000 (99) 
69 new IBD; 69 controls Vit A, Vit E, Vit C, β-carotene, Mg, B1, B12, 
Folate, Cu, Zn, Se, GSHPx 
Low to control: UC: β-carotene, Mg, Se, 
Zn lower in UC; CD low B12 
 
Geerling et al 
1998 (100) 
32 CD in remission; 32 
controls 
Vit A, Vit E, Vit C, β-carotene, Mg, B1, B12, 
Folate, Cu, Zn, Se, GSHPx 
Low to control: β-carotene, Vit C, Vit E, 
Se, Mg, GSHPx, Zn, Vit D  
No difference for Vit E/cholesterol; 
Se associated with % body fat; A 
high proportion at risk of deficiencies 
Kuroki et al 
1993 (175) 
24 (plus adolescents) 
CD; 24 controls 
A, E, B1, B2, B6, B12, C, Niacin, Biotin, 
Pantothenic acid, Folate,  
Low to control: Vit A, Vit E, B1, B2, B6; 
Folate; High to control: pantothenic acid 
No disease location or activity effect; 
B2 and niacin inversely correlated 
with CDAI 
Fernandez-
Banares et al 
1989 (180) 
23 IBD active ; 89 
controls 
Vit A, β-carotenoid, Vit E, B1, B2, B6, B12, 
Folate, Biotin, Vit C 
Low to control: Vit A, β-carotenoid, 
biotin, folate, Vit C, Vit B1 
Vit E lower in colitis but Vit E: 
Cholesterol normal; B2 lower but B6 
higher in colitis; Vit B12 lower in 
upper GI disease  
 
PAEDIATRIC STUDIES 
Ojuawo & 
Keith 2002 
(181) 
74 new IBD; 40 controls Zn, Se, Cu Low to control: Se, Zn only for CD; Cu 
higher than UC and control 
 
 49 
Levy et al 
2002 (145) 
22 CD & 10 control Retinol, β-carotene, α-tocopherol, γ-
tocopherol 
Low to control: Retinol No difference between active and 
inactive disease 
Bousvaros et 
al 1998 (177)  
97 (plus young adults) 
IBD; 23 control 
Vit A, Vit E Low to reference: 14.4% low Vit A; 
6.2% low Vit E 
Deficiencies more prevalent in active 
CD  
Hoffenberg et 
al 1997 (182)  
24 IBD; 23 controls Vit C, Vit A, Vit E β-carotenoid, γ-
tocopherol, retinol binding protein, 
glutathione, GSHPx, Se 
Low to control: Vit C; High to control: 
GSHPx, Vit E & Vit E/ Cholesterol 
CD compared to control:  high 
glutathione, GSHPx, Vit E; UC 
compared to CD lower Vit A; 
antioxidants inverse correlation with 
anthropometry 
Thomas et al 
1994 (183) 
39 active CD; 86 
controls 
Se, GSHPx in erythrocytes and serum Low to control: 10% low Se, GSHPx 
high in plasma but low in erythrocytes 
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1.3.7.1. Dietary intake  
Poor diet, with suboptimal intake in energy and nutrients, has always been considered the 
key contributor to undernutrition seen in IBD (184). Food aversion to avoid exacerbation of 
GI symptoms and anorexia mediated by the interaction of proinflammatory cytokines with 
appetite hormones (185-187) reduces intake in IBD patients, particularly during the active 
phase of the disease course (184;188). Nevertheless, results from studies that assessed 
dietary intake in IBD patients are conflicting. Some studies reported energy intakes close to 
the national guidelines or to healthy subjects (97;99;100;189) but others did not (87;190). In 
the only paediatric study Thomas et al. (190) showed that children with active CD consumed 
on average 420 kcals less than the intake of their siblings (matched for height, sex and 
weight) whereas for 21%, the energy intake was lower than national recommendations 
compared with 10% in the control group. 
Apart from the adequacy of energy intake there are also good reasons to assume that 
the micronutrient intake of CD patients is impaired despite no obvious differences in the 
energy intake with compared wit the healthy population. Food aversion and elimination diets 
with avoidance of high fibre foods and dairy products (87) may compromise a balanced 
micronutrient intake. Data on micronutrient intake are contradictory and no conclusions can 
be drawn. Some authors reported suboptimal intakes of micronutrients in IBD patients, 
compared with the healthy control and the national recommendations, whereas others failed 
to confirm these findings (Table 1.3.4).  
 
1.3.7.2. Energy requirements and metabolism 
Dietary intake, along with resting metabolic rate, physical activity expenditure and diet-
induced thermogenesis are major components of the energy balance equilibrium. Failure to 
find clear differences in the caloric intake of IBD patients in some studies, and the differences 
in body composition observed in some others, as discussed above (Section 1.3.2), led to 
investigation of the other components of the energy balance equation.   
Results of studies on the basal metabolic needs of patients with IBD are inconsistent 
and no obvious differences have been found with healthy controls (91;97;104). However 
when normalisation of the basic metabolic rate for the amount of FFM was considered, a 
higher basic metabolic rate/FFM ratio was commonly found in CD compared with UC 
patients and healthy controls. This may show that IBD patients may have increased energy 
expenditure per unit of FFM but low lean body mass.  
Several studies on the energy metabolism of patients with IBD found that the non-
protein respiratory quotient was significantly lower in CD compared with UC patients or 
healthy controls suggesting an increased lipid oxidation rate in CD patients that  
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Table 1.3.4: Major studies assessed dietary intake of micronutrients in patients with IBD 
Study Subjects  Design Results 
ADULT STUDIES 
Aghdassi et al 
2007 (189) 
74 CD  7d diet records Low to recommendations: Vit A, Vit E, Vit D, Vit B1, Vit B2, Vit B6, Vit C, β-
carotenoid, Niacin, Folate, Mg, Ca, Fe, Zn; No difference between active & 
inactive disease 
Guerreiro et al 
2007 (87) 
78 CD mild disease; 80 controls Semi-quant FFQ Lower than controls: Ca, Vit C, Vit D, Vit E, Vit K;  
Lower than controls for recommendations: Ca, Vit A, Vit C, Vit D, Vit E  
Filippi et al 2006 
(97)  
54 CD in remission; 25 controls 3 d diet records Lower than controls:  
       Females: β-carotene, Vit B1, B6, C, Mg; Higher for Zn 
       Males lower β-carotene, Vit C 
Low to controls for recommendations: Zn, β-carotene, Vit B1, Vit B6, Vit C, 
Vit E, Mg 
Geerling et al 
2000 (99) 
69 recent IBD; 69 controls Diet history & FFQ Lower than control: Ca, B2, P in UC; No differences in CD 
Geerling et al 
1998 (100)  
32 CD in remission; 32 controls Diet history & FFQ Lower than control: P 
Lower than controls for recommendations: Vit A 
 
PAEDIATRIC STUDIES 
Thomas et al 
1993 (190) 
24 CD; 17 control siblings 5 d dietary records Lower than Control: Fe, Cu, Zn, Folate, Vit C 
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paralleled the lower FM seen in the former group of patients (91;98;191;192). Al-Jaouni et al 
(193) also found increased fat oxidation in CD patients that correlated positively with disease 
activity.  
Higher diet induced thermogenesis, another small component in the energy balance 
equation, was found in one study (98) which could explain the lower weight and higher risk of 
undernutrition in IBD. Although there was no difference in the resting metabolic rate between 
healthy controls and CD patients, diet induced thermogenesis was higher (6% vs 10% 
respectively). However diametrically opposite results were presented by Al-Jaouni et al (193) 
who additionally found  that diet induced thermogenesis was lower in patients with active 
compared with inactive disease.  
 
1.3.7.3. Malabsorption  
Malabsorption and energy loss due to non-digestion of food or malabsorption of nutrients 
could potentially influence energy balance, and partially explain undernutrition in patients 
with IBD. However, apart from some reports on specific micronutrients (194-197) in patients 
with ileal resection or with bile acid malabsorption, (198), rigorous evidence is lacking to 
support loss of dietary energy or other micronutrients due to malabsorption. Recently a small 
study in Israel (199) found that malabsorption is a major contributor to underweight in adult 
CD patients in remission. The authors found that GI energy excretion was higher in an 
underweight group with CD than in a normal weight group despite no differences between 
the two groups for dietary energy intake or resting metabolic rate. Similarly in another study 
malabsorption and increased faecal fat were observed in severely undernourished patients 
with CD (200). Interestingly, gastric acid and pancreatic enzyme secretion were severely 
impaired in 80% of these patients, which may be linked to the associated malabsorption 
(200). In fact following nutritional rehabilitation, stool fat output and malabsorption reduced 
with concomitant improvements in pancreatic enzyme synthesis, stores and secretion.      
In theory the absorption of specific nutrients should be impaired when the disease is 
located at the site of specific nutrient absorption or the area has been resected. CD patients 
with ileal disease or resection are traditionally susceptible to vitamin B12 deficiency due to 
inadequate absorption (201). Iron absorption may also be diminished in active paediatric CD 
due to the excessive production of hepcidin, a hepatic peptide mediating the absorption of 
iron at the level of the enterocyte (167).   
 
1.3.7.4. Gut losses 
Apart from malabsorption in IBD, loss of nutrients can occur as a result of excessive 
intestinal mucosal sloughing, and through protein enteropathy from the ruptured gut in the 
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acute phase of the disease. Studies using whole gut lavage have shown that disease activity 
was closely paralleled by GI protein loss (202).  
 
1.3.7.5. Drug-nutrient interaction   
Several drugs used in IBD can interfere with the absorption, metabolism and excretion of 
nutrients. Two examples are the antagonistic interaction of methotrexate with folate 
metabolism and the long-term effect of steroids on calcium excretion and bone resorption.  
 
 
1.4. Anaemia in IBD 
Anaemia is one of the potential major nutritional issues in IBD.  The term anaemia originates 
from the Greek word ‘Αναιµία’ meaning without blood and is a deficiency of erythrocytes or 
functional haemoglobin (Hb). This results in a reduced ability of the blood to transfer oxygen 
to the tissues, causing tissue hypoxia.  
There are no universal established guidelines to define anaemia or a lower 
concentration of haemoglobin below which a person is characterised as anaemic. As a result 
the use of different reference range data often classifies the same subject into different 
states (anaemic or non anaemic) (203). The World Health Organization defines anaemia as 
a haemoglobin concentration less than 12 g/dl for non-pregnant women and <13 g/dl for 
adult men, whereas for children different age adjusted cut-offs are proposed (204) (Table 
1.4.1). A haemoglobin concentration below 10 g/dl is commonly described as severe 
anaemia independent of sex and age. 
 
Table 1.4.1: Age and sex adjusted cut-offs for the definition of anaemia according to WHO (204) 
and Dallman et al (205).   
Age or gender group Haemoglobin   
(g/dl) 
 Age or gender group Haemoglobin 
(g/dl) 
 
WHO 
 
 
Dallman et al 1979  
6 to 59 mth 11  0.5-1.9 y 11 
5-11 y 11.5  2-4 y 11 
12-14 y 12  5-7 y 11.5 
Non-pregnant women 
(>15 y) 
12  8-11 12 
Pregnant women 11  12-14    Female 
             Male 
12 
12.5 
Men (>15 y) 13  15-17 Female   
             Male 
 
12 
13 
   18-49 Female 
             Male 
12 
14 
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As the characterisation of the morphology (size, colour, shape) of erythrocytes is 
done with quick and cheap laboratory tests, it offers a starting point for the description of 
anaemia type. RBC can be characterized as microcytic (RBC too small), macrocytic (RBC 
too large), normocytic (normal size), hypochromic (Hb concentration too low), hyperchromic 
(Hb concentration too high), normochromic (Hb concentration normal), and combinations of 
RBC size and Hb concentration (206;207).   
Surrogates for the investigation of suspected anaemia and differentiation of different 
types are: serum ferritin, serum iron, serum transferrin, folate, and vitamin B12. Difficulties in 
diagnosis of anaemia arise when more than one type of anaemia with opposite effects on the 
haematological profile coexist (208). Moreover, as for many haematologically indices (serum 
iron, transferrin, ferritin) serum concentrations can be affected by the acute phase response, 
in various clinical conditions (IBD, malignancies, infection), their diagnostic value and 
interpretation can be ambiguous (209). A prime example of this is when active disease may 
result in a spuriously raised serum ferritin concentration masking an underlying iron 
deficiency caused by GI bleeding and poor dietary intake in IBD. When the diagnosis 
remains obscure, a bone marrow sample allows direct examination of the precursors to red 
cells.  
 
1.4.1. Anaemia in IBD 
Compared with the average awareness of other extraintestinal disease complications such 
as arthritis and nutritional status, the topic of anaemia in IBD receives little attention from 
clinicians. Anaemia is one of the most frequent comorbid conditions in IBD-related mortality 
(210). Overt or occult intestinal bleeding is a major symptom and a drop in haemoglobin 
occurs with each flare up in CD and UC. Anaemia alone or in conjunction with abnormal ESR 
levels demonstrates high positive predictive value for IBD diagnosis and in previous studies 
performed better than serologic antibodies (pANCA and ASCA) (211;212).  
Two predominant types of anaemia have been identified in the context of IBD. Iron 
deficient anaemia (IDA) and the anaemia of chronic disease (ACD), which account for the 
majority of the cases. Anaemias associated with vitamin B12 and folate deficiency, or drug 
associated anaemia due to the long-term use of medication to manage IBD, have 
occasionally been reported but these are uncommon (Table 1.4.2) (213;214). 
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Table 1.4.2: Aetiology of IBD associated anaemia (adapted by Gasche et al. 2007 (215)) 
Common Iron deficient anaemia 
 Anaemia of chronic disease 
 
Occasional 
 
Cobalamin (B12) deficiency 
 Folate deficiency 
 Drug induced anaemia 
 
Exceptional 
 
Haemolysis 
 Myelodysplastic syndrome 
 Aplastic anaemia (often drug induced) 
 Inborn haemoglobinopathies or disorders of erythropoiesis 
 
1.4.1.1. Iron deficient anaemia in IBD 
Iron filings dissolved in vinegar were consumed by the ancient Greeks eager to acquire 
strength, and in 1600 AD iron was noted for its ability to restore “young girls when pallid, 
sickly and lacking colour to health and beauty” (216). Iron has a pivotal role in many 
metabolic processes including haemopoiesis, immunity and energy production, and the 
average adult contains 3-5 g of iron, of which two thirds are incorporated in haemoglobin 
(217). A normal balanced Western diet provides about 12-15 mg of iron daily, of which 5-
10% is absorbed, principally in the duodenum and upper jejunum, where the acidic 
conditions help the absorption of iron in the ferrous form. Absorption is facilitated by the 
presence of other reducing substances, such as HCl and ascorbic acid and inhibited by 
reduction of gastric acidity (eg use of anti-acid) (207;218;219). The body has the capacity to 
increase its iron absorption in the face of increased demands like pregnancy, growth spurt, 
and iron deficiency status and reduce it when iron stores are excessively filled.  
Once absorbed from the bowel, iron is transported across the mucosal cell to the 
bloodstream, where it is carried by the protein transferrin to developing red cells in the bone 
marrow and also to immune and liver cells. Hepatic iron stores comprise ferritin, a labile and 
readily accessible source of iron, and haemosiderin, an insoluble form found predominantly 
in macrophages. About 1 mg of iron a day is shed from the body in urine, faeces, sweat, and 
cells turnover from the skin and the GI tract (220). Menstrual losses of an additional 20 mg a 
month happen in women of reproductive age (208). 
Iron deficient anaemia is classified morphologically as hypochromic and microcytic. In 
chronic iron deficiency the mean cell volume (MCV), mean cell haemoglobin (MCH) and 
mean cell haemoglobin concentration (MCHC) are all reduced compared to the age and 
gender specific reference range. Serum iron, ferritin levels and transferrin saturation are 
reduced too whereas the total iron binding capacity is elevated (218;221) (Table 1.4.3).  
Bone marrow aspirates or biopsies demonstrate micronormoblastic hyperplasia of erythroid 
elements and decrease or absence of stainable iron particularly in macrophages (220;222). 
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Iron deficient anaemia is the major cause of anaemia in IBD, and this is ascribed to a 
negative iron balance from excessive iron loss through GI bleeding, increased epithelial 
sloughing in chronic GI inflammation, reduced dietary intake (223), as well as impairment of 
iron absorption, particularly during the active phase of the disease (167) or when the disease 
is located at the major sites of iron absorption (224).  
As many of the systemic biological markers of the iron body stores are affected by the 
acute phase response, their diagnostic value in IBD is poor and can be misleading (Table 
1.4.3). Decrease in serum iron and downregulation of transferrin is part of the acute phase 
response, causing functional iron deficiency, a state that can be misinterpreted as iron 
deficiency in a patient with active inflammation (209). On the other hand inflammation can 
cause false elevation of ferritin levels bringing ferritin levels of patients with true iron 
deficiency into the normal range (225). As a result higher cut offs have been proposed for 
ferritin in active IBD and evaluation in conjunction with other haematological parameters to 
detect iron depleted anaemic patients (215;226). Determination of serum transferrin receptor 
has been proposed as a diagnostic marker to distinguish IDA from other types of anaemia in 
IBD (227;228). This soluble transferrin receptor is elevated in iron deficiency and high rate 
erythropoiesis, whereas it is slightly low to normal in ACD providing a reliable marker to 
distinguish between IDA and other types of anaemia in IBD such as ACD (228). 
  
1.4.1.2. Anaemia of chronic disease 
The production of inflammatory cytokines in chronic inflammation, and malignancy has 
significant systemic effects including impaired haemopoiesis, and manifestation of ACD 
(216). Anaemia of chronic disease is second only to IDA in IBD (215;229).   
Anaemia of chronic disease is refractory to the use of iron supplementation and is 
usually characterized by a moderate reduction in haemoglobin whereas the erythrocytes 
morphology is normal although slight hypochromia and moderate microcytosis can also be 
present (216). In contrast to IDA the total iron binding capacity is reduced or unchanged and 
the serum ferritin level is increased (Table 1.4.3). Bone marrow aspirates often show 
micronormoblastic hyperplasia with increased iron depots and a decrease in the number of 
iron containing erythroblasts (222). The measurement of the soluble form of transferrin 
receptor in serum may be an alternative to differentiate ACD from other types of anaemia 
and particularly IDA as described above (216;230). 
The pathogenesis of ACD is not fully understood but recent evidence suggests this is 
immune driven and mediated by the action of inflammatory cytokines (231;232). Cytokines 
(IFN-γ, IL-10, TNF-ɑ) and cells of the reticuloendothelial system induce changes in iron 
absorption (167), iron metabolism (insufficient iron release from reticuloendothelial cells), the 
proliferation of erythroid progenitor cells, the production of erythropoietin, and the life span of 
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red cells, all of which contribute to the pathogenesis of anaemia (231;232). Treatment of 
ACD is controversial and there is no universally accepted approach. The primary aim 
includes resolution of the inflammatory process, and downregulation of the expression of 
inflammatory cytokines. Use of human recombinant erythropoietin in conjunction with iron 
supplementation has been tested successfully in IBD studies (233-235).      
 
Table 1.4.3: Characteristics and differences of the haematological presentation of IDA and ACD 
in IBD (adapted from Weiss 2005 (231)) 
 Iron deficient anaemia Anaemia of chronic disease 
RBC colour (MCH) Hypochromic Normo or slightly hypochromic  
RBC size (MCV) Microcytic Norma or slightly microcytic 
Plasma iron Very Low  Low 
Transferrin High Low 
Transferrin saturation Low Low 
Total iron binding capacity High (decrease in active 
inflammation) 
Low 
Ferritin Low (increase in active 
inflammation) 
Normal to High 
Erythrocyte 
protoporphyrin 
High High 
Serum transferrin receptor High Normal 
 
1.4.1.3. Megaloblastic anaemias (Vit B12 and folate deficiency) 
Folate and vitamin B12 deficiency cause megaloblastic anaemia and the latter pernicious 
anaemia. Morphologically megaloblastic anaemias are characterized by large immature 
dysfunctional RBC (macrocytic) and are confirmed diagnostically by low serum levels of B12 
and folate. Raised homocysteine concentrations are observed in folate and B12 deficiency 
and can also be used diagnostically. A bone marrow examination is usually performed to 
confirm megaloblastic hyperplasia. 
 
Vitamin B12 deficient anaemia 
Vitamin B12 is involved as an enzyme cofactor in a number of biochemical reactions and the 
synthesis of certain nucleic acids. In a state of B12 deficiency DNA replication is disturbed 
and nuclear maturation is arrested resulting in abnormally large dysfunctional red blood cells 
(megaloblasts) and anaemia onset. Reticulocyte counts are low and aspiration of bone 
marrow shows upregulated cell proliferation with characteristic megaloblastic abnormalities 
such as enlarged erythroid lineage cells. An increased MCV in conjunction with decreased 
vitamin B12 levels are characteristic of B12 associated megalobIastic anaemia. With a daily 
requirement for vitamin B12 of 1-3 µg and body stores of 5 mg clinical manifestation of B12 
deficiency occurs late.  
Formation of a protective complex with intrinsic factor produced by the gastric parietal 
cells is necessary for the absorption of vitamin in the terminal ileum. Any condition that alters 
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intrinsic factor production, such as inflammation of the gastric mucosa or malignancy, may 
interfere with the supply of vitamin B12. Similarly as B12 absorption takes place in the terminal 
ileum, patients with active disease at this site or those who had their terminal ileum resected  
may have increased risk of developing B12 deficiency (236). Regular monitoring of the B12 
status of these patients has been suggested (215). 
 
Folate deficient anaemia 
Natural folates (237) are largely found in the polyglutamate form, and these are absorbed in 
the duodenum and jejunum after deconjugation and conversion to the monoglutamate 5-
methyl tetrahydrofolate. On average 50-60% of dietary folate is absorbed. Similar to B12, 
folate participates in the synthesis of certain nucleic acids, and a deficit status presents the 
same hematologic findings as vitamin B12 with macrocytic anaemia. An inadequate diet, 
impaired absorption, or both usually cause folate deficiency. Of great concern are patients on 
medication with antagonists of folate metabolism or absorption. A prime example in 
gastroenterology is the patients on sulfasalazine, and the effect of the latter on the 
absorption of folate, as well as those on methrotrexate, an immunosuppressive agent, which 
interferes with the normal metabolism of folate. Diagnosis is based on macrocytic red blood 
cell maturation, as well as decreased serum or red blood cell folate levels. In combined iron 
and folate deficiency, the red blood cell folate level can be normal and the megaloblastic 
changes in erythroid cells may be obscured.  
 
1.4.1.4. Drug induced anaemia in IBD 
Long-term use of specific medication in chronic illness can interfere with normal 
haemopoiesis and subsequently lead to anaemia. Drugs used in the treatment of IBD, such 
as sulphasalazine, and methotrexate, can be associated with development of macrocytic 
anaemia attributed to secondary deficiency of folic acid. Prophylactic folic acid 
supplementation in these patients is recommended although as sulfasalazine has been 
commonly replaced by mesalazine, any drug interaction with folate lacks clinical relevance.  
Azathioprine can cause myelosuppresion although nowadays monitoring of the bone 
marrow function by continuous blood monitoring protocols and the exclusion of use in 
patients with thiopurine methyltransferase deficiency has limited its incidence. Increase of 
MCV accompanies long term therapy with azathioprine  (238) and is commonly used as 
marker of drug efficacy and compliance although it may also obstruct the early recognition of 
IDA (236).  
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1.4.2. Clinical consequences of anaemia 
Since all human cells, tissues and organs depend on oxygen supply, anaemia onset is 
accompanied by a wide variety of clinical consequences. Significant determinants of the 
clinical picture of an anaemic patient are the type of anaemia and its degree. Commonly 
patients with mild anaemia develop pallor, headaches, dizziness, weakness or fatigue and 
poor concentration, whereas in more severe conditions shortness of breath and tachycardia 
are often reported. Angular stomatitis, finger clubbing, pica (consumption of non-food such 
as dirt, paper, wax, grass and hair) are signs of severe iron deficiency. Glossitis, neural tube 
defects and neuropathy are signs of folate and B12 deficiency. In megaloblastic anaemia due 
to folate deficiency central nervous system symptoms are not present in contrast to B12 
deficiency. Folate supplementation may improve the (reversible) haematologic symptoms of 
megaloblastic anaemia even if they are caused by vitamin B12 deficiency, but does not stop 
progression of the (partially irreversible) neurologic manifestations of vitamin B12 deficiency. 
Therefore it is indicated that folate supplementation in deficient patients be accompanied by 
B12 substitution to avoid masking of B12 deficiency by improvement of the haematologic 
presentation on folate replenishment.  
Anaemia impairs cognitive function and reduces quality of life (239) confirmed in 
studies where resolution of anaemia was accompanied by improvement in quality of life 
(240). For a long time it was thought that the clinical symptoms of anaemia occurred only 
when the haemoglobin level dropped abruptly as it had been suggested that patients would 
adapt to low haemoglobin levels if anaemia developed slowly. This has led to the concept of 
asymptomatic anaemia. However it was later shown that the process of adaptation to chronic 
anaemia was in fact adaptation to lower quality of life and that this could be reversed. 
 
Table 1.4.4: Main therapeutic approaches in the management of anaemia in IBD 
Type of anaemia Therapy 
Iron deficient anaemia Diet rich in iron 
 Oral iron supplementation  
 Intravenous iron infusion 
 Recombinant erythropoietin 
 
Nutritional anaemias Diet rich in micronutrients (B12 & folate) 
 Oral folate supplementation 
 Intramuscular B12 injection 
 
Anaemia of chronic disease Recombinant erythropoetin & oral/intravenous iron  
Excessive bleeding/Very low haemoglobin Blood donor transfusion  
 
1.4.3. Treatment of anaemia with particular reference to IBD 
Guidelines on the diagnosis and management of iron deficiency and anaemia in IBD have 
recently been published, without however distinguishing between adults and paediatric 
 60 
patients (215). For the treatment of anaemia it is not only important to identify the type and 
the severity of the anaemia but also the nature of the anaemia so that therapy can be 
targeted at the underlying mechanism and be adjusted to the patient’s needs.  
With the advent of new more effective medication, that makes mucosal healing 
possible (90) or affects the inflammatory cascade at the initial step, a lower prevalence of 
anaemia may be anticipated. However such a theoretical approach has not been tested in 
clinical trials. In an anaemic patient in the active phase of disease the treatment of the 
underlying condition should be the primary target before any attempt to correct anaemia. 
This is particularly important in the management of ACD where the inflammatory response is 
the major contributor to the aetiology of ACD. The choice of treatment depends on the 
degree of anaemia. Gasche et al proposed a therapeutic algorithm in IBD associated 
anaemia together with consensus guidelines without however distinguishing between adult 
and paediatric patients (215). The main therapeutic approaches in the management of 
anaemia in IBD are outlined in Table 1.4.4. 
 
1.4.4. Review of the studies on prevalence and predictors of 
anaemia in IBD 
An extensive literature search was carried out, using Pubmed and searching the reference 
lists of original papers and reviews providing information on the prevalence of anaemia in 
IBD. Adult studies were excluded, as the primary scope of this review was to evaluate the 
prevalence of anaemia only in children with IBD.  
Overall nine original articles and one study published in abstract form reported the 
prevalence of anaemia in paediatric IBD. Two systematic reviews including mainly adult 
studies (229;236) described in total four of these paediatric studies. In two other studies, 
measurements of haemoglobin were carried out and mean values were reported without 
reference to the overall prevalence of anaemia (20;83). 
All but two studies were conducted in North America (Table 1.4.5); one study with 32 
UC children in Europe (237), and one from Israel (228). Most studies measured anaemia in 
children younger than 18 years. Three studies expanded their inclusion criteria to young 
adults (228;241;242). The sample size varied from 11-526 children with only one reporting 
prevalence of anaemia in over 100 patients (243).  
The definition of anaemia within the studies varied remarkably. All but two (241;242) 
used haemoglobin measurements to define anaemia, two used haematocrit cut offs 
(241;242), and in another (244), no definition of anaemia was given. The lower haemoglobin 
cut offs to distinguish between anaemic and non anaemic patients ranged from 10.5 to 13 
mg /dl. All but three studies used generic cut offs to define anaemia in both girls and boys 
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whereas three studies used age adapted thresholds, as age related changes in haematologic 
indices are well recognized (221). All but two studies assessed anaemia close to the time of 
diagnosis. One study enrolled only patients with severe colitis (Table 1.4.5). 
On the whole the prevalence of anaemia in paediatric IBD ranged between 41% and 
88%. A mean estimate cannot be drawn. Neither can temporal changes be evaluated due to 
differences in the definition of anaemia between studies (245). Compared with the two 
systematic reviews which reported studies in mainly adult patients, prevalence of anaemia in 
children overall is reported to be higher. Wilson et al (229) estimated the prevalence of 
anaemia to be between 6-74% numerically lower than the range reported in the paediatric 
studies reviewed.      
As documentation of anaemia was usually a secondary outcome in most of the 
paediatric studies only a few authors linked anaemia with disease and sociodemographic 
characteristics. Mack and his colleagues (243) showed that anaemia was associated with 
severity of disease activity. They observed that anaemia was more common in patients with 
severe disease than those with mild disease activity. The same group showed that in young 
patients (6-11 y) with severe disease, haemoglobin concentration was higher in CD than in 
UC (p< 0.006). No such difference was observed for the older group of children (≥ 12 y) or 
for children with mild or moderate disease. A negative association between haematocrit 
levels and disease activity has been described previously for CD patients particularly those 
who had isolated disease in the small intestine (246). Although Weinstein et al. (83) did not 
report the prevalence of anaemia, they found that mean haemoglobin concentration was 
lower in CD than UC, a finding that was more marked in the older group of patients (≥ 11 y). 
No such difference in the mean haemoglobin concentration was found between UC and CD 
in a state population based study in the United States (20). In a study published in abstract 
form only, Thayu et al (247) measured prevalence of anaemia in paediatric CD and tried to 
identify disease predictors associated with it. Anaemic patients had higher values of PCDAI 
and ESR than non-anaemic patients and the presence of upper GI tract disease was 
significantly associated with anaemia. Gender, duration of symptoms, body composition, or 
growth parameters were not predictors of anaemia.  
Similar data from adult studies suggested an association between the presence of 
anaemia and high scores on the disease activity indices (214;235). Schreiber (235) found 
that anaemia was more common in CD than in UC patients whereas in a study from Israel, 
that accounted for the prevalence of anaemia by sex, the prevalence of anaemia was higher 
in women than in men (66.6% vs. 27.5% respectively) (248). Reilly (249) in a study of the 
impact of parenteral nutrition on clinical outcome found that the prevalence of anaemia was 
lower in CD patients with only small bowel involvement (33.3%) than in patients with disease 
involving the large bowel with or without small bowel. In contrast, RBC, haemoglobin and 
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anaemia were lower in patients with ileocolitis than in patients with small intestine 
involvement in a Japanese cohort of CD patients (250). Undernourished patients were more 
likely to be anaemic than well-nourished CD patients in another study (251).  
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Table 1.4.5: Studies that measured the prevalence of anaemia in paediatric IBD 
Study Country Age n (Male) Disease Definition of anaemia Prevalence of 
anaemia Predictors of anaemia Comments 
Mack et al 2007 (243) US & 
Canada 
<16 526 (310) 392 CD < 6 y;    Hb<11 
6-11 y;  Hb<11.5 
>11 y;   F: <12 
                M: <13 
68% Severe disease; In 6-11 
y group with severe 
disease Hb was lower 
in UC than CD  
 
Howarth et al 2007 
(252) 
UK <16 32 (11) 32 UC Hb < 12 62.5% N/A  
Khan et al 2002 (211) US ≤18 90 (45) 51 UC 1-10 y; Hb<10.5 
>10 y; Hb <11.5 
41% N/A  
Thomas & Sinatra 
1989 (253) 
US ≤18 24 (17) 24 CD Hb < 12  71% N/A  
Beeken 1979 (254) US 8-21 11 (8)  11 CD Hct < 36 72.7% N/A Did not 
measure 
anaemia at 
diagnosis 
Burbige et al 1975 
(213) 
US <16 58 (37) 58 CD Hb < 11 51.7% N/A  
Revel-Vilk et al 2000 
(228)  
Israel 9-22 63 (34) 5 CD MCV < 77 fl 
F: Hb < 12; Ferritin < 6 µg/l  
M: Hb < 12.5; Ferritin < 23 
µg/l  
 
 
41.3% 
11 IDA 
15 ACD 
N/A Did not 
measure 
anaemia at 
diagnosis 
Werlin & Grand 1977 
(242)  
US 6-20 19 (8) 5 CD 
 Hct ≤ 30 73.7% N/A New and 
patients with 
long-standing 
disease; Only 
with severe 
colitis 
Thayu et al 2005 (247) US 5-18 78 (44) 78 CD <5 centile for age & sex 77% High PCDAI and ESR; 
Upper GI disease 
involvement 
 
Gryboski 1994 (244)  US ≤10 N/A 40 CD N/A 75% CD; 
88.4% UC 
Upper GI disease 
involvement 
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1.4.5. Conclusion 
The prevalence of anaemia in paediatric IBD is not well documented and the evidence 
comes from a limited number of studies with methodological flaws. Most studies included 
small sample sizes with only one study documenting the prevalence of anaemia in more than 
100 patients. The definition of anaemia between the studies is heterogeneous and does not 
allow a direct comparison between the studies or assessment of secular trends in anaemia 
prevalence. Indeed the prevalence of anaemia in most of the current studies was a 
secondary outcome rather than a primary aim, and may have resulted in unrepresentative 
selective groups of patients that does not allow the extrapolation and generalization of 
findings. Thus the need of population based studies measuring anaemia at diagnosis before 
medical treatment has been applied is necessary to appropriately characterise prevalence 
and determinants of anaemia in paediatric IBD.   
There is a lack of evidence on factors that might predispose to anaemia. Knowledge 
of this could help tackle the development of anaemia at an early stage. In light of new 
consensus guidelines on the categorization of disease location and behaviour new studies 
should be conducted to address whether disease phenotype favours anaemia. 
Undernutrition, growth faltering or demographics may also differ between anaemic and non 
anaemic IBD patients and should be investigated further.   
To the best of our knowledge no study has measured the outcome and prognosis of 
anaemia during the natural history of the disease. As new treatments are now available 
which achieve mucosal healing (90) and tackle inflammatory cascade activation at the initial 
stages, temporal changes in the prevalence of anaemia and lower incidence at follow up 
should be expected. In particular possible association with specific treatment modalities 
deserves to be studied further.  Such a study is described in Chapter 6 of this thesis. 
 
 
1.5. Nutritional therapy in IBD 
 
“Now to perform a true physician’s part, and show I am perfect master 
of my art, I will prescribe what diet you should use, what food you 
ought to take and what refuse. –Ovid 43 BC” 
 
It is very attractive for the health professional to propose that he/she can improve the 
patient’s condition by dietary manipulation. In contrast to coeliac disease, where the mucosal 
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lesion resolves with restriction of dietary gluten, the role of dietary treatment in IBD 
management is more complicated and controversial.  
In paediatric CD the main focus of the dietetic intervention is on the artificial 
nutritional therapy which is defined as the provision of nutrients and energy in an artificial 
liquid food supplement. These can be administered orally, or when this is not possible 
intranasally through a nasogastric tube, or a stoma in the GI tract, for long-term nutritional 
support.  
Artificial nutritional therapies can be classified by the nitrogen source; derived from 
either amino acids or intact protein component. Elemental feeds are developed by mixing 
single amino acids with other simple nutrient sources, are entirely free of dietary antigens 
and are commonly used in patients with food allergies. Semi-elemental feeds contain small 
oligopeptides (protein hydrosylates) and present less antigenic load than polymeric feeds, 
which contain whole protein. The protein comes predominantly from milk but also from egg 
and soya. Polymeric feeds are more palatable and cheaper than the other two forms and 
reduce the need for NG administration (255). In this thesis, wherever nutritional therapy is 
referred to it implies only artificial nutritional support unless otherwise stated. 
This section is a concise review of the role of nutritional therapy in the management 
of IBD with a particular focus on the evidence in paediatric CD. The role of EEN in the 
induction of disease remission and nutritional rehabilitation in active paediatric CD is 
discussed in detail as is the evidence for mechanisms of action.  Using subject specific 
keywords in Pubmed, more than 200 primary sources of evidence were retrieved on the 
nutritional management of CD. All the paediatric studies were reviewed and appropriate 
reference will be made to adult studies when evidence specific to children is scarce. Studies 
on the effect of EN on micronutrient status, and intestinal microbiota in IBD are described 
separately in the text in more detail. A summary of the paediatric studies on nutritional 
management of IBD is displayed in the evidence Table 1.5.1.   
 
1.5.1. Nutritional therapy and disease activity in IBD 
Nutritional support in the form of EEN, or rarely as total parenteral nutrition, is the 
mainstream treatment for induction of clinical remission in active paediatric CD in the UK, 
although different patterns of use are reported worldwide (256). In a survey of practice 
patterns 62% of western European paediatric gastroenterologists reported use of nutritional 
therapy compared with only 4% of their North American colleagues, who preferred 
corticosteroid use (256). It is noteworthy that EEN was not even mentioned in a recent state 
of the art North American review on treatment options in paediatric CD (257). 
 
 66 
Table 1.5.1: Evidence table of all paediatric studies on the nutritional therapy in paediatric IBD 
Study Aim Treatment Patients Outcomes Results Comments 
Rodrigues 
et al 2007 
(255)  
Comparison 
between ED & PD 
on compliance, 
remission effect, 
use of NG tube, 
use of EEN on 
subsequent relapse 
Retrospective; 
EEN (PD or 
ED); 6 wk 
98 with active 
disease newly 
diagnosed 
% remission rate; 
compliance rate; 
use of NG tube; 
reuse of EEN for 
subsequent relapse 
No difference in any of the 
outcome apart from the use 
of NG that was lower in PD  
Remission rate: 64% for 
ED and 51% for PD (ns) 
Day et al 
2006 (258)  
Effect of EEN on 
disease activity 
Retrospective; 
EEN (PD); 6-8 
wk, some 
continued on 
supplementary 
feeds 
27 with active 
disease; newly 
diagnosed and with 
longstanding disease 
CA; inflammatory 
markers 
89% completed their EEN 
course; no association 
between efficacy with 
disease location; most 
children improved within the 
first 4 wk; wt increased but 
in less degree in non 
responders 
Remission rate better in 
new than long-standing 
disease; Cs sparing effect 
from EEN; Long remission 
on follow up; CA 
improved; Inflammatory 
markers improved 
Borrelli et 
al 2006 
(259)  
Comparison 
between EEN & Cs 
on mucosal healing 
RCT; EEN 
(PD); 10 wk vs 
Cs 
37 children (19 EEN) CA; histology; 
endoscopy; 
mucosal healing; 
albumin, CRP, 
ESR; 
anthropometry; 
side effects 
No difference in clinical 
remission between EEN & 
Cs (79% vs 67%); CRP, 
ESR and albumin improved 
towards reference; No 
difference for Ht; Wt gain 
higher in EEN; less side 
effects in EEN (23%) vs Cs 
(67%) 
14/19 in EEN vs 6/18 in 
the Cs showed mucosal 
healing; Only children on 
EEN presented 
improvement in histologic 
and endoscopic healing; 
good response for both 
colonic and ileal; well 
designed study; no 
concomitant treatment 
Johnson 
et al 2006 
(260) 
Effect or EEN and 
partial EN on 
disease activity 
RCT; EEN (ED 
or partial EN 
(50% ED & 
normal diet)); 6 
wk 
50 with active 
disease 
CA; anthropometry; 
skinfolds; CRP; 
ESR; Hb; platelets; 
albumin 
Remission in partial EN 
was 15% vs 42% in EEN; 
Only in EEN improvement 
of serum inflammatory 
markers, albumin, ESR and 
diarrhoea 
Skinfolds improved; no 
difference between 
formulas 
Berni-
Canani et 
al 2006 
(261) 
Effect of EEN on 
disease activity 
(short and long 
term efficacy) 
Retrospective, 
EEN (PD, SED, 
ED) vs Cs; 8 
wk 
47 newly diagnosed 
with active disease 
(37 on EEN & 10 on 
Cs) 
CA; endoscopy; 
albumin; iron; 
histology; % 
relapse in 1y follow 
up 
86.5% achieved remission; 
CA reduced in all groups; 
Endoscopic and histology 
improvement more 
pronounced in EEN (no 
difference between type of 
Duration of clinical 
remission longer in EEN 
than in Cs; wt increased 
by 12% but no difference 
between EEN and Cs; Ht 
gain higher in EEN than in 
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EEN); 7 children on EEN 
achieved histological 
remission but none in Cs; 
albumin and iron status 
improved in EEN  
Cs; 90% reported adverse 
effects on Cs whereas 
32.4% in EEN 
Gavin et al 
2005 (262) 
Energy intake in 
EEN 
EEN (PD-
Modulen); 6-8 
wk 
40 with active 
disease 
CA; anthropometry; 
% of recommended 
dietary intake  
CRP decreased (78% less 
than 2mg/l); median wt 
increase 11%; energy 
intake in 82% of patients 
was around 118% of EAR; 
low BMI SDS at start was 
correlated with more wt 
gain 
No disease site effect on 
remission rate 
Knight et 
al 2005 
(263)  
Effect of EEN on 
short and long term 
outcome 
 (ED and 4 
PD); 8 wk EEN 
44 with active 
disease 
CA; albumin; CRP; 
time to relapse 
90% achieved remission; 
62% relapsed within a y; 
EEN postponed Cs use for 
68 wk; 
No disease site effect on 
remission rate but colonic 
a trend to relapse earlier 
Afzal et al 
2005 (264) 
Efficacy of EEN on 
disease activity; 
Association with 
disease location 
EEN (PD); 8 wk 65 with active 
disease 
CA; histology; 
endoscopy 
Remission rate lower in 
colonic than disease 
involving ileum; CA 
improvement was better in 
disease involving the ileum; 
endoscopy and histology 
improved only in disease 
involving ileum 
 
Afzal et al 
2004 (265) 
Effect of EEN on 
disease activity; 
Association 
between quality of 
life and mucosal 
healing 
 
 
EEN (PD); 8 wk  26 with active 
disease 
CA; quality of life ; 
endoscopy; 
histology;  
88.5% in remission; quality 
of life improved; histology 
and endoscopy improved; 
endoscopic or histological 
findings did not correlate 
with quality of life 
 
Ludvigsso
n et al 
2004 (266)  
Comparison of ED 
vs PD on disease 
activity 
Multicenter 
RCT; 6 wk  
31 with active 
disease 
CA; remission rates No difference in remission 
rates; 69% in ED vs 82% 
PD achieved remission; no 
difference in disease 
improvement between new 
and old CD patients; no 
Higher wt gain in PD; 
patients had either quick 
(within 2 wk) or delayed 
(up to 6 wk) response 
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association with disease 
location 
Bannerjee 
et al 2004 
(267)  
Effect of EEN on 
inflammatory 
markers, growth 
stimulating markers 
and nutritional 
restitution 
EEN (PD); 6 wk  12 with active 
disease 
CA; anthropometry; 
skinfolds; CRP; 
ESR; IL-6; IGF-1; 
IGFBP-3; leptin,  
ESR, IL-6 improved to 
normal by d 3; CA, CRP, 
IGF-1 improved by d 7; wt, 
skinfolds, leptin, improved 
later after 14-21 d 
Body composition markers 
measured not so sensitive 
to acute change as 
inflammatory and growth 
markers; anti-inflammatory 
and growth effects 
preceded nutritional status 
markers  
Cameron 
& 
Middleton 
2003 (268) 
Effect of ED on 
orofacial CD  
Case report; 
ED 
Case report Disease improved 
within 2 d 
  
Akobeng  
et al 2002 
(269) 
Effect of EEN (low 
or high in 
glutamine) on IGF-
1  
DBRCT; EEN 
(ED); 2 types of 
ED (high & low 
in glutamine); 4 
wk 
15 with active 
disease 
IGF-1; 
anthropometry; 
MAC 
IGF-1 was low at baseline 
and did not differ at the end 
of the study; proportionally 
more children on low 
glutamine presented 
increase in IGF-1 compared 
with the high glutamine 
feeds  
MAC, and anthropometry 
improved only in the low 
glutamine group 
Akobeng 
et al 2000 
(270)  
Effect of EEN (low 
or high in 
glutamine) on 
disease activity 
DBRCT; EEN 
(ED high and 
low in 
glutamine) 4 wk 
18 with active 
disease 
CA; orosomucoid; 
platelets; ESR; 
abumin 
Not difference in remission 
rates (55.5% in normal vs 
44.4% in glutamine 
enriched); Improvement of 
CA was better in low than in 
high glutamine EEN 
 
Fell et al 
2000 (90)  
Effect of EEN on 
mucosal healing 
and mucosal 
inflammatory 
markers 
EEN (PD); 8 wk 29 with active 
disease 
CA; anthropometry; 
CRP; TNF-α; 
mucosal levels of 
IL-1β, IL-8, IL-10, 
INF-γ, TGF-β1; 
endoscopy; 
histology 
79% in remission; CA, 
CRP, TNF-α decreased; wt 
increased; histology and 
endoscopy improved; IL-1β, 
IL-8, INF-γ decreased after 
treatment; TGF-β1 
increased  
In TI, histologic 
improvement was 
observed in 13/20; colonic 
improvement was 
observed in 12/25; 
Complete healing 
occurred in 8 and 2 cases 
with TI and colonic 
disease respectively.   
Beattie et 
al 1998 
Effect of EEN on 
growth 
EEN; PD; 8 wk 
plus two mth on 
14 with active 
disease 
CA; IGF-1; IGFBP-
3; anthropometry; 
Wt increased, but not ht; 
skinfolds unchanged; CRP 
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(271)  supplementary 
feeds 
skinfolds, CRP decreased within two wk; 
IGF-1 & IGFBP-3 increased 
Azcue et 
al 1997 
(104) 
Effect on EEN on 
body composition 
and energy 
expenditure 
EEN (ED) vs 
Cs; 4 wk  
24 children with 
active CD, 19 
anorexic, 22 healthy 
controls 
Body composition 
(double labelled 
water, BIA, total 
body K, extra and 
intracellular water 
with bromide 
dilution); REE with 
indirect calorimetric 
All body composition 
parameters improved in 
EEN; REE increased also 
in EEN; ht increased only in 
EEN 
Intracellular water and 
lean mass accretion were 
significantly higher 
in the EEN than in the 
prednisolone group; 
patients on Cs trend for 
higher FM at the end of 
treatment 
 
Khoshoo 
et al 1996 
(272) 
Comparison 
between low and 
high fat EEN on 
disease activity 
Crossover 
RCT; EEN; 
SED (high fat 
vs low fat); 
6wks 
14 adolescents  CA (PCDAI); 
skinfolds; body 
composition with 
bioimpedance 
No difference between the 
formulas; improvement on 
body composition & 
skinfolds; improvement in 
CA 
Patients on concomitant 
medication (Cs, 
antibiotics, 5-ASAs); Cs 
requirements decreased 
Wilschans
ki et al 
1996 (273) 
Effect of 
supplementary 
feeds following 
EEN on 
maintenance of 
remission 
EEN; (ED or 
SED) followed 
by nocturnal or 
not 
supplementary 
feeds 
65 with active 
disease 
CA (PCDAI); Hb, 
ESR; albumin; 
anthropometry 
CA, ESR reduced; 
haemoglobin and albumin 
improved; less patients 
relapsed in supplementary 
feeds; growth velocity 
improved with EEN 
compared with previous y 
and ht velocity higher in 
supplemented group  
72% got in remission; 60% 
relapsed within 12 mth 
Papadopo
ulou et al 
1995 (274) 
Comparison 
between Cs & EEN 
on disease activity 
EEN; ED vs Cs 
(historical 
control); 6 wk  
58 (30 on EEN) CA; anthropometry CA improved in both 
treatments; Disease 
improvement better on ED; 
patients with proximal 
disease had longer 
remission period; ht 
improvement was better in 
EEN than Cs; albumin and 
Hb improved in EEN but not 
on Cs 
 
Breese et 
al 1995 
(275)   
Effect of EEN on 
immunological 
response  
EEN (ED&PD) 
vs Cs vs 
cyclosporine; 8 
wk 
18 (6 on EEN) with 
small intestine 
involvement 
% lymphokine 
secreting cells that 
produce IL-2 & INF-
γ; histology 
Mucosal healing improved 
in EEN but not in Cs; % 
lymphokine secreting cells 
that produce IL-2 & INF-γ 
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reduced 
Beattie et 
al 1994 
(276)  
Effect of EEN on 
disease activity 
Case series; 
EEN; PD 
(Nestle TGF-
beta2); 8 wk 
7 with small bowel; 
newly diagnosed 
CA; CRP, ESR, 
anthropometry; 
histology 
CRP, ESR decreased; wt 
increased; CA decreased; 
ht velocity improved; 
histology improved in 6/7; 
2/7 relapsed in 1 y 
 
Ruuska et 
al 1994 
(277)  
Comparison 
between Cs & EEN 
on disease activity 
RCT; EEN (PD) 
vs Cs; 8 wk 
exclusively and 
PEN for 
following 3 wk 
19 with active 
disease 
CA; CRP; ESR; Hb; 
IgG; IgA; 
Prealbumin; Iron 
No difference in remission 
rates, CRP, IgG, IgA, 
prealbumin, iron; more 
patients on EEN remained 
in remission at follow up 
CA reduced, improved 
within two wk of treatment 
initiation; Wt increased the 
first 4 wk and remained 
stable then after 
Thomas et 
al 1993 
(190) 
Comparison of 
EEN vs Cs 
RCT; EEN; ED; 
4 wk 
24 with active 
disease (12 EEN) 
CA; anthropometry CA reduced in both 
treatments; no difference 
between treatments; ht 
velocity improved only in 
EEN; no difference with 
disease location 
 
Thomas et 
al 1993 
(278) 
Effect of EEN & Cs 
on IGF-1 and 
IGFBP-1 
RCT; EEN (ED) 
vs Cs & 
sulphasalazine; 
4 wk 
29 (13 on EEN) with 
active disease 
IGF-1; IGFBP-1; 
anthropometry 
IGF-1 increased in both 
treatments; higher increase 
in Cs; IGFBP-1 decreased 
only in Cs; ht velocity was 
greater in EEN than in Cs  
EEN improved growth 
despite higher increase of 
dietary intake in Cs; 
Perhaps Cs over-ride the 
benefits from increased 
energy intake, IGF-1 and 
reduced IGFBP-1 
Polk et al 
1992 (279)  
Effect of 
intermittent EEN on 
growth and disease 
activity  
One mth of 
EEN (ED) 
followed by 2 
wk of exclusion 
and low fibre 
diet and then 2 
mth on free diet 
6 with growth failure 
(only one patient with 
active disease) 
CA; anthropometry; 
IGF-1; albumin; 
skinfolds 
CA reduced; ht, wt, IGF-1, 
albumin improved; no 
changes in skinfolds 
Concomitant treatment 
(Cs, antibiotics, 5-ASA, 
mercaptopurine) 
Aiges et al 
1989 (280) 
Effect of nocturnal 
supplementation on 
growth 
Nocturnal 
partial 
supplementatio
n with PD; 1 y 
8 adolescents with 
growth failure and 
quiescent or mild 
disease & 4 controls 
CA; anthropometry  Wt gain and ht velocity 
increased compared with 
last y and controls; CA 
improved compared with 
last y in subjects but not in 
controls 
On concomitant treatment 
with Cs 
Belli et al 
1988 (281) 
Effect of 
intermittent EEN on 
EEN; 1 wk on 
ED followed by 
8 with growth failure 
and 4 controls 
CA; anthropometry; 
skinfolds; ESR; Hb; 
Wt, ht, skinfolds, urinary 
creatinine increased 
On concomitant treatment 
with Cs and 5-ASAs 
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growth 3 wk on normal 
diet for 3 mth 
TIBC; folic acid; 
urinary creatinine 
compared with previous y 
and controls; CA decreased 
and use of Cs decreased 
compared with previous y 
and controls 
Sanderson 
et al 1987 
(282) 
Comparison 
between Cs & EEN 
on disease activity 
RCT; EEN; 
SED; 6 wk 
17 longstanding CD; 
(8 on EEN) with 
active disease; small 
bowel disease 
CA; ESR; CRP; 
albumin; 
anthropometry 
Improvement in CA, ESR, 
CRP, albumin, wt; No 
difference in CA between 
EEN and Cs; growth 
velocity improved only in 
EEN 
 
Sanderson 
et al 1987 
(283)  
Effect of EEN on 
gut permeability 
EEN; ED; 6 wk 14 with active 
disease with small 
bowel involvement & 
7 controls with no 
small bowel 
involvement 
CA; gut 
permeability 
(lactulose/rhamnos
e); ESR; 
anthropometry 
Gut permeability improved; 
50% had permeability 
levels within normal range 
after treatment; wt 
increased; CA & ESR 
decreased in parallel with 
permeability improvement 
 
Blair et al 
1986 (284)  
Preoperative 
nutritional support 
with EEN 
EEN; ED; 5 wk 
to 4.5 mth 
11 with small bowel 
involvement, 
preoperative 
CA; ESR; Hb; 
albumin; 
anthropometry, 
steroid reduction 
ESR reduced; Hb, albumin, 
anthropometry increased; 
steroid use reduced, 
fistulas improved; 
postoperative complication 
reduced, reduced rates of 
postoperative relapses  
 
O’Morain 
et al 1983 
(285)  
Effect of EEN on 
disease activity 
EEN; ED; 4 wk 15 with active 
disease and small 
bowel involvement 
ESR; Hb; albumin; 
anthropometry 
Inflammatory markers 
improved within 1-2 wk; 
ESR, decreased, Hb and 
albumin increased, some 
children had wt and ht 
improvement 
Patients on concomitant 
treatments 
Navarro et 
al 1982 
(286) 
Effect of EEN on 
disease activity 
EEN; 2 to 7 
mth; followed 
by 
supplementary 
feeds from 12-
22 mth 
17 underweight 
children; 10/17 
growth retarded 
CA No difference between Cs 
and EEN; Improvement of 
patients with stenotic 
disease; reduced steroids 
dependency 
Patients on 5-ASA 
Morin et al 
1982 (287) 
Effect of EEN on 
disease activity, 
EEN; ED; 21 d  10 newly diagnosed 
with active disease 
CA; bacterial 
counts; folate; 
CA reduced; wt, skinfolds 
improved; No changes in 
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body composition, 
gut flora, vitamin 
levels  
carotene; 
anthropometry; 
skinfolds  
bacteria; folate increased 
carotene decreased 
Morin 
1980 (288)  
Effect of EEN on 
growth 
EEN; ED; 6 wk 4 with growth failure; 
some but not all 
active 
CA; anthropometry; 
skinfolds 
CA improved; ht (1.8 cm) 
and wt (3.8 kg) improved; 
skinfolds improved; children 
continued growing after end 
of EEN 
 
ED: Elemental diet; PD: polymeric diet; CA: clinical activity; Cs: corticosteroids; wt: weight; ht: height; TI terminal ileum; DBRCT: double blind randomized control trial
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As it is unethical not to treat patients with active disease, no placebo controlled trial has been 
conducted so far to test the efficacy of EEN in IBD. Instead the efficacy of EEN to induce 
disease remission in active CD has been compared with that of other treatments, mainly 
steroids, in several investigations (Table 1.5.1). These have been reviewed in a few review 
articles and recently in an updated Cochrane meta-analysis of RCT (289) as presented 
below. With regard to UC there is little information available, although overall it seems that 
nutritional support does not possess a particular role in the management of active UC.  
 
1.5.1.1. Nutritional therapy in adults with active CD 
It is now more than 30 years since a group of surgeons reported the benefits of EEN in 
adults with active CD. Patients awaiting surgery for management of treatment-resistant 
disease experienced disease remission while receiving nutritional support for preoperative 
nutritional rehabilitation and bowel rest (290). Following this observation, O’Morain et al (285) 
conducted the first clinical trial in adult CD patients and found that elemental EEN was 
comparable in inducing clinical remission and correcting serum inflammatory markers 
compared with corticosteroids treatment. Subsequent adult studies confirmed these 
observations (291;292) although a European multicentre study, involving 107 adults CD 
patients showed that combined treatment of steroids and sulphasalazine was more effective 
than semi-elemental feeds in the induction of clinical remission (293). Three meta-analyses 
between 1995-1996 pooling the results of individual clinical trials concluded that although 
enteral feeding has a role in the management of CD it is inferior to steroids in achieving 
disease remission (294-296). Similar conclusions were recently reached by a Cochrane 
review in 2007 (289) which included eight trials with 212 patients treated with EEN and 179 
treated with steroids, and yielded a pooled OR of 0.33 (95% CI 0.21 to 0.53) favouring 
steroid therapy. Remission rates varied considerably (20% to 84.2%) in the individual studies 
which could be due to differences in the study populations, route of administration, outcome 
measurements and methodology (289). 
   
1.5.1.2. Nutritional therapy in children with active CD 
Despite the conclusions of the three metanalyses, reporting a clear superiority of steroids to 
induce clinical remission in active CD, two subsequent metanalyses were conducted, 
including RCTs in paediatric only CD patients (297;298). Pooling the results of five paediatric 
studies with a total number of 147 children Heuschkel et al (298) found no difference (RR = 
0.95 [95% CI: 0.67-1.34]) between EEN and corticosteroid treatment to achieve clinical 
remission (Fig 1) which was confirmed in an updated meta-analysis (297) including two 
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subsequent trials, (259;299). The overall reported remission rates on treatment with EEN 
varied from 42% (260) to 90% of cases (263) among the individual studies (Table 1.5.1). 
 
Figure  1: Forrest plot of RCT on the effect of EEN on induction of clinical remission in 
paediatric active CD (adapted from Heuschkel et al (298))  
 
 
1.5.1.3. Effect of nutritional therapy in remission maintenance 
As IBD is chronic in nature, and there is no effective curative treatment, a large number of 
patients are anticipated to relapse within a year of remission induction (300;301) with some 
relapsing soon after food re-introduction (302). Patients with complicated disease (ie fistulae, 
strictures, perianal disease) are more susceptible to early relapse (303). In a large (n=113) 
adult retrospective analysis, 22% of patients relapsed in the first six months after EEN 
treatment whereas the probability of maintaining remission at three years was 38% (303). 
Likewise 2/3 of the patients in paediatric studies are estimated to relapse within a year of 
EEN induction of remission (263;273). No difference in the time to first relapse has been 
found between clinical remission induced with EEN or steroids in both adult and paediatric 
reviews (289;298) although a recent paediatric trial found higher relapsing rates in the 
steroid, compared with the EEN group, which was ascribed by the authors to the better 
mucosal healing achieved in the latter group of patients (261). 
Following establishment of disease remission, second line treatments are commonly 
applied to prevent a subsequent relapse. Retaining a patient on EEN to prolong remission is 
impractical, if not unethical, and therefore a few studies tested the efficacy of supplementary 
nutritional support to maintain clinical remission and tackle a subsequent clinical flare up. In a 
Japanese adult study (304), adult patients who received half their total energy requirements 
as elemental diet and the remaining half by normal diet had a significantly lower relapse rate 
(34.6%) than patients who received unrestricted normal diet (64%) (OR: 0.4 [95% CI 0.16 to 
0.98]). Similar results were presented recently by Yamamoto (305;306) and Verma (307;308) 
in two adult Japanese and two adult British studies respectively. In the Japanese studies 
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supplementary EN in parallel with a low fat diet prolonged disease remission, prevented 
increase in mucosal inflammation and inflammatory markers (306) and prevented post-
surgical clinical recurrence compared with an unsupplemented group of patients (305). 
Likewise partial supplementation of an unrestricted diet was more likely to prolong remission 
(307) compared with an unsupplemented control group, and moreover gradually tapered 
steroid usage in British patients with steroid dependent disease (308).  
 
1.5.1.4. Exclusive vs partial nutritional therapy in induction of disease 
remission 
The origin of the exclusivity aspect of EN treatment is unknown and is possibly based on a 
putative mechanism of action through bowel rest. This theoretical concept was only recently 
tested in a randomized controlled trial of 50 paediatric patients with active CD who 
responded better on an exclusive course of nutritional therapy than to a partial regime (50% 
of dietary intake) in conjunction with free diet (260). The EEN group had a remission rate of 
42%, which was significantly higher than that of 15% observed in the partial EN group.      
 
1.5.2. Nutritional therapy and mechanisms of action in CD 
Although there is extensive clinical experience and literature supporting the use of nutritional 
therapy in CD, the mechanisms of action and ideal formulation remain unknown and are still 
under investigation. There is still much debate about putative mechanisms of action mainly 
because the gut is a difficult organ to study directly. Therefore most of the evidence derives 
from in-vitro models and other surrogate indices of intestinal events that may not always 
represent events occurring at the mucosal site. Some of these hypothetical mechanisms are 
presented in Table 1.5.2 and are discussed below in detail.  
 
Table 1.5.2: Proposed mechanisms of induction of remission with EEN in active CD 
Bowel rest Low antigenic load 
Anti-inflammatory 
effect 
Mucosal trophic 
effect Nutritional effect 
Reduces 
intestinal 
secretions 
Low in microbial 
antigens 
Reduction in systemic 
markers of 
inflammation 
Improves intestinal 
permeability 
Improves energy/protein 
status 
Reduces gut 
motility 
Low in dietary 
antigens/allergens 
Direct mucosal anti-
inflammatory effect 
Accelerates 
intestinal healing 
Replenishes micronutrient 
deficiencies 
 
1.5.2.1. Effect of nutritional therapy on inflammatory markers 
In parallel with the resolution of clinical GI symptoms (stool frequency, abdominal pain, 
perirectal bleeding), systemic inflammatory markers improve and return to normal levels 
within a few days of treatment with EEN (267). Several studies have shown that the clinical 
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activity response to EEN coincides with reduction in ESR, circulating CRP and other pro-
inflammatory cytokines (Table 1.5.1).  
Although the fall of systemic inflammatory markers is essentially a secondary 
response to GI inflammation and disease improvement, there is now strong evidence to 
suggest direct anti-inflammatory and immunomodulatory properties of EEN at the mucosal 
level (275;309) such as downregulation of mucosal proinflammatory cytokine mRNA (IL-1, 
IFN-γ, IL-8) in both terminal ileum and colon of paediatric patients with CD. Indeed these 
changes coincided with improvement in clinical activity, mucosal healing and circulating 
inflammatory markers (ESR, TNF-α, CRP) (90). Meister et al (310) in an in vitro experiment 
observed that incubation of mucosal biopsies from adult CD patients with elemental diet 
resulted in an increase in the ratio of anti-inflammatory/pro-inflammatory cytokines (IL-1 
receptor antagonist/IL-1β). However incubation of biopsies from UC patients with elemental 
feeds did not improve the anti-inflammatory/pro-inflammatory ratio, in accordance with the 
lack of clinical effectiveness of nutritional therapy to suppress inflammation and induce 
remission in patients with active UC. Likewise Yamamoto showed return of mucosal pro-
inflammatory cytokines (IL-1β, IL-1ra, IL-6, IL-8, TNF-a) to normal healthy levels in Japanese 
adult patients with active CD at the end of EEN (309), and prevention of increase in patients 
on long-term nutritional support (306). In fact the endoscopic and histologic improvement in 
the first of these studies was associated with a parallel decline of the mucosal cytokines and 
an increase of the IL-1ra/IL-1β ratio (309).    
As assessing mucosal inflammation with blood markers may not be sensitive or 
specific to intestinal inflammation, and repeat endoscopies are impractical, expensive and 
require general anaesthesia in children, surrogate indices of local intestinal inflammation are 
required particularly for routine monitoring of disease activity. Nowadays new faecal markers 
of intestinal inflammation have recently become available that allow assessment of the 
disease at the site of presentation. Calprotectin and lactoferrin are two potential candidate 
markers with excellent diagnostic value to differentiate between intestinal inflammation and 
other functional digestive disorders (311). Both are non-invasive, cheap and could offer a 
suitable means to monitor intestinal inflammation and response to treatment. No study has 
yet assessed changes of these markers during nutritional therapy. On the contrary a study of 
the use of steroids in active CD failed to find changes in calprotectin levels despite 
improvement in clinical activity, suggesting that steroids offer symptomatic relief without 
however resolving intestinal inflammation and achieving mucosal healing (312).  The effect of 
EEN on calprotectin is investigated in Chapter 6. 
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1.5.2.2. Effect of nutritional therapy on endoscopic, histological 
improvement and mucosal healing   
There is a growing view that healing of the intestinal mucosa in IBD patients should be the 
principal therapeutic objective because only agents promoting mucosal healing may modify 
the longterm course of the disease. The primary objective of nutritional therapy is to induce 
clinical remission with minimal side effects. Because the inflammatory process is located in 
the intestinal mucosa, clinical remission should ideally be associated with a reduction of 
mucosal inflammation and mucosal healing. Various paediatric (90;264;276) and adult 
studies (300;309) have shown that mucosal healing is achieved with EEN more often than 
treatment with steroids whereas endoscopic and histological lesions repair does not coincide 
with clinical improvement when using steroids (259;261;275;313;314). A recent Italian study 
(259) showed improvement in endoscopic and histological findings at the end of treatment 
only in the group of patients on EEN. The proportion of children showing mucosal healing 
was significantly higher in the EEN (14/19) than the steroid group (6/18). Failure to achieve 
mucosal healing on steroid treatment might account for the higher relapse rate observed 
compared with a EEN treated control group of children, in another recent Italian study (261). 
Similar results were presented by Yamamoto et al (309) in adult patients with CD. Endocopic 
healing and improvement rates were 40% and 77% whereas histological healing and 
improvement were 20% and 55% for steroids versus EEN respectively. The authors 
speculated that clinical remission occurs first, preceding endoscopic improvement, whereas 
histological improvement takes place last.     
 
1.5.2.3. Effect of nutritional therapy on intestinal permeability 
In active CD, intestinal permeability is increased and its extent is positively associated with 
disease activity (315) and is a strong predictor of clinical relapse (316). Impaired intestinal 
barrier function may facilitate contact of mucosal immune-competent cells with antigenic 
substances from food and bacterial products from the host’s intestinal flora activating the 
mucosal immune system. Some studies have shown that improvement in clinical disease 
activity coincides with reduction in intestinal permeability (283;317;318).   
 
1.5.2.4. Nutritional therapy and antigenic effect 
The initial speculation that the effectiveness of nutritional therapy in CD is due to a reduced 
antigenic load in the elemental feeds compared to the whole protein was revised in light of 
evidence suggesting no difference in the clinical efficacy of polymeric, semi-elemental and 
elemental feeds (300;302;319;320). This was recently reconfirmed by a Cochrane meta-
analysis in adult studies (289). Similarly in children a recent retrospective analysis of case 
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series (261) and a randomized multicenter controlled trial (266) found no difference in 
disease activity improvement and remission rate between polymeric and elemental feeds. 
Remission rates were 69% on elemental diet compared to 82% in the polymeric feeding 
group.  
 
1.5.2.5. Nutritional therapy and gut rest  
One of the first indications and proposed modes of action of EEN in CD was the property of 
being liquid and readily absorbable in the proximal part of the GI tract, minimizing 
participation of the digestive system in the chemical and mechanical process of digestion and 
absorption of the nutrients. This was postulated to provide a degree of bowel rest and 
subsequently to accelerate healing in the already traumatized intestinal mucosa. However 
subsequent evidence (321;322) and a key study by Greenberg et al (323) found no 
difference in clinical remission between patients treated with TPN and bowel rest, a 
polymeric enteral feed, or peripheral nutrition with oral diet. This demonstrated that bowel 
rest was not the mechanism responsible for diet-induced remission in CD. Indeed, as 
colonocytes depend on exogenous nutrient provision through the diet, there are valid 
reasons to recommend the addition of fibre, and prebiotics in nutritional therapy feeds as 
these could promote intestinal health either by producing SCFA or by modulating an 
imbalanced commensal intestinal flora, towards an optimal healthier one (324).   
 
1.5.2.6. Amount and type of fat 
Long chain fatty acids may modulate eicosanoid synthesis and other immunomodulatory 
mechanisms thereby influencing disease outcome. It was therefore speculated that the 
amount and type of fat may be a determinant of the efficacy of EEN. In particular, ingestion 
of ω-3 fatty acids might suppress mucosal inflammation whereas ingestion of ω-6 fatty acids 
might stimulate the inflammatory cascade (325). A few studies compared nutritional 
formulations of different types and amounts of fat without however clear-cut results 
(261;320;326). The topic was recently reviewed by Zachos et al (289) in a Cochrane review 
that included only RCTs, which concluded that there is no evidence to suggest a difference in 
the efficacy to induce disease remission between low and high fat EEN. Moreover the equal 
therapeutic effect of polymeric and elemental feeds with high and low concentration of fat 
respectively, suggests a mechanism of action independent of the fat content in the feeds 
(319;320;327).  On the other hand the type of fat may be a clue to the efficacy of EEN. 
Bamba et al  observed decreased rates of remission with increasing amount of ώ-6 fatty 
acids in the elemental feeds. In contrast, a well designed double blind RCT European 
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multicenter study had to stop early because of low remission rates achieved in the low 
linolenic/high oleic compared with the high linolenic/low oleic formula (328). 
 
1.5.2.7. Other aspects of nutritional therapy in the management of active 
CD 
Nutritional therapy efficacy and disease location 
At the moment there is limited data to suggest a better efficacy of nutritional therapies in CD 
patients with a specific disease phenotype (289;303) despite scarce evidence suggesting 
that patients with small bowel involvement respond better to EEN (329). A recent paediatric 
study showed that children with active CD do not respond well to EEN when the ileum is not 
involved  although these results were not replicated by a Italian paediatric (259) and a 
Japanese adult study (309). Indeed there are case reports that EEN was even beneficial in 
orofacial presentation of CD (268). 
As far as maintenance of disease remission is concerned, Teahon et al (303) in a 
retrospective analysis of more than 100 case series found that adult patients with isolated 
ileal and small bowel disease were more likely to remain in long-term remission compared 
with patients with colonic, or ileocolonic disease after induction of clinical remission with 
nutritional therapy. Similarly Gavin et al (262) in a paediatric retrospective study, found that 
patients with colonic disease tended to relapse earlier despite no obvious effect of the 
disease phenotype on induction of clinical remission with EEN.  
  
Effect on nutritional therapy on disease activity in new and longstanding 
disease 
Whether new patients respond better to EEN than those with long-standing disease, is quite 
controversial. Some studies showed that newly diagnosed patients are more able to respond 
to EEN than patients with long-standing disease (329) whereas others found no difference 
(266;330). 
 
1.5.2.8. Effect of EN on nutritional status 
1.5.2.8.1. Effect of nutritional therapy on weight and body composition in IBD 
Regardless of whether EEN therapy is equal to or slightly inferior to steroids in inducing 
remission, its use is advocated by its nutrition promoting properties contrary to the 
detrimental side effects of long-term steroid usage on growth, body composition, bone health 
and body image. Improvement of the patients’ protein-energy nutritional status has always 
been considered as one of the mechanisms of EEN action, although recent studies have 
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shown that anti-inflammatory properties preceded any changes in nutritional status 
(267;331). Moreover no difference in remission rates was found between malnourished and 
normal nourished adult CD patients on treatment with EEN. 
In both adult (292;300;301;320) and paediatric studies (Table 1.5.1) nutritional 
therapy is accompanied by significant improvement of pre-treatment anthropometry. Weight 
gain accompanies disease improvement (276) and is component of the PCDAI and other 
disease activity indices (332). 
A few authors have also used body composition techniques to assess changes in fat 
and lean mass during nutritional therapy in adults (300;301) and paediatric patients (Table 
1.5.1). Improvement in surrogate measures of body composition, like skinfolds thickness and 
upper arm circumference, were commonly reported by some (260;267;272;281;287;288) but 
not all the studies (271;279). However none of these studies appropriately 
expressed/converted raw measurements of body composition to age and sex reference 
standardized values, as z-scores, and therefore contradictory results could be attributed to 
differences in the age and gender characteristics between the comparison groups.  
Two paediatric studies assessed changes in the body composition of children with 
CD undergoing treatment with nutritional therapy. Khoshoo et al (272) used bioimpedance 
and skinfold measurements to assess changes in body composition in adolescents with 
active CD on treatment with EEN. Although their results may have been flawed by the 
concomitant use of steroids, they observed significant improvement in FFM assessed by 
both methods. In the second study Azcue et al (104) using highly sophisticated techniques 
(isotope dilution, extracellular bromide dilution, bioimpedance, total body potassium) 
assessed body composition changes and body fluid distribution and observed increments in 
all body compartments after treatment with EEN. Noteworthy differences in fat and lean 
mass accretion were observed between patients on EEN and corticosteroids. Steroid 
patients tended to accumulate more fat whereas intracellular water and lean mass accretion 
were significantly higher in the EEN group. This observation coincides with recent evidence 
that EN promotes protein anabolism by suppressing proteolysis, and increasing protein 
synthesis in adolescents with CD in remission (333), an effect that contrasts to the 
documented catabolic effects of steroids. 
 
1.5.2.8.2. Effect of nutritional therapy on growth in CD 
Linear growth retardation is commonly seen in children with IBD, predominantly CD (Section 
1.3.3). Both suboptimal dietary intake and an inhibitory effect of inflammatory response 
cytokines are implicated (334). Substantial evidence suggests that nutritional therapy, both 
elemental and polymeric formulation, has growth-promoting effects (297). Nutritional therapy 
either exclusively (271;276), supplementary (273;280) or with intermittent course 
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administration (279) improved height velocity (271;276;278) and accelerated linear 
development in growth retarded children (280;281;288). This is an important advantage over 
the use of steroids and their well-documented growth inhibiting effects. In particular growth 
velocity improved in patients on EEN but remained unchanged (282) or improved to a lesser 
extent in patients on steroids (261;271;274). 
The exact mechanism of the growth promoting effect of nutritional therapy is unknown 
and is speculated to be due to a composite effect from both nutritional replenishment and 
reversal of the inhibitory effect of inflammatory cytokines on growth hormonal mediators of 
growth like IGF-1 (267;271;278;279). It is noteworthy that a recent small study observed that 
the growth promoting effects of EEN preceded nutritional rehabilitation (267). 
 
1.5.2.8.3. Effect on nutritional therapy on micronutrient status 
Although a recent study showed that disease improvement precedes nutritional rehabilitation 
and may suggest that nutrition rehabilitation is not implicated as a mechanism of action of 
EEN, the authors of this study assessed only indices of energy-protein status (267). Whether 
disease improvement is a direct effect of improvement and replenishment of micronutrient 
status from EEN has not been investigated. Micronutrients play a vital role in metabolism, 
antioxidant status and the integrity of the colonic epithelium. Reactive oxygen species exhibit 
deleterious effects on epithelial cells in CD and studies have shown decreased levels of 
antioxidant enzymes and vitamins in the intestinal mucosa and in the plasma of patients with 
CD (Section 1.3.6). Replenishment of micronutrient status during EEN is one of the possible 
modes of action mediating the efficacy of EEN in CD where micronutrient deficiencies and 
malnutrition are common as opposed to its inefficacy in UC were deficiencies in minerals and 
vitamins are unusual.  
Moreover, there are additional reasons why replenishment of micronutrient in EEN is 
important. Conventional EEN regimes, intended for use in active CD, provide age and 
gender specific energy requirements, as reflected by the increase in body weight and 
anabolic effects, but there is no evidence to ensure that the micronutrient content of these 
feeds is adequate to replenish deficiencies or supply the essential requirements of these 
patients. The dietary adequacy of micronutrients in these feeds has been ascribed to the 
provision of national reference daily intakes, originally established to cover the needs of the 
healthy population, but whether the same requirements apply to patients with CD is 
questionable. A study (335) 20 years ago failed to show improvement of vitamin status of 
IBD adults on EEN despite provision of higher amounts of micronutrients than the RDA.  
Moreover EEN feeds are “artificial food” made of composite simple food ingredients and 
nutrients for which recommended allowances have been established and therefore may lack 
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‘non-nutrient compounds’ that occur naturally in food (e.g. polypenols), ave important role in 
the human health, but whose supplementation in artificial feeds is uncommon.  
An extensive literature search was carried out by the researcher in 2004 and updated in 
2008 to review all studies on the effect of EEN therapy on blood micronutrient status in IBD 
patients. Studies using total parenteral nutrition were excluded. Overall seven studies were 
retrieved. The studies were heterogeneous in design, subject characteristics, duration or type 
of feeds used, and the mode of nutritional support (Table 1.5.3). Four studies were 
conducted in CD adults, whereas two included UC patients. All but one study used EEN. One 
used partial supplementation of normal diet. The duration of nutritional therapy varied from 
12 days to one year. Only one adult study including UC patients assessed a wide range of 
micronutrients. The rest assessed a limited number of micronutrients, focusing mainly on 
antioxidant trace elements and vitamins. Some studies assessed changes of the enzymatic 
antioxidant systems and one study measured changes in oxidative stress (Table 1.5.3).  
The results were inconsistent and no overall conclusions could be drawn. Nutrients 
like Se increased in some studies but decreased in others (Table 1.5.3). Similar results were 
found for other nutrients like vitamin A. The use of different feed formulae and duration of 
administration among studies could explain some of these differences. No study in children 
as investigated changes in a wide range of vitamins. Thomas et al (183) assessed only 
changes in Se, whereas Akobeng et al (336) studied additionally vitamins A, E and C. 
The as yet limited evidence does not support a mechanism for the therapeutic action 
of EEN that is mediated by micronutrient replenishment. Phylactos et al (148) showed that 
paediatric CD is characterized by reduced activity of enzymatic antioxidant systems in 
erythrocytes, but this did not improve with eight weeks treatment with EEN despite 
improvement in disease activity and systemic markers of inflammation (CRP and TNF-α). 
Although these results imply that the anti-inflammatory action of EEN in CD is caused by 
some mechanism other than restitution of specific antioxidants it still remains to be 
addressed whether disease improvement is associated with changes in other micronutrients.  
Akobeng et al  (336) did not find significant changes in the antioxidant mechanisms or 
markers of oxidative stress of children with CD on four weeks of EEN. However the authors 
did not report changes of clinical activity or inflammatory markers and association. 
There is limited evidence to suggest any micronutrient changes during therapy with 
EEN and how these correlate with the disease activity and inflammatory markers. 
Extrapolation of the results from adult studies to paediatric patients is inappropriate given the 
differences in the nutrient requirements between adults and children. The most 
comprehensive study in children included only four antioxidant nutrients and the duration of 
the EEN course was limited to one month. The recommended duration of EEN is now 
between six to eight weeks and different results might be expected. More evidence is needed 
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as to whether EEN fully meets the nutritional needs of children with CD and whether or not it 
replenishes any deficiencies. Failure of EEN to cover the nutritional needs of children with 
CD will have implications for both the feed manufacturers and clinical practice.  
Changes in micronutrient status with EEN and correlation with disease activity need 
to be further studied although the interpretation of the results is difficult as other factors 
beyond nutritional status and actual nutrient stores can affect serum circulating levels. As 
discussed in Section 1.3.6 the acute phase response during inflammation can affect serum 
nutrient circulating levels irrespective of body stores and therefore measurements in other 
tissues or cells might be more appropriate measures of body micronutrient status (179). The 
effect of EEN on micronutrient status in investigated in Chapter 5 
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Table 1.5.3: Studies on the effect of EN therapy on the systemic micronutrient status in adult and paediatric IBD. 
Study Subjects  Nutritional therapy Micronutrient Micronutrient change 
ADULT STUDIES 
Johtatsu et al 2007 (337) 8 CD Partial EN; 1y; Elental 
low in Se and Zn 
Se, Zn, Cu. Serum 
selenoprotein, GSHPx 
Se and Zn depleted; Improved by 
supplementation with Se and Zn 
Abad-Lacruz et al 1988 
(335)  
8 malnourished IBD EEN; 12-28 d  Vit A, β-carotene, Vit E, 
Tocopherol:Cholesterol, 
B1, B2, B6, B12, Folate, 
Biotin, Vit C 
Folate, biotin, b-carotene, vit C, 
tocopherol/chol unchanged; B1, B2 
decreased; vit A and E increased 
Teahon et al 1995 (331) 19 CD  EEN 5 wk; E028 & 
Vivonex 
Fe, Mg, Cu, Zn  Fe increased, Cu decreased 
Fernandez-Banares et al 
1990 (294) 
7 malnourished IBD EEN; 20 d Zn, Se, Cu Zn, Cu did not improve, Cu:Zn ratio 
decreased; Se increased 
PAEDIATRIC STUDIES 
Akobeng et al 2007 (336)  15 CD EEN; 4 wk; 2 formulas 
with different glutamine 
content 
Vit A, Vit E, Vit C; 
Malondialdehyde, Se, 
urate, glutathione 
Se improved; Vit E and Vit C reduced; No 
effect on Vit A, glutathione, urate, MHA  
Phylactos et al 2001 (148) 14 CD EEN; 8 wk; Nestle 
(CT3211) 
Antioxidants enzymatic 
system (Se-GPx, Cu/Zn-
SOD) 
No change 
Thomas et al 1994 (183) 11 CD EEN E028 Se, GSHPx Se decreased; Se increased on the steroid 
group 
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1.6. Intestinal microbiota in IBD  
1.6.1. Introduction to human intestinal microbiota 
It has been known from early in the history of microbiology that the gut of people and other 
animals is inhabited by microbial species, mostly bacteria. Louis Pasteur first expressed his 
views to the French Academy of Sciences in 1885 on the importance of bacteria in the 
digestion of food believing that life in the absence of microbes would be impossible (338). 
Many species of bacteria have evolved and adapted to live and grow in the human 
gut. The human intestinal habitat contains 300–1000 different species of bacteria, and the 
number of microbial cells within the large bowel lumen is tenfold the number of eukaryotic 
cells in the human body (339). The stomach and small intestine contain only a few species of 
bacteria adhering to the epithelia and some other bacteria in transit. The scarcity of bacteria 
in the upper tract seems to be primarily because of the composition of the luminal milieu 
(acid, bile, pancreatic secretion), which kills most ingested microorganisms, and secondly 
due to the propulsive GI motor activity towards the ileum. In contrast, the large intestine 
contains a complex and dynamic microbial ecosystem with high densities of living bacteria 
(around 60% of faecal mass), which achieve concentrations of up to 1011 or 1012 cells/g of 
luminal contents  (340).  
Members of nine bacterial phyla were found to inhabit the human GI tract of which 
Firmicutes, Bacteroidetes, and Actinobacteria are dominant. Members of Proteobacteria are 
also common and diverse, but they are usually secondary to the above (Fig 2).  Anaerobic 
bacteria outnumber aerobic bacteria by a factor of 100-1000 (339). The genera bacteroides, 
bifidobacterium, eubacterium, clostridium, peptococcus, peptostreptococcus, and 
ruminococcus are predominant in the human gut, whereas facultative anaerobes such as 
escherichia, enterobacter, enterococcus, klebsiella, lactobacillus, and proteus are among the 
subdominant genera. Although the human gut harbors several hundreds of species 
belonging to common genera, within individuals an idiosyncratic  combination of predominant 
species is present (341).  
Many factors determine the microbial composition of the intestinal milieu (Fig 3). 
Colonization of the human GI tract starts immediately after birth and occurs within a few days 
of life. Mode of delivery and feeding method are early determinants of bacterial colonization 
(342). Although stable throughout adulthood the composition of the individual’s flora changes 
in old age (343) and can also fluctuate due to circumstances, for instance in antibiotic 
treatment (344), or after dietary intervention with probiotics or fibre administration (345). Host 
genotype is also a determinant of gut microbiota diversity with a higher degree of bacterial 
similarity existing between relatives, particularly twins, than between people who are not 
related but live in the same environment (318).  
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The characterization of intestinal microbiota in vivo, and its spatial distribution is 
limited by restrictions in the accessibility of the GI tract. Thus most of our knowledge on 
intestinal microbiota composition and function comes from analysis of colonic luminal 
material, mainly faeces.  Although faecal samples are easy to obtain, they represent only an 
approximate representation of the intestinal microbial environment, and metabolic activity, 
mainly that of the rectosigmoid region, which differs considerably from the microbiota in other 
segments of the GI tract (Fig 4) (346).  Marteau collected caecal and faecal samples from 
healthy adults and found that the caecum harbored 100 times fewer anaerobes and 
facultative anaerobes represented a substantial fraction compared with the faecal microbiota 
(346). Faecal microbiota differs considerably from the bacteria adherent to the mucosa lining 
(347) and considerable research is now undertaken on the importance of the latter and its 
interaction with the intestinal epithelium in health and disease (348).  
 
Figure  2: Small subunit rRNA-based phylogenetic tree of the distinct phylotypes that have 
been found in the human GI tract (adapted from Rajilic-Stojanovic et al 2007 (349))  
 
 
The relative proportion of 
phylotypes that correspond to 
cultured representatives is 
indicated by different 
darkness of filling. Black fills 
indicate phylotypes detected 
in cultivation independent 
studies, while white indicates 
species detected in 
cultivation-base studies. The 
reference bar indicates 10% 
sequence divergence. 
Numbers of distinct 
phylotypes are given for each 
phylogenetic group.  
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Figure 3: Determinants of intestinal microbiota diversity and metabolic activity 
 
  
 
Figure 4: Regional differences in large bowel function in the human (adapted from Cummings 
1997 (350))  
 
 
 
 
1.6.2. Methods for characterization of the intestinal microbiota 
Much of our knowledge on the composition of the human gut microbiota is derived from 
bacteriological analyses that used traditional techniques of cultures on growth media, 
microscopy, and the determination of the fermentation properties and other biochemical 
specificities of bacterial isolates (340). Although these techniques are still useful in research 
and in clinical practice they are unable to culture all bacteria even under the most robust 
techniques and conditions (338). Even in the 1970 researchers had observed that the total 
counts of bacteria measured in faecal smears were higher than the total viable colony-
forming units obtained by traditional culture methods on growth media. A recent approximate 
Gut Microbiota Gastrointestinal disease 
Diet Genes 
Gut motility 
Delivery and mode of setting 
Age 
Antibiotics & drugs 
Left Side 
• Protein rich 
• Low moisture 
• SCFAs low 
• Residence 12-36 h 
• pH neutral 
• Slow bacterial growth 
• Main gases H2 & CO2 & CH4 
• Ammonia, phenols 
Right Side 
• Carbohydrate rich 
• High moisture 
• SCFAs rich 
• Residence 6-16 h  
• pH acidic 
• High bacterial growth 
• Main gases H2 & CO2 
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estimate is that 60% to 80% of the bacteria in the digestive tract remain uncultured with 
conventional microbiology techniques.  
This problem was overcome in the last decade by the emergence of molecular 
bacteriology techniques (351). Use of culture independent analytical approaches that utilize 
information from bacterial genetic material were the way forward. These techniques utilise 
the small subunit RNA (16S rRNA most commonly in the case of bacteria) that contains 
regions of nucleotide base sequence that are highly conserved and are interspersed with 
hypervariable regions, known as V regions. These regions contain signatures of phylogenetic 
groups even species and allow the characterization of bacteria from division, down to 
species level (338).  
The combination of polymerase chain reaction (PCR) with denaturating or 
temperature gradient gel electrophoresis (TGGE) is a relatively new approach to monitor the 
diversity of complex bacterial ecosystems (352;353) and was firstly used by Zoetendal (341) 
for colonic contents. Bacterial DNA is extracted from the faecal sample and a variable region 
of the 16S rRNA gene is amplified by PCR from the DNA. The PCR product obtained from a 
sample contains 16S fragments of the same size but different sequence from all bacterial 
types present in that sample. Thereafter the various types are separated from each other by 
gel electrophoresis. The double stranded 16S fragments migrate through a polyacrylamide 
gel of homogenous consistency or containing a gradient of urea and formamide until they are 
partially denaturated by the temperature of the running buffer or the chemical conditions of 
the gel. Because of the variation in the 16S sequences of the different bacterial species, 
“DNA melting temperatures” are also different and therefore the different 16S species will 
stop “running” at different points across the gel. The separation of 16S fragments produces a 
profile of the dominant bacterial community “fingerprint” in which each bacterium is 
represented by a single band (352;353).  
Another robust method to explore the intestinal microbiota is fluorescent in situ 
hybridization (FISH). Oligonucleotide probes, labeled with fluorescent dyes target 16S rRNA 
sequences inside the bacterial cells. Although an array of different specific probes can be 
used to recognize from single strains up to whole bacterial groups the use of large numbers 
of probes is impractical and the technique is restricted to the identification of bacteria for 
which specific probes exist. The method is best for enumeration of the numerically 
predominant members of the microbiota with a detection limit of 106 cells per g. A big 
advantage of this method is that bacteria can be detected in situ, which allows determination 
of the spatial organization of communities in the gut (354). 
As a detailed description of other molecular techniques of probing the gut microbiota 
is beyond the scope of this thesis the reader is referred to relevant review articles 
(340;355;356). 
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1.6.3. Intestinal microbiota in health and disease 
This abundant endogenous microbial load plays an important role in the homeostasis of the 
colon and the health of the host. Evidence from a plethora of studies, showed that this 
“neglected organ” exerts important metabolic, trophic and protective functions under a 
continual “cross-talk” between the commensal bacteria and intestinal epithelial cells 
(339;357;358) (Table 1.6.1). 
The tremendous impact of indigenous luminal flora on the development and 
maturation of gut homeostasis is clearly illustrated by comparative studies of germ-free and 
conventionalized animals. Studies in gnotobiotic animals have shown that experimentally 
colonizing the intestine of germ-free rodents with single species selected from the indigenous 
flora has profound impact on the anatomical, physiological, and immunological development 
of the host, including effects on the epithelial cell functions and the composition of the gut-
associated lymphoid tissue (357).  
On the other hand some commensal bacteria can be opportunistic pathogens and a 
source of infection and sepsis under certain circumstances, as when the gut barrier is 
physically or functionally breached or when the bacterial profile is disturbed by the use of 
broad-spectrum antibiotics (359). Similarly a breakdown of tolerance to the indigenous 
microbiota is thought to be the key step in the development of intestinal inflammatory 
disorders like CD and UC. This is presented in detail in the Section 1.7.2.3.4. 
Much current research aims to improve or sustain colonic health by modulating the 
profile and the metabolic activity of gut microbiota to a “healthier pattern” with the use of live 
beneficial food grade bacteria (probiotics) and the ingestion of food non-nutrient compounds 
that promote the growth and metabolic activity or the beneficial indigenous microbiota 
(prebiotics) (345). 
 
Table 1.6.1: Main functions of commensal intestinal microbiota in health (adapted from O’Hara 
& Shahanan (360)) 
Protective functions Structural functions Metabolic functions 
Pathogen displacement Barrier fortification Salvage of energy 
Nutrient competition with 
pathogens 
Epithelial cells differentiation and 
proliferation 
Ion absorption and promotion 
of water absorption 
Receptor competition with 
pathogens 
Apical tightening of tight junctions Vitamin K, folate, biotin 
production 
Production of antimicrobial 
factors 
Angiogenesis  Production of SCFA 
Immune system development  Production of harmful 
metabolites (NH3, H2S, amines) 
 
Perhaps the most interesting topic in GI physiology and microbiology is the delegate 
ability of the gut associated immune system (GALT) to interpret the intestinal ecosystem and 
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to distinguish between episodic pathogens and commensal bacteria and whether or not to 
induce a subsequent immune response.  
The epithelium provides the first line of defence to the intestinal luminal 
microenvironment and plays an important role in sampling of commensal bacteria, pathogens 
or other antigens. Specialised types of immunosensory cells located at the intestinal 
epithelium are responsible and for the preservation of homeostasis or induction of immune 
response. Apart from the surface epithelial cells, M cells and dendritic cells have the ability to 
discriminate pathogenic from commensal bacteria in part, by using two major host pattern 
recognition receptor systems the family of Toll-like receptors and the nucleotide-binding 
oligomerization domain/caspase recruitment domain isoforms (NOD/CARD) (357;361). 
These receptors exert a fundamental role via immune-cell activation in response to specific 
microbial-associated molecular patterns like peptidoglycan, lipotechoic acids, 
lipopolysaccharide and flagellin. 
 
1.6.4. Main functions of intestinal microbiota 
How elephants grow and maintain their enormous body on an apparently poor diet consisting 
of leaves is noteworthy, particularly when they are actually monogastric and lack a rumen to 
maximise energy absorption.  The answer lies in the structure of the digestive tract and like 
in many other monogastric animals, they host a highly developed caecum and large intestine 
with an abundant microbiota that salvage what the digestive enzymes cannot digest in the 
upper GI tract (350). With more bacterial cells in the gut than eukaryotic cells in the human 
body the collective metabolic activity of the normal flora represents a virtual hidden organ 
that would rival the activity of the liver (362). 
 
1.6.4.1. Fermentation 
The major metabolic function of the colonic microbiota is the fermentation of food matrices 
that escape digestion or absorption in the upper digestive tract, along with endogenous 
mucus or sloughed epithelial cells. The substrate availability in the human colon is estimated 
to be 20-60 g of carbohydrates and 5-20 g of protein per day in healthy individuals (350). 
Fermentation involves a variety of reactions and metabolic processes in the anaerobic 
microbial milieu of the GI tract yielding metabolizable energy for microbial growth and 
maintenance, and a variety of metabolic products for use by the host (363). The major end 
products of bacterial fermentation of carbohydrates in the large bowel are organic acids such 
as lactate, and short chain fatty acids (SCFA) together with hydrogen and carbon dioxide and 
methane. Protein fermentation also leads to SCFA, hydrogen and carbon dioxide. In addition 
branched chain fatty acids (BCFA) such as isobutyrate, isovalerate and 2-methylbutyrate are 
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produced by the fermentation of the respective amino acids valine, leucine, and isoleucine. 
Ammonia, amines and phenols are also produced from protein fermentation (350). 
Fermentation is not the same throughout the large intestine (Fig 4) (364;365). In the 
caecum and right colon, fermentation is very intense with high production of SCFA, and a 
drop of the luminal pH to as low as 4.5 (364;365). In contrast as available substrate is limited 
in the distal colon fermentation of proteins occurs, with subsequent production of ammonia, 
branched chain amino acids and phenolic compounds, and increase of pH towards neutral. 
The average concentration of SCFA is as high as 70 to 140 mM in the proximal colon and 
falls to 20 to 70 mM in the distal colon (365;366). 
 
1.6.4.2. Short chain fatty acids 
Short chain fatty acids are organic fatty acids with a carbon chain of one to eight atoms. They 
are the primary end products of bacterial fermentation of carbohydrates, particularly 
indigestible polysaccharides and oligosaccharides, and to a lesser extent from proteins and 
amino acids (364;365). The predominant SCFA is acetate followed by propionate and 
butyrate in a molar ratio of around 60:20:20 respectively in healthy people (364;365) but this 
may be modified by dietary intervention (350).   
SCFA production is regulated and depends on a number of factors such as the 
amount and the type of microbiota and fermentable material present in the lumen, and the 
gut transit time (364;367). Different non-starch polysaccharides (fibre) yield different qualities 
and quantities of SCFA. For example resistant starch is more fermentable than oat bran or 
cellulose and produces more butyrate than pectin (366;368). Disease, mainly GI disorders, 
can also determine the qualitative and quantitative characteristics of SCFA production.  
The absorption of SCFA in the caecum and the colon is a very efficient process with 
only a small amount excreted in faeces (369). Passive diffusion of protonated SCFA and 
anion Na+/K+ exchange with parallel transport of water are two major mechanisms of 
absorption.   Once absorbed, SCFA are metabolized at three major sites (369). 
1) Colonic epithelial cells use butyrate and to a lesser extent propionate and acetate for 
energy production and maintenance 
2) Liver cells metabolize propionate eg for gluconeogenesis and acetate for lipogenesis 
3) Muscle cells and other tissues produce energy from the oxidation of residual acetate 
Acetate 
Acetate is the principal SCFA produced in the colon by fermentation. In humans acetate is 
not metabolized locally at the colon but is absorbed and transferred in the circulation 
(369;370). Acetate is mainly a fuel source for the host and participates in the de novo lipid 
and cholesterol synthesis sparing fatty acid oxidation.  
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Propionate 
Propionate, the second major fermentation product, is readily absorbed and taken up by the 
liver where it constitutes a precursor of glucose production in gluconeogenesis (364;371). It 
can be used as metabolic fuel by colonocytes but with less efficiency than butyrate. 
Propionate may also be a mediator in the regulation of cholesterol synthesis most likely by 
inhibition of the cholesterol synthesis enzyme 3-hydroxy-3-methylglutaryl-CoA sythetase and 
reductase (372). A few studies examining the use of propionate supplementation as a 
potential cholesterol lowering agent gave contradictory results (373).   
Butyrate 
Butyrate has attracted the most attention. Compared with acetate and propionate, it is mostly 
taken up and used by the colonocytes although a small amount is absorbed and circulates in 
the bloodstream. Butyrate is the preferred fuel of the colonic epithelial cells and is used 
preferentially over propionate and acetate in a ratio of 90:30:50 and it is preferred over 
glucose or glutamine supplied by the blood stream (374-376). The percentage oxygen 
consumption attributable to butyrate, when this is the only colonic substrate, is around 70%. 
There is good evidence from animal models and in vitro experiments that butyrate has cell 
proliferative properties triggering differentiation in normal mucosa and in cancer cells induces 
growth arrest and apoptosis (377-379).    
 
1.6.4.2.1. Function of SCFA in health and disease 
The role of SCFA has been the topic of extensive research over the last 30 years. SCFA play 
an important role in the homeostasis and function of the large bowel (Table 1.6.2).  
 
Table 1.6.2: Biological role and health benefits of SCFA in human 
SCFA Health benefits 
All SCFA Absorption of Na, K, Ca and water (380) 
 Gut motility (381-383) 
 Energy fuel for gut epithelium (375;376) 
 Gut mucosa blood flow (384;385) 
 Inhibit growth of pathogens and formation of carcinogenic compounds 
Acetate Energy substrate for the host 
 Substrate for lipogenesis 
Propionate Substrate for gluconeogenesis 
 Cholesterol metabolism 
Butyrate  Gut epithelial proliferation and differentiation (386;387) 
 Trophic effect (388;389) 
 Induces apoptosis to cancinogenic cells (379)  
 Anti-inflammatory properties (390) 
 
Appraisal of the important biological role of SCFA in colonic health was the spark for 
scientists to investigate SCFA metabolism and production as determinants of the 
pathogenesis of several digestive disorders.  
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Harig et al (391) proposed that diversion colitis was secondary to a nutritional 
deficiency of the colonic epithelium due to the absence of SCFA and Kiely et al  presented 
five cases studies of children with diversion colitis that improved in all cases with treatment 
on SCFA. However these results were not replicated (391) in a prospective double blind 
placebo control trial.  
It is suggested that dietary fibre will provide prophylaxis from colonic cancer although 
the exact mechanism by which this happens is unclear. This protective effect may be 
mediated by the production of SCFA and particularly butyrate (392). Butyrate exerts two 
contradictory effects on normal host and cancer cells. It inhibits proliferation and stimulates 
differentiation on human cells lines whilst inducing apoptosis in carcinoma cells lines (379).   
However, increased concentrations of butyrate may have detrimental effects in some 
GI conditions and this has been implicated in the mucosal injury seen in necrotizing 
enterocolitis (393;394). Data from preterm infants suggested that excessive production of 
butyrate during the third week of life may be involved in the pathogenesis of necrotizing 
enterocolitis commonly seen in this group of patients (395). Nevertheless excessive 
concentrations of butyrate may be an indication of alterations in the composition of 
microbiota, rather than a cause of enterocolitis, as full term children produce predominantly 
acetate and lactate during the first weeks of life (396).  
In a recent in-vitro experiment on cancer cell lines, butyrate at low concentration 
promoted intestinal barrier function whereas the opposite effect was observed at high 
concentrations (397).  The role of SCFA in IBD is discussed later in Section (1.7.1.1). 
 
1.6.4.3. Lactate 
Lactic acid is another product of fermentative action of the colonic microbiota on 
polysaccharides, predominately produced by lactobacilli and bifidobacteria, in the caecum 
(398). Lactate is found in D and L isomer form in the intestinal lumen and does not normally 
occur in high concentrations as it is further metabolized to other SCFA, mainly butyrate by 
colonic bacteria (399;400). D-lactate is produced solely by the colonic microbiota. L-lactate is 
also produced by the intestinal epithelium making the discrimination of origin difficult in 
colonic contents.  
Of particular interest is D-lactate as it has been implicated in clinical GI conditions 
involving short segments of small intestine, such in necrotizing enterocolitis, and short bowel 
syndrome (398). Delivery of unabsorbed carbohydrates in these conditions increases the 
colonic supply of fermentative material and subsequently increases production of lactic acid 
and SCFA. This lowers the colonic pH and favors the growth of acid-resistant lactic acid 
bacteria that further ferment sugars to lactic acid and further reduce pH. In fact a lowering of 
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pH in acidic values although does not affect the production of lactate it inhibits its utilization 
by other lactate-utilizing bacteria (401). All these events subsequently result in the excessive 
accumulation of lactic acid in the colon and transmission to the circulation resulting to 
acidemia and metabolic acidosis (398).   
In addition, similar to the other bacterial metabolites in the colon, lactate 
concentration in the large intestine may depend on a balance between production, intestinal 
absorption, and utilization by the commensal microbiota.   
 
1.6.4.4. Other bacterial metabolites 
Anaerobic metabolism of peptides and proteins by the intestinal microbiota along with the 
production of SCFA, generates a series of other metabolites such as, ammonia, amines, 
phenols, thiols, methane, and sulphide. Although the exact role of these molecules is not fully 
understood, in vitro and animal studies have implicated them in the aetiology of GI disorders 
such as colonic cancer and IBD (Section 1.7.1).    
      
1.6.4.4.1. Hydrogen 
Hydrogen gas production is an integral part of bacterial fermentation and it is excreted in 
breath and flatus. In addition, a large proportion is disposed by three bacterial reactions 
(350). 
1) Methanogenic bacteria reduce CO2 to CH4 consuming H2 in this process 
2) Sulphate reducing bacteria (SRB) and protein fermenting bacteria reduce sulphate 
and sulphur from amino acids to sulfide and hydrogen sulphide 
3) Variable amounts of hydrogen are also consumed by acetogenic bacteria which 
reduce CO2 to acetic acid.  
 
1.6.4.4.2. Sulphide 
The large intestine harbours a class of gram-negative anaerobes that reduce sulphate and 
sulphites to sulphide. Sulphate reducing bacteria inhabit the distal colon and compete with 
methanogenic bacteria for utilization of the colonic hydrogen pool (402;403). Their 
predominant genus, Desulfovibrios, use gaseous hydrogen as an electron donor in sulphate 
reduction reactions and account for substantial deposit of hydrogen in the colon. Sulphide is 
also produced by protein-fermenting bacteria via the metabolism of unabsorbed sulphur 
containing amino acids. Thus dietary protein and inorganic sulphur can increase faecal 
excretion of sulphide in human studies in a dose response fashion (404).  
Faecal sulphide concentrations represent a small amount of the actual production in 
the gut. Levitt et al (405) estimated that more than 95% of the produced sulphide leaves the 
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colonic content and is absorbed by the mucosa. In the colonic lumen, sulphide occurs in two 
chemical forms; free as hydrogen sulphide, and bound to divalent metal ions (Fe, Cu, Zn). In 
healthy subjects bound sulphide constitutes about 75-95% of total sulphide and its metabolic 
toxicity, although unknown, is believed to be negligible (406).  
Sulphide’s biological role, beyond the disposal of colonic hydrogen, is not well 
understood. In vitro experiments suggested toxic properties and inhibition of butyrate 
oxidation at the colonocyte (407) whereas recent evidence attributed potential beneficial anti-
inflammatory effects to sulphide in GI health (408). 
   
1.6.4.4.3. Ammonia 
Ammonia is produced by the action of bacteria on dietary peptides, endogenous cellular 
debris and intestinal secretions (409) in the distal colon, particularly in the absence of 
fermentable fibre. Faecal ammonia may be associated with colon carcinogenesis, whereas 
excess accumulation in the circulation in liver disease is responsible for hepatic 
encephalopathy in these disorders.   
 
1.6.4.4.4. Faecal pH 
Colonic pH is used as an index of bacterial activity and the colonic microenvironment, but it is 
also important for the delivery of pH controlled-release drugs (410). Inaccessibility of the 
digestive tract does not allow direct pH measurements at the different segments of the colon 
and therefore faecal samples are used as a rough estimate of the colonic conditions and 
metabolic activity although on the whole it better reflects  bacteria activity and conditions in 
the rectum.  
Most studies that measured pH values at the different parts of the digestive tract, in 
health and disease, are derived from gut autopsy of cadavers, or in vivo investigations with 
the use of radiotelemetry capsules (411) that are not practical for routine continuous 
surveillance. Measurements of luminal pH in the normal GI tract have shown a progressive 
increase from pH 6.6 at the jejunum to 7.5 at the terminal ileum, a decrease to pH 6.4 on 
passage to the caecum and then a further rise to pH 7 at the left colon (412). 
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1.7. Intestinal microbiota in IBD 
The enormous bacterial concentration and its close contact to the GI mucosa, the largest 
surface of the body, equipped with a highly sophisticated gut associated lymphoid tissue 
(GALT) immune system has always been incriminated luminal bacteria in the pathogenesis 
of IBD. This in parallel with the lesson learned with the discovery of the role of Helicobacter 
pylori in peptic ulcer disease, gastritis and gastric cancer triggered a considerable amount of 
research into the interaction between the intestinal microbiota and the mucosal epithelium in 
the pathogenesis of IBD. In IBD the most widely held view is that the development of disease 
reflects an immune response to the normal microbiota, rather than to a pathogen. The exact 
mechanism remains unknown and may be multifactorial which could explain the different 
phenotypic presentations of the disease. There is good evidence to suggest intestinal 
microbiota composition and its metabolic activity in the pathogenesis of IBD and perpetuation 
of intestinal injury. The following section (Section 1.7.1) is an outline of the evidence 
published thus far.  
 
1.7.1. Metabolic activity of intestinal microbiota in IBD 
1.7.1.1. Short chain fatty acids and IBD 
A considerable amount of research has been undertaken on the metabolic activity of 
commensal bacteria in IBD, on the basis of evidence suggesting a central role of SCFA in 
colonic health. A potential association between bacterial metabolites and IBD pathogenesis 
was further intensified in light of evidence suggesting that butyrate modulates mucosal 
inflammation and proinflammatory cytokine expression via a mechanism that involves 
inhibition of activation of the nuclear factor-kappaB (NfκB) pathway (390;413-416). 
For the purposes of this study, an extensive review of all studies on SCFA in IBD was 
carried out using Pubmed. The retrieved studies were classified into four subject categories.  
1. Colonic concentration of SCFA in IBD 
2. Metabolism of SCFA in IBD 
3. Animal experiments on the effect of SCFA in IBD 
4. Clinical trials on SCFA use in IBD 
Colonic concentration of SCFA in IBD 
In total six studies measured the colonic concentration of SCFA in IBD patients and all but 
one (417) were done in adults (Table 1.7.1). A recent study  by van Nuenen et al (418) 
described the metabolic activity of the faecal microbiota of eight IBD patients, in an in-vitro 
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model of the colon, and found significantly increased production of SCFA and BCFA 
compared with stool samples of six healthy controls.  
Different results were found among the studies, which measured SCFA 
concentrations in colonic contents of IBD patients, and therefore it is not possible to draw 
firm conclusions. Vernia et al (419) found significantly lower concentrations of SCFA and 
butyrate in 24 hour stool collections of 18 UC patients (87±11 mmol/kg) compared with 16 
healthy controls (133±12 mmol/kg) and 20 CD patients (132±13 mmol/kg). These results are 
in contrast to those by Roediger (420) in faecal dialysates of UC adults and Treem et al (417) 
in spot stool samples of IBD children, who found significant higher levels of butyrate 
compared with healthy controls.  
Inconsistent results have been reported for an association linking disease activity with 
the concentration of colonic SCFA in IBD patients (Table 1.7.1). Hove et al  found no 
association with the faecal concentration of SCFA, whereas Roediger et al (420) observed 
high levels of butyrate increasing with disease severity in faecal dialysates of UC patients 
and Treem et al (417) found high levels of butyrate in active and low levels of acetate in 
quiescent UC children but no effect in spot stool samples of CD children.  
Indeed Roediger et al (420) found that increased levels of butyrate in faecal dialysate 
correlated positively with the histological disease activity scores in mucosal biopsies whereas 
in a subsequent paper by Vernia (421) SCFA were found to be high in quiescent and mild 
UC (163±47 mmol/kg) and (148±63 mmol/kg) respectively, but were significantly decreased 
in severe disease (65±47 mmol/kg). In particular butyrate levels were low in severe UC 
(4.3±5 mmol/kg) compared to controls (13.7±8.4 mmol/kg) with the inference being that in 
severe disease there is relative butyrate deficiency and energy deficits to colonocytes. 
The use of different methodologies among the studies with the use of different types 
of material for analysis (faecal water, spot samples, 24hrs collection) may partially explain 
these contradictory results (Table 1.7.1). 
Metabolism of SCFA in IBD 
The failure to confirm the hypothesis that IBD pathogenesis is the result of low SCFA 
production and on the contrary the increased concentrations observed in some of the studies 
(417;420) redirected subsequent research towards the colonocyte metabolism of SCFA. 
In 1980, Roediger was the first to report that butyrate oxidation, was significantly 
impaired in UC, both during the active phase of the disease and in remission (422). 
Enhanced glucose and glutamine oxidation resulted as a compensatory mechanism. Their 
hypothesis, that IBD pathogenesis was the result of impaired butyrate metabolism was 
supported by the same group which showed that inhibition of beta-oxidation of fatty acids 
induced experimental colitis in rats and hence may be primarily associated with the 
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pathogenesis of UC (423). Nevertheless a causative association between butyrate and colitis 
was disputed by others who although observing diminished oxidation of butyrate in 
experimental models of colitis, reported that histological abnormalities preceded the defects 
in butyrate oxidation (424). Indeed the fact that disease remission was associated with 
normal oxidation and active disease with decreased oxidation in another study (425), 
suggests that UC mucosa is not intrinsically altered in butyrate oxidation, making this unlikely 
to be a primary causal defect leading to inflammation in UC. 
Recently two studies attracted interest in the defects of butyrate metabolism in IBD. 
Santhana et al (426) suggested that the impaired oxidation of butyrate in UC was the result 
of impairment in the last enzyme (mitochondrial acetoacetylCoA thiolase) that participates in 
butyrate oxidation inside mitochondria. Suboptimal enzymatic activity was found both in 
normal and inflamed mucosa of UC patients. This was the result of increased oxidative 
stress at the mucosal level, which modified protein structure, and functionality of the enzyme. 
Interestingly similar defect was not found in CD patients. In the second study Thibault et al. 
(427) proposed that impaired butyrate oxidation was not a primary defect but the result of a 
decreased intracellular concentration of butyrate, due to low cellular uptake of butyrate in IBD 
patients. This was due to a defect in the production of one of the butyrate transporters 
caused by the action of pro-inflammatory cytokines.  Thus there is some evidence 
suggesting impaired butyrate metabolism in IBD mainly UC. Evidence in CD is limited and 
non supportive thus far.  
Use of SCFA for the treatment of IBD 
The suggestion that diminished butyrate metabolism may cause energy deficiency in UC 
colonocytes (422), coupled with some observations of low colonic SCFA in patients with UC  
prompted the use of SCFA in animal models and in clinical trials for the management of UC 
primarily of the distal colon.  
Animal model of colitis, have been used to study the efficacy of exogenous 
administration of SCFA on disease activity and mechanisms of action (Table 1.7.2). All of the 
studies reviewed used rectal enemas of butyrate, alone or in conjunction with 5-ASAs and 
compared the results against a placebo control group (eg saline). Butyrate improved disease 
activity, colonic macroscopic and microscopic histological findings in most studies (428-430) 
and improved mucosal barrier function and colonocytes viability in one (415).  
The mechanisms that might be involved in the amelioration of colitis by butyrate 
administration include decreased expression and activation of the NFκB proinflammatory 
cascade with subsequent reduction in the secretion of pro-inflammatory cytokines (415;430). 
Moreover butyrate administration improved the expression of trefoil factor 3 that is implicated 
in epithelium integrity, protection and wound healing (430).  
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The first clinical report of the use of SCFA to treat IBD was an open label trial of a 
mixture of the three basic SCFA in 12 patients with refractory distal colitis. Of the ten patients 
who completed a six week trial, nine improved (431). Since then 12 additional clinical trials 
were identified that used SCFA in IBD (Table 1.7.3). All apart from one study (432) were 
done in UC patients mainly with distal colitis. The most common vehicle for butyrate 
administration was a sodium butyrate enema. Two studies used oral derivatives of butyrate 
(432;433). Five studies had a randomized double blind placebo controlled group although 
actual blinding was difficult, if not impossible, due to the strong odor of butyrate in rectal 
enemas. The number of patients in the studies varied between nine and 51. None of the 
studies was performed in paediatric patients.  
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Table 1.7.1: Colonic concentration of SCFA in IBD patients  
Study Design Results 
Van Nuenen  et al 2004 
(418) 
In-vitro colonic model; Production of 
bacterial metabolites in faecal samples; 8 
IBD & 6 healthy controls;  
SCFA & BCFA production was higher in IBD than control samples  
Hove & Mortensen 1995 
(434) 
Spot stool samples (103 UC, 127 CD, 70 
other GI), 20 healthy controls; including 
patients with gut resection 
No difference with controls; No effect of disease activity or length of small or 
large bowel on faecal SCFA concentration.  
Treem et al 1994 (417) Spot stool samples children (17 UC, 22 
CD, 12 healthy) 
No difference between CD & UC for SCFA; Acetate lower & butyrate higher in 
CD & UC compared with healthy controls; No difference between active & 
inactive for CD; In UC changes with activity: SCFA low in moderate-severe UC; 
Butyrate high in quiescent/mild UC 
Vernia et al 1998°  (421) Faecal water (62 UC ) SCF A high in quiescent/mild but decreased in severe disease 
Vernia et al 1988b (419) 24 hours faecal collections (18 UC & 20 
CD), 16 controls  
SCFA and particularly butyrate lower in UC than CD and healthy controls 
Roediger et al 1982 (420) Faecal dialysates (65 UC), 16 control SCFA and mainly butyrate increased in severe disease; raised butyrate 
correlated with severity of mucosa 
 
 
Table 1.7.2: Effect of SCFA administration in animal models of colitis 
Study Intervention Outcome Results 
Song et al 2006 (430)  Sodium butyrate enema, 
5-ASAs, combination, 
saline  
Colonic damage; Tissue 
Myeloperoxidase; Trefoil factor 3 mRNA 
expression; Serum IL-1β production ; 
NFκΒ expression 
All apart from saline reduced diarrhoea, improved 
colonic damage, myeloperoxidase activity, increased 
trefoil factor 3 mRNA expression, decreased serum IL-
1β production and NFκΒ expression; Better effect with 
combination 
Venkatraman et al 2003 
(415) 
Butyrate enema, saline Intestinal permeability; Cell viability Improved cell viability & mucosal permeability & PMN 
neutrophil infiltration; Inhibited heat shock protein 
expression & activation of NFκB 
Butzner et al 1996 (428)  Butyrate enema, saline, 
no treatment 
Colonic damage; Tissue 
Myeloperoxidase; Sodium absorption  
In butyrate treated group diarrheoa stopped; Colonic 
damage and sodium absorption improved; 
Myeloperoxidase activity decreased 
D’Argenio et al 1994 (429)  Sodium butyrate, 
mesalamine, combination 
or saline enema 
Throboxane B2 Sodium butyrate alone or plus mesalamine reduced 
histological activity; Transglutaminase increased, in 
butyrate and in combination; Combination reduced 
throboxane B2 synthesis  
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Table 1.7.3: Clinical trials of the effect of SCFA in IBD patients 
Study Subjects Intervention Outcome Results 
Di Sabatino et al 
2005 (432) 
13 mild/moderate CD Open label; 4 g/d butyrate for 
8 wk  
Endo, Hist, CA, cytokines, NFκB 
before and after treatment  
69% clinical improvement; Endo, Hist 
improved in ileocaecum, ESR, NFκB and 
IL-1β decreased 
Vernia et al 2003 
(435) 
51 distal UC, refractory to 
topical 5-ASA/steroids 
RDBPC multicenter; 2 g 5-
ASA and 160mM sodium 
butyrate enema or placebo 
for 6 wk  
Endo; Hist; CA Remission rate and disease improved, 
bowel movements & urgency better in 
intervention 
Luhrs et al 2002 
(414) 
11 distal UC Open label; butyrate enema 
100 mM or placebo for 8 wk 
Endo; Hist; CA Hist, CA improved; less mucosal 
macrophages positive for NFκB 
translocation 
Vernia et al 2000 
(433) 
30 mild/moderate UC RDBPC; Oral butyrate 4g/d 
plus mesalazine  2.4g/d or 
placebo 
Endo; Hist; CA Endo, Hist, CA improved in both arms; 
better improvement vs baseline for 
intervention 
Scheppach et al 
1996 (436) 
47 active distal UC RDBPC; SCFA or butyrate 
enema vs placebo 
Endo; Hist; clinical, inflammatory 
markers activity at 4 and 8 wk 
Fewer segments were endoscopically 
affected on butyrate subjects than 
placebo 
Steinhart et al 
1996 (437)  
38 active distal UC RDBPC; Butyrate enema vs 
placebo for 3 wk 
Endo; Hist; CA at baseline 3 and 6 
wk 
No difference between intervention and 
placebo 
Patz et al 1996 
(438) 
10 distal UC refractory to 
5-ASA & steroids 
Open label; SCFA enema for 
6 wk 
Endo; Hist; CA at baseline and 6 wk 50% had clinical and endoscopic 
improvement; no histological 
improvement 
Vernia et al 1995a 
(439) 
40 mild/moderate distal 
UC 
RDBPC; SCFA enema vs 
placebo for 6 wk 
Endo; Hist; CA at baseline and 6 wk Endo; Hist; CA improved 
Vernia et al 1995b 
(440)  
9 refractory to therapy Open label; Sodium butyrate 
and 5-ASA for 4 wk 
Endo; Hist; CA Endo; Hist; CA improved in 7 out of 9 
patients 
Steinhart et al 
1994 (441) 
10 distal UC; refractory to 
rectal therapy/ oral 5-ASA 
Open label; Butyrate enemas 
for 6 wk 
Endo; CA at 3 & 6 wk 6 out of 10 improved; disease score 
decreased 
Senagore et al 
1992 (442) 
45 proctosigmoiditis 
 
Open label; Steroid enema vs 
5-ASA enema vs SCFA 
Endo; Hist; CA at 6 wk Same proportion of patients improved in 
the three groups 
Scheppach et al 
1992 (443) 
10 distal UC refractory to 
therapy 
Single blind crossover; 
Butyrate enema and placebo 
for 2 wk 
Endo; Hist; CA Stool frequency ⇓; PR blood decreased; 
Endo and Hist improved 
Breuer et al 1991 
(444) 
12 distal UC reftractory to 
therapy 
Open label; SCFA enema Endo; Hist; CA CA and Hist improved 
RDBPC: Randomised double blind placebo control trial; Endoscopy: endo; Histology: hist: Clinical activity: CA
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All the open label studies and the majority of the randomized control trials favored the 
use of butyrate enemas in distal refractory UC although those with relatively large sample 
size did not find any difference in histological and endoscopic outcomes between treatment 
and placebo groups (Table 1.7.3). In most studies with a positive outcome, improvement of 
clinical disease activity was accompanied by improvement of inflammatory markers, 
histology and endoscopic findings. In two studies that tried to clarify mechanisms of action, 
use of butyrate was associated with decreased expression and activation of NFκB pathway 
(414;432).  
In summary considering the available evidence, the cost of treatment, and drug 
associated side effects, butyrate could be a promising adjuvant in the management of distal 
colitis. On the other hand, considering the limited evidence in CD, in conjunction with current 
evidence linking commensal intestinal microbiota with CD aetiology (see Section 1.7), more 
studies should be anticipated. In particular use of butyrate enemas should be considered in 
the context of paediatric trials as a possible agent for sparing the use of other medication 
with severe side effects on bone health and linear growth. In addition other vehicles of 
butyrate administration should be developed for extensive disease as the use of butyrate 
enemas is practically limited to distal colitis only.   
 
1.7.1.2. Lactate in IBD 
Previous studies reported high colonic concentrations of lactic acid and particularly of the L-
isomer in active distal UC (421;434;445). This may suggest increased mucosal production or 
impaired metabolism of lactic acid by lactate utilizing bacteria in the low luminal pH that may 
be encountered in IBD patients (410). A recent in vitro study in faecal samples, showed that 
although lactate production was sustained at pH less than 5.2, the utilization of lactate was 
reduced resulting in its excessive accumulation (401). On the other hand lactic acid 
concentration is positively associated with stool volume, steatorrhoea, and malabsorption 
(446) and might explain the increased levels seen in patients with active disease and severe 
diarrhoea.  
In the only paediatric study that measured faecal lactate in IBD, no statistical 
significant differences were found between the two types of IBD diseases or compared with a 
healthy control group (417). Van Nuenen et al (418) in an in-vitro model of colonic 
fermentation found comparable results in lactate production rates in faecal microbiota of 
healthy and IBD patients.  
 
1.7.1.3. Ammonia in IBD 
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Two studies measured colonic ammonia in IBD and in both cases this was higher than the 
healthy control group.  Roediger et al (420) measured ammonia among other bacterial 
metabolites in the colon of patients with UC and healthy controls and found that UC patients, 
particularly those with histological findings of severe disease, had higher levels of ammonia 
compared with non-inflammatory conditions. Similarly Van Nuenen et al (418) in an in-vitro 
model of colonic fermentation found higher production of ammonia by the faecal microbiota 
of eight IBD (5 CD) patients compared with healthy subjects. Increased concentration and 
production of ammonia could infer increased proteolytic action or impaired utilization by the 
intestinal microbiota in IBD patients.  
 
1.7.1.4. Colonic pH in IBD 
In IBD patients different and contradictory patterns of luminal pH have been reported in the 
literature (410). Ewe et al (447) did not find any difference in luminal pH values across the GI 
tract between patients with active IBD and healthy controls. Similar results were presented 
by Press et al (448) although higher luminal pH was measured in the terminal ileum, caecum, 
and ascending colon of UC patients compared with healthy controls. In the same study 
comparable results were found between active and inactive disease.  
In contrast very low pH values (2.3-3.4) were recorded in the caecum and right side 
of the colon in severely active UC (449) compared with healthy subjects but not in CD 
patients with ileocaecal resection (450). Luminal pH in the right colon of the patients with 
ileocaecal resection was higher by 0.5 units compared with healthy controls (450). Sasaki et 
al (411) measured comparable luminal pH in the stomach and small intestine of CD and 
healthy controls, but the colonic pH profiles differed with lower values observed in active or 
quiescent CD than seen in controls. The overall mean luminal pH in the right colon was 
5.3±0.3 for the patients versus 6.8±0.2 for the healthy controls (p < 0.01) and that in the left 
colon was 5.3±0.7 versus 7.2± (p < 0.01). 
Many factors can determine colonic pH including the amount and type of fermentable 
material in the colon, the type and number of the bacterial species, colonic motility, 
production, absorption, or utilisation of the fermentation products by other colonic bacterial, 
as well as abnormalities in the secretion of bicarbonate and the buffering effect of mucus and 
blood in active colonic disease (410). Alterations in these factors may explain the different 
results observed in the studies above.  
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1.7.1.5. Sulphide in IBD 
Several lines of evidence pointed to sulphur metabolism, being implicated in the aetiology of 
mucosal injury in IBD. A prime example is the use of sulphated polysaccharides, to induce 
features of colitis in animal models (451).  
First Roediger and colleagues  found that fatty acid oxidation at the epithelium lining 
could be hampered by a range of sulphur containing compounds. Among those tested, 
sodium hydrogen sulphide selectively reduced fatty acid beta oxidation at the level of short 
chain acyl dehydrogenation (407;452) and caused greatest mucosal injury. Based on these 
observations a hypothesis was proposed that cellular inhibition of butyrate by sulphides can 
induce energy deficient state in colonocytes resulting in mucosal inflammation and injury.  
An extensive literature review was carried out to identify studies linking IBD with sulphide 
metabolism. The retrieved studies in IBD were categorized into the following four categories. 
 
1. Prevalence of Sulphate Reducing Bacteria (SRB) in UC and comparison with healthy 
subjects. 
2. Luminal concentrations and production rate of sulphide in UC and comparison with 
healthy controls. 
3. Functionality of sulphide detoxification pathways in IBD. 
4. Pharmaceutical intervention and sulphide metabolism. 
 
Prevalence of SRB in UC and comparison with healthy subjects  
Increased numbers of SRB bacteria in faecal samples of UC patients have been reported in 
some studies. Loubinoux et al (453) using cultivation techniques on selective growth media 
linked with multiplex PCR found that SRB were more frequently observed in IBD patients 
(68%) than in healthy controls (24%) or patients with other GI disorders (37%). Moreover 
different SRB strains were observed between healthy and IBD subjects suggesting strain 
specific differences between IBD and healthy controls. In particular the prevalence of 
Desulfovibrio Piger was significantly higher in IBD (55%) compared with healthy individuals 
(12%) or patients with other GI disorders (25%). Association of SBR counts with disease 
activity was reported by one study (454), which found that total viable counts of SRB were 
increased in patients with clinical and endoscopic active disease activity compared with 
patients with quiescent disease (454).   
On the other hand recent studies using robust molecular biology techniques of 
bacterial community analysis failed to confirm the results from bacteriological studies of 
increased growth or number of SRB counts. For example Fite et al detected SRB in all 
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mucosal samples of IBD patients and healthy individuals using molecular microbiology 
techniques (455).  
 
Sulphide concentration and production 
There is inadequate evidence to suggest that luminal sulphide concentrations are different in 
IBD patients. A group from the University of Dundee, Scotland, showed that in untreated UC 
patients faecal sulphide excretion was higher than in healthy controls and treatment with 5-
ASAs lowered both concentration and production of sulphide (454;456). On the contrary 
comparable free and total faecal sulphide concentrations in IBD and healthy controls were 
presented by others (406;457). No association between luminal sulphide concentration and 
disease activity or location have been found (457).  
Compared with healthy subjects, a two to threefold increase in sulphide production 
rate has been found in faecal and mucosal samples of UC patients (458;459). Addition of 
various organic sulphur containing substrates (mucin and taurocholate) increased hydrogen 
sulphide release much more readily than sulphate intake implicating the action of other 
protein fermenting bacteria in the production of sulphide over and above the SRB. Increased 
production of sulphide has been reported also in pouchitis, an inflammatory condition of the 
ileal-anal pouch of UC patients (460).  
 
Different form of sulphide, different effect?  
Only a few studies have tried to account for the origin of the measured concentrations of 
faecal sulphide in samples from IBD patients. Sulphide occurs in two forms in the intestinal 
tract, free as hydrogen sulphide and bound to divalent metal ions. Differences in the toxicity 
of the two forms and failure to distinguish between them in the studies might explain some of 
the discrepancies reported above. Jorgensen & Mortensen (406) hypothesized that the 
binding ability of faecal material to sulphide was low in UC compared with healthy controls 
but they failed to prove this. 
 
Functionality of sulphide detoxification pathways in IBD 
Faecal sulphide concentrations represent a balance between production and removal of this 
toxic metabolite. Epithelial enzymes react with this and produce other sulphur containing 
compounds which are less harmful for the colonic mucosa (461;462). Thus elevated 
concentrations of sulphide could be a secondary result of defective detoxification 
mechanisms in the large bowel (463) although the evidence so far is circumstantial and not 
supportive (462). 
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Pharmaceutical intervention and sulphide metabolism  
In view of a possible causative role of sulphide in IBD mucosal injury, a few studies 
investigated whether the action of mainstream IBD drugs is mediated through changes in the 
metabolism of sulphide in the gut. Among them, 5-ASAs such as sulphasalazine reduced the 
production of sulphide but not the growth of SRB in in-vitro experiments (454;456) and 
subsequently differences in the concentration of faecal sulphide were observed between 
patients on treatment with 5-ASAs and those not. Moore et al (457) however did not confirm 
these results and indeed found comparable sulphide concentrations between patients on 5-
ASAs and others on different medical regimes. Difference in disease activity between these 
studies may explain this discrepancy.  
The results of the effect of metronidazole and ciprofloxacin, two commonly used 
antibiotics, on the production of sulphide and SRB counts have been contradictory (460;464). 
Recently prebiotic ingestion reduced hydrogen sulphide concentrations but not SRB counts 
in healthy volunteers and may thus have a putative place in the treatment of patients with UC 
(464). Other new agents, like bismouth based derivatives, have also been proposed for use 
in IBD to inhibit the growth of SRB and suppress production of hydrogen sulphide (460).  
 
Hydrogen Sulphide in IBD. History Revised? 
Despite the evidence that hydrogen sulphide can be a toxic mediator in gut health, recent 
studies found paradoxical actions depending on its concentration and the circumstances in 
which it is generated. For example, hydrogen sulphide may play a role in protecting gastric 
mucosal tissue from injury and exerts anti-inflammatory actions, and potentially inhibits 
leukocyte adherence to the vascular endothelium (465). Fiorucci and his colleagues (466) in 
a recent study compared the regular form of mesalamine with a new hydrogen sulphide 
releasing derivative and found that the latter was more effective than mesalamine in reducing 
the severity of animal colitis. In particular the new derivative was more effective in reducing 
granulocyte infiltration into the colonic tissue, and furthermore reduced the expression of 
mRNA for several key proinflammatory cytokines and chemokines.  
 
Effect of dietary sulphate and sulphur containing nutrients on sulphide 
production 
Diet is a strong determinant of faecal sulphide concentration (467). A diet rich in sulphur 
containing amino acids increases the production and excretion of sulphide in a dose 
dependent manner (404) by the action of protein fermenting bacteria. Similarly ingestion of 
sulphate products increased generation of sulphide by the action of SRB in the colon in one 
study (468) but not in a rat model given sulphate supplemented drinking water for one year 
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(469). An association with dietary sources of sulphur may justify discrepancies found 
between studies, such as the elevated levels of sulphide previously reported by Pitcher (454) 
in active UC but not by Moore. The high sulphide concentrations observed in the first study 
could actually be an epiphenomenon, related to sulphur amino acid fermentation of the 
mucus  and excessive sloughed cells in active disease or increased dietary intake of sulphur 
containing food that has been shown to precede disease exacerbation (470).   
 
Effect of transit time on sulphide production  
Gut transit time can also affect sulphide production and comprise a confounding factor in the 
interpretation of sulphide’s role in health and disease. Concentration of faecal sulphide and 
reduction rates of faecal sulphate are increased in faster intestinal transit times and are 
decreased in slower transit (468) and may explain any differences between active and 
inactive disease.   
 
1.7.2. Gut microbiota composition and IBD 
An imbalanced enteric microenvironment may provide a constant stimulus that activates the 
inflammatory cascade in patients with genetic defects in gut barrier function, innate and 
adaptive immune system. In the following section (Section 1.7.2.1) the topic will be reviewed 
and the essence of the enormous amount of evidence that implicates the enteric microbiota 
in the pathogenesis of IBD will be presented. For an in depth review of the state of the art the 
reader is referred to the recent report by Sartor (30).  
 
1.7.2.1. Clinical human evidence associating the gut microbiota in IBD 
There is both clinical and experimental evidence to implicate the intestinal microbiota in the 
onset and perturbation of IBD microbiota. Further to the localization of disease to intestinal 
segments with the highest bacteria concentration, clinical evidence linking the intestinal 
microbiota to IBD, comes from the observation that faecal stream diversion prevents and 
treats CD, whereas exacerbation occurs upon restoration of the faecal flow (471).  
Therapeutic intervention with selective antibiotics to decrease postoperative 
recurrence of ileal disease (472), along with the beneficial use of probiotic preparations in 
maintenance of remission in UC, and prevention of pouchitis, implicates the endogenous 
intestinal microbiota as a key player in the intestinal inflammation seen in IBD (75;76;473). 
Moreover there is persuasive evidence for loss of immunologic tolerance to components of 
the commensal flora in patients with IBD as this is reflected in serologic and cellular immune 
reactivity to enteric microbes (474;475).  
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1.7.2.2. Experimental evidence from animal models of colitis 
Studies in animal models of colitis have made a major contribution to our understanding of 
the importance of dysregulation of interactions between host mucosal cells and the resident 
luminal bacteria in the pathogenesis of IBD.  Several genetically engineered rodents develop 
chronic intestinal inflammation under conventional conditions but fail to develop colitis in a 
germ-free state (476). Administration of a normal colonic microbiota induces inflammation, 
although different bacteria exhibit different effects (477) or lead to different phenotypic 
disease characteristics. For example in interleukin-10 deficient mice, E. coli induced proximal 
colitis whereas Enterococcus faecalis led to the development of distal colitis (478). Similar to 
human studies, the involvement of intestinal microbiota in disease aetiology is supported by 
the administration of probiotic bacterial strains in animal models of colitis which modify 
disease expression by favorably altering bacterial composition, immune status, and 
inflammatory response (479).  
 
1.7.2.3. Putative mechanisms to implicate intestinal microbiota in IBD 
Compared with the scientific progress from epidemiological evidence in identification of 
genes implicated in IBD onset, the exact mechanisms by which gut bacteria are involved in 
IBD pathogenesis remain largely elusive. Four mechanistic theories have been proposed and 
are described in the following section (30;474).  
 
a. Microbial pathogens or functional changes in commensal bacteria trigger intestinal 
inflammation. 
b. Defective intestinal barrier function allows bacteria or their components/products to 
contact and activate the gut-associated immune system. 
c. Intolerance and defective host immune response to commensal microbiota initiates 
and perpetuates inflammation. 
d. IBD is the result of disruption of a harmonic microbial symbiosis in the intestinal 
ecosystem. 
 
1.7.2.3.1. Microbial pathogens or functional changes in commensal bacteria  
Since the first descriptions by Samuel Wilks in 1859 and Burrel Crohn in 1932, extensive 
work has been directed to the identification of a specific pathogen that could be of aetiologic 
importance in IBD. Among the microbes of historical interest that have been postulated to 
play a role in the pathogenesis of IBD are: Mycobacterium avium subspecies 
paratuberculosis, Listeria, Pseudomonas species, and Helicobacter pylori (474). Although no 
definite bacterium has yet been identified a few have been suggested. However identifying a 
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pathogen as a cause of IBD is rather difficult, as many of the bacteria in the human intestinal 
ecosystem are not yet culturable or a potential pathogen may be part of the subdominant 
intestinal microbiota that current molecular methods of analysis are not able to identify.  
Mycobacterium avium subspecies paratuberculosis has been most intensely 
investigated but there are still arguments regarding its role in the causation of IBD, mainly 
CD (30). In ruminants infection with Mycobacterium causes spontaneous granulomatous 
enterocolitis similar to CD and it was first cultured from resected CD tissues in 1984 (480). 
Since this first observation a few studies have reported detection of Mycobacterium avium 
subspecies paratuberculosis in IBD patients using slow growing culture (481), polymerase 
chain reaction, FISH (482), or a metagenomic approach (483) but the detection rates varied 
between 0% and 100% (456;484) suggesting other or additional causes of IBD. Recently a 
metagenomic analysis of the gut microbiota (483), did not detect Mycobacterium avium 
subspecies paratuberculosis 16S rRNA in mucosal specimens of a large number or patients 
with IBD. Likewise a large well-designed double-blinded placebo controlled RCT using an 
antibiotic cocktail failed to sustain remission in CD (485).  
Among the non-mycobacterial species, E. coli warranted considerable attention. 
Prevalence of E. coli has been reported as 3-4 times higher in the mucosal microbiota of 
patients with IBD (486) whereas novel adherent-invasive E.coli have also been described to 
colonize the ileal epithelium of patients with CD (487;488). In ileal specimens, adherent-
invasive E. coli were found in 22% of CD chronic lesions compared with 6% of controls. 
Similar findings were found by Baumgart et al (487) who observed adherent-invasive E. coli 
in more than a third of CD patients with active ileal disease but there was a low recovery in 
healthy controls. Recently Darfeuille-Michaud and his colleagues found that adherent-
invasive E.coli adhesion occurs via specific binding sites on the bacterial surface and is 
secondary to increased expression of a carcinoembryonic antigen-related cell adhesion 
molecule 6 propagated by the action of IFN-gamma or TNF-a stimulation, prior adherence by 
adherent-invasive E. coli (AIEC) bacteria (224).  
Although an infection from a potentially unknown pathogen cannot be excluded 
completely, currently there is not enough evidence to implicate one in the pathogenesis of 
IBD. In addition, the strongest argument against a persistent infection in IBD aetiology is the 
beneficial effect of host immunosuppression and steroids in disease management that 
indirectly precludes a pathogen as the sole causative mediator in IBD.  
 
1.7.2.3.2. Defective intestinal barrier function  
Preservation of intestinal homeostasis and inactivation of GALT depends on the 
maintenance of an impermeable mucosal barrier, and rapid repair of epithelial defects when 
the latter is breached. Abnormalities in the mucus-epithelial layer composition may facilitate 
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direct contact between colonic bacteria and the intestinal mucosa. This may exert an 
antigenic stimulus that activates the immune system, initiates inflammation, and further 
promotes intestinal permeability and tissue injury.  
There are several lines of evidence suggesting enhanced mucosal permeability in 
IBD (489;490) but it is still unknown whether this is a primary defect in IBD patients or a 
consequential event following disease onset. The importance of effective barrier exclusion in 
the pathogenesis of IBD is better illustrated by experimentally altered tight epithelial junctions 
in mouse models tend to predispose to severe gut inflammation (491). Genetically 
determined changes in the mucus, particularly glycosylation of the mucous glycoproteins 
may result in weakening of the mucous barrier in patients with IBD. Endogenous luminal 
bacteria or their components could degrade mucus, penetrate into the mucus layer, activate 
the local immune system, enhance recruitment of inflammatory cells and provoke 
inflammation (492;493). 
 
1.7.2.3.3. Defective host immune response to bacteria 
A defect in the innate immune response of the GALT may be implicated in the inflammatory 
process seen in IBD. Recognition of commensal bacteria and prevention of an acute immune 
response is regulated through bacterial-host crosstalk at the level of the mucosal epithelium. 
This cross-talk occurs through microbial associated molecular patterns that are recognized 
by pattern recognition receptors, such as toll-like receptors. Toll like receptor expression 
appears to be carefully regulated to mute a proinflammatory response towards mutualistic 
organisms in healthy individuals but to initiate inflammatory response in the case of 
pathogens (30).  
Polymorphisms in toll like receptors have been linked to CD pathogenesis. In 2001 
two independent groups identified the CARD15 gene on chromosome 16q as a susceptibility 
gene in CD (27;28). Three common polymorphisms were found to be associated with 
development of CD. The CARD15 protein functions as an intracellular receptor for a 
structural motif (muramyl dipeptide) of peptidoglycan a common component of bacterial cell 
walls. Upon recognition of muramyl dipeptide, CARD15 activates the NF-κB pathway a key 
step in the inflammatory response. Because of this CARD15 is considered a proinflammatory 
molecule. In CD the associated mutations impair the proinflammatory function of CARD15 
that has potentially serious consequences involving reduced antibacterial action from 
impaired production of defensins and other antimicrobial peptides from Paneth cells in both 
ileal and colonic CD (26;494;495). Other CD related genetic polymorphisms in the pattern 
recognition receptors such as toll like receptor 4, the autophagy gene ATC 16L1 which 
regulates intracellular microbial processing and killing further support the hypothesis that a 
subset of CD patients may have defective innate immune response to microbial antigens 
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(496;497). Defective mechanisms of bacteria killing could lead to defective clearance of 
bacterial antigens with parallel activation of the T cells mediated immune response.   
 
1.7.2.3.4 Dysbiosis of commensal microbiota 
Failure to identify a pathogen in IBD along with supportive clinical and experimental evidence 
suggesting involvement of normal gut microbiota in IBD, directed the focus of the subsequent 
research on the dominant intestinal microbiota. It is now generally accepted that commensal 
enteric bacteria provide the constant antigenic stimulus that continuously activates 
pathogenic T cells, causing chronic intestinal injury. The exact mechanism still remains 
unidentified but a disruption of colonic bacterial balance is incriminated.  
It has been postulated that disruption of commensal microbiota homeostasis may 
spark an aberrant immune response. A decreased ratio of protective to unprotective bacterial 
species, might reduce the production of epithelial energy substrates, increase exposure of 
bacterial proinflammatory antigens to mucosal T cells, activate the local immune response 
and overall disrupt the host tolerance to its endogenous bacteria. This concept of a 
breakdown of balance between putative species of “protective” versus “harmful” intestinal 
bacteria has been termed “dysbiosis” (498) and has been the objective and subsequent 
outcome of several investigations that tried to explain the association of gut bacteria with IBD 
pathogenesis.  
Previous studies that used conventional microbiology techniques and cultures on 
selective growth media, reported substantial differences in the microbiota composition 
between IBD patients and healthy controls, with increasing prevalence of streptococci, 
reduced numbers of bifidobacteria (499;500) and increased presence of Bacteroides fragilis 
(501;502). However due to the inability of traditional microbiology methods to culture the 
majority of luminal bacteria these results had to be revisited in the era of the new molecular 
bacteriology techniques. 
 
Review of studies on the composition of commensal microbiota in IBD 
In the following section the recent evidence suggesting dysbiosis as the causative 
mechanism of the initiation and perpetuation of inflammatory response is summarised. Due 
to the plethora of relevant studies and as it is out of the primary scope of this thesis, the 
literature review is limited to studies published in the last decade which coincides with the 
flowering of applied molecular bacteriology in clinical gastroenterology. 
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Research strategy and description of studies 
A comprehensive literature search was carried out to retrieve all studies published on the 
topic from 1998 to May 2008. Identification of additional articles was achieved via scrutiny of 
reference lists of major reviews articles. In total 27 original studies were identified with a 
boom in publications after 2004. At the beginning of this PhD there were six studies in total 
on the diversity and composition of intestinal microbiota in IBD. Twenty-one studies have 
been published since (Table 1.7.4) with the majority focusing on the mucosal associated 
microbiota.  
Most studies used a healthy control group for comparison whereas others looked into 
differences with other GI disorders or differences between the two types of IBD (CD & UC). A 
few studies looked into the spatial organization of the mucosal associated microbiota and 
some attempted to link the bacterial diversity and phylogeny with disease activity and 
dissimilarities in the bacterial composition profiles between inflamed and healthy mucosa. 
Two studies assessed temporal changes of the intestinal microbiota using colonic contents.  
Molecular bacteriology with analysis of bacterial community profiles using molecular 
fingerprinting techniques (TGGE, TTGE, DGGE) and/or characterization of the microbiota 
with species-specific bacterial probes (FISH, PCR) were most common methods used. Some 
authors used PCR amplification, with subsequent cloning and sequencing and recently two 
studies used a broad metagenomic approach to characterize the whole indigenous bacterial 
intestinal diversity in IBD patients. It is noteworthy that all but one study (503) assessed the 
microbiota of adult patients with IBD. The only paediatric study explored the mucosal 
microbiota of children with IBD. Thus far no study has been published on the bacterial 
composition of faecal microbiota of paediatric CD.    
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Table 1.7.4: Evidence table of studies on the diversity and composition of faecal and mucosal microbiota of IBD patients 
Study Aim Disease Methods Results-Comments 
Martinez et al 2008 
(504) 
Temporal changes in 
faecal microbiota on 
longstanding remission 
UC on remission 
for 1 year; H 
DGGE Similarity index declined in UC but was stable in H; Biodiversity was 
significantly lower in UC than H  
Swidsinski et al 2008 
(505)  
Composition & spatial 
organization of faecal 
microbiota; Disease activity 
effect 
CD, UC, IC, 
coeliac, self limiting 
colitis, other GI 
disorders 
Microscopy & 
FISH 
Bacterial profile opposite for 6 out of 11 FISH probes between UC & 
CD; Disease diagnosis based on analysis of the spatial organization 
& composition of bacteria & leucocytes in stool samples; Spatial 
differences between bacteria of IBD & H or other G disorders; 
Common habitual bacteria lower in IBD than H; C Coccoides group 
reduced in CD & UC; Bacteroidaceae higher in UC than CD; 
Faecalibacterium prausnitzii reduced in CD only but not UC;  
Bifidobacteriaceae absent in 56% of CD; Bifidobacteriaceae mean 
concentration higher in UC than H; Enterobacteriaceae increased in 
CD with increasing activity but not in UC; Concentration of habitual 
decreased with increasing inflammation in UC & CD; Occurrence & 
concentrations of Bifidobacteriaceae in CD lower in active disease 
than in remission & significantly lower than UC 
Baumgart et al 2007 
(487)  
Composition & spatial 
organization of ileal 
mucosal microbiota 
CD colitis & ileitis, 
H 
Culture, FISH, 
quantitative 
PCR, RAPD-
PCR, cloning 
sequencing 
In ileitis E. coli higher & Clostridiales depleted compared with CD 
colitis, or H; The number of E. coli correlated with severity of ileal 
disease; Invasive E coli was restricted to inflamed mucosa; E coli 
novel in phylogeny with pathogen like behaviour; No evidence of 
Mycobacterium avium subspecies paratuberculosis, Shigella & 
Listeria 
Frank et al 2007 
(483) 
Composition of mucosal 
microbiota 
CD, UC non-IBD 
patients 
Metagenomics, 
quantitative 
PCR 
Depletion of Firmicutes-Lachnospiraceae subgroup & Bacteroidetes 
phyla; Increase in Proteobacteria & Bacillus subgroup; Abnormal 
microbiota was associated with occurrence of abscesses 
Sokol  et al 2007 
(506) 
Comparison of mucosal 
microbiota in inflamed & 
healthy tissue 
UC TTGE No difference was found. 
Vasquez et al 2007 
(507)  
Composition of mucosal 
microbiota; comparison 
between healthy & 
inflamed ileal tissue 
CD surgical 
samples 
TTGE, FISH High similarity between inflamed & non inflamed, No intraepithelial 
bacteria were detected or bacteria in direct contact  
Martinez et al 2006 
(508) 
Composition of mucosal 
microbiota  
CD, UC, ischemic 
colitis, H 
DGGE, 
sequencing 
Patient-to-patient bacterial variability higher in CD than in H & UC; In 
CD prevalence of Clostridia, Ruminococcus torques, E. coli higher 
whereas for Faecalibacterium prausnitzii lower than H; Some 
opportunistic pathogens (Enterobacter, Proteus, Haemophilus, 
Klebsiella occasionally found in CD but not in H 
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Conte et al 2006 
(503) 
Composition of mucosal 
microbiota 
Newly diagnosed 
CD, UC, IC, 
lymphonodular 
hyperplasia, H, 
children 
Culture, real 
time RT-PCR 
Higher number of aerobic & facultative anaerobic bacteria in IBD 
than in H; Increased concentration of mucosa associated bacteria; 
Occurrence of B. vulgatus lower in IBD whereas E. coli higher than 
H; Klebsiella occurred in IC; Pathogens were not isolated; No 
differences for bifidobacteria, C coccoides group, Faecalibacterium 
prausnitzii; Higher colonization in rectum & ileum 
Bibiloni et al 2006 
(509)  
Composition of mucosal 
microbiota; comparison 
between healthy & 
inflamed tissue 
Active, newly 
diagnosed, 
untreated CD & 
UC, H;  
DGGE, cloning, 
PCR & RT-
PCR 
UC patients higher number of mucosa associated bacteria than CD 
or H; No difference in bacteria between inflamed & healthy tissue; 
High number of unclassified bacteria belonging to Bacteroidetes in 
CD; Different bacteria composition between CD & UC & with healthy; 
No differences for M. avium, paratuberculosis, H. Pylori, C. difficile, 
SRB, lactic acid bacteria & bifidobacteria 
Gophna et al 2006 
(510)  
Composition of mucosal 
microbiota; comparison 
between healthy & 
inflamed tissue 
 
 
CD, UC, H PCR, cloning, 
sequencing 
Proteobacteria (Acinetobacter junni, Klebsiella pneumoniae, SRB), 
Bacteroidetes (B. fragilis) higher in CD than H or UC but Firmicutes 
(clostridia class) lower; No difference between UC & H; No 
differences between inflamed & healthy tissue 
Ott et al 2006 (511) Composition of mucosal 
fungal microbiota 
IBD, H FISH, DGGE, 
cloning, 
sequencing 
Diversity has increased in IBD; different composition with H 
Sokol et al 2006 
(512) 
Composition of faecal 
microbiota  
CD, UC, infectious 
colitis, H 
FISH  IBD microbiota comprises of unusual bacteria; C. coccoides group 
was reduced in UC & C. leptum group in CD 
Manichanh et al 2006 
(513)  
Composition of faecal 
microbiota 
CD in remission, H Metagenomics 
& FISH 
Reduced diversity of Firmicutes phyla in CD; C leptum group was 
less abundant in CD than H; Presence of unknown species was 
more common in CD than in H  
Scanlan et al 2006 
(514) 
Temporal changes in 
faecal dominant & 
selective subdominant 
microbiota; Disease activity 
effect   
CD, H DGGE Dominant microbiota stability changed in CD; Reduced diversity in 
CD compared with H; In remission diversity & stability more stable 
compared with active disease; Clostridium & Bacteroides were 
reduced in a proportion of CD but in none of the H; Inter-individual 
similarity was higher in H than CD; No temporal changes for 
bacterial stability or diversity for Bifidobacteria for CD or H; Lactic 
acid bacteria were complex & host specific & changed with time in 
both CD & H. Diversity higher in H than CD 
Seksik et al 2005 
(515) 
Composition of mucosal 
microbiota; comparison 
between healthy & 
inflamed tissue 
CD TTGE Bacterial diversity remained high in ulcerated & non ulcerated 
mucosa 
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Mylonaki et al 2005 
(516)  
Composition of rectal 
mucosa microbiota 
CD, UC, H FISH In UC less bifidobacteria but more E coli; E coli & Clostridia higher in 
active than inactive UC; E coli higher in CD; Individual bacteria & 
clusters were detected in the lamina propria of CD & UC. None was 
detected in H  
Swidsinski et al 2005 
(517) 
Composition & spatial 
organization of mucosal 
microbiota  
CD, UC, self 
limiting colitis, IBS, 
H 
FISH Higher concentrations of mucosal bacteria in IBD; Bacteroides 
fragilis prevalent in IBD; Eubacterium rectale-clostridium coccoides 
less prevalent in IBD; No patient with bacterial infiltration of the 
mucosa  
Lepage et al 2005 
(518) 
Comparison of mucosal 
microbiota composition 
along the GI tract; 
Comparison with faecal 
microbiota 
CD, UC, H TTGE Mucosal microbiota diversity stable along the GI tract; No differences 
with disease activity but differences with faecal microbiota 
Bullock et al 2004 
(519) 
Composition of faecal 
microbiota; Disease activity 
effect  
UC FISH & DGGE Lactobacilli number lower in active disease 
Ott et al 2004 (520) Composition of mucosa 
microbiota 
CD, UC, non-IBD 
GI inflammatory 
conditions, H 
SSCP, cloning, 
sequencing, 
real time PCR  
Diversity was reduced to 50% in CD & to 30% in UC; Anaerobic 
bacteria (Bacteroides, Eubacterium, Lactobacillus species were 
reduced) 
Macfarlane et al 2004 
(340) 
Composition of mucosal 
rectal microbiota 
UC, H Culture, FISH UC lower ratio of anaerobes to facultative anaerobes than H; 
Bifidobacteria counts 30 times higher in H than UC: 
Peptostreptococci were only detected in UC; Bacteria diffused in the 
mucus of UC but not in H 
Prindiville et al 2004 
(521) 
Composition of mucosal 
microbiota  
CD (some surgical 
specimens too), H;  
PCR, cloning, 
sequencing 
In CD colon more facultative aerobes than H; In small bowel 
Ruminococcus gravus (C Coccoides) was increased whereas C 
leptum & Prevotella nigrescens decreased in CD; No difference 
between healthy & inflamed mucosa 
Mangin et al 2004 
(522)  
Composition of faecal 
microbiota 
CD, H PCR, cloning, 
sequencing 
All CD shared B. Vulgatus but none in H; E coli isolated in 50% of 
CD but not in H; Numerous other clones belonged to uncommon 
bacteria in CD 
Seksik et al 2003 
(523) 
Composition of faecal 
microbiota; Disease activity 
effect 
CD colitis, H TTGE, 
quantitative 
dot-blot 
hybridisation 
Enterobacteria higher in CD; Diversity remained high but varied in 
active & quiescent disease  
30% of microbiota belonged to yet undefined phylogenetic groups 
Kleessen et al 2002 
(524)  
Composition & spatial 
organization of mucosal 
microbiota  
CD, UC, H FISH Mucosa adherent & invading bacteria in IBD; Bacterial invasion of 
the mucosa was evident in 83.3% of colonic specimens from the UC 
patients, in 55.6% of the ileal and in 25% of the colonic specimens 
from the CD patients; No bacteria were detected in the tissues of the 
H. 
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Swidsinski et al 2002 
(525) 
Composition & spatial 
organization of mucosal 
microbiota 
CD, UC, IC, self 
limiting colitis, H 
Culture, FISH, 
quantitative 
PCR, cloning, 
sequencing, 
electron 
microscope 
Mucosal bacteria concentration high in IBD; Higher in CD; 
Concentration increasing with severity; no phylogenetic differences;  
No evidence of mycobacteria or listeria; Bacteroides & E coli higher 
in IBD; Intracellular bacteria observed in mucosa with the high 
bacterial load; No bacteria in lamina propria 
Schultsz  et al 1999 
(493) 
Composition & spatial 
organization of mucosal 
microbiota of the rectum 
Active CD, UC, H In situ 
hybridization 
Bacteria more common & in higher concentration in IBD; Bacteria 
were localized within mucus layer, but were not adherent to 
epithelium; No presence in lamina propria; No correlation between 
the bacterial counts & the degree of inflammation or the use of anti-
inflammatory medication 
H: healthy
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Characterization of intestinal microbiota in IBD 
Microbial diversity and abundance is reported to be decreased in IBD compared with healthy 
controls (504;513;520) with a decrease up to 50% in CD and to 30% in UC. Only one study 
investigated the diversity of yeasts which was found to be increased in IBD patients (526). 
Inter-individual similarity of bacterial community profiles is reportedly high in healthy or UC 
but not CD subjects indicating that the former two groups share more common bacteria 
among individuals than CD patients (504;514). 
With regard to the composition of the intestinal microbiota, higher numbers of aerobic 
and facultative anaerobic bacteria have been reported in IBD (503;521;527) signalling a 
different intestinal ecosystem compared with healthy people. Frequently characterization of 
the bacterial composition revealed increased numbers of enterobacteriaceae (523), mainly E. 
coli  (516;522) and decrease in Firmicutes (483;513) with selectively decreased Clostridium 
species (487;505;510;512;514;517;521;525). Recently in a comprehensive analysis of 190 
IBD tissue samples Frank et al, using a metagenomic approach, (483) confirmed these 
previous observations and found decreased numbers of the phylum Firmicutes and 
Bacteroidetes and a parallel increase in Proteobacteria and Actonibacteria (483). 
An “unhealthy” colonic microbiota mucosa with reduced putative beneficial species 
like bifidobacteria or lactobacilli and occasionally an increase in commensal opportunistic 
pathogens like E. coli has been reported by few (505;516;519;520) but not all investigators 
(509). It is noteworthy that bifidobacteria was found at 30-fold higher levels in healthy than 
UC mucosal cultures and the presence of peptostreptococci was only identified in the latter 
specimens (527). 
Undefined new bacterial species that do not belong to common dominant microbiota 
were typically seen in IBD mucosal and faecal specimens and the possible contribution of 
these strains to IBD remains elusive (509;513;520;522;523;528).  
Comparisons of the faecal microbiota of patients with CD, UC and infectious colitis 
showed significant differences suggesting that observed modifications of the flora are not 
only because of the ecological changes induced by colitis (512).  
 
Evidence of bacterial pathogens in IBD 
Identification of pathogens was only a secondary objective in the studies reviewed, and the 
majority did not find clear evidence for pathogens such as Mycobacteria, Listeria, (487;525) 
H. pylori, C. difficile, and SRB (509). Occasionally some authors detected opportunistic 
pathogens in mucosa samples of patients with CD only but not in healthy or UC subjects 
(503;504;510). Bacteroides vulgatus, a mucus degrading bacterium which initiates colitis in 
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transgenic HLA-B27 rats (477), was detected, in most of the faecal samples of patients with 
CD but was rarely retrieved from healthy participants in a French study  and this is in 
agreement with previous studies using traditional microbiology on growth media.   
 
IBD microbiota and disease activity 
The notion that intestinal microbiota composition might influence disease activity and explain 
the remitting and relapsing disease course has been challenged by a few researchers, 
although it is difficult to distinguish whether any difference seen has a primary causal effect 
or is a secondary to the disease process. Some authors found that the diversity of microbiota 
or individual bacterial species (505) were different between active and inactive disease (523) 
(Table 1.7.4).  
An association between disease activity and specific bacterial species was recently 
reported by Baumgart et al (487) who found that in CD with ileal involvement E. coli numbers 
in situ correlated with the severity of ileal disease. Likewise in a previous study Swidsinski et 
al  found increased concentration of mucosa adherent bacteria with increasing severity and 
Bullock et al (519) found lower concentration for lactobacilli in active compared to quiescent 
UC disease. Swidsinski et al (505) recently found that with increasing intestinal inflammation, 
loss of the habitual microbiota occurred in both CD and UC. In the same study, species-
specific changes were observed between active and quiescent disease in CD with 
Enterobacteriaceae increased and bifidobacteria decreased in active compared with inactive 
CD. 
A  localized bacterial dysbiosis, and alterations in the mucosal microbiota between 
inflamed and healthy tissue has not been found in the majority of studies 
(506;507;509;510;521). Only Baumgart et al (487) observed a high presence of adherent and 
invasive E. coli in the inflamed but not in healthy mucosa of CD patients with ileum 
involvement. Failure to identify any difference between the microbiota of healthy and 
inflamed areas is contrary to the hypothesis of a localized “dysbiosis” which could explain the 
intestinal lesions and the disease distribution mainly in CD.  
 
Spatial organization of bacterial microbiota 
The well documented differences between faecal and mucosal associated microbiota (347) 
and the direct contact of the latter to the intestinal epithelium prompted a considerable 
amount of research to be directed towards the spatial organization of the mucosal associated 
microbiota. 
Several studies have repeatedly shown that the epithelial surface or mucus layer of 
IBD patients contains a higher number of bacteria compared with controls 
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(487;493;509;517;524;525). Bacterial infiltration and detection of intracellular bacteria in the 
intestinal epithelium and lamina propria of patients with IBD were reported by some 
investigators  particularly, in specimens with increased number of mucosal associated 
bacteria, but not by all (493;507;517). An interesting observation is that intracellular E. coli 
were observed in the inflamed tissue of ileal but not CD colitis, despite the higher 
concentration of bacteria lining the villi of the latter.  
 
Differences in the gut microbiota between CD and UC 
Disease specific differences in the commensal microbiota profiles were described in several 
studies (505;509;510;524;525). Swidsinski et al (525) found a higher concentration of 
mucosal adherent bacteria in CD than in UC, but no phylogenic differences were described. 
In a following study, the same group (505) showed a different bacterial profile between UC 
and CD for six out of 11 FISH probes used. In particular Faecalbacterium prausnitzii was 
dramatically reduced in CD only but was unaffected in UC. In 56% of the CD patients 
bifidobacteria were undetectable, whereas the mean concentration of the latter was higher in 
UC than in healthy faecal specimens. Based on these overt disease specific bacterial 
differences and in conjunction with differences in the faecal leucocytes concentrations, 
diagnostic cutoffs were proposed by the authors to discriminate between active CD and UC. 
Similarly Gophna et al (510) found significant phylogenetic differences between CD and UC 
and an overall more unbalanced microbiota in CD than in UC.  
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Temporal changes of microbiota in IBD 
Stability of the diversity and composition of the dominant intestinal microbiota is 
characteristic of healthy adults. Disturbance occurs in some GI diseases as well as with 
dietary or pharmaceutical intervention. Only two studies assessed temporal changes of the 
intestinal microbiota in IBD. Martinez observed a decline in the bacterial similarity index of 
UC patients on longstanding remission of one year. No changes were seen for the healthy 
subjects who preserved both their bacterial diversity and similarity (504). Likewise Scanlan et 
al (514) found unstable microbiota profiles and decreasing diversity in CD patients who had 
achieved clinical remission with steroid treatment. However no changes in the bacterial 
profile stability or diversity of bifidobacteria species were observed. A disease activity effect 
was observed with a more stable diversity in quiescent than in active disease (514).  
 
Microbiota diversity along the GI tract in IBD 
No major differences were observed in the diversity of the dominant mucosal-associated 
microbiota along the digestive tract in IBD patients (518) although Baumgart et al (487) found 
that invasive-adherent E. coli occurred more often in CD with ileal involvement than in 
inflammation confined to the colon. 
 
Paediatric studies of intestinal microbiota in IBD 
To the best of my knowledge only one study has investigated the intestinal microbiota of 
paediatric patients with IBD. Conte and his colleagues (503) investigated and characterized 
the predominant composition of the mucosa associated intestinal microbiota in colonoscopic 
specimens of paediatric patients with newly diagnosed IBD, children with lymphonodular 
hyperplasia and healthy controls. Using traditional culturing procedures linked with novel 
molecular biology techniques, the authors found more mucosa associated bacteria and 
measured higher numbers of aerobic and facultative aerobic bacteria in IBD than in healthy 
controls. Pathogens were not isolated (Yersinia, Campylobacter, etc), nor were differences 
for bifidobacteria, C. coccoides group, Faecalibacterium prausnitzii, observed, as opposed to 
some adult studies (Table 1.7.4). Occurrence of B. vulgatus was lower and E. coli was 
increased in IBD compared with healthy children. 
 
1.7.2.3.5. Conclusion 
Bacterial dysbiosis in the luminal microenvironment rather than a single pathogen has been 
proposed as a putative mechanism in IBD aetiopathogenesis (498), and overall this 
comprehensive review supports this hypothesis. However a pathogen as causative factor in 
 121 
IBD cannot be entirely excluded. One should bear in mind that these studies have mostly 
assessed the dominant intestinal microbiota qualitatively and therefore cannot fully exclude 
quantitative differences, qualitative differences in the subdominant bacteria or a pathogen 
that which is unable to be isolated and be studied with contemporary techniques. 
In summary commensal intestinal microbiota is distinguishable in IBD from that of 
healthy subjects: 
a. With increased numbers of bacteria in the mucus layer or in contact with 
epithelial cells 
b. Reduced bacterial diversity 
c. Unstable bacterial diversity over time 
d. Colonisation by uncommon, unidentified bacteria 
e. Reduction in several “beneficial” species and increase of opportunistic 
pathogens 
f. Disease activity associated changes 
Changes in the microbiota of patients with IBD are difficult to interpret clinically 
although many of the depleted bacteria are major butyrate producers and their reduction 
might therefore compromise production of epithelial energy substrates (513).  
In considering dysbiosis as a key factor in the pathogenesis of IBD, perhaps the most 
difficult question is to distinguish between cause and effect: “Is dysbiosis just a secondary 
phenomenon of IBD or is it actually the cause of it?” All the former studies were unable to 
answer this as they recruited patients with established disease. Only a large cohort 
longitudinal study with follow up measurements prior to disease onset could identify 
differences in gut microbiota diversity and metabolism between healthy people and patients 
who developed IBD at follow up. It was surprising that evidence concerning gut microbiota in 
paediatric IBD comes from a single study in patients with active disease. Extrapolation of the 
results from adult studies may not be appropriate. Although both adults and children share 
common pathology and clinical characteristics, the phenotypic characteristics and response 
to treatment are different. Paediatric IBD is more extensive and aggressive than in adults and 
perhaps differences in adult microbiota might explain that. More studies are needed to 
explore the composition of the intestinal microbiota in paediatric IBD and how this fluctuates 
with disease activity.   
 
1.7.2.4. Enteral nutrition, gut flora and metabolism in patients with IBD 
Although the commensal gut microbiota is stable over time (341), its composition can 
fluctuate under circumstances such as in health and disease. Nutrition is a strong 
determinant of the microbiota composition and metabolic activity, and although daily changes 
in a normal diet are coupled with minor modifications of the faecal flora, radical changes of a 
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person’s diet such as artificial nutrition can affect the composition and metabolic activity of 
the commensal bacteria (529).  
On the other hand commensal intestinal microbiota is implicated in the disease 
pathogenesis in IBD, and “dysbiosis” is considered as one of the putative mechanisms that 
may be implicated in intestinal inflammation and mucosal injury (Section 1.7.2.3.4). Thus 
modification of the commensal microbiota to a more beneficial/balanced microbiota could be 
a possible mechanism of action for EEN and could also explain the better efficacy of EEN in 
sites of the GI tract (264) where abnormal microbiota is usually encountered. Although 
modification of the intestinal microbiota has always been suggested as one of the potential 
mechanisms of action in relevant topic reviews (276;530) none of those cited an appropriate 
study. Thus far the only peer-reviewed evidence comes from an Italian study by Lionetti et al 
(531) and a recent Australian by Leach et at (532). 
The first by Lionetti et al (531) in a clinical study, collected serial stool samples from 
nine patients on EEN treated with a polymeric feed for eight weeks. Using molecular 
methods of bacterial community profile analysis, they found evident changes in the dominant 
gut microbiota as a consequence of EEN treatment. Ongoing changes were also seen 
beyond eight weeks whilst children maintained supplementary formula. In contrast, samples 
from healthy children showed stable bacterial profiles with no variation over time. In the 
second study Leach et al (532) collected serial stools samples from six CD children during 
EEN, and at four weeks and at four months after treatment, and compared their bacterial 
composition patterns and diversity with seven healthy children. The diversity of bacteria was 
assessed with DGGE and changes in the global bacterial, and group specific diversity and 
similarity patterns were measured. Although bacterial diversity did not differ significantly 
between healthy and CD children at treatment initiation a lower diversity was found at the 
end of treatment in the CD group compared with the healthy controls. Bacteroides-prevotella 
and Clostridium coccoides bacterial species were significantly decreased in the CD group 
compared with the healthy controls at the end of EEN treatment. Moreover the similarity 
index of bacterial diversity was low during treatment for all bacterial groups studied, and was 
significantly lower than healthy subjects. However no pairwise comparison of changes in 
bacterial diversity and similarity patterns were reported during EEN to investigate changes 
during treatment.     
Disease improvement and amelioration of intestinal inflammation might be a result of 
changes in the production of bacterial metabolites which have been implicated in the 
pathogenesis of IBD, like SCFA and sulphide. Such a putative mode of action has been 
proposed by Day et al (533) in a recent review whereas possible prebiotic properties have 
also been attributed to the feeds (531). However to the best of our knowledge most of the 
commercial feeds commonly used for the management of CD, and particularly those tested 
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by the studies above lack non-digestible carbohydrate which could impart a prebiotic effect to 
the supplement.  
 Beyond the limited evidence of relevant studies in the area of IBD, studies that 
assessed the effect of EEN on the gut microbiota of healthy people or patients with other 
morbidities may be of relevance. The evidence on this topic has been recently reviewed by 
Whelan et al. (529) In a series of studies, it was concluded that the evidence of an effect of 
EN on the intestinal bacterial metabolism is inconclusive. Results from individual studies 
were contradictory with some showing large reductions in the total number and type of 
bacteria, and others suggesting no changes or increase in particular bacterial species. Apart 
from differences in study design, methodological flaws, and different types of nutritional 
formulae, the additional limitations of the use of conventional bacteriological techniques 
might explain these discrepancies (529). In keeping with the ability of nutritional therapy to 
affect colonic fermentation, most of the studies observed reduction in the production of 
SCFA, particularly butyrate, in healthy subjects on low residue feeds (529).  
In a recent double blind RCT with cross over design, Whelan et al (324) administered 
a standard low residue diet or one high in fructoligosaccharides and fibre in 10 healthy adults 
exclusively for 14 days with a six week wash out period. In both treatments reductions in total 
faecal bacteria were observed with FISH analysis although these were higher in the low 
residue regime. Although the low residue diet did not alter the diversity of microbiota, the 
high residue diet increased bifidobacteria and reduced clostridia concentration and relative 
proportion compared with baseline. Similarly the low residue feed reduced the concentration 
of total and major SCFA compared with baseline values whereas in the fortified feeds group, 
reductions were observed only for butyrate. Marked changes were observed in the relative 
proportion of each SCFA, following consumption of the feeds. Consumption of the low 
residue feed resulted in an increase in the relative proportion of acetate, isobutyrate, and 
isovalerate and a reduction in the percentage of butyrate compared with baseline values. For 
the high residue formulae similar changes with the alternative feeds were observed only for 
acetate and butyrate. Regarding changes in  faecal pH, administration of both low and high 
residue diet, increased pH significantly although the increase was lower in the latter.  
 In other GI disorders Schneider et al (534) in a cross sectional study of eight patients 
on nutritional therapy with feeds low in residue, demonstrated concentrations which were 
lower for faecal anaerobes and higher for aerobes, despite no difference compared with 
healthy controls for bacteroides, clostridia, and bifidobacteria. In a third group on total 
parenteral nutrition, both aerobes and anaerobes decreased dramatically. Despite 
differences in bacterial populations, there were no differences between patients, and healthy 
controls in the concentrations of total SCFA, acetate, propionate or butyrate. In the total 
parenteral group, total SCFA were decreased compared with the EN group.    
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Extrapolating the results from studies in healthy subjects or similar investigations in 
other digestive disorders, in the context of IBD is inappropriate. Changes in gut bacteria 
population and metabolic activity can be attributed to both the effect of nutritional therapy and 
disease-mediated effects as commensal microbiota are strongly implicated in IBD 
pathogenesis. In the studies reviewed by Whelan (529) in healthy subjects any changes 
could be ascribed mainly to the effect of the nutritional therapy. In IBD this could be the 
additional outcome of disease improvement. The effect of EEN on the gut microbial flora 
deserves further exploration. Alterations in the bacterial populations and metabolic activity 
may alter interactions with the intestinal epithelium, thereby leading to modulation of 
inflammation. With the advent of new methods of analysis of bacterial flora, more evidence is 
anticipated. 
 
1.8. Overall conclusions and proposed areas of research 
From the pathogenesis of the disease to its management, nutrition plays an important role in 
paediatric IBD. The extensive literature review presented above was a compilation of the 
evidence on nutritional aspects in IBD and aimed to identify areas of interest for further 
research. Although good evidence is emerging from research and clinical experience to 
advocate the role of EEN in disease management there is a substantial lack of studies 
investigating its mechanisms of action. This combined with the evidence that implicates the 
commensal microbiota in disease pathogenesis led the researcher to postulate a mechanism 
of EEN action mediated through modulation of intestinal microbiota diversity and/or metabolic 
activity. In 2004 when this PhD started there was no published evidence, which explored this 
although leading reviews on the topic often cited this as a mechanism of action. More 
evidence was therefore needed to address these anecdotal speculations. The two studies 
that followed were of small number of patients and were restricted only to changes in 
bacterial diversity. None of these explored changed in the metabolic activity of the 
commensal microbiota. A study that assessed changes in metabolic activity and bacterial 
diversity is presented in Chapter 7. 
 As was described in Section 1.5, nutritional therapy has a double role in paediatric 
CD. This is mainly to induce clinical remission, and in parallel, to improve nutritional status in 
active paediatric CD. Although changes in basic anthropometry have been described in 
almost all of the studies, changes in body composition and micronutrient status have not 
been reported extensively. New methods of body composition are now available which allow 
measurements at bedside.  These are explored in Chapter 4. 
Micronutrients play an important role in health, and in IBD, there is evidence to 
suggest an additional role in disease pathogenesis, and intestinal injury. Consensus 
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guidelines from North America suggest that all patients should be screened regularly for 
micronutrient deficiencies. However any speculation on micronutrient deficiencies in IBD is 
based on studies from adult studies, case reports and studies of individual micronutrients. 
Moreover low levels observed in many of the and their association with disease activity has 
to be revisited as recent evidence suggests that disease activity and acute phase response 
can spuriously change the serum levels of micronutrients and any association with activity 
markers may actually be artefactual.  This is investigated in Chapter 5. 
On the other hand the role of other unconventional nutritional therapies, such as 
probiotics, and special diets are increasing in the general population but the evidence from 
paediatric IBD studies is limited. As many of these therapies, have a good record of efficacy, 
increase in their use, by IBD patients should be anticipated. Moreover avoidance of specific 
food groups, as part of adherence on exclusion diets, can impact on the micronutrient status 
of the patients and affect their health negatively. The use of nutritional therapies, special 
diets and alternative medicine is explored in Chapter 2.  
The aim of this doctorate therefore was to study the use of unconventional nutritional 
therapies by paediatric IBD patients and the effect of EEN on the intestinal microbiota and 
nutritional status, by measuring body composition, micronutrient status and disease activity. 
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CHAPTER TWO 
 
 
 
 
 
Dietary modifications, nutritional supplements 
and alternative medicine in paediatric patients 
with IBD. 
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OUTLINE 
This chapter describes a questionnaire survey to assess the use of special diets, nutritional 
supplements and alternative medicine in a paediatric population of Scottish children with IBD. 
Predictors and reasons of use are discussed. This study has already been published. 
Alimentary Pharmacology and Therapeutics. 2008 15;27(2):155-65 
 
2.1. Introduction 
The aetiology of IBD remains unknown and the most effective medications commonly have 
side effects that limit patients’ acceptance and long-term compliance. In children, the 
additional issues of growth, maturity and body image make disease management more 
complicated and troublesome for health professionals, the patients themselves and their 
guardians (34). Although most patients rely on conventional medicine, some may combine or 
replace this with unconventional-alternative remedies for the management of their condition 
(60;68). 
Complementary an alternative medicine (CAM) use by the general population is 
widespread around the world (48) and increasing over time (Section 1.2.2). CAM use is 
reported as high in chronic illness and gastrointestinal patients (47;50;51;56;60-
62;66;69;70;535). In particular, the prevalence of CAM use in IBD patients has been reported 
to be higher than in healthy people (61) and although early studies estimated that 4% of 
patients use CAM (62), recent surveys reported a sharp increase to 72% (69). However no 
definite figures can be drawn. The use of CAM varies widely between studies and this could 
reflect differences in study design, responding populations (68;536), cultural specificities or 
preferences (46), but most of all the different definitions of CAM (48). There is no clear 
definition of which specific methods and remedies comprise CAM and which do not. Some 
studies included therapies like prayer (46;537) and exercise in the definition and others 
excluded the use of multivitamins purchased over the counter (63). Therapies with good 
evidence of clinical efficacy, but which are not prescribed as conventional medicine, like 
probiotics, were included in only a few studies (64;66). In fact with more scientific evidence 
accumulating around the efficacy of such products (75;538) and their commercialization, it is 
anticipated that more patients will use them in the future. New branches of established CAM 
disciplines are continually being developed, taught in medical schools, used in hospital or in 
primary healthcare (54;56;539), reimbursed by insurance companies, and integrated into 
conventional medicine (540). 
Although there have been some studies on the use of CAM in adult IBD patients 
(46;63;68;539) the prevalence of CAM in paediatric populations is not well studied. 
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Differences in disease management regimes between adult and paediatric patients (34), as 
well as the issues of growth, maturity and image make the extrapolation of the results from 
adult studies difficult. Indeed the use of CAM by paediatric patients reflects the choice of their 
guardians and not the patients’, and rather how the former perceive and cope with their 
child’s disease.   
Most paediatric surveys have been conducted in the US (64) and Australia (66) with 
only one multinational study which included only a small sample of UK patients from a single 
hospital in London, UK (65). Disease management protocols differ between countries (256) 
and as the use of CAM in adults was associated with the type and use of specific 
medications (68;541), different patterns of CAM use should be expected worldwide. 
The main purpose of the present study was the evaluation of current and past CAM 
use by a paediatric IBD population in the West of Scotland, including types of CAM with good 
records of clinical efficacy, the reasons of their choice, and parental attitudes on CAM use. A 
secondary outcome was to report any factors associated with CAM use including new 
predictors like growth and anthropometry and serial post diagnostic laboratory markers of 
disease activity.  
 
2.2. Materials and methods 
All paediatric (<18 y old) IBD patients, along with their guardians, who attended their follow 
up clinical appointments at Yorkhill Royal Hospital of Sick Children, Glasgow were eligible to 
participate. This is the biggest tertiary paediatric IBD referral centre in Scotland, serving 
approximately half of the Scottish paediatric population and is predominately in charge of the 
management of almost all children with IBD in the greater region of the West of Scotland. At 
the time of the study, there was no private paediatric clinic. This allowed inclusion of nearly 
all paediatric patients diagnosed with IBD and residing in the West of Scotland. 
Given that each patient visits the IBD outpatients clinic at least once a year for 
medical review (independent of disease activity), it was anticipated that all IBD patients, and 
their guardians, could be approached within a year. All recently diagnosed patients (< 3 
months) were excluded, as they would not have had much time to consider CAM treatment. 
Patients with other severe concomitant chronic illness were also excluded.  
The study protocol was approved by the Local Research Ethics Committee and the 
Research and Development Office at Yorkhill Hospitals. 
 
2.2.1. Recruitment 
An independent clinical researcher explained the research to the patients and their 
guardians. An information leaflet was given to the guardians and an age adapted version to 
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the patients themselves. If both agreed to participate, a blank questionnaire was provided 
with a post-paid, pre-addressed envelope and the method of completion was demonstrated 
on a template questionnaire by the researcher. Participants could ask questions on clarity. 
The guardian filled in the questionnaire at home and returned it by post. A second 
questionnaire was posted to all participants that had not responded within 15 days.  
 
2.2.2. Questionnaire 
The instrument consisted of 40 questions and took approximately 15 min to complete 
(Appendix). A preliminary questionnaire was compiled using two existing questionnaires 
(64;66). The questionnaires were then modified with the inclusion and exclusion of questions 
to reflect the use, and types of CAM commonly used in the UK. CAM was defined as those 
unconventional remedies and treatments that are not normally taught in UK medical schools, 
as established approaches to IBD management, are not reimbursed by the NHS nor 
recommended by our medical staff. Exercise and prayers were not included. 
The face validity of the questionnaire was checked by several health professionals 
and the first 10 participants were asked anonymously to comment on questionnaire clarity 
and ease of use. Appropriate amendments were made to the questions and the structure of 
the instrument. 
The first section of the questionnaire described the patient’s socio-demographic and 
disease characteristics. The following section focused on the use of CAM and listed four 
groups of therapies namely Dietary modifications, Herbals, Nutritional Supplements, and 
Alternative Therapists. The guardians answered whether the child used, or had recently used 
any of these especially for the management of IBD.  The time from symptoms onset to 
diagnosis is quite variable and patients may have had the opportunity to use CAM before 
diagnosis, however to ensure all patients had significant time to try CAM after diagnosis this 
survey asked carers to document any type of CAM used three months post-diagnosis. 
In total, 35 different types of CAM were described and there was an open question at 
the end of each group for any CAM not on the list. Although multivitamins and dietary 
modifications were included, it was made clear to participants to report only those that were 
purchased over the counter or not recommended by their hospital medical staff.  
The next section, applied only to those patients that had used CAM. Participants were 
asked to report sources of information on CAM, reasons they had chosen these, their 
effectiveness, cost and doctor’s awareness of their CAM use. The last section, directed to all 
the respondents consisted of five questions addressing parental attitudes about CAM, and 
the use of CAM by other members of their family or the patients themselves for other health 
reason.  
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To ensure anonymity, confidentiality and undistorted responses the questionnaires 
were not numbered and parents asked not to add any identifiers. An invisible number was 
located on each questionnaire to identify non-respondents for subsequent mailing.  
On a supplementary form, detached from the main questionnaire, but with the same 
invisible number, the researchers recorded information on disease characteristics, post 
diagnostic laboratory data, conventional treatments, growth and anthropometry (Appendix). 
This form was reattached to the main questionnaire when the latter was returned to the 
researchers by the participants.  
 
2.2.3. Statistical analysis 
The prevalence of CAM use was estimated as the total number of patients reporting CAM 
use of any type divided by the total number of respondents. Categorical variables were 
presented as frequencies and means with standard deviations and medians with inter-
quartile range for parametric and non parametric variables respectively.  
Binary and nominal logistic regression analyses (Minitab 13) were undertaken  to 
determine potential predictors of CAM use. Candidate predictors were suggested a priori. 
These included age, sex, disease type, phenotype and duration, total number and types of 
medication since diagnosis, serial post diagnostic laboratory data on CRP (C-Reactive 
Protein), haemoglobin, albumin, ESR (Erythrocyte Sedimentation Rate), IBD operation, BMI 
(Body Mass Index), height and height velocity z-score at recruitment, six and 12 months 
before, parental use of CAM, CAM use for other reason, social deprivation score (Scottish 
Index of Multiple Deprivation; http://www.scotland.gov.uk/Topics/Statistics/SIMD/Overview), 
parental education and age. For purposes of analysis, patients were grouped into “Self-
prescribed CAM Users” (including dietary modifications, nutritional and herbal supplement 
users) and “CAM Therapist Users” (those who consulted an alternative therapist) as 
proposed by Harris and Rees (48) to permit comparison with other studies (537). The 
strength of association between use of CAM and associated factors was measured by odds 
ratio and 95% CI.  
The process of selection and inclusion of variables in the multivariate model was 
based on univariate logistic regression analysis. Associated predictors with p-values < 0.1 
were entered in a multivariate model and their independent association tested using 
backward stepwise regression. The final model included only those predictors with p-value 
less than 0.05 as independent predictors of CAM use for the binary analysis, whereas for the 
nominal regression analysis the final model considered only predictors with p-value less than 
0.05 for at least one of the comparisons.  
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2.3. Results  
2.3.1. Recruitment 
Approximately 480,000 children are serviced by the Yorkhill hospitals, and 159 patients 
visited the IBD outpatient clinic between June 2005 and July 2006 and this covers the IBD 
population serviced by the IBD clinic. Twenty four patients were not eligible to participate. 
From 135 eligible patients 104 were approached (77% of the eligible population) along with 
their guardians and all consented to participate.  Due to logistic constraints it was not 
possible to approach all patients and 31 who visited the clinic in the time of the study were 
not recruited. Eighty six including 40 female patients completed and returned the survey (83 
% response) and all were used in the analysis. All but one patient were of Caucasian origin. 
 
2.3.2. Respondents demographic characteristics 
The median age of patients at recruitment was 12.7 (4.8 – 17.5) y. There was almost equal 
distribution of the family social deprivation score (Scottish Index of Multiple Deprivation) 
(Table 2.1). The majority of the responding parents were more than 31 y old and 56% had 
higher education (college and university combined) (Table 2.1).  
 
Table 2.1: Demographic characteristics of participants in a Scottish survey on the use of CAM 
by children with IBD 
Demographics  Parental age† N (%) patients 
Gender (M/F) 46/40  18-30    5 (6) 
Age (y mean ± SD) 12.7 ± 2.8  31-45  58 (68) 
   46-60+  22 (26) 
 
Social deprivation* 
(quintiles) 
N (%) patients Parental education† N (%) patients 
 1  16 (20) Standard Grade (year 11)  25 (33) 
 2  15 (18) Highers (year 12)  8 ( 11) 
 3  13 (16) Further Education/College  18 (24) 
 4  22 (27) University  24 (32) 
 5  15 (19)   
*Scottish Index of Multiple Deprivation 2004; based on six individual domains of current income, employment, housing, health, 
education, skills and training and geographic access to services and telecommunications † responding parent 
 
2.3.3. Patients disease characteristics 
Crohn’s disease patients accounted for two thirds of participants, whereas 26% had UC, and 
9% were classified as IC according to standard endoscopy, histology and radiology criteria. 
The median age at diagnosis was 10.3 y (range: 1.9-14.5) with median disease duration of 
2.4 y (0.4-7) at time of recruitment. The majority of patients had been treated with 5-
aminosalicylates, azathioprine, steroids and EEN (Table 2.2). The majority of them had a 
repeat course of EEN or oral steroids. 12% of patients had had a major operation for IBD that 
included resection of part of their gut. 
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2.3.4. Patients anthropometry and growth data 
The mean BMI z-score of the respondents was 0.2 SD with 2.4% classified underweight (BMI 
z-score < 2 SD) and 3.6% obese (BMI z-score > 2 SD).  
 
Table 2.2: Disease characteristics and post diagnostic medication of participants in a Scottish 
survey on the use of CAM by children with IBD 
Disease type (n=86) N (%) patients Disease location  N (%) patients 
Crohn’s disease 56 (65) Lower GI 33 (42) 
Ulcerative colitis 22 (26) Upper & Lower 42 (53) 
Indeterminate colitis 8 (9) Upper 4 (5) 
    
Total post-diagnostic 
medication No N (%) of patients 
Total post-diagnostic 
medication type 
N (%) of 
patients 
≤2 6 (7) 5-ASAS 16 (81) 
3 8 (10) Azathioprine 58 (68) 
4 19 (23) Steroids 55 (65) 
5 10 (12) Vitamins / Minerals 55 (65) 
6 12 (14) EEN 51 (60) 
7 8 (10) Caloric Supplements 37 (43) 
8 10 (12) Antibiotics 36 (42) 
≥9 10 (12) Omeprazole 20 (24) 
Gut Resection 10 (12) Methotrexate 15 (18) 
  Infliximab 8 (9) 
No of oral steroid 
courses 
N (%) of patients No of EEN courses N (%) of patients 
0 36 (42) 0 36 (42) 
1 17 (20) 1 24 (28) 
2 15 (18) 2 15 (18) 
3 12 (14) 3 4 (5) 
>3 5 (6) >3 6 (7) 
Biochemistry* Median; (Range) Hospitalization (last 2 y) N (%) of patients 
Albumin (g/l)  39  (24-47) 0 34 (40) 
CRP (mg/l)  7  (7-100) 1 20 (24) 
Haemoglobin (g/dl)   11.8  (8.4-14.7) 2 14 (17) 
ESR (mm/hr)  20.7  (3-66) >2       16 (19) 
* Median of all available post-diagnosis values 
 
The mean height z-score was –0.4 SD with 7.2% presenting values less than -2 SD 
suggesting possible growth retardation. Their median height velocity at six and 12 months 
was 0.9 and 0.8 SD respectively. 
 
2.3.5. Use of CAM 
Fifty two of the eighty six respondents (61%) reported prior use of CAM for the management 
of IBD and 37% were using some form of CAM on recruitment. A quarter of the respondents 
(21/86) had consulted at least one alternative therapist whereas only three patients were 
using that kind of CAM on recruitment (Table 2.3). 
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Table 2.3 Past and recent users of CAM in a Scottish survey of children with IBD grouped into 
“self-prescribed CAM users” and “CAM therapist users” 
Type of CAM User N (%) Ever used 
(n=86) 
N (%) Recently used 
(n=86) 
“Self-prescribed CAM users” 31 (37) 29 (34) 
“CAM therapist users” 21 (24) 3 (3) 
Overall CAM use 52 (61) 32 (37) 
 
Probiotics, dairy free diet, omega-3/fish oils and aloe were the most common therapies, 
followed by gluten free diet, homeopathy, massage and over the counter multi and 
megavitamins (Table 2.4). The median and interquartile range of total number of CAM 
therapies ever used was three (range: 2-6) CAM and two (range: 1-2) in the recent users.  
 
Table 2.4: Use of dietary modifications, nutritional supplements, herbals and alternative 
therapists in a Scottish survey on the use of CAM by children with IBD  
 N (%) Ever used 
(n=86) 
N (%) Recently used 
(n=86) 
Dietary modifications 
    Dairy free diet 
 
24 (28) 
 
12 (14) 
    Gluten free diet 13 (15) 2 (2) 
    Low residue diet 8 (9) 3 (3) 
    Low sugar diet 4 (5) 0 (0) 
   Vegeterian diet 4 (5) 0 (0) 
   Other diets 5 (6) 1 (1) 
   
Herbals 
    Aloe 
 
16 (19) 
 
2 (2) 
    Garlic 8 (9) 0 (0) 
    Echinacea 8 (9) 1 (1) 
    Evening primrose 7 (8) 0 (0) 
    Other herbals 19 (23) 1 (1) 
   
Nutritional supplements 
    Probiotics 
 
38 (44) 
 
17 (20) 
    Fish / Omega-3 Oils 25 (27) 7 (8) 
    Vitamins / Minerals 12 (14) 3 (3) 
    Prebiotics 8 (9) 1 (1) 
    ‘Active’ dairy products 8 (9) 2 (2) 
    Other nutritional supplements 11 (13) 3 (3) 
   
Alternative therapists 
    Homeopathy 
 
12 (14) 
 
1 (1) 
    Massage 11 (13) 1 (1) 
    Aromatherapy 8 (9) 0 (0) 
    Yoga 5 (6) 0 (0) 
    Relaxation 5 (6) 1 (1) 
    Chiropractic 4 (5) 0 (0) 
    Reflexology 4 (5) 0 (0) 
    Other alternative therapists 14 (16) 0 (0) 
 
Seventy three percent (38/52) of CAM users answered the relevant section on CAM use. Of 
14 respondents that skipped the section, only one was a “CAM Therapist User”. Of these 22 
revealed the use of CAM to their doctor. 50% reported that their doctor reacted positively, 
37% neutrally and 12% negatively to the use of CAM. Most participants that did not report 
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the use of CAM to their doctor, thought that it was not important for their doctor to know or 
they forgot to do so.  Parents reported that they received information about CAM from 
personal recommendations, magazines, newspapers and the Internet (Table 2.5).  
 
Table 2.5: Reasons of use and sources of information on CAM in a Scottish survey on the use 
of CAM by children with IBD  
 
Reasons given for using CAM included an attempt to complement conventional treatment, 
personal experience with CAM use, frustration with conventional medication side effects and 
the belief that CAM is natural and harmless (Table 2.5).  
Approximately equal numbers (16 and 17 respectively) of CAM users judged CAM 
use effective and not effective. One patient reported deterioration of the disease condition 
and one mentioned side effects. More “CAM Therapist Users” (12/16) labelled CAM effective 
compared to “Self-prescribed CAM Users” (p=0.022). Fifteen of 38 users found CAM 
expensive although most of these (10/15) had consulted an alternative therapist.  
Twenty seven percent of all respondents had discussed CAM with their doctors and 
most were “CAM Therapist Users” (p=0.003). 16% of the children had used a type of CAM 
for other reasons whereas 32 % of the patients’ relatives had used CAM.  
Most of the parents were positive about the use of CAM, but the majority (40/53) had 
already used CAM for their child’s IBD (Table 2.6). 89% of the respondents would give their 
child CAM if they felt it to be useful although 50 out of 73 were already CAM users. In 
addition 52% of the respondents were not wary of using CAM, 57% of them would be happy 
for their child to use any type of CAM and 86% agreed with the statement that “doctors 
should be supportive of people using CAM”. On the other hand the majority of the 
respondents had no opinion about CAM safety and agreed with the statement that “not 
enough is known about CAM” (Table 2.6).  
Reasons of CAM use N (%) Sources of information N (%) 
Complement conventional treatment 21 (45) Read about it 18 (47) 
Personal experience 16 (42) Recommended by friends 18 (47) 
CAM is natural and harmless 12 (32) Internet search 10  (26) 
Frustration with medication side effects  11 (29) Recommended by health professional 7 (18) 
Dissatisfaction with medication 5 (13) Other reason 7 (18) 
Other reason 7 (10)   
CAM is more effective 1 (3)   
Lack of confidence in medication 1 (3)   
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Table 2.6: Attitude on CAM use by parents of children with IBD in a Scottish survey of the use 
of CAM 
 Disagree 
N (%) 
No opinion 
N (%) 
Agree  
N (%) 
Not a person that would use CAM 53 (74) 11 15) 8 (11) 
Doctors should be supportive of CAM 3 (4) 8 (10) 66 (86) 
Wary of using CAM 39 (52) 3 (4) 33 (44) 
CAM is very safe 16 (21) 36 (49) 22 (30) 
Not enough is known about CAM 8 (11) 15 (20) 51 (69) 
Would be happy my child to use any CAM 19 (25) 14 (18) 44 (57) 
Would give CAM only if doctor says so  31 (39) 9 (12) 39 (49) 
Would give CAM if I felt to be helpful 6 (7) 3 (4) 73 (89) 
 
2.3.6. Predictors of CAM use 
Parents under 46y and of high parental educational level were the strongest independent 
predictors that distinguished CAM users in the multivariate analysis (Table 2.7). Use of CAM 
for other health reason, and an increased number of oral steroid courses were additional 
variables that differentiated “CAM Therapist Users” from non users although a positive 
association between disease duration and use of “CAM Therapist Users” revealed in the 
univariate analysis was lost in the multivariate model. 
 
2.4. Discussion 
Knowledge of CAM use by children with IBD is imperative. Some of these treatments have 
severe adverse effects with reports in the literature of death, anaphylaxis, renal failure and 
malignancies (77;542) whereas for those with good safety records in adults, the same doses 
used in adults, may not be safe in children with a smaller drug distribution volume. Moreover 
possible unpredicted interactions with conventional medicine, could reduce or delay the 
efficacy of the prescribed treatment with subsequent detrimental prognostic effects (543). 
Paediatric data on CAM use by IBD patients is scarce and to the best of our 
knowledge this study is the biggest paediatric study so far in the UK and Europe. Unlike 
previous surveys (65) only patients younger than 18 y were recruited to ensure that the 
measured CAM use was not confounded by “adult children”. 
In this study the number of non respondents was small and any difference between 
respondents and non respondents should not change the overall findings significantly. 
Response is of utmost importance in a study where a goal is to generalize the results to the 
entire population. Poor response rate raise concerns that existing differences between 
responders and non-responders would significantly change the results.  
Although three patients approached in this study were of Asian origin, none of them 
returned the questionnaire in agreement with an adult survey where significantly less Asians 
than Europeans responded (47). However no difference in the use of CAM was found 
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between Asians and Europeans in that study and therefore the children with Asian origin in 
this study would be unlikely to differ from the responders.  
The study design approached a geographically diverse sample, representative of half 
of the whole Scottish paediatric IBD population in contrast to other surveys with 
predominantly severely ill patients from a single tertiary hospital (65). This was achieved 
because there was no other public or private paediatric clinics and the hospital management 
protocol ensured that each patient visits the hospital at least once a year independent of 
disease activity. Indeed the sample’s disease and demographic characteristics, mirrored the 
results of a Scottish national study (16) and a prospective epidemiological survey in the UK 
(11). This study surveyed only those patients who were diagnosed in a conventional clinic.   
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Table 2.7: Predictors of CAM use by Scottish children with IBD based on univariate and multivariate logistic analysis with p-values, 95% CI and 
odds ratios. 
 
All Users “CAM Therapist Users” “Self-Prescribed Users” 
Univariate analysis  P OR 95%CI P OR 95%CI P OR 95%CI  
Diagnosis age  0.127 0.9 0.7 - 1.0  0.051 0.8 0.7 - 1.0  0.388 0.9  0.8 - 1.1 
Disease duration  0.517 1.1  0.9 - 1.4  0.048 1.3 1.0 - 1.8  0.541 0.9 0.7 - 1.2 
Parental age*  0.007 4.0 1.5 - 11.3  0.047 4.2 1.0 - 17.1  0.022 4.0 1.2 - 12.9 
Parental education†  0.001 5.8 2.0 - 16.2  0.001 12.7 2.9 - 55.9  0.017 3.9 1.3 - 11.9 
CAM for other reason  0.155; 2.7  0.7 - 10.5  0.028 5.4 1.2 - 24.2  0.659 1.4 0.3 - 7.0 
CAM use by family  0.360  1.6  0.6 - 4.1  0.061 3.1 0.9 - 10.0  0.951 1.0 0.3 - 2.9 
Steroid use  0.065;  2.3  0.9 - 5.8  0.144  2.5  0.7 - 8.5  0.116 2.3 0.8 - 6.3 
No of steroids courses  0.588  1.1  0.8 - 1.5  0.074  1.4  1.0 - 2.0  0.519 0.9 0.6 - 1.3 
Multivariate analysis  
Parental age*  0.005 6.6 1.8 - 24.3  0.012 21.4 2 - 232.6  0.021 5.5 1.3 - 23.8 
Parental education†  0.001 9.1 2.4 - 33.7  0.002 18.9 2.8 - 125.3  0.008 7.0 1.7 - 29.3 
CAM for other reason  0.128 4.5 0.6 - 30.8  0.009 25.3 2.3 - 283.7  0.434 2.3 0.3 - 18.8 
No of steroids courses  0.436 1.2 0.7 - 2.0  0.021 2.5 1.1 - 5.4  0.908 1.0 0.5 - 1.7 
* Age groups 18-30 and 31-45 unified 
† Unified into two groups (Standard Grade and Highers; College and University) 
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However, it is unlikely in the area surveyed that any child with IBD will never visit an 
NHS clinic and therefore very few who distrust conventional treatment will have been missed.  
Demonstration of the questionnaire and its completion at home ensured confidentiality and 
clarity of the questions. The anonymity of the questionnaire allowed undistorted responses 
and encouraged reliable answers and may have contributed to the high response rate.  
Consistent with previous paediatric studies (64-66;544), this study found that a large 
proportion of IBD children use CAM, to a similar or greater extent than adults (63;541). More 
than half of the children used some form of CAM and a quarter visited alternative therapists. 
This is much higher than the 10% use of alternative therapists reported for the general 
population in the UK National Omnibus Survey. The estimated use of CAM in this study is 
lower than the 72% of the survey population in an Australian study, but higher than the 41% 
found in a multinational study (65), 22% and 51% in a Canadian (544) and American 
paediatric survey (64) respectively. It is possible that the increased use of CAM in this study 
reflects an increase over time, but this needs to be verified in a longitudinal study in the same 
population. A direct comparison between paediatric studies is hampered by differences in the 
study design, responding population, and definitions of CAM (48). Although this study did not 
compare the results with those from a healthy cohort, the questionnaire used in this study 
was specific for the past and current use of CAM for IBD management and also asked 
participants whether they had used CAM for other medical reason than IBD management. 
The fact that different answers were given in the section on IBD CAM use and in the section 
of CAM use for other reasons or for parental use shows that the questionnaire used was 
clear and specific for CAM use for IBD management. 
In the current survey, probiotics, dairy free diet and fish oils were the most prevalent 
types of CAM, followed by aloe and homeopathy. This is consistent with previous paediatric 
studies in the USA (64) and Australia (66) which used similar questionnaires. In contrast the 
multicentre survey by Heuschkel and his colleagues (65) found only 6% of their participants 
used probiotics and only 2% in their centre in London compared to the 44% found in this 
Scottish survey. The higher use of probiotics in the current study parallels the increase in the 
number of studies suggesting a beneficial effect in IBD management (75;76) and increased 
availability and advertising. The belief that dairy products can exacerbate the disease and 
that patients restrict their consumption has already been well documented (545;546). The 
lower incidence of multi or megavitamin use than in other studies (65) could be attributed to 
the questionnaire being specific for vitamin supplements not prescribed by the medical team. 
It is noteworthy that three of the most commonly used CAM in this survey (probiotics, omega 
oils and aloe vera) already have controlled trials for adults published in the literature 
(74;76;547), are suggested through support groups and websites and which could have 
affected the choice of these treatments.  Although it would be interesting to know whether the 
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patients used these treatments to maintain remission or to suppress a relapse, the 
questionnaire was not designed to address this.   
This study considered a wide range of possible predictors for CAM use. 
Demographically no relation to age, gender, or disease diagnosis (UC vs CD) has been 
found in both adult (46;74;76;536;541;547-549) and paediatric surveys and the results are in 
accordance. Young parental age and higher education level were independently associated 
with CAM usage, a finding commonly reported in the general paediatric population (550). It 
may be that young educated parents, are more open or seek information on innovative 
methods of disease management, or do not trust conventional medicine.  It has been 
reported (12) previously that early onset CD is associated with affluence, however, in this 
study the spread of patients between deprivation scores based on (SIMD) was roughly 
equivalent and there was no higher number in the higher affluent scores.  Social deprivation 
was not found to be a predictor of CAM use.  
In contrast to other studies that assessed medication on recruitment, this study also 
considered the total number and types of medication that each patient was on since 
diagnosis as a better depiction of disease activity history. No association between these 
indices and use of CAM was found confirming results from other paediatric (66;298) and 
adult studies (60;537). Although an association between CAM use and steroid use was not 
found, in contrast to findings in adults by Hilsden (541), an independent association between 
the number of steroid courses and the use of alternative therapists was evident. This has 
been previously reported in adults on high intravenous doses of steroids (68;541). No such 
association was found between repeated courses of EEN and CAM use. Although both 
repeated steroids and EEN courses reflect disease relapses, these findings suggest that the 
side effects of steroids and patients’ desire to terminate or avoid their use may be more 
important than disease activity. This was reported as a reason for using CAM in the current 
study and also by 63% of adults IBD patients in a German survey (68;541). 
As EEN is the standard treatment for paediatric CD in the UK, caloric 
supplementation was not a predictor of CAM use in this study unlike that of Markowitz in the 
USA (64) where different management protocols are followed (256).  
Reading about CAM, friends’ recommendation and internet searches were the main 
sources of information about CAM similar to previous adult (549) and paediatric surveys (66). 
The chronic nature of the disease and the lack of a definite cure are highlighted by the fact 
that most of the participants chose CAM to complement conventional medicine. Frustration 
with conventional medicine side effects has been continually reported as the main reason 
adult IBD patients used CAM (60;65;66;68;541;551) and this coincides with the observation 
that only 4% of patients with gastroesophageal reflux disease (for which effective medication 
with minimal side effects is available) tried to treat their condition with CAM (552). Moreover 
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recently medication side effects have been documented as the most important parental 
concern for their child with IBD (553) and could justify the need for alternative therapies with 
fewer or no side effects.  
Most surveys in both adults and paediatric patients have shown a self-reported 
benefit of CAM use (65;66;539). In the present study half of the users considered CAM use 
effective, although any possible improvement was subjectively assessed by the patients 
themselves and it is impossible to distinguish whether this was attributed to the concomitant 
conventional medication, to the CAM use per se or to a spontaneous improvement due to a 
documented placebo effect (373). Only two patients reported an adverse effect in contrast 
with adult surveys (549). This is not surprising as the majority of therapies used by 
participants in the present study included nutritional remedies and exclusion diets generally 
characterised with good safety records.  
Fewer patients in this study told their doctor they were using CAM than in previous 
studies (65). This lack of disclosure is undesirable as CAM may impact on conventional 
medicine or have side effects. The majority of the respondents wanted their doctor to be 
supportive of CAM. Adult IBD patients in Germany (68) believed that a combination of 
methods using CAM and conventional medicine should be offered within one integrative 
clinical institution.  
Most of the parents in the present study said “they would be happy for their child to 
use of CAM” but agreed that “not much is known about CAM safety”. The chronic nature of 
the condition and the desire to ensure the best possible outcome for their child is reflected in 
that almost 90% of the respondents stated they would choose CAM if they felt these were 
useful and some of them would do so even if medical advice was against it.  
Use of CAM is high in paediatric IBD patients in Scotland and paradoxically parallels 
the development of new and more effective medications and modes of disease management. 
With increasing use of CAM more quality studies and clinical trials are needed to shed light 
on their efficacy and better inform parents, patients and medical staff. So far the results of 
clinical trials are too limited and most too flawed to suggest use of CAM in clinical practice. 
Rather than actively discouraging or encouraging use, health professionals should 
encourage IBD patients to report CAM use and should be aware of all the alternative 
therapeutic choices that are available to their patients. Several hospitals worldwide have 
published policies and guidelines on CAM use and the American Academy of Paediatrics 
published a relevant article on counselling families who choose CAM for their child with 
chronic illness or disability (554).  
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OUTLINE 
This chapter describes a retrospective study of the prevalence of anaemia at diagnosis in 
paediatric patients with IBD and its progression over a one year follow up using case review 
analysis. Predictors of anaemia incidence at diagnosis and at follow up were explored.   
 
3.1. Introduction 
Anaemia is one of the extraintestinal co-morbidities in IBD. Overt or occult intestinal bleeding 
is among the major presenting symptoms of the new IBD patient (33) and a drop in 
haemoglobin levels occurs with each flare up (246). In IBD two types of anaemia prevail, iron 
deficient anaemia, due to an iron poor diet and/or haemoglobin losses through 
gastrointestinal bleeding, and the ACD with unspecified pathogenesis (236). This topic has 
been reviewed extensively in Section 1.4.  
Since all human cells, tissues and organs depend on an adequate oxygen supply, the 
onset of anaemia is accompanied by a variety of clinical manifestations for both the children 
and adults (Section 1.4.2). Nonetheless compared to the average awareness of other 
extraintestinal disease complications, such as arthritis and poor nutritional status, the issue 
of anaemia in IBD disease usually receives little attention from the clinician. While a possible 
explanation would be a low prevalence of anaemia in IBD, this is not supported by current 
evidence (229;236).  
Thus far the evidence of the prevalence of anaemia in IBD patients comes mainly 
from adult studies and relevant studies in children are scarce (Table 1.4.5). Moreover all but 
one of the paediatric studies (243) were undertaken in small (<100) patient groups (Table 
1.4.5). In most of these studies, anaemia prevalence was a secondary rather than a primary 
outcome (228) and thus may have included selective samples that do not allow the 
extrapolation and generalization of the findings to the general IBD population. Moreover 
studies that recruited children with longstanding IBD (242) may have underestimated the true 
anaemia prevalence at diagnosis, due to a confounding effect of concomitant medical 
intervention. Although most of the authors used haemoglobin concentration thresholds to 
define anaemia, the definition varied remarkably among the studies (Table 1.4.5). In fact 
most of the authors (252;253) failed to cite an appropriate reference source for the definition 
of anaemia. As normal levels of haemoglobin vary considerably with age and gender (205), it 
is essential to use appropriate and specific cut offs.  
Potential predictors of anaemia were addressed in a few studies. Mack and 
colleagues (243) showed that increased disease activity was a significant predictor of 
anaemia at diagnosis in paediatric IBD. Similarly Weinstein and colleagues (83), although 
they did not describe the prevalence of anaemia, found that haemoglobin was lower in CD 
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than UC, a finding stronger in the oldest age group of patients (≥ 11 y). Only one study (247), 
published in abstract form, measured prevalence of anaemia in paediatric CD and attempted 
to link it with the nutritional status of the patients and disease characteristics at diagnosis. In 
this study, anaemic patients had higher values of PCDAI and ESR than their non-anaemic 
peers, and the presence of upper GI tract disease was significantly associated with anaemia 
incidence. Gender, duration of symptoms prior to diagnosis, body composition, or growth 
parameters were not predictors of anaemia at diagnosis (247).  
In summary the prevalence of anaemia in paediatric IBD is under-documented and 
not well assessed. Most of the evidence comes from small studies using variable definitions 
of anaemia and do not allow a direct comparison between studies or assessment of temporal 
changes of anaemia prevalence. Only one study has been published in the UK, the rest of 
Europe with a small sample of 32 UC children (252). Whether anaemia is more common in 
groups of patients, with specific disease characteristics has not been studied extensively in 
paediatric studies. In light of new consensus guidelines on the classification of disease 
location and behaviour (6) further studies should be conducted to address whether disease 
phenotype predisposes to anaemia. Undernutrition and growth parameters may also differ 
between anaemic and non-anaemic IBD patients and should be investigated further.  
To the best of our knowledge, no study has measured the outcome and prognosis of 
anaemia, during the natural history course of the disease. As early and better diagnosis is 
now available and new treatments are available that induce mucosal healing and tackle the 
inflammatory cascade at the initial stages, a decrease in the prevalence of anaemia at 
presentation and at follow up should be expected.  
The aim of this study was to measure the prevalence of anaemia at diagnosis in a 
large representative population of children with IBD. Predictors of the incidence of anaemia 
at diagnosis and its progression at follow up were explored.  
 
3.2. Subjects and methods 
All paediatric patients that attended the IBD outpatient clinic between 2002 and 2007 were 
considered for analysis. Although no prospective IBD database existed at the time of the 
study, all the eligible patients were identified via their electronic attendance records of the 
IBD outpatient clinic. These were accessible through the hospital electronic patient database.  
For the purpose of this study two groups of patients were characterized. The first to 
describe the prevalence and predictors of anaemia at diagnosis, and a sub-group of this to 
look at the progress of anaemia over a 1y follow up.  
Patients’ demographics and disease characteristics were retrieved from the hospital 
internal electronic patient database (Table 3.1). Patients whose haemoglobin level was not 
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available at diagnosis and those with concomitant illness that could potentially affect 
haematological parameters, independently of IBD, were excluded.  
For the sub-group analysis, the case notes of a random sample of patients were 
reviewed and information on disease, medication, and anthropometry (Table 3.1) was culled 
at diagnosis and wherever available at approximately six and 12 month follow up. Although 
patients who received blood transfusion for acute management of severe anaemia or were 
on supplementation with oral iron at follow up were included, their results are presented and 
discussed appropriately.  
 
3.2.1. Statistical analysis 
All data were entered into an electronic database and the prevalence of anaemia calculated 
as the ratio of the number of anaemic patients by the total number of patients. For the 
definition of anaemia, gender and age specific haemoglobin cut offs were used (205) (Table 
1.4.1). A haemoglobin concentration less than 10 mg/dl was characterized as severe 
anaemia according to WHO recommendations (Table 1.4.1). Patients with haemoglobin 
concentration lower than their age and gender defined cut offs, but above 10 mg/dl were 
classified as mildly anaemic. Differences between groups were assessed with 2-sample t-
test and analysis of variance (ANOVA) for parametric variables and Mann-Whitney or 
Kruskal-Wallis for non-normally distributed data. Difference for categorical data was 
assessed with chi-square test or Fisher’s exact test for 2x2 tables with small counts. 
Potential predictors of anaemia were studied using univariate nominal and binary logistic 
regression analysis. All predictors with p-value less than 0.1 were entered in a multivariate 
model and their independent association with the response was assessed using backward 
stepwise regression analysis. A model with p-values less than 0.05 for all predictors was 
considered the final model. Odd ratios and 95% confidence intervals were calculated. 
 
3.3. Results 
3.3.1. Prevalence and predictors of anaemia at diagnosis 
3.3.1.1. Patients demographics and disease characteristics 
Between April 2002 and December 2007, 272 IBD patients visited the outpatient clinic at 
Yorkhill RHSC. As the Yorkhill RHSC is the only tertiary paediatric referral centre for care of  
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Table 3.1: Demographics, disease, medication, nutrition, biochemical and haematological, data 
collected for the study of anaemia in paediatric IBD at diagnosis (whole group) and at follow up 
(sub-group)  
Data 
 
Whole group Subgroup 
Demographics  
  
Gender √ √ 
Age(decimal y) √ √ 
 
Social deprivation score* √  
Disease 
   
Age at diagnosis √ √ 
Diagnosis delay  √ 
Type of disease √ √ 
Site of involvement √ √ 
Bowel motility at diagnosis  √ 
 
Blood in stool at diagnosis  √ 
Medication 
   
EEN; (No of courses)  √ 
Oral steroids; (No of courses)  √ 
IV steroids  √ 
Aminosalicylates  √ 
AZA  √ 
Methotrexate  √ 
Infliximab  √ 
Antibiotics  √ 
Vitamins-Minerals  √ 
Oral iron  √ 
Caloric supplements  √ 
 
Gut resection  √ 
Anthropometry 
   
Body weight   √ 
Body height  √ 
 
Weight loss at diagnosis  √ 
Haematology 
   
Red blood cells count √ √ 
Haemoglobin concentration √ √ 
Haematocrit concentration √ √ 
MCV concentration √ √ 
 
MCH concentration √ √ 
Inflammatory markers 
   
ESR √ √  
CRP √ √ 
 
   
Biochemistry Albumin √ √ 
Folate (serum & RBC) √  
B12 √  
 
Ferritin √  
* Scottish Index of Multiple Deprivation 
 
all IBD children in the West of Scotland region, the identifiable sample of this corresponded 
roughly to the whole population of paediatric IBD patients.  
All patients had been diagnosed according to standard clinical, endoscopic, 
histological and radiological findings. Those patients whose haematology profile was not 
available close to the date of diagnosis (n=34) or were suffering from other concomitant 
conditions that could impact on their haematological profile (cystic fibrosis; n=2) were 
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excluded. Overall 236 patients (87% of the population) had measurements of haematology at 
diagnosis and fulfilled the inclusion criteria.  
The majority of participants had CD whereas for 5.5% a diagnosis of IC was deemed 
appropriate (Table 3.2). There was a higher prevalence of males to females, due to more 
males than females being diagnosed with CD. No gender predominance was observed for 
UC or IC patients. The mean age at diagnosis was 10.6 y (SD; 3.1) with UC patients 
diagnosed at an earlier age than CD (p<0.04). No gender effect was observed regarding the 
age at diagnosis (Table 3.2). 
The majority of the CD patients had involvement of the colon (Table 3.2) but 
involvement of the upper digestive tract and ileum were also common. None of the UC 
patients studied had isolated proctitis as opposed to the high prevalence of pancolitis, which 
was the commonest site of disease involvement. 
No difference in the social deprivation score (SIMD 2004) was found among the 
different types of disease. Indeed the IBD population was equally distributed in the five 
classes of social deprivation (Table 3.2). 
 
3.3.1.2. Basic haematology profile at diagnosis 
Full blood counts were available for 233 of the patients whereas three had only haemoglobin 
measurements (Table 3.2). All these three patients had been transferred from a district 
general hospital and no local haematology report was available close to the time of 
diagnosis.   
Approximately 50% of the patients had haemoglobin less than 10.8 g/dl (Fig 5) . As a 
group, girls had significantly lower RBC, haemoglobin and haematocrit values (all p<0.003) 
than boys. A disease dependent effect was found for RBC. Red blood count was higher in 
CD than UC or IC patients (p<0.0001) but no similar differences were observed for 
haemoglobin or haematocrit levels (Table 3.3). However more boys than girls had been 
diagnosed with CD which may explain these results. No difference was found between boys 
and girls for mean corpuscular volume and mean corpuscular haemoglobin.  
Similar to the whole group analysis, girls with CD had lower RBC, haemoglobin and 
haematocrit concentration than boys. No gender effect was found for MCV and MCH. In 
contrast, none of the haematological parameters assessed (RBC, Hb, Hct, MCV, MCH) 
differed between boys and girls in UC and IBDU children.   
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Table 3.2: Demographics, social deprivation scores, and disease characteristics of paediatric IBD patients at diagnosis 
 CD UC IBDU Total 
 M F M F M F  
Gender (n) 93 58 33 37 7 8 236 
Age at diagnosis (mean±SD) 11.1 ± 2.9 11 ± 2.8 9.8 ± 3.5 9.9 ± 3.5 10.8 ± 1.8 8.5 ± 3.5 10.6 ± 3.1 
Deprivation Score (n) 
       
1 17 ; (18) 11 ; (19) 9 ; (27) 5 ; (13) 1 ; (14) 2 ; (25) 45 ; (19) 
2 15 ; (16)     8 ; (14) 9 ; (27) 5 ; (13) 0 ; (0)              4 ; (50) 41 ; (17) 
3 15 ; (16) 11 ; (19) 6 ; (18) 11 ; (30) 2 ; (29) 0 ; (0) 45 ; (19) 
4 21 ; (23) 14 ; (24) 6 ; (18) 9 ; (24) 0 ; (0) 2 ; (25) 52 ; (22) 
5 25 ; (27) 13 ; (22) 3 ; (9) 7 ; (19)               4 ; (57) 0 ; (0) 52 ; (22) 
 
       
Montreal classification (n)* 
       
L1 3 ; (3) 2 ; (3)     5 ; (2) 
L2 30 ; (32) 19 ; (33)     49 ; (21) 
L3 54 ; (58) 37 ; (64)     91 ; (39) 
L4 61 ; (66) 32 ; (55)     93 ; (39) 
B1 82 ; (88) 49 ; (84)     131 ; (55) 
B2 9 ; (10) 5 ; (9)     14 ; (6) 
B3 1 ; (1) 1 ; (2)     2 ; (1) 
E1   0 ; (0) 0 ; (0)   0 ; (0) 
E2   2 ; (7) 4 ; (12)   6 ; (2) 
E3   27 ; (93) 29 ; (88)   56 ; (24) 
* P denominator to characterize perianal disease was not available 
 
Table 3.3: Haematological characteristics of paediatric IBD patients at diagnosis (mean ± SD) 
 CD  UC  IBDU  Total 
 M F  M F  M F   
RBC (x 1012 )  4.6  ±  0.4  4.4  ±  0.5   4.3  ±  0.4  4.2  ±  0.5  4.5  ±  0.8  3.8  ±  0.6  4.4  ±  0.5 
Haemoglobin (g/dl)  11.1  ±  1.6  10.6  ±  1.5   10.9  ±  1.6   10.5  ±  2.3  12.2  ±  2.8   9.3  ±  2   10.8  ±  1.8 
Haematocrit (%)  35  ±  3.8  33.4  ±  4.0   33.7  ±  3.9  32.7  ±  5.9  35.5  ±  6.7  30.7  ±  4.9   34.0  ±  4.5 
MCV (fl)  75.8  ±  6.6  76.6  ±  6.5   78.3  ±  5.1  78.1  ±  8.4  70.4  ±  18.2  80.4  ±  7.5   76.7  ±  7.4 
MCH (pg)  24.2  ±  3.3  24.4  ±  3.1   25.2  ±  2.3  25  ±  3.7  26.6  ±  3.4  24.3  ±  3.4   24.6  ±  3.2 
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Figure  5: Distribution of haemoglobin concentration (mg/dl) in paediatric patients with CD at 
diagnosis 
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3.3.1.3. Systemic markers of disease activity at diagnosis in IBD patients 
ESR, CRP, albumin and platelets levels were available for 195, 205, 202 and 225 patients 
respectively (Table 3.4). Compared to UC children, CD patients had significantly higher CRP 
concentration and ESR (p<0.0001 & p=0.004 respectively) and lower serum levels of 
albumin at diagnosis (p<0.0001). There was no difference for the same markers between UC 
and IBDU patients (Table 3.4). ESR and CRP were higher in CD than IBDU. No difference 
was found between boys and girls for any of the systemic markers of disease activity. The 
mean platelet concentration was higher in girls than boys but did not reach statistical 
significance (p=0.057). 
Overall more than 70% of patients presented at diagnosis with raised ESR, whereas 
59%, 52%, and 48% had abnormal levels of CRP, albumin and platelets respectively (Table 
3.4). There was no difference between genders. More CD patients (38.5%) had all the 
systemic markers of disease activity abnormal compared to UC (9.5%) and IBDU patients 
(0%). Noteworthy none of the IBDU patients had all of the systemic markers of disease 
activity abnormal. In fact the majority of these patients presented with normal markers of 
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inflammation at diagnosis, although the numbers are too small and preclude statistical 
analysis. Twenty nine percent of IBD children had all the systemic markers of disease activity 
abnormal as opposed to 14% of the cohort with respective values within the normal 
reference range.  
 
3.3.1.4. Prevalence of anaemia 
Defining anaemia with gender, and age specific haemoglobin concentration cut offs (205), 
73% of the subjects presented with anaemia and 32% suffered from severe anaemia 
(haemoglobin concentration less than 10) (Fig 5). Severe anaemia was more common in 
girls than in boys (Fig 6). No difference in the prevalence of anaemia was found between the 
different types of disease (Fig 7).   
 
Figure  6: Prevalence of anaemia and degree of severity between IBD boys and girls at 
diagnosis 
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Figure  7: Prevalence of anaemia and degree of severity according to type of IBD in children 
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3.3.1.5. Correlation of haemoglobin concentration with systemic markers 
of disease activity 
Since ESR, CRP platelets and albumin concentration did not follow a normal distribution their 
concentrations were ranked and Spearman correlation calculated as the most appropriate 
measure of their association with haemoglobin. ESR, CRP and platelets counts were 
negatively correlated (r=-0.38, -0.30 and –0.52 respectively) (all p<0.0001) with haemoglobin 
concentration (Fig 8). Accordingly albumin was positively and strongly associated with 
haemoglobin levels (r=0.56 p<0.0001). 
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Table 3.4: Systemic markers of disease activity in paediatric patients with IBD at diagnosis 
 CD UC IBDU Total 
 M F M F M F  
ESR (mm/hr) (mean ± SD) 
 40.4  ±  23.9  46.8  ±  25.7  29.9  ±  23.3  35.6  ±  24.0  25.2  ±  33.4  26.3  ± 12  39.2 ± 24.8 
CRP (mg/l) (mean ± SD) 
 33.9  ±  39.7  45.9  ±  54.6  13.6  ±  26.2  28.7  ±  52.5  7.0  ±  0.0  20  ±  19  32.3 ± 44.6 
Albumin (g/l) (mean ± SD) 
 32.3  ±  6.1  31.6  ±  7.4  36.2  ±  4.8  36.2  ±  7.3  34.5  ±  11.8  31.1  ±  8.5  33.3 ± 6.9 
Platelets x 109 (mean ± SD)   
 474.4  ± 145.1  528.5  ± 176.6  442.1  ± 179.4  489.6 ±  171.7  394  ± 158 459.1 ±164.4  482.4 ± 164.3 
 
       
Abnormal ESR n;(%) 
 60; (77) 44; (86) 14; (58) 20; (67) 2; (40) 4; (57) 144; (74) 
Adnormal CRP n;(%) 64; (74) 35; (70) 8; (29)   10; (33) 0; (0) 3; (60) 120; (59) 
Abnormal albumin n;(%) 55; (65) 29; (62) 10; (38) 7; (23) 1; (17) 3; (43) 105; (52) 
Abnormal platelets n;(%) 45; (51) 29; (55) 10; (34) 17; (46) 3; (43) 4; (50) 109; (48) 
 
       
Disease activity score n;(%)* 
       
0 7; (10) 5; (13) 4; 22 4; 17 2; 40 1; 25 23; (14) 
1 9; (12) ;3 (8) 5; 28 9; 37 2; 40 0; 0 28; (17) 
2 9; (13) 6; (15) 1; 6 4; 17 0; 0 2; 50 22; (14) 
3 20; (29) 8; (21) 6; 33 5; 21 1; 20 1; 25 41; (26) 
4 25; (36) 17; (43) 2; 11 2; 8 0; 0 0; 0 46; (29) 
* Sum of abnormal systemic markers of disease activity [CRP>7 mg/L), ESR>20 mm/h, Albumin <35 g/L, Platelets>450 x 109 )] 
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Figure  8: Rank correlation between haemoglobin concentration and systemic markers of disease activity in cildren with IBD 
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3.3.1.6. Predictors of anaemia incidence at diagnosis 
Potential predictors of anaemia were defined a priori. Disease type and anatomic location, 
age at diagnosis, gender, social deprivation, and systemic markers of disease activity were 
tested with nominal logistic regression to assess their independent association with anaemia 
prevalence and degree (moderate or severe) of severity.  
In the univariate analysis females were more likely to be severely anaemic than boys 
(p=0.005) (Table 3.5). Increased concentrations of ESR, CRP, platelets and low albumin 
concentration were strongly associated with mild and severe anaemia (Table 3.5). Similarly 
abnormal levels of ESR (> 20 mm/h), CRP (>7 mg/l) platelets (> 450 x 109) and albumin (< 
35 g/l) were also associated with mild and severe anaemia (Table 3.5).  
In the multivariate analysis, disease activity score (sum of the number of abnormal 
systemic markers of disease activity) was the only independent predictor of mild and severe 
anaemia. Indeed the risk of being anaemic or severely anaemic was substantially higher with 
an increasing number of total abnormal systemic markers of disease activity. Any child with 
all systemic markers of disease activity abnormal at diagnosis (ESR, CRP, albumin) had 96 
times more chance to be severely anaemic compared with those IBD children who presented 
with normal serology. The odd ratios of being anaemic augmented proportionally with the 
total number of abnormal systemic markers of disease activity (Table 3.5). This effect was 
stronger in severe than mild anaemia. Gender was also a predictor of anaemia and its 
degree of severity with girls being more severely anaemic than boys (Table 3.5).   
Table 3.5: Predictors of anaemia incidence at diagnosis in paediatric IBD patients with 
univariate and multivariate regression analysis   
Predictors Mild anaemia Severe anaemia 
 Univar p-value OR  95%C  Univar p-value OR 95%C 
Sex (male) 
  NS  0.017 0.43 0.22-0.86 
ESR (mm/hr) 
 0.0001 1.04  1.02-1.06  0.0001 1.05 1.03-1.07 
CRP (mg/l) 
 0.007 1.02  1.01-1.04  0.003 1.03  1.01-1.04 
Albumin (g/l) 
 0.0001 0.88 0.82-0.94  0.0001 0.78 0.72-0.84 
Platelet (x 109) 
 0.0001 1.01 1.00-1.01  0.0001 1.01 1.01-1.02 
Abnormal ESR* 
 0.001 3.78 1.74-8.21  0.0001 5.11  2.16-12.06 
Abnormal CRP* 
 0.005 2.79 1.37-5.68  0.0001 3.78 1.79-7.97 
Abnormal albumin* 
 0.007 2.73 1.31-5.69  0.0001 10.0  4.33-23.07 
Abnormal platelet* 
 0.0001 4.14  1.91-8.98  0.0001 14.42  6.22-33.43 
Disease activity score* 
  
One   NS   NS 
Two   NS   NS 
Three  0.01 5.83 1.52-22.41  0.0001 26.25  4.64-148.38 
Four  0.001 13.33  2.82-63.11  0.0001 65.50 10.12-450.08 
 
 
 
 Multivar p-value OR 95% CI 
Gender (male) 
 0.322 0.64 0.26-1.56  0.003 0.20 0.07-0.58 
Disease activity score* 
  
One  0.139 2.5  0.74-8.61  0.870 1.2 0.14-10.17 
Two  0.141 2.8 0.71-10.63  0.128 4.38 0.65-29.42 
Three  0.007 6.5  1.65-25.65  0.0001 40.2  6.44-250.93 
Four  0.001 14.63 3.03-70.61  0.0001 96.27 13.26-699.12 
*Sum of abnormal systemic markers of disease activity [CRP>7 mg/L), ESR>20 mm/h, Albumin <35 g/L, Platelets>450 x 109 )] 
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Age at diagnosis, social deprivation score, site of disease involvement, disease 
behaviour (inflammatory, stricturing, fistulising) checked independently for CD and UC did 
not predict anaemia.  
 
3.3.1.7. Temporal changes of anaemia prevalence at diagnosis 
No apparent trend in the prevalence or degree of anaemia severity was observed (Table 3.6) 
between 2001-2007. 
 
Table 3.6: Temporal trend of anaemia prevalence and severity at diagnosis in paediatric 
patients with IBD diagnosed between 2001 and 2007 
Patients 2001 2002 2003 2004 2005 2006 2007 
All anaemic (n) 12 22 17 19 24 28 22 
All non-anaemic (n) 5 8 11 8 6 10 9 
Total diagnosed (n) 17 30 28 27 30 38 31 
Total anaemic (%) 70.6 73.3 60.7 70.4 80 73.7 71 
Mild anaemic (%) 23.5 46.7 32.1 44.4 66.7 36.8 25.8 
Severely anaemic (%) 47.1 26.7 28.6 25.9 13.3 36.8 45.2 
 
3.3.1.8. Classification of anaemia type 
Due to the retrospective design of this study it was difficult to differentiate among the different 
types of anaemia. A rough approach was attempted evaluating haematology parameters on 
the size (MCV) and colour of erythrocytes (MCH). No patient had features of macrocytic 
anaemia (MCV > 100). Four patients had MCV values greater than 90 fl. Of these four 
patients, one was severely anaemic (Hb; 7.7), one was mildly anaemic (Hb; 11.9) and two 
had normal levels of haemoglobin. Overall 41% of the patients had low MCV according to 
Dallman’s (205) reference range. Similarly setting 27 pg as the lower reference threshold of 
mean corpuscular haemoglobin, 76% of the subjects had suboptimal levels consistent with 
hypochromic anaemia. 
 
3.3.1.9. Ferritin, folate and B12 concentration 
For 122 children information on ferritin concentration was available within four months of 
diagnosis. Ninety one of them were anaemic but 29 patients had normal levels of ferritin (> 
10 µg/l) and normal mean corpuscular volume reflecting normocytic anaemia possibly 
attributed to ACD. Serum ferritin concentration was positively associated with CRP 
(Spearman r: 0.33 p<0.001) and negatively with serum albumin (Spearman r: –0.21 p<0.03) 
and was significantly higher in CD than in UC patients. 
Twenty five and 26 patients had measurements of folate (serum & red blood cells) 
and B12 respectively within four months of diagnosis. No patient had suboptimal levels 
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compared to the hospital reference range [(B12:193-982 ng/l); (RBC folate: 93-641 µg/l); 
(serum folate: 3-17 µg/l)]. Erythrocyte folate concentration was significantly higher in CD than 
in UC patients (Table 3.7). Serum but not RBC concentration of folate was negatively 
associated with platelets concentration (Spearman r -0.50 p<0.02).  
 
Table 3.7: Systemic concentrations of serum ferritin, folate and vitamin B12 levels in paediatric 
patients with IBD at diagnosis 
Vitamin/Ferritin CD 
(Median       Range) 
UC 
(Median      Range) 
P-value* 
Ferritin (ng/l)  
 23.0 2.0- 343.0  12.5 2.0- 226.0 0.02 
Serum folate (µg/l) 
 9.2 4.2- 15.8  7.5 2.7- 16.6 0.71 
RBC folate (µg/l) 
 517.0 237.0-1195.0  251.0 236.0- 752.0 0.02 
Serum B12 (ng/l)  621.0 246.0-1879.0 807 251.0-1611.0 0.75 
* Mann Whitney Test 
 
3.3.2 Prevalence and predictors of anaemia at follow up 
3.3.2.1. Patients characteristics 
The medical case notes were available for review in 179 children. Of these 12 were recently 
diagnosed and no follow up data were available at six months. One hundred and twenty-nine 
children had follow up measurements of haemoglobin at six and 12 months post-diagnosis. 
For the rest (38 patients) follow up measurements of haemoglobin were recorded either at 
six or 12 months (Fig 9). The disease and demographic characteristics of the patients are 
displayed in Table 3.8. There was no statistical significant difference between the whole 
group presented above and the subgroup of the follow up analysis.  
The type of medical treatment and the total number of steroid and completed EEN 
courses for each patient were collected from diagnosis through one year follow up. The 
proportion of patients on different treatments is presented in Table 3.9. As expected the 
majority of CD and UC patients were treated with the two common mainstream first line 
treatments, EEN and steroids respectively. Aminosalicylates were the mainstream treatment 
to maintain disease remission in both diseases. Iron supplements had been used by 1/3 of 
the CD and IBDU patients and half of the UC patients. 4% of the patients had a major 
surgery with part of the gut resected. Blood transfusion was administered in 8% of the 
patients during the follow up period.  
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Figure  9: Flow diagram of patients included in the study on the prevalence of anaemia in 
paediatric IBD patients 
 
 
 
Table 3.8: Demographics, age at diagnosis and diagnosis delay of paediatric IBD patiets who 
participated in a study on the prevalence of anaemia at follow up 
 CD UC IBDU Total  
 M F M F M F  
Gender (n) 68 45 26 31 4 5 179 
Diagnosis  
age (y) (mean 
± SD) 
11.0 ± 2.7 10.6 ± 2.8  9.9 ± 3.6  9.2 ± 3.3 11.3 ±  1.5  8 ±  4.6 10.3 ± 3.1 
Diagnosis 
delay (mth) 
(mean ± SD)  
11.7 ± 16.8  8.4 ± 10.9 10.8 ± 14.2  6.0 ± 4.9 15.2± 15.5  4.3 ± 3.4  9.6 ± 13.3 
 
Table 3.9: Total types of medical therapy used by paediatric IBD patients during one year of 
follow up post-diagnosis  
Percent of patients n;(%) CD UC IBDU All IBD 
EEN 80; (78) 2; (5) 2; (9) 84; (50) 
Oral steroids 43; (42) 33; (77) 13; (59) 89; (53) 
I.V. steroids 13; (13) 6; (14) 5; (23) 24; (14) 
5-ASAs 74; (72) 40; (93) 15; (68) 129; (77) 
Azathioprine 60; (59) 33; (33) 10; (45) 84; (50) 
Methotrexate 12; (12) 0; (0) 0; (0) 12; (7) 
Infliximab 6; (6) 1; (2) 1; (5) 8; (5) 
Antibiotics 46; (45) 11; (26) 7; (32) 64; (38) 
Vitamins 35; (34) 11; (26) 5; (23) 51; (30) 
Caloric supplements 47; (46) 2; (9) 4; (9) 53; (32) 
Iron supplements 36; (35) 24; (56) 7; (32) 67; (40) 
Surgery 3; (3) 2; (5) 1; (5) 6; (4) 
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Omeprazole/Ranitidine 28; (27) 7; (16) 10; (45) 45; (27) 
Rectal steroids 9; (9) 9; (21) 6; (27) 24; (14) 
Laxatives 9; (9) 2; (5) 1; (5) 12; (7) 
Blood transfusion 6; (6) 5; (10) 3; (13) 14; (8) 
 
3.3.2.2. Sub group anthropometric characteristics at diagnosis and 
follow up 
For 175 of the children basic anthropometric measurements were collected at diagnosis 
(Table 3.10). Standard deviation scores (z-scores) were calculated using the British 
normative data (94). A z-score of less than –2 SD for height and BMI were consistent with 
the definition of growth retardation and underweight respectively (Figs 10 & 11).  
BMI z-scores did not differ between boys and girls at diagnosis and 12 months follow 
up. At six months girls had significantly higher BMI z-scores than boys (p=0.028) (Table 
3.11). Children with CD presented with significantly lower BMI and weight z-score than 
patients with UC or IBDU at diagnosis, and at all time points at follow up (p-values <0.0001). 
For those patients with follow up anthropometric measurements recorded at six and 12 
months, changes since diagnosis were assessed with ANOVA of repeated measures and 
Bonferroni post-hoc pairwise comparisons. BMI z-scores increased at follow with a mean 
increase of 0.95 and 1 SD at six and 12 months (p<0.0001). No difference in BMI z-scores 
was observed between six and 12 months.  
At diagnosis 29% of the CD patients compared to 4% in UC and 11% in IBDU 
presented with BMI z-scores less than –2 SD (p<0.0001). At six and 12 months follow up 
fewer patients suffered from underweight. Five percent and 1% of the CD children as well as 
0% and 5% of UC patients respectively had BMI z-scores keeping in line with the definition of 
underweight (BMI z-score <-2 SD) at six and 12 months. Although none of the patients was 
obese (BMI z-score >2SD) at diagnosis, at six and 12 months follow up, over 12% of the UC 
patients had a BMI z-score above their age and gender defined obesity threshold  (BMI z-
score >2). On the contrary approximately 2% of CD children were defined as obese (BMI>2 
SD) at follow up. Weight loss prior to disease diagnosis was more frequently experienced in 
CD children than their peers with UC or IBDU (p=0.011).  
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Table 3.10: Anthropometric characteristics (mean ± SD), and prevalence (%) of underweight, obesity and short stature in newly diagnosed 
paediatric IBD patients  
 CD UC IBDU* Total  
 M  F M F M F  
Diagnosis weight (kg)  
 31.3 ± 11.2  31.5 ±  11.5  32.7  ±  14.2  30.8  ±  12.4  33.1 ± 5.2  32.1 ± 20.6  31.5  ±  12.1 
Weight z-score 
 -1.2  ±  1.4  -0.9  ±  1.1  -0.3  ±  1.1  -0.4  ±  1.0  -0.5 ± 1.0  0.2  ± 2.0  -0.8  ±  1.3 
Diagnosis height (cm) 
 140  ±  17.6  137.5  ±  17.8  137  ±  21.9  133.6  ±  19.4  144.6 ±  7.1  127.6  ±  30.1  137.6  ±  18.8 
Height z-score 
 -0.6  ±  1.2  -0.6  ±  0.9  -0.3  ±  1.1  -0.2  ±  1.0  0 ± 0.6  0.5  ±  2.2  -0.5  ± 1.1 
BMI (kg/m2) 
 15.6  ±  2.5  16.2  ±  3  17.1  ±  2.5  16.5  ±  2.5  15.7 ±  1.4  17.6  ±  3.7  16.2  ± 2.6 
BMI z-score 
 -1.2  ±  1.6  -0.9  ± 1.4  -0.2  ±  1.2  -0.4  ±  1.0  -0.9 ±  1.0  0  ±  1.5  -0.8  ±  1.4 
Height z-score<-2 n;(%) 11; (17) 2 ; (5) 1 ; (4) 0 ; (0) 0 ; (0) 1; (20) 15 ;(9) 
BMI z-score<-2 n;(%) 22 ;(33) 9 ;(21) 2 ;(8)  0 ;(0) 1 ;(25) 0; (0) 34; 20 
BMI z-score>2 n;(%) 0 ; (0)            0 ; (0)           0 ; (0)            0 ; (0)              0 ; (0)             0 ;(0)           0 ; (0) 
Weight loss n;(%) 43 ;(74) 32 ;(82) 58 ;(11) 61 ;(11) 25 ; (1) 50 ;(2) 70 ; (103) 
 
Table 3.11: Anthropometric characteristics (mean ± SD), and prevalence (%) of underweight, obesity and short stature of paediatric IBD patients at 
6 mth post-diagnosis (mean ± SD) 
 CD UC IBDU Total 
 M F M F M F  
Weight (kg) at 6 mth 
 36.0  ±  13.0  36.8  ±  11.6  37.5  ±  14.5  38.1  ±  18.0  36.2  ±  6.2 38.6  ±  27.2  36.8  ±  14.0 
Weight z-score (SD) at 6 mth 
 -0.6  ±  1.3  -0.4  ±  0.9  0.3  ±  1.0  0.5  ±  1.1  -0.3  ±  1.1  0.8  ±  1.7  -0.2  ±  1.2 
Height (cm) at 6 mth 
 140.7  ±  17.6  140.1  ±  17.1  137.3  ±  21.4  134.1  ±  20.8  143.7  ±  7.8  127.6  ±  29.9  138.6  ±  18.9 
Height z-score (SD) at 6 mth 
 -0.8  ±  1.2  -0.5 ± 0.9  -0.4  ±  0.7  -0.3  ±  1.1  -0.5  ±  0.5  -0.2  ±  1.5  -0.6  ±  1.1 
BMI (kg/m2) at 6 mth 
 17.6 ±  3.0  18.0  ±  2.5  19.0  ±  3.1  19.8  ±  4.3  16.3  ±  1.5  20.7  ±  5.8  18.3  ±  3.4 
BMI z-score (SD) at 6 mth 
 -0.2  ±  1.3  0.0  ±  0.9  0.7  ±  1.0  0.8  ±  1  -0.6  ±  1.3  1.2  ±  1.1  0.2 ±  1.2 
Height z-score<-2 at 6 mth n;(%)   11; (17) 3; (8) 0; (0) 1; (4) 0; (0) 1; (20) 16; (10) 
BMI z-score<-2 at 6 mth n;(%) 5; (8) 0; (0) 0; (0) 0; (0) 0; (0) 0; (0) 5; (3) 
BMI z-score>2 at 6 mth n;(%) 3; (5) 0; (0) 2; (11) 4; (15) 0; (0) 2; (40) 11; (7) 
 
 
 
 159 
 
 
 
 
 
 
 
 
 
Table 3.12: Anthropometric characteristics (mean ± SD), prevalence (%) of underweight, obesity and short stature of paediatric IBD patients at 12 
mth post-diagnosis (mean; SD) 
 CD UC IBDU Total 
 M F M F M F  
Weight (kg) at 12 mth 
 37.7  ±  12.7  37.5 ±  11.6  40  ±  18.3 40.1  ±  19.3  38.8  ±  11.1  38.4  ±  28.1  38.4  ±  14.5 
Weight z-score (SD) at 12 mth 
 -0.6  ±  1.1  -0.4  ±  0.9  0.4  ±  1.2  0.3  ±  1.6  -0.1  ±  0.3  -0.3  ±  2.0  -0.3  ±  1.2 
Height (cm) at 12 mth 144  ±  18.3 141.2 ±  16.5 140.9 ±  23.5 140  ±  18.7 147  ±  8.5 130.6  ±  27.7 142  ±  18.5 
Height z-score (SD) at 12 mth 
 -0.9  ±  1.2  -0.7  ±  0.9  -0.2  ±  1.0  0  ±  1.2  -0.2  ±  0.6  -1.7  ±  0.7  -0.6  ±  1.1 
BMI (kg/m2) at 12 mth 
 17.6  ±  2.4  18.2  ±  2.6  19  ±  3.3 19.3  ±  5.6  17.8  ±  3.1  20.4  ±  7.6  18.3  ±  3.3 
BMI z-score (SD) at 12 mth  
 -0.2  ±  1.0  0.0  ±  0.9  0.7  ±  1.3  0.3  ± 1.7  0.0  ±  1.0  0.8  ±  1.7  0.1  ±  1.2 
Height z-score<-2 at 12 mth n;(%) 
  8; (14) 4; (11)   0; (0)   0; (0)   0; (0)   1; (50)   (9) 
BMI z-score<-2 at 12 mth n;(%) 
  1; (2) 0; (0)   1; (5)   1; (5)   0; (0)   0; (0)   3; (2) 
BMI z-score>2 at 12 mth n;(%) 
  2; (3) 0; (0)   1; (5)   4; (18)   0; (0)   0; (0)   7; (5) 
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Compared to UC children, CD patients had significantly lower height z-score at 
diagnosis (p=0.025) and at 12 months follow up (p=0.002) (Table 3.12). Similar to BMI z-
score, no difference was found between boys and girls for height. Height z-score decreased 
by an average of 0.2 SD at six and 12 months follow up (p-<0.0001). No difference in the 
mean height z-scores change was found between six and 12 months.   
Thirteen percent of the CD patients had suboptimal height consistent with the 
definition of short stature (height z-score <-2). No significant changes were presented at six 
and 12 months of follow up. Less than 2.5% of the UC patients had height z-score less than 
–2 SD at any time point over the follow up. Although no clear conclusions can be drawn, 
growth retardation tended to be more common in CD boys than girls at diagnosis (Fisher’s 
exact test p<0.075). At follow up no difference in the prevalence of growth retardation was 
observed between the two genders for any type of IBD. 
 
Figure  10: Distribution of height z-scores at diagnosis on IBD paediatric patients 
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Figure  11: Distribution of BMI z-scores at diagnosis on IBD paediatric patients 
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3.3.2.3. Changes in haematology at six and 12 months follow up 
Haemoglobin values and full blood counts were available for 179, 153, and 143 patients at 
diagnosis and at six and 12 months follow up respectively (Table 3.13). The mean 
haemoglobin concentration was less than 11 g/dl at diagnosis but significantly improved at 
follow up (p<0.0001). Mean values were 11.8 and 11.9 g/dl at six and 12 months follow up 
respectively. The same trends of change were observed for the other haematological 
parameters of interest (Hct, MCV, MCH, RBC) (Table 3.13).   
  
3.2.4. Changes of anaemia prevalence and severity at follow up 
The progression of anaemia prevalence and degree of severity at follow up is shown in Fig 
12 and displayed per disease type in Table 3.14. The proportion of patients with severe 
anaemia decreased from 32% at baseline to 10% at six and 12 months follow up whereas 
the respective number of non-anaemic patients increased at follow up (Fig 12). Similar trends 
were observed for CD and UC. For IBDU no changes were observed compared to baseline 
values although definite conclusions are difficult to be drawn due to the small numbers of 
patients in this group (n=9) 
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Figure  12: Prevalence and degree of anaemia in paediatric IBD at diagnosis and six and 12 
months of follow up 
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3.3.2.5. Individual changes in anaemia severity classification at follow up 
Patients were categorized into four groups according to the change of anaemia classification 
at six and 12 months follow up. Two groups included those patients who were anaemic at 
diagnosis and either improved to non anaemic or remained anaemic at follow up, and two 
other groups with those patients who were not anaemic at diagnosis and either remained so 
or deteriorated at follow up (Table 3.15). Approximately 30% of the anaemic patients became 
non anaemic at follow up and similarly around 8% who were not anaemic deteriorated at 
follow up (Table 3.15).    
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Table 3.13: Haematological characteristics at diagnosis, six and 12 mth of follow up of paediatric IBD patients (mean ± SD) 
 Diagnosis Follow up 6 mth Follow up 12 mth 
 CD UC IBDU CD UC IBDU CD UC IBDU 
RBC (x 1012 ) 
 4.6  ±  0.4  4.2  ±  0.5  4.3  ±  0.5  4.6  ±  0.5  4.6  ±  0.4  4.4  ±  0.5  4.5  ±  0.4  4.5  ±  0.5  4.4  ±  0.6 
Haemoglobin (g/dl) 10.7  ±  1.4 10.5  ±  2.0 11.2  ±  2.1 11.9  ±  1.4 12.0  ±  1.3 11.6  ±  1.8 11.6  ±  1.4 12.3  ±  1.3 11.8  ±  1.8 
Haematocrit (%) 34.1  ±  3.8 32.6  ±  4.9 34  ±  5.1 36.6  ±  3.4 37.2  ±  3.3 35.8  ±  4.2 35.8  ±  3.3 36.9  ±  3.1 36.1  ±  4.7 
MCV (fl) 74.5  ±  6.3 77.8  ±  6.0 79.3  ±  7.2 79.4  ±  6.8 81.9  ±  7.9 80.3  ±  8.3 80.0  ±  6.9 82.8  ±  6.0 83.0  ±  6.6 
MCH (pg) 23.4  ±  2.8 24.8  ±  2.8 26.3  ±  3.9 25.8  ±  3.0 26.5  ±  2.9 26.0  ±  3.7 26.2  ±  4.1 27.5  ±  2.4 27.1  ±  3.0 
 
 
Table 3.14: Prevalence and degree of severity of anaemia at diagnosis six and 12 mth follow up in paediatric patients with IBD 
 CD UC IBDU 
 Non  
anaemic 
Mild 
anaemia 
Severe 
anaemia 
Non 
anaemic 
Mild 
anaemia 
Severe 
anaemia 
Non 
anaemic 
Mild 
anaemia 
Severe 
anaemia 
Baseline n;(%) 20; (19) 50; (46) 37; (35) 11; (22) 21; (43) 17; (35) 10; (43) 9; (39) 4; (18) 
Follow up 6 mth 
n;(%) 
42; (43) 46; (4) 10; (10) 25; (54) 15; (33) 6;(13) 5; (56) 4; (44) 0; (0) 
Follow up 12 mth 
n;(%) 
29; (32) 52; (57) 10; (11) 20; (51) 17; (44) 2; (5) 6; (46) 5; (39) 2; (15) 
 
 
Table 3.15: Change in -individual anaemia classification patterns in paediatric IBD patients between six and 12 mth post-diagnosis  
Follow up 6 mth Follow up 12 mth 
Anaemia pattern 
change* 
AA n;(%) NN n;(%) AN n;(%) NA n;(%) Anaemia pattern 
change* 
AA n;(%) NN n;(%) AN n;(%) NA n;(%) 
CD  (n=98) 47; (48) 16; (16) 27; (28) 8; (8) CD   ( n=96) 58; (60) 9; (10) 22; (23) 7; (7) 
UC  (n=46) 17 ; (37) 7 ; (15) 18 ; (39) 4 ; (9) UC    ( n=43) 18 ; (42) 9 ; (20) 14 ; (33) 2 ; (5) 
IBDU (n=9) 4 ; (44) 3 ; (34) 2 ; (22) 0 ; (0) IBDU  (n=4) 3 ; (75) 1 ; (25) 0 ; (0) 0 ; (0) 
Total (n=153)  68; (44) 26; (17) 47; (31) 12; (8) Total (n=143) 79; (55) 19; (13) 36; (25) 6; (7) 
* AA= Anaemic at diagnosis and at follow up; NN Non anaemic at diagnosis and at follow up 
* AN= Anaemic at diagnosis but Non anaemic at follow up; NA= Non anaemic at diagnosis but anaemic at follow up  
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3.3.2.6. Changes in haemoglobin concentration at six and 12 months   
Changes in the concentration of haemoglobin were calculated for each child separately as 
the numeric difference from diagnosis levels, at six and 12 months follow up. No difference in 
the mean haemoglobin change was found between the diseases (Table 3.16) (p>0.200). 
Compared to baseline, only the girls’ haemoglobin levels improved at 12 but not at six 
months follow up.  
For analysis purposes, patients were grouped into two categories based on the 
direction of haemoglobin concentration change at six and 12 months follow up. Two groups 
were assigned. Those patients whose haemoglobin concentration either increased or 
remained unchanged compared to diagnosis and those whose haemoglobin deteriorated at 
follow up. For approximately 67%-70% of the patients, haemoglobin concentration improved, 
compared to diagnosis, at six and 12 months follow up. No significant difference in the 
pattern of haemoglobin change was observed between the disease types (Table 3.16) 
 
Table 3.16: Mean changes in haemoglobin concentration (mean ± SD) and percent of IBD 
patients whose haemoglobin concentration improved from diagnosis at six and 12 mth of 
follow up  
 CD UC IBDU 
Mean Hb change (6 mth) (mg/dl) 1 ± 1.5 (n=98) 1.3 ± 2 (n=46) 1.4 ± 2.4 (n=9) 
Mean Hb change (12 mth) (mg/dl) 0.8 ± 1.5 (n=96) 1.7 ± 2.1 (n=43) 1.4 ± 3.3 (n=4) 
N;(%) patients whose Hb improved 
(6mth) 
68; (69) 31; (67) 6; (67) 
N;(%) patients whose Hb improved 
(12mth) 
68; (71) 29; (67) 3; (75) 
 
3.3.2.7. Predictors of improvement of haemoglobin concentration at six 
and 12 months  
Potential predictors were chosen a-priori and their association with the direction of 
haemoglobin change (improvement or deterioration) at follow up was examined with 
univariate and multivariate logistic regression analysis as described above (Section 3.2.1).  
 Similar to the main cohort analysis, systemic markers of disease activity, and female 
gender were the most significant features that characterized anaemic patients at diagnosis. 
Weight loss prior to diagnosis, low BMI and delayed diagnosis were the most important 
predictors of anaemia occurrence and degree severity at diagnosis in univariate analysis 
(Table 3.17). However in multivariate analysis only the level of serum albumin remained 
significant predictors (Table 3.17).   
In subgroup analysis (follow up data), abnormal systemic markers of disease activity 
and low haemoglobin concentration at diagnosis were among the predictors that 
differentiated those patients who improved from those that deteriorated at six and 12 months 
follow up. Improvement of disease activity, as reflected by an increase in albumin and 
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decrease of ESR levels at follow up, was also associated with improvement of haemoglobin 
levels (Table 3.18 & 3.19).  
 
Table 3.17: Predictors of anaemia incidence at diagnosis in paediatric IBD patients (group of 
patients with follow up data at six and/or 12 monts of follow up). Univariate and multivariate 
logistic regression analysis (p-value; OR; 95% CI) 
Predictors Mild anaemia Severe anaemia 
 Univariate 
 p-value OR  95% CI    p-value OR  95% CI 
Sex (male) 
   NS  0.038 0.42 0.19 - 0.95 
ESR (mm/hr) 
 0.009 1.03 1.01 - 1.05  0.001 1.04  1.01 - 1.06 
CRP (mg/l) 
 0.035 1.02  1.01 - 1.04  0.003 1.03 1.01 - 1.04 
Albumin (g/l) 
 0.000 1.83  0.76 - 0.91  0.001 0.75  0.67 - 0.83 
Diagnosis delay (mth) 
 0.058 0.97 0.95 - 1.00  0.022 0.96 0.93 - 0.99 
BMI z-score (SD) 
 0.001 0.59 0.43 - 0.81  0.003  0.60 0.43 - 0.84 
Weight loss (Yes) 
 0.042 2.47  1.03 - 5.93  0.004  4.44  1.63 - 12.10 
 
  
 Multivariate 
 
 p-value OR  95% CI  p-value OR  95% CI 
Albumin (g/l) 
 0.0001 0.83 0.76 - 0.91  0.0001 0.75  0.67 - 0.83 
 
Although in univariate analysis iron supplementation was strongly associated with 
haemoglobin improvement at 12 months for both diseases in multivariate analysis this 
association remained significant only for CD (Table 3.20). In UC patients, improvement of 
serum albumin and low haemoglobin concentration at diagnosis were predictors of 
haemoglobin levels improvement at follow up (Table 3.20). On the other hand in CD 
additional characteristics differentiated patients whose haemoglobin improved from those 
who did not. In particular a decrease in ESR levels, and increase in BMI and growth 
acceleration at six and 12 months predicted improvement of haemoglobin concentration 
(Table 3.20).  
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Table 3.18: Predictors of haemoglobin concentration increase (comparison with those who deteriorated) at six mth follow up in paediatric IBD 
patients (univariate logistic regression; p-value; OR; 95% CI) 
Predictors*  IBD CD UC 
   p-value OR 95% CI  p-value OR 95% CI  p-value OR 95% CI 
Haematology Haemoglobin concentration 
at diagnosis 
 0.0001 1.8 1.4 - 2.3  0.004 1.6 1.2 - 2.3  0.006 2.0 1.2 - 3.2 
Disease 
markers 
ESR concentration at 
diagnosis 
 0.036 1.0 0.9 - 1.0  0.087 1.0 0.9 – 1.0  0.521 1.0 0.9 – 1.0 
 ESR concentration decrease 
at follow up 
 0.008 1.0 1.0 - 1.1  0.008 1.0 1.0 - 1.1  0.700 1.0 1.0 - 1.1 
 CRP concentration decrease 
at follow up 
 0.033 1.0 1.0 - 1.1  0.030 1.0 1.0 - 1.1  0.612 1.0 0.9-1.0 
 Albumin concentration at 
diagnosis 
 0.0001 1.2 1.1 - 1.3  0.002 1.2 1.1 - 1.3  0.028 1.3 1.0 - 1.6 
 Albumin concentration 
increase at follow up 
 0.0001 0.8 0.8 - 0.9  0.003 0.9 0.8 -1.0  0.015 0.7 0.6 - 0.9 
Anthropometry BMI z-score at diagnosis  0.015 1.4 1.1 - 1.9  0.028 1.4 1.0 -2.0  0.339 1.4 0.7 - 2.7 
 BMI z-score increase at 
follow up 
 0.006 0.5 0.3 - 0.8  0.028 0.6 0.3 - 0.9  0.290 0.6 0.2 - 1.6 
* Predictors studied but not significantly associated: age, type of disease, gender, CRP at diagnosis, height z-score at diagnosis, height z-score change at follow up, growth retardation (height z-
score<-2SD), weight loss prior to diagnosis, underweight (BMI <-2SD) 
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Table 3.19: Predictors of haemoglobin concentration increase (comparison with those who deteriorated) at 12 mth follow up (univariate logistic 
regression; p-value; OR; 95% CI) 
Predictors  IBD CD UC 
 
  p-value OR 95% CI  p-value OR 95% CI  p-value OR 95% CI 
Medication Oral iron supplementation  0.001 0.2 0.1 - 0.6  0.012 0.2 0.1 - 0.7  0.009  0.1  0.0 - 0.6 
Haematics Haemoglobin concentration at 
diagnosis 
 0.0001 2.3:  1.7 - 3.3  0.001 1.9: 1.3-2.9  0.002 5.6: 2 .0- 17.9 
Disease markers ESR concentration at diagnosis  0.106 1.0 0.9 – 1.0  0.819 1.0 0.9 – 1.0  0.038 0.9 0.9 – 1.0 
 ESR concentration decrease at 
follow up 
 0.010 1.0 1.0 - 1.1  0.107 1.0 0.9 – 1.0  0.055 1.1 1.0 - 1.2 
 CRP concentration diagnosis  0.094   1.0 0.9 – 1.0  0.112  1.0 0.9 – 1 0  0.418 1.0 0.9 – 1.0 
 CRP concentration decrease at 
follow up 
 0.068 1.0 1.0 - 1.1  0.079 1.0 1.0 - 1.1  0.508 1.0 1.0 - 1.1 
 Albumin concentration at 
diagnosis 
 0.0001 1.2 1.1 - 1.3  0.001 1.2: 1.1 - 1.3  0.040  1.3 1.0 - 1.6 
 Albumin concentration increase 
at Follow up 
 0.0001 0.8: 0.8 - 0.9  0.002 0.9 0.8 - 0.9  0.038 0.8 0.0 –.6-1 
Anthropometry BMI z-score at diagnosis  0.056 1.3: 1.0 - 1.7  0.157 1.3: 0.9 - 1.8  0.148 1.7 0.8 - 3.5 
 BMI z-score increase at follow up  0.008 0.6: 0.4 - 0.9  0.005 0.4 0.3 - 0.8  0.818 0.9 0.5 - 1.7 
 Height z-score increase at follow 
up 
 0.101 0.5: 0.3 - 1.1  0.013 0.2 0.1 - 0.7  0.825 0.9 0.4 – 2.0] 
 
 Weight loss at diagnosis  0.002 0.3: 0.1 - 0.6  0.018 0.3 0.1 - 0.8  0.101 0.3 0.1 - 1.3 
 
Predictors studied but not significantly associated: age, type of disease, gender, CRP at diagnosis, height z-score at diagnosis, growth retardation (height z-score<-2SD), underweight (BMI <-2SD), 
all types of medication used, number if oral steroid courses, number of EEN courses,   
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Table 3.20: Predictors of haemoglobin concentration increase (comparison with those who deteriorated) at six and 12 mth follow up in paediatric 
IBD patients (multivariate logistic regression ; p-value; OR; 95% CI) 
Predictors IBD CD UC 
6 mth Follow up  
 p-Value  OR  95%CI  p-Value  OR  95%CI  p-Value  OR  95%CI 
Haemoglobin concentration at 
diagnosis  
 0.020 1.7 1.1 - 2.5  0.018 2.4 1.2 - 4.9  
ESR concentration at diagnosis  0.042 1.0 1.1 - 1.1  0.023 1.1 1.0 - 1.1  
Decrease in ESR concentration at 
6 mth  
 0.025 1.0 1.0 - 1.1  0.034 1.1 1.0 - 1.1  
Increase in albumin concentration 
at 6 mth 
 0.003 0.8 0.7 - 0.9  0.006 0.7 0.5 - 0.9  0.015 0.7 0.6 - 0.9 
BMI z-score at diagnosis  0.032 1.8 1.1 - 2.9  0.008 2.9 1.3 - 6.4  
Increase in BMI z-score at 6 mth  0.025 2.9 1.1 - 7.5  0.002 15.4 2.7 - 86.8  
12 mth Follow up  
   
Haemoglobin concentration at 
diagnosis  
 0.0001 2.6 1.6 - 4.3  0.029 1.7 1.1 - 2.8  0.002 6.0:  2.0 - 17.9 
ESR concentration at diagnosis  .037 1.0 1.0 -1.1   
Decrease in ESR concentration at 
12 mth  
 0.017 1.1 1.0 - 1.1   
Increase in albumin concentration 
at 12 mth 
 0.027 0.9 0.8 – 1.0  0.006   0.9 : 0.8 –1.0   
Oral iron supplementation   0.043   0.2:  0.1 - 0.9  
Height z-score increase at 12 mth   0.008 0.1 0.0 - 0.5  
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3.4. Discussion 
Anaemia is one of the extra-intestinal complications of IBD affecting body homeostasis, 
quality of life and, in children, may impair cognitive development (Section 1.4.2). The 
prevalence of anaemia in adult IBD is well reported but similar evidence in children is scarce 
(229).  
Poor study design, with small sample size (213;242;252;253) and the use of 
inappropriate generic criteria to define anaemia were some of the drawbacks of previous 
paediatric reports. As it is well accepted that haemoglobin normal levels vary considerably 
with age and gender (205) the use of relevant cut offs is essential. In previous studies, both 
children with long-standing disease and newly diagnosed patients were recruited which may 
have induced selection bias to the estimation of anaemia prevalence at diagnosis (Table 
1.4.5). In contrast this current study included only patients on disease presentation and 
before medical therapy was applied. 
The Yorkhill Royal Hospital of Sick Children is the only paediatric referral hospital 
exclusively in charge of the care of all the children with IBD at the geographical area of the 
West of Scotland. This allowed to define a representative sample of the general Scottish IBD 
population and avoid selection bias that may have occurred in previous studies, which 
included only patients with active disease (242). In fact the demographic and disease 
characteristics of the population of the current study are in strong accordance with previous 
British epidemiological surveys (16;33) allowing the extrapolation of the results to the general 
Scottish paediatric IBD population.     
In this big retrospective study, the prevalence of anaemia was high with 
approximately three quarters of the patients presenting with some degree of anaemia, and 
one third suffering from severe anaemia at diagnosis. Severe anaemia was more common in 
females with no difference observed between CD and UC. Blood loss from menstruation may 
explain this predisposition to girls despite the use of gender and age specific haemoglobin 
cut offs to define anaemia.    
Red blood cell counts were significantly higher in UC than CD despite no significant 
differences in haemoglobin levels or other haematological markers. Although it is difficult to 
elucidate the exact reason of this difference, a possible explanation would be the different 
causes of anaemia in the two diseases. Overt gastrointestinal bleeding with RBC loss is 
more common in UC than CD (33) and may be an additional major contributor to the origin of 
anaemia beyond any other causes like reduced iron intake and the disease affect. 
Gastrointestinal bleeding and poor dietary intake are typical clinical manifestations of 
the newly diagnosed IBD patient and may explain the strong association found in this study 
between systemic markers of disease activity and haemoglobin concentration. In fact the 
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total number of abnormal systemic markers of disease activity was the strongest 
independent predictor of anaemia occurrence and degree of its severity. A patient with 
abnormal CRP, ESR, serum albumin and increased number of platelet counts had an 
approximately 100 fold chance of severe anaemia.  
Disease location with involvement of the upper digestive tract, where dietary iron is 
absorbed, has been associated with anaemia occurrence in previous reports (244;247) but 
the results of this current study are not in accordance. New guidelines were used to define 
the anatomic location of the disease and failed to find any difference in anaemia prevalence 
between patients with upper and lower gastrointestinal involvement or between patients with 
extensive or disease of limited extent. Indeed the absence of difference in anaemia 
occurrence between CD and UC advocates that iron malabsorption is not the sole 
determinant of anaemia onset. Other factors such as intestinal bleeding, and a diet low in 
iron (223) could equally contribute to anaemia aetiology. Unfortunately, due to the 
retrospective design of this study no dietary assessment was available to address this 
possibility. On the other hand no association was found between overt self-reported 
gastrointestinal bleeding and anaemia although faecal occult blood cannot be excluded.    
Similar to disease location, disease behaviour was not significantly associated with 
anaemia incidence. Inflammatory, penetrating and stricture disease behaviour did not 
differentiate anaemic from non-anaemic patients. However perianal disease involvement was 
not included in the disease phenotypic characterization and consequently this study cannot 
answer whether there are differences in the prevalence of anaemia in patients with perianal 
abscesses. The lack of relevant information was due to the retrospective nature of the study 
and under-documentation of perianal disease in the electronic pathology reports used to 
assess the disease location. 
A high risk of undernutrition, as reflected by prior weight loss and low at disease 
diagnosis, differentiated anaemic from non anaemic patients. However this association 
disappeared when serum albumin levels were added in the multivariate model suggesting 
that disease activity may be a more significant predictor of anaemia occurrence. 
Nevertheless albumin levels can be influenced by both inflammation and under-nutrition and 
a dependency with BMI may have confounded the results. Indeed when albumin substituted 
with ESR in the multivariate model, BMI remained a statistically significant independent 
predictor of anaemia.   
The prevalence of anaemia varied between 2001 and 2007 but no overall temporal 
trends can be drawn. There was no decrease in the prevalence of anaemia over time despite 
our expectations. Temporal changes may have happened due to a shorter interval between 
symptoms onset and disease diagnosis nowadays. This would prevent the onset or allow 
timely correction of anaemia at early stages. However there was no difference in the 
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diagnosis delay within the short period assessed. Instead a significant association was found 
between anaemia occurrence and prompt diagnosis. This could be due to an inverse 
association between anaemia and diagnosis delay. It is possible that early onset of anaemia 
onset accelerates clinical investigations and hence prompt disease diagnosis, rather than a 
diagnosis delay predisposing to anaemia.  
This study aimed to assess the prevalence of anaemia and its progression at follow 
up. Due to the retrospective design of this study it was not possible to measure additional 
haematological parameters to differentiate between the types of anaemia. Based on the size 
of RBC, no patient suffered from megalocytic anaemia and this suggests that the primary 
cause of anaemia in IBD is IDA or ACD. Ferritin levels were available in a few patients and a 
significant positive correlation was found with CRP and a negative association with serum 
albumin concentration. Although at first sight this seems paradoxical and may suggest that 
iron stores are improved with active systemic disease or undernutrition, strong evidence 
suggests that ferritin is a positive acute phase respondent that increases independently of 
the actual body iron stores in inflammatory conditions, infection and cancer (555). This study 
among others suggests that ferritin is an unreliable marker of body iron stores in patients with 
active IBD where systemic inflammation is present. The acute phase response and ACD 
could also explain why some anaemic patients had normal MCV and ferritin levels. Other 
surrogate markers should be used with better diagnostic value in order to differentiate 
between the different types of anaemia in IBD. Soluble serum receptor of transferrin is a 
potent marker but its use is limited to research only scale (228).  
Although there are a few case reports of nutritional anaemias caused by folate and 
vitamin B12 deficiency, none of the 26 patients studied had suboptimal levels of vitamin B12 or 
folate. Indeed there was no association between ileal defined disease and low levels of B12. 
This discrepancy with previous adult studies (236) may be ascribed to differences in subject 
characteristics and recruitment of patients with longstanding disease rather than the newly 
diagnosed patients this study included. It is likely that vitamin B12 body stores, although 
small, are adequate to sustain serum levels and prevent B12 deficient anaemia in newly 
presented patients. Conversely, this may be more common in patients with longstanding 
disease and depleted vitamin stores.   
Changes in the pattern of anaemia prevalence over the natural history of the disease 
have not been described in adult or paediatric studies. This is the first study which assessed 
anaemia prevalence at follow up. Although anaemia prevalence remained high at follow up, a 
significant decline was observed which coincided with a significant increase in mean 
haemoglobin concentration by approximately 1 g/dl at follow up.  Nevertheless more than 
half of the patients were anaemic at six months and 12 months post-diagnosis showing that a 
considerable number of patients remain anaemic within a year of diagnosis. 
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With regard to changes in the severity of anaemia, one third of the children presented 
at diagnosis haemoglobin levels less than 10 g/dl, but only 10% were severely anaemic at 
follow up. On an individual basis approximately 50% of the patients anaemic at diagnosis 
remained so at follow up, and 31% improved to normal haemoglobin levels. Eight percent of 
the patients with normal levels of haemoglobin at diagnosis deteriorated and became 
anaemic at follow up. Although subgroup analysis might reveal any disease or demographic 
differences compared to the rest of the groups, the sample sizes are too small and preclude 
reliable statistical analysis 
Several predictors of haemoglobin concentration improvement or deterioration were 
evaluated at follow up. Improvement of baseline serum albumin level at follow up was among 
the strongest predictors in univariate and multivariate analysis which differentiated those 
patients whose haemoglobin improved at follow up from those who did not. On the contrary 
CRP and ESR changes were not strong predictors of haemoglobin improvement particularly 
in UC patients. This discrepancy could show that other factors beyond changes in disease 
activity determine haemoglobin improvement or deterioration. In particular serum albumin, a 
negative acute phase respondent can be further decreased by poor nutritional status and 
subsequently increase of haemoglobin levels in response to improvement of serum albumin 
may coincide not only with amelioration of disease activity but also with nutritional 
rehabilitation. In support of this is that a BMI increase and linear growth acceleration in CD 
patients were strongly associated with improvement of haemoglobin levels, an effect that 
was independent of any improvement in the systemic markers of disease activity.  
Despite no difference in the prevalence of anaemia between CD and UC patients at 
any point of follow up, disease specific differences were found in the predictors of 
haemoglobin change. A low haemoglobin at diagnosis and improvement of albumin at follow 
up were the strongest predictors of haemoglobin improvement at follow up in UC children. In 
contrast, improvement of fundamental anthropometry and ESR were additional factors 
independently associated with increase of haemoglobin at follow up only in CD patients.   
As might be expected oral iron supplementation was independently associated with 
improvement of haemoglobin levels in patients with CD. This effect was independent of 
changes in systemic markers of disease activity or improvement of nutritional status. 
Although some patients who received blood transfusion were included, this was not a 
significant predictor of haemoglobin anaemia improvement at follow up. It is possible that any 
favourable effect of blood transfusion on haemoglobin levels is either short term and 
counteracted by the increased disease severity and gross intestinal bleeding that is usually 
seen in this group of patients. In contrast to expectations, use of nutritional support did not 
differentiate those patients with improved haemoglobin levels at follow up from those who 
deteriorated. This study speculated that nutritional therapy and in particularly the number of 
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EEN courses would be strongly associated with haemoglobin improvement. However, 
frequent use of EEN nutrition also denotes increased disease activity and the number of 
courses corresponds to clinical relapses. As disease activity was found to be inversely 
associated with reduced haemoglobin levels in this study, any beneficial effect of nutritional 
support is counterbalanced by the negative effect of disease activity.  
Although it was not among the primary aims, this study provided useful information on 
the nutritional status body composition and disease characteristics of children with IBD at 
diagnosis and over a year follow up. Disease specific differences in anthropometric 
characteristics were found between children with CD and UC as reported by others. CD 
children presented with significantly lower BMI z-scores than children with UC at diagnosis 
and at all time points of follow up. As a result the prevalence of underweight and growth 
retarded children was significantly higher in CD than UC children. Although this may be 
attributed to the involvement of upper digestive tract, and subsequent nutrient loss from 
malabsorption in CD, other factors could be implicated too. Crohn’s disease and UC, 
although part of the same disease constellation, have different mechanisms of pathogenesis, 
and immunological responses that may affect nutritional status in a different way. As the 
findings of this study suggest, patients with CD have more abnormal systemic markers of 
disease activity compared to UC children, and it is perhaps due to the increased production 
of inflammatory markers and pro-inflammatory cytokines that CD children more often 
experience growth retardation and suboptimal nutritional status. This coincides with evidence 
that suggests that pro-inflammatory cytokines are partially responsible for growth retardation 
and suboptimal nutritional status (111). Future studies in this area should address this and 
whether different cytokines exert a different role on growth and nutritional status. It was 
exciting to find that the majority of the children with suboptimal weight at diagnosis caught up 
within six months of follow up. The proportion of patients who presented BMI lower than -2 
SD at 12 months did not differ significantly from the normal distribution seen in the general 
healthy population.  Although no IBD patient was obese at diagnosis, more than 10% percent 
of the UC children could be classified obese at follow up. This reverse in nutritional status 
could be a combination, of disease improvement, nutritional support and the side effects of 
the use of steroid treatment.  
In the biggest study in Europe and the UK, the prevalence of anaemia is high in 
paediatric IBD at diagnosis. Disease activity and nutritional status at diagnosis and their 
change at follow up are the most important predictors of anaemia occurrence and its 
evolution during the course of disease. Future research should be focused on the part of 
patients who deteriorated at follow up. This study just explored any potential association 
between the use of medication and prevalence of haemoglobin at follow up and therefore it is 
difficult to conclude on any causative association. Further well controlled trials should 
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investigate the collateral therapeutic effects of new anti-inflammatory agents and nutritional 
therapies to correct anaemia. This is particular important in the case of ACD whose 
pathogenesis is predominantly attributed to the excessive production of pro-inflammatory 
cytokines (231). It was noteworthy to find that there is a lack of studies on the dietary 
assessment of paediatric patients of IBD. A diet poor in iron unable to compensate with the 
excessive gastrointestinal losses may equally contribute to the onset of anaemia in IBD. Iron 
balance studies could be designed where the equilibrium of iron balance is monitored to 
accurately assess intake, use, and gastrointestinal losses. In any case a diet rich in iron 
containing foods should be encouraged. Oral iron supplementation, although supported by 
the findings of the current retrospective study, should be used cautiously in the light of animal 
studies and in-vitro models suggesting that excessive production of free radicals and 
oxidative stress at the site of tissue lesion may have possible implications for increased risk 
of colonic carcinogenesis (236). 
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CHAPTER FOUR 
 
 
Comparison of body composition assessment 
in healthy children with leg to leg bioelectrical 
impedance and DXA analysis 
 176 
OUTLINE 
This chapter describes a study that assessed the validity of a simple body composition 
method, based on bioimpedance, to measure accurately body composition in healthy 
children. The secondary aim of this study was to measure the body composition of a 
representative cohort of healthy Scottish children and to compare it with the body 
composition of CD children who participated in the studies of this thesis. The results of the 
second part of this study are presented in Chapter 5. 
 
4.1. Introduction 
Assessment of body composition is important in health and disease. Measurement of body 
fat stores is important in obesity and calorie restricting diets, as is measurement of muscle 
mass in chronic catabolic disorders.  
Measuring body composition has been a constant challenge and at the moment no 
standard method is universally accepted to measure body compartments accurately and 
precisely (92). Chemical analysis of human cadavers is the only way body composition can 
be determined accurately but imaging techniques and the multi-compartment model (556) 
are considered the best approaches, usually cited as “gold standard” methods (557). Other 
techniques like stable isotope dilution, underwater weighing, total body dual x-ray 
absorptiometry (DEXA) known as “reference methods” rather than “gold standards”, are good 
alternatives with minimal error, but are mainly laboratory based methods, and hence 
impractical in large scale community studies or for routine clinical use.  
Practical, cheap, safe and patient friendly methods of body composition assessment 
for clinical bedside use are needed. Fundamental anthropometry and growth charts, 
calculation of BMI, or use of prediction equations based on height and weight are not able to 
differentiate between fatness and lean mass (558). Although in healthy adults and children 
BMI, originally an index of morbidity risk, correlates well with fatness (93), their diagnostic 
value to differentiate fat from lean mass is questionable, particularly in disease. Multiple 
clinical conditions like oedema or dehydration, and use of steroids can affect body weight 
irrespective of changes in the actual muscle and fat stores. Hence the use of anthropometry 
can be inaccurate and misleading.  
Skinfold thickness measurements have been the only method used for surveillance of 
body stores in routine clinical practice. However they are prone to inter-observer error, need 
well trained personnel and may cause discomfort in young children.  Although reliable in the 
assessment of groups or populations, skinfold thickness measurements are not reliable in 
estimating the body composition of individuals. (559).  
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The advent of bioelectrical impedance analysis (BIA) was welcomed as a potential 
alternative at the beginning of the 80’s. The equipment is non-invasive, portable, quick to 
use, provides direct results and needs less subject cooperation than any other method 
making it viable for field and routine use.    
The fundamental principle behind BIA is the measurement of the resistance of the 
human body to an insensible electric current circulating through the body (560). The 
measured resistance/impedance or more correctly the impedance index (Height2/Resistance) 
is proportionally related to total body water volume and consequently total fat free mass 
(FFM), assuming a constant hydration of FFM containing virtually all the body’s conducting 
electrolytes (560). Nevertheless the relationship between total body water and impedance 
must be established empirically and there is evidence that this differs between populations, 
races, sexes and ages (561). The National Institute of Health published a consensus article 
that highlights the importance of comparing the impedance instruments with reference 
methods and that predictive equations are useful only for subjects who closely match the 
reference population from which they were derived (562;563). 
The traditional method is based on the measurement of impedance between the hand 
and foot. A new alternative has recently been introduced that measures the impedance from 
an electrical circuit between the legs (564). This adapted technique resembles a household 
bathroom scales with the subject required to stand briefly on two metallic footplates. Unlike 
the conventional technique there is no need for the attachment of electrodes at precise 
anatomical sites and weight is simultaneously measured avoiding any transcription errors.  
Many studies have compared and validated or compared the traditional hand to foot 
technique with other “reference methods” both in adult (565-568) and paediatric populations 
(569;570) but the derived equations cannot be applied to the foot to foot appliance due to 
difference in the measuring segments of the body (hand to foot vs foot to foot) (571). 
Relevant studies for the foot to foot method are scarce (572) particularly in paediatric 
populations (573;574) and so the validity of the new foot to foot system with its inbuilt 
manufacturer’s equations needed to be tested.  
The primary purpose of this study was to compare the foot to foot technique of body 
composition with respective DXA measurements in a healthy cohort of Scottish children. This 
would allow to consider its appropriateness for use in the assessment of body composition in 
paediatric patients with CD. The second aim of this study was to compare the body 
composition of this healthy control cohort with a cohort of children with CD which is 
presented in a following chapter (Chapter 5). 
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4.2. Subjects and methods 
4.2.1. Subjects 
A subgroup of children from a larger study on bone health and body composition, in 
mainstream and specialist sport schools, was recruited for the purpose of this study. 
Potential participants were approached by posted invitation letters to lists of patients kindly 
supplied by their general practitioners. Exclusion criteria were acute or chronic illness and 
concomitant medication use known to induce changes in body composition. The volunteers 
were from mainstream schools in the area of Glasgow. Children were selected to provide an 
equal distribution of ages, genders, and BMIs. Written informed consent was obtained from 
all children and their parents. The study protocol was approved by the local research ethics 
committee and the research and development office.  
 
4.2.2. Basic anthropometry 
Anthropometric measurements were conducted according to standard procedures. A trained 
dietitian and a paediatric endocrinologist performed all measurements. Each investigator 
performed a single type of measurement. Weight was measured to the nearest 100 g using a 
calibrated digital beam scale (SECA, Birmingham, UK). Subjects were weighed in light 
clothing or wearing a hospital gown. Height was measured to the nearest 1 mm using a wall-
mounted stadiometer according to the Frankfurt plane position. BMI was computed as the 
fraction of weight to the squared height and corresponding z-scores were calculated using 
British national reference data (575).  
 
4.2.3. Body composition 
4.2.3.1. Foot to foot impedance measurements 
Bioelectrical impedance analysis (BIA) was performed with the foot to foot technique using a 
TANITA body fat analyser (TBF-300, Tokyo, Japan) which provides a print out of the 
measured weight, impedance, and two compartment body composition analysis. Gender, 
age and height to the nearest centimetre were entered manually into the keypad interface. 
Subjects stood on the two metal sole-pad electrodes embedded on the platform scales. The 
electrode for each foot was subdivided into anterior and posterior electrodes. A current was 
applied through the anterior portion of the footpad electrodes and the voltage drop was 
measured in the posterior portion. The impedance measurement used a 50 kHz, 500 µA 
insensible current. Subjects were asked to have only a light meal at least one hour before 
their measurements and were asked to void their bladder before the start of the 
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measurements. All the measurements were done after a period of at least 10 min standing 
upright to minimize potential errors from acute shifts in fluid distribution. Body composition for 
all subjects was estimated using the standard inbuilt prediction equations of the 
manufacturer, as no other appropriate equation is available in the literature. Every 
measurement was taken in duplicate and averaged unless the difference in two impedance 
measurements was greater than 10 Ohms.  
 
4.2.3.2. DXA measurements 
Whole body DXA scans were performed with a narrow fan beam Lunar Prodigy densitometer 
(GE Healthcare) and phantoms analysed using the Encore software (Version 8.80.001). The 
DXA technique is based on the attenuation properties of bone, lean and fat tissues at two 
different x-rays energies and it measures directly the bone mineral content, lean and fat 
mass (FM) (576;577).  
Whole body composition was analyzed for bone mass and soft tissue and the latter 
was subdivided into lean and FM. Bone mass content added to lean mass corresponded to 
FFM in accordance with the two-compartment model. Each scan took approximately five min 
to complete. The DXA scans were carried out randomly prior to or after the BIA 
measurements. 
 
4.2.4. Statistical analysis 
The difference between paired data was tested with one sample t-test and one sample 
Wilcoxon Sign Rank test, for normally and non-parametric distributed values. Normality of the 
data was checked with the Darling-Anderson test. Spearman rank correlation coefficients 
were calculated for BIA and DXA for all body composition measures. Linear regression 
analysis with best fitting line was used to predict DXA FFM measurements by the respective 
TANITA values. The agreement between the two methods, was evaluated with Bland-Altman 
plots, by plotting the individual differences of a measure, between the two methods, against 
their mean (578). The bias of the method is equal to the mean difference of the methods. 
Limits of agreement between BIA and DXA were calculated as the mean difference of the 
two methods ± 1.96 times the standard deviation of the mean difference. The effect of size of 
the measurement on the agreement of the methods was assessed by calculating the R2 co-
efficient of the linear regression model of the differences of the measures against their mean 
value. Statistical significance was set at p< 0.05. Standard deviation scores (z-scores) for % 
FM were calculated using British reference data (579) kindly provided by Professor Tim Cole. 
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4.3. Results 
4.3.1. Sample characteristics and basic anthropometry 
117 children aged (6.8-18.9) agreed to participate.  All participants completed all 
measurements successfully.  Most of the children were of Caucasian origin (n=107). 
Demographics, anthropometry and body composition data grouped by sex are presented in 
Table 4.1. No difference was found between boys and girls for age and fundamental 
anthropometry. Height z-scores did not differ significantly from zero (p-value=0.540) but BMI 
z-scores were slightly higher than the British reference population (575) (p <0.0001).  
 
4.3.2. Body composition analysis 
For both methods the mean FM, expressed as absolute values (kg) or as percentage of body 
weight, was lower in boys than girls despite no significant mean differences in BMI, body 
weight and height (Table 4.1). Likewise the percentage FFM but not absolute FFM was 
higher in boys than girls. No gender-associated difference was found for the %FM z-scores. 
Females had significantly higher measurements of impedance than boys as expected.   
 
4.3.3. Comparison between DXA and TANITA 
4.3.3.1. Correlation of the methods 
As expected all body composition compartments (FM, FFM, %FM and %FFM) estimates by 
BIA were positively and highly correlated with those by DXA (Table 4.2). The Spearman rank 
correlations coefficient between DXA and BIA measures of FFM, FM, %FFM and %FM were 
high for both genders (Table 4.2 Fig 14-16). Fat free mass calculated by DXA was linearly 
regressed against FFM predicted by TANITA. A FFM prediction line was drawn that 
explained 96% of the measurements variance (Fig 13). 
 
4.3.3.2. Biases and limits of agreement between the methods 
4.3.3.2.1. Crude measurements of body composition 
The differences in body composition measures between the two methods were normally 
distributed (Anderson-Darling normality test) and the use of Bland-Altman plot was deemed 
valid and no log transformation of the data was required. Mean absolute values and 
percentages of FM and FFM were statistically different between DXA and TANITA (all p-
values <0.0001). Defining DXA as the “reference method”, TANITA overestimated %FFM by 
a mean of 4.5% and underestimated FM by -2.1 kg of fat (Table 4.3). Nonetheless, in all 
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cases, the limits of agreement between the methods were wide and therefore the methods 
were not interchangeable at an individual level (Table 4.3). Biases and limits of agreement 
for absolute measures and % FM and FFM are displayed in Figs 16-18 and summarized in 
Table 4.3 for the whole group and separately for boys and girls. Taking body fat as a prime 
example, TANITA may underestimate or overestimate %FM as much as -13.3% and 4.3% 
respectively. The mean bias between the two methods was higher in girls than boys but in 
both cases the limits of agreement for all body composition measurements were wide (Table 
4.3). 
A weak but statistically significant effect of the size of measurement on the 
agreement of the methods was observed that partially justifies the broad limits of agreement 
(Table 4.4). However when the data were analyzed separately for boys and girls, a size of 
measurement effect was observed in males but not in females (Table 4.4). With increasing 
body fatness the measurement bias between TANITA and DXA became progressively 
negative in boys. In particular TANITA consistently underestimated %FM in boys with body 
fat more than 20% whereas the measurement error was variable in males with lower %FM. 
No similar patterns were observed for females (Fig 18).   
 
4.3.3.2.2. Z-scores of body composition measurements  
Percent FM values by both methods were converted to z-scores using the British reference 
range (579). The age and gender adjusted bias of foot to foot BIA for %FM was -1.3 SD with 
wide limits of agreement (Table 4.3; Fig 19). In contrast to %FM crude values, increase of 
%FM z-scores influenced the bias between the two methods in a similar way for both 
genders (Figs 20-21). For children with normal or high %FM z-score, the bias for foot to foot 
BIA was small and lay close to the line of method agreement. On the other hand the limits of 
agreement were wide and varied considerably for children with very low %FM z-score (Table 
4.3; Figs 20-21).         
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Table 4.1: Demographics, anthropometry and body composition characteristics (mean; SD) of 
healthy Scottish children (mean ± SD)  
Measurement F (n=63) M (n=57) Total (n=117) 
Age (decimal y) 
 12.6  ±  3.2  12.4  ±  3.7  12.5  ±  3.4 
Height (cm) 
 149.2  ±  14.0  152.0  ±  20.0  150.5  ±  17.0 
Weight (kg) 
 46.4  ±  17.7  47.8  ±  19.1  47.0  ±  18.3 
Height z-score 
 0.0  ±  1.0  0.1  ±  1.0  0.06  ±  1.0 
Weight z-score 
 0.3  ±  1.2  0.5  ±  1.1  0.4  ±  1.1 
BMI 
 20.2  ±  4.8  19.7  ±  3.9  20.0  ±  4.4 
BMI z-score 
 0.4  ±  1.2  0.6 ±  1.1  0.5  ±  1.1 
 
   
TANITA 
   
Impedance (Ohms) 
 601.0 ±  71.0*  564.0 ±  72.0  584.0  ±  74 
FFM (%) 
 77.3  ±  9.5*  83.4  ±  7.4  80.1  ±  9.1 
FFM (kg) 
 34.0 ±  8.9  39.1  ±  15.5  36.4  ±  12.6 
FM (%) 
 22.7  ±  9.5*  16.6  ±  7.4  19.9  ±  9.1 
FM (kg) 
 11.7  ±  10.1*  8.1  ±  5.8  10.0  ±  8.5 
FM (%) z-score 
 -1.1  ±  4.0  -0.7  ±  2.4  -0.9  ±  3.3 
Total body water 
 24.9  ±  6.5  28.6  ±  11.4  26.6  ±  9.2 
 
   
DXA 
   
Total body mass (kg) 
 45.5  ±  17.5  47.4  ±  19.1  46.4  ±  18.2 
FFM (kg) 
 31.6  ±  8.6  37.3  ±  14.4  34.2  ±  11.9 
FFM (%) 
 72.0  ±  9.2*  79.9  ±  9.3  75.7  ±  10.0 
FM (%) 
 28.0  ±  9.2*  20.1  ±  9.3  24.3  ±  10.0 
FM (kg) 
 13.9  ±  10.1*  10.1  ±  7.6  12.2  ±  9.2 
FM (%) z-score 
 0.6  ±  1.7  0.1  ±  1.9  0.3  ±  1.8 
 
   
* Difference between genders p< 0.05 (two sample t-test or Mann-Whitney test) 
 
 
 
Figure  13: Linear regression with best fitting line for FFM (kg) between TANITA and DXA 
measurements of body composition 
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Table 4.2: Spearman rank correlation (r coefficient and p-values) for body composition variables between DXA and TANITA in healthy Scottish 
boys and girls  
 
 Males  Females  Whole group  
 R coefficient p-value R coefficient p-value R coefficient p-value 
FFM (Kg) 0.99 0.001 0.96 0.001 0.98 0.001 
FFM (%) 0.79 0.001 0.85 0.001 0.86 0.001 
FM (Kg) 0.92 0.001 0.95 0.001 0.94 0.001 
FM (%) 0.79 0.001 0.85 0.001 0.86 0.001 
 
 
Table 4.3: Measurement bias with 95% limits of agreement for body composition measurement between DXA and TANITA in healthy Scottish boys 
and girls  
 Males Females Whole group 
 Bias Limits of agreement Bias Limits of agreement Bias Limits of agreement 
FFM (Kg) 1.8  -3.6: 7.3 2.4  -2.0: 6.9 2.2  -2.8: 7.1 
FFM (%) 3.5  -4.8: 11.8 5.3  -3.6: 14.2 4.5  -4.3: 13.3 
FM (Kg) -2  -7.2: 3.2 -2.2  -6.4: 6.9 -2.1  -6.8: 2.5 
FM (%) -3.5  -11.8: 4.8 -5.3  -14.2: 3.6 -4.5  -13.3: 4.3 
FM (%) z-score -0.8  -4.0: 2.3 -1.2  -3.7: 1.2 -1.3  -6.0 5:4 
 
 
Table 4.4: Effect of the size of the measurement on the agreement of the methods in healthy Scottish boys and girls. R coefficient, slope (β 
coefficient), and p-values 
 Males Females Whole group 
 R Slope p-value R Slope p-value R Slope p-value 
FFM (Kg) 15.8 0.1 0.003 2.4 0.04 0.223 6.6 0.1 0.003 
FFM (%) 20.3 -0.2 0.001 0.5 0.03 0.592 4.4 -0.1 0.023 
FM (Kg) 44.5 -0.3 0.001 0.0 0 0.997 7.0 -0.1 0.004 
FM (%) 20.3 -0.2 0.001 0.5 0.03 0.592 4.4 -0.1 0.023 
FM (%) z-score 8.3 0.26 0.019 27.3 0.35 0.001 15.5 0.29 0.001 
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Figure  14: Spearman rank correlation for body composition measures between TANITA and DXA in healthy children (whole group) 
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Figure  15: Spearman rank correlation for body composition measures between TANITA and DXA in healthy children (males) 
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Figure  16 : Spearman rank correlation for body composition measures between TANITA and DXA in healthy children (females) 
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Figure 17: Bland Altman plots with 95% limits of agreement and regression line for body composition measures between TANITA and DXA in 
healthy children (whole group) 
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Figure  18: Bland Altman plots with 95% limits of agreement and regression line for body composition measures between TANITA and DXA in 
healthy children (females) 
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Figure  19: Bland Altman plots with 95% limits of agreement and regression line for body composition measures between TANITA and DXA in 
healthy children (males) 
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Figure  20: Bland Altman plots with 95% limits of agreement and regression line for %FM z-scores between TANITA and DXA imn healthy children 
(whole group) 
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Figure  21: Bland Altman plots with 95% limits of agreement and regression line for body composition measures between TANITA and DXA in 
healthy children (analysis by gender) 
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4.4. Discussion 
Body composition assessment is important in disease where changes of body weight do not 
always parallel alterations in body muscle and fat stores. A prime example is the chronic use 
of steroids, where body fat stores increase in parallel to fluid retention and muscle wasting.  
There are several methods to assess body composition but at the moment none is 
able to assess accurately the body composition in the living human. Some of the most 
precise methods are impractical in clinical use or in large public health surveys whereas the 
accuracy of the more practical bedside methods is questionable and should always be tested 
against reference methods to the population intended for use. Indeed that was the primary 
aim of this study. To test the validity of a foot to foot BIA appliance against a body 
composition reference method.  
In the current study, measurements of body composition carried out by the two 
different methods were highly correlated. This is not surprising as body composition in BIA is 
predicted by mathematical models, where body weight contributes substantially to the 
estimation of FM or muscle stores. On the other hand correlation does not parallel the 
agreement between the methods and whether these are inter-changeable at individual level 
(578). Thus the agreement of the two body composition methods was assessed using Bland-
Altman plots. The overall bias of BIA was estimated to approximately +2.2 kg of FFM or -
4.5% of FM and the limits of agreement were wide for all the body composition parameters. 
In practice this corresponds to underestimation or overestimation of real %FM by an extra 
13.3% to -4.3% fat respectively. In a 35 kg child with actual body fat of 15% the BIA 
predicted %FM can be between 1.7% to 19.3%. Measurements of body composition with 
TANITA tended to underestimate FM and, accordingly overestimate FFM in a higher degree 
in girls than boys. However in both cases the bias was large and the limits of agreement 
wide.  
The findings of this study are in accordance with previous work (573) where the same 
model of TANITA underestimated FM and overestimated FFM in a cohort of British eight y 
old children and, by Lazzer et al (580) in overweight/obese adolescents (Table 4.5). Opposite 
results and overestimation of FM by TANITA were also reported (581) and this may be due 
to the different devices and prediction algorithms used to calculate FM in the studies or 
different sample characteristics and the physiological changes that occur in body 
composition with age and gender (582). 
In this study a gender specific effect of the size of the measurement on the 
agreement of the methods was found and should be considered when interpreting results 
with TANITA. In boys with increasing percentage fat, TANITA tended to underestimate fat 
more. Lazzer et colleagues (580) showed that two different foot to foot BIA appliances 
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underestimated low %FM but overestimated high %FM in overweight/obese children when 
compared with DXA body composition assessments. Both these findings are particularly 
important when assessing or monitoring body composition changes in overweight and obese 
children. On the other hand one should always bear in mind that DXA is a reference method 
rather than an actual “gold standard” (556;558;583) and its accuracy may be influenced by 
the size of the measurement (584), the location of FM (585) and the hydration of the FFM 
(586).  
In this study it is presented for first time a new way of analyzing the agreement of 
body composition methods by converting %FM in z-scores using recent British normative 
data (579). In this way any age and gender confounding effect on the assessment of the 
effect of the size of the measurement on the agreement of the two methods was eliminated. 
Indeed similar patterns were observed for boys and girls in contrast to the crude values of 
%FM. A better agreement was found between the methods for children with %FM around or 
above the mean of the reference population. In contrast the limits of agreement were wide for 
negative %FM z-scores and thus TANITA consistently underestimated %FM is children with 
extremely low body fat. Poor validity of body composition methods is common at the 
extremes of body composition (573). This can be attributed to small/inadequate sample sizes 
recruited in order to validate body composition at the two edges of the body composition 
spectrum or to the invalidation of the theoretical body composition constants in obese and 
underweight subjects.  
In this study body composition presented poor agreement with DXA to assess body 
composition in healthy Scottish children and therefore the two methods are not 
interchangeable. However the estimation error of BIA techniques is inherent to the error that 
the prediction equations cause when they are used in populations different from those for 
which they have been validated. Manipulation of body impedance values in a way that would 
be independent of such prediction equations, may be a better and most reliable method to 
use BIA. Recently Professor Wright and colleagues, University of Glasgow, developed a new 
method to use bioimpedance measurements and classify children as having relatively high, 
average or low fatness and leanness independently (587).     
Although BIA may not be accurate to precisely assess body composition its use to 
assess longitudinal changes in follow up studies may be more useful. Its sensitivity to detect 
changes in body composition should be addressed with follow up studies measuring body 
composition at intervals with BIA and other reference methods (588;589).  
This study was carried out to evaluate the validity of TANITA to assess body 
composition in patients with CD. However this study recruited only healthy children as this 
was a more convenient sample of a pre-existing ongoing study and therefore the validity of 
the method may be different in disease where the theoretical assumptions and constants that 
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each method considers in the estimation of body composition may not be valid (590;591). 
Separate validation studies, in patients’ groups, are needed to check the validity of BIA 
(569;590). In paediatric IBD, Dung et al (592) tested the validity of several published hand to 
foot BIA prediction equations to assess FFM accurately compared to DXA measurements 
and proposed a new prediction equation for estimation of FFM in children with CD. In the 
same way validation of the foot to foot BIA appliance against reference methods of body 
composition, may offer a potential tool to easily, quickly and safely monitor body composition 
in paediatric patients with IBD.  
Although it was found that the foot to foot appliance is not accurate enough to assess 
body composition in children, this technique was still used in the studies of this thesis. This 
was because there is no other alternative method of body composition to use for routine 
clinical and research investigations. Methods like double-labelled water, and DXA scans 
although more reliable than the foot to for bioimpedance are difficult to be used in clinical 
settings, are expensive and need much co-operation from the participants. Moreover the 
results of this study give more insight on how to evaluate and interpret the findings in 
following studies of this thesis where it was used the foot to foot bioimpedance.  
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Table 4.5: Paediatric studies comparing foot to foot BIA devices with DXA in the assessment of body composition in healthy Scottish children 
Study Sample BIA equipment Age Bias Size and gender effect 
Hosking et 2006 
(573)  
203 (106 M); British Tanita TBF-300M 8.3 ± 0.3 BIA underestimated FM & 
%FM and overestimated FFM 
& %FFM 
In small boys %FM was overestimated 
whereas in big boys it was 
underestimated; No similar effect in girls  
Lazzer et al 2003 
(580)  
53 (20 M); 
overweight/obese 
adolescents; French 
Tanita TBF-625 & 
Tefal Bodymaster 
Vision 
14.1 ± 1.4 Both devices underestimated 
%FM 
Bias higher in boys than girls; 
Both devices underestimated low %FM 
but overestimated high %FM particularly 
in boys 
Sung et al 2001 
(581) 
49;17 obese; 
Chinese 
Tanita TBF-401 13 ± 3.1 BIA significantly 
overestimated FM but not 
%FM 
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CHAPTER FIVE 
 
 
 
The effect of exclusive enteral nutrition on 
body composition and micronutrient status in 
children with active CD 
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OUTLINE 
This chapter describes a prospective observational study on the effect of EEN on body 
composition and micronutrient status in paediatric patients with active CD. Associations 
between systemic markers of disease activity, gut markers of disease activity and indices of 
nutritional status are explored. 
 
5.1. Introduction  
Exclusive enteral nutrition is the mainstream treatment of active paediatric CD in UK with 
double benefit. It induces clinical remission in more than 60% of the cases, and at the same 
time improves the nutritional status of the patient (297). This has been described extensively 
in Section 1.5. 
In IBD malnutrition can occur with all its different facets. Protein-energy 
undernutrition, low circulating levels of micronutrients and poor bone health are all seen in 
IBD patients (35) (Section 1.3). Vitamins, trace elements and minerals are key nutrients of 
the body’s harmonic function and homeostasis, and in IBD they play an additional role (Table 
1.3.2). Zinc, selenium and carotenoids are important components of the body’s antioxidant 
system and may protect biological molecules from oxidative damage caused by the 
excessive production of reactive oxidative species from the activated immune system in IBD.  
Until now the mechanism of EEN action in inducing remission remains unexplained 
(Section 1.5.2). Early suggestions that nutritional replenishment is the main mechanism have 
been revised by recent evidence that EEN has direct anti-inflammatory effects, which 
precede nutritional rehabilitation (267). On the other hand a therapeutic mode of action 
mediated by changes in micronutrient status is possible but has not been investigated 
thoroughly thus far. Two previous studies were limited to the effect of EEN on the body’s 
antioxidant systems and stores (148;336) and only one of these (148) made associations 
with concomitant changes in disease activity. The authors of this study (148) showed that CD 
children had reduced activity in enzymatic antioxidant systems in erythrocytes, which did not 
improve with eight weeks treatment on EEN despite parallel improvement of the clinical 
activity and systemic inflammatory markers (CRP and TNF-a). Although these results imply 
that the therapeutic action of EEN in CD is independent of changes in the antioxidant 
systems, changes in other micronutrient status during EEN and their association with 
disease activity need to be clarified further. Likewise Akobeng and colleagues (336) did not 
find significant changes in antioxidant mechanisms or markers of oxidative stress in children 
with CD after a four week course with EEN. However they did not assess disease activity or 
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changes in inflammatory markers levels and how these correlate to changes in the 
micronutrient status.  
There are other valid reasons why monitoring micronutrient status during EEN is 
important in CD. Improvement of protein-energy status in CD children under treatment with 
EEN, is reflected by overt changes in body anthropometry but whether these changes 
coincide with replenishment or maintenance of micronutrient body stores is unknown and not 
easy to assess. Although most commercially available feeds provide the recommended 
micronutrient requirements for healthy children their corresponding adequacy in CD patients 
is uncertain. Malabsorption, increased consumption and increased needs in CD may require 
higher intakes than those established for healthy children. Abad-Lacruz et al (335), 20 years 
ago, failed to show improvement in the vitamin status of IBD adults on EEN despite provision 
of micronutrients in doses significantly higher than the recommended dietary allowance. 
Moreover nutritional supplements are “artificial composite food” made up of simple nutrients 
for which recommended allowances have been established and thus may be insufficient in 
non-nutrients that naturally occur in food but are rarely included in artificial feeds.  
Thus far no paediatric study has assessed changes in the status of a large number of 
vitamins and minerals in CD under treatment with EEN. The objective of this study was to 
measure the body composition and micronutrient status of children with CD and to assess 
their change under EEN. A second aim was to explore any association between systemic 
markers of disease activity, gut markers of disease activity and indices of nutritional status 
including body composition measures and micronutrient blood status. 
 
5.2. Subjects and methods 
5.2.1. Subjects 
Participants of this study were children CD who took part in a study on the effect of EEN on 
the nutritional status (Chapter 5), disease activity markers (Chapter 6), and gut bacterial 
metabolic activity and diversity (Chapter 7) of paediatric patients with CD (Fig 22).  
All the paediatric CD patients with active disease (<16 y old) who commenced an 
EEN course, as part of their standard medical management were eligible to participate. 
These patients were either newly diagnosed or patients with longstanding disease in clinical 
relapse. Newly diagnosed patients were approached within two days of colonoscopy or when 
the biopsy histology report was announced for patients with dubious endoscopic findings. 
The patients with longstanding disease in relapse were recruited at the end of their outpatient 
clinical appointment. An introductory letter and an information leaflet (Appendix) about the 
study were posted to all patients with long standing disease to allow them more time to 
consider the study in case they were eligible for recruitment.  
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Figure  22: Study flowchart on the effect of EEN on inflammatory response, nutritional status and gut microbiota 
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5.2.2. Exclusive enteral nutrition 
In all cases, the patients followed an eight weeks planned EEN course with a polymeric 
casein-based liquid supplement enriched with Transforming Growth Factor-β (Modulen®, 
Nestle). The feeds provided the recommended daily energy requirements for age and gender 
(COMA, 1990) favouring a higher intake of protein. A higher energy intake (200-500 kcals) 
was given to those children who presented underweight. The feeds were administered orally 
or when not tolerable via a fine bore nasogastric tube or a percutaneous endoscopic 
gastrostomy. No other foodstuffs were allowed during the treatment with the exception of 
water, tea and clear mints. At the end of treatment, a step-by-step food reintroduction 
program was followed before the patient returned to normal diet. Patients with suboptimal 
nutritional status were asked to continue supplementary feeds (500 kcals / d) in addition to 
their normal diet for one to two weeks after treatment completion.  
 
5.2.3. Blood sampling and initial manipulation 
For the purposes of this study, three blood samples were obtained from CD children before 
EEN initiation, on treatment cessation and whilst patients were on their normal diet. As it was 
deemed unethical to venopuncture children for research only purposes, extra blood was 
taken when patients were due to give clinical monitoring samples. Eight ml of venous blood 
were collected for research purposes in NH Trace Elements Sodium Heparin tubes 
(Vacuette, 456080, Austria). Six ml were centrifuged at 3500 g for 15 min at 4 oC and the 
plasma fraction was separated from the rest of the cellular matrices. Five hundred µl of 
plasma were stabilized with 6% metaphosphoric acid (Sigma Aldrich, 239275, UK) to prevent 
vitamin C oxidation. The samples were processed within an hour of blood sampling. All 
bloods and serum specimens were stored at –70oC covered in aluminium foil for a maximum 
of six months until further analysis.   
 
5.2.4. Micronutrient assays 
In total, 19 micronutrients were measured in the serum, whole blood or erythrocytes of 
children with CD. Ferritin was measured as a marker of iron status and  total cholesterol to 
adjust vitamin E concentrations for total lipid concentration.  
Serum calcium and phosphate were available from the patients’ biochemical reports 
and had been analyzed according to standard hospital protocols. The remaining nutrients 
were measured in the Scottish Trace Element and Micronutrient Reference Laboratory, GRI.  
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Trace elements (Zn, Se, Cu) 
Briefly trace elements zinc, copper, and selenium were measured with an inductively coupled 
plasma mass spectrometer (ICP-MS) using germanium as an internal standard.  
 
Vitamin B1 
The method measures thiamine disphosphate (B1) in whole blood as an index of vitamin B1 
status. The thiamine disphosphate is oxidised using post column derivatisation with alkaline 
potassium ferriccyanide to form the fluorescent thiochrome derivative which is measured by 
reverse phase HPLC with fluorescent detection. The sensitivity of the method is down to 
5µg/L the intra and inter CV% are 6% and 7% respectively.  
 
Vitamin B2 
Packed red cells are precipitated with methanol, centrifuged and the supernatant is injected 
for HPLC analysis. Flavin adenine, dinucleotide, flavin mononucleotide and riboflavin are 
separated on an isocratic HPLC system with a reverse phase column and detected by 
fluorescence . The CV of the method is 3.6% at a mean whole blood flavin adenine 
dinucleotide value of 135 nmol/L and 4.8% at a red cell flavin adenine dinucleotide mean 
value of 2.8 nmol/gHb.  
 
Vitamin A & E and carotenoids 
Serum is deproteinised with ethanol containing internal standard. After centrifugation the 
vitamins, carotenoids and internal standard are extracted with hexane. The hexane is 
evaporated and the residue is dissolved in the developing solvent. An aliquot of this solution 
is injected onto a C18 reversed phase chromatographic column and absorbance 
measurements at 325 nm and 295 nm for vitamin A and E respectively and 450 nm for 
carotenoids. Peak height ratios are used to quantify vitamins and carotenoids. Β-carotene is 
calculated by area. The intra and inter batch imprecision of the method is described in Table 
5.1.  
 
Table 5.1: Coefficient of variance for vitamin A, E and carotenoids assay 
Nutrient Intra-batch imprecision Inter-batch imprecision 
Retinol 5.4 7.8 
α-tocopherol 2.0 7.0 
Lutein 6.9 9.8 
Lycopene 9.0 14.0 
α-carotenoid 6.5 16.5 
β-carotenoid 7.6 15.0 
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Vitamin C 
Blood samples are stabilised to prevent oxidation and deproteinised with metaphosphoric 
acid. Following centrifugation and separation, an aliquot of the supernatant is injected on a 
C18 reverse chromatographic column and the ascorbic acid concentration assayed using an 
electrochemical detector. The within batch CV is 1.03% at a level of 31.66 µmol/L and the 
between batch CV is 3.69% at a level of 38.16 µmol/L.  
 
Vitamin B6  
The method measures pyridoxal-5-phosphate concentration in red blood cells as an index of 
vitamin B6 status. Pyridoxal-5-phosphate and pyridoxal are converted to their semi-
carbazone fluorescence derivatives which are measured by reverse phase HPLC with 
fluorimetric detection. Pyridoxal is measured directly using its natural fluorescence. The intra 
assay CV for pyridoxal-5-phosphate is 5.2% at 367 pmol/gHb and 6.9% at 370 pmol/gHb.  
 
Vitamin D 
The 25-Hydroxy vitamin D was measured with a IDS 25-Hydroxy vitamin D EIA kit 
(Immunodiagnostic Systems Ltd., Boldon, UK) is an enzyme immunoassay for the 
quantitation of 25-OH D and other hydroxylated metabolites in serum or plasma. Calibrators, 
controls and samples are diluted with biotin labelled 25-OH D. The diluted samples are 
incubated in microtitre wells which are coated with a highly specific sheep 25-OH D antibody 
for two hours at room temperature before aspiration and washing. Enzyme (horseradish 
peroxidase) labelled avidin, is added and binds selectively to complexed biotin and, following 
a further wash step, colour is developed using a chromogenic substrate (TMB). The 
absorbance of the stopped reaction mixtures are read in a microtitre plate reader, colour 
intensity developed being inversely proportional to the concentration of 25-OH D. The intra 
assay %CV of the method is 5.3, 5.6, 6.7 for mean concentrations of 39, 67.1, 165 nmol/L 
respectively. The inter assay %CV is 4.6, 6.4, 8.7 for mean concentrations of 40.3, 72.0, 132 
nmol/L respectively.   
    
5.2.5. Markers of disease activity 
Haemoglobin, erythrocyte sedimentation rate, serum albumin and CRP were assayed 
according to standard hospital methods and were readily available from the patients’ 
biochemical and haematological reports. Gut inflammation was assessed by measuring the 
faecal levels of calprotectin in stool samples collected close to the day of blood sampling. 
Faecal calprotectin was measured with a commercial available ELISA kit (Phical®, CALPRO, 
Lysaker, Norway) and according to the manufacturer’s specifications. The outline of the 
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assay is described in Chapter 6.2.5. Changes in the levels of disease activity markers during 
EEN are presented in Chapter 6. 
 
5.2.6. Anthropometry and body composition 
Changes of baseline anthropometric characteristics and body composition were assessed 
during treatment with EEN. Measurement of weight, height and body composition 
assessment by BIA, were performed before, after one month, at the end of treatment, and 
when patients returned to normal diet according to standard protocols as described in detail 
in Chapter 4. Measurements were obtained at the clinic, or when not possible, home visits 
were done. Triceps skinfold thickness and mid upper arm circumference were measured on 
the left arm midway between the acromion and olecranon according to standard procedures 
by a trained researcher. Measurements were performed at least twice and values averaged if 
the difference between the two measurements was minimal.  
 
5.2.7. Statistical analysis 
Descriptive statistics are presented as mean and standard deviation, or medians with ranges 
for continuous data, and with counts and proportions for categorical data. Comparisons 
between groups were done using 2 sample t-test and Mann-Whitney test. Changes in 
micronutrient concentration during EEN were assessed with Wilcoxon signed-rank test. 
Likewise the effect of EEN on body composition measures was evaluated using anova of 
repeated measures with Bonferroni post-hoc test. Anthropometry and %FM were converted 
to z-scores using British national data (579;593). To assess the adequacy of circulating 
micronutrients in house laboratory reference range was used (Appendix). Association 
between micronutrient levels, body composition measures and disease activity markers were 
assessed with Spearman’s rank correlation coefficient.    
 
5.3. Results  
5.3.1. Recruitment 
Between October 2005 and August 2007 approximately 60 children started on EEN as part 
of their standard clinical management. Thirty one children were invited to participate, six 
children refused participation, and two withdrew the day after recruitment. One patient’s 
participation was terminated deliberately after a final biopsy histology report was consistent 
with UC diagnosis. One patient experienced a cerebral vascular accident while on treatment 
with EEN and stopped treatment within a week of recruitment. For two patients, disease 
activity further deteriorated and both had to stop EEN and initiate a regime of steroids. Two 
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other patients were recruited 15 days and 21 days after EEN initiation and their results are 
not included in the arm of the study on the effect of EEN on longitudinal changes in 
nutritional status.  
For 25 CD children at least one blood specimen was obtained during the 
observational period. For 13 of these patients, three serial samples were obtained before 
EEN treatment, close to the time of EEN cessation and on normal diet. For the rest 12 
patients the full set of bloods was not available for a number of reasons (e.g. patients 
withdrew, patients were not due to have routine clinical bloods).  
Similarly basic anthropometry and body composition measures were obtained for 25 
CD children. For 16 of these children serial measurements of body composition were 
available over their nutritional therapy course. For the rest no serial follow up measurements 
were available or obtained due to a variety of reason (disease exacerbation and EEN 
termination, withdrew, impractical to take measurements).    
 
5.3.2. Body composition and micronutrient status in children with 
CD. (Cross-sectional data) 
 
5.3.2.1. Comparison of body composition between CD and healthy 
controls 
Body composition measurements were obtained for 11 children close to the date of initiation 
of EEN, and for 14 children at their follow up clinical appointment, and whilst patients were 
on normal diet (Table 5.2).  The majority of participants had abnormal systemic and gut 
specific inflammatory markers indicative of active disease (Table 5.2). Extensive disease with 
involvement of the upper and lower GI tract was the predominant site of disease location 
(Table 5.2). There was no significant difference in disease activity markers between boys 
and girls or between samples collected the day before the EEN initiation and those collected 
at follow up and whilst patients were on normal diet.  
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Table 5.2: Disease location, medical treatment, concentration and percent of patients with 
abnormal systemic and gut disease activity markers of children with CD 
Characteristics F (n=11) M (n=14) All (n=25) 
*Disease location (n) 
   
    Ileitis (L1)  1 1 
    Colitis (L2) 1 1 2 
    Upper colitis (L2L4) 3 5 8 
    Ileocolitis (L3) 2 0 2 
    Upper ileocolitis (L3L4) 5 7 12 
Concomitant treatment (n) 
   
    Steroids (tapering dose) 1 1 2 
    Aminosalicylates 2 2 4 
    Immunosuppresants 1 8 9 
    Antibiotics 1  1 
    Caloric supplements 1 1 2 
    None 8 5 13 
Disease activity markers 
   
Albumin (g/l) (mean ± SD)  30.8  ±  6.4  29.4  ±  7.3  30  ±  6.8 
$Abnormal albumin (n;%)   7     ;    64       8      ;       57     15      ;        83 
CRP (mg/l) (mean ± SD)  17.5  ±  13.2  31.5  ±  27.4  25.7  ±  23.3 
$Abnormal CRP  (n;%)   6      ;    55     11     ;        79  17        ;        68 
ESR (mm/h) (mean ± SD)  49.8  ±  34.7  39.5  ±  23.8  44.2  ±  29.1 
$Abnormal ESR (n;%)      9       ;    82     11      ;      85 20          ; 83 
Calprotectin (mg/l) (mean ± SD) 1965  ± 547 1903  ±  757 1934  ±  639 
$Abnormal calprotectin (n;%) 11         ;  100 15         ;  100 25         ;  100 
* Based on Montreal classification 
$ Abnormal to the laboratory or manufacturer reference range   
 
The mean body weight, BMI and % body fat z-scores of children with CD were negative and 
at least one SD lower than the national reference data indicating that the participants as 
group were substantially underweight and presented fat deficits (Table 5.3). There was no 
significant difference in height, weight, BMI and %FM z-scores between boys and girls. No 
statistics analysis was conducted for the raw data (before conversion to z-scores) as the 
results would be misleading due to normal biological differences that occur in body 
composition with gender, age and maturation.  
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Table 5.3: Basic anthropometry and body composition characteristics (mean ± SD) with 
percent (%) of underweight, short stature in paediatric patients with CD  
Measurement F M Total 
Patients (n) 
  11   14   25 
Age (y) 
 11.1 ±  2.9  12.5  ±  1.8  11.9  ±  2.4 
Weight (kg) 
 32.8  ±  13.4  36.3  ±  9.9  34.6  ±  11.6 
Weight z-score (SD) 
 -1.0  ±  1.4  -1.1  ±  1.3  -1.1  ±  1.3 
Height (cm) 
 142.5  ±  19.8  149.4   ±  11.1  146.1  ±  15.8 
Height z-score (SD) 
 -0.1  ±  1.4  -0.5  ±  0.9  -0.3  ±  1.2 
Height z-score < 2 SD (n;%) 
  1; 10%   1; 9%   2; 9.5% 
BMI (kg/m2) 
 15.5  ±  2.3  16  ±  2.3  15.7  ±  2.3 
BMI z-score (SD) 
 -1.3  ±  1.1  -1.3  ±  1.3  -1.3  ±  1.2 
BMI z-score < 2 SD (n;%) 
  3; 30%   3; 27%   6; 29% 
% Fat mass  
 16.9  ±  9.2  11.7  ±  3.1  14  ±  6.9 
% Fat mass  z-score (SD) 
 -4.5  ±  9.4  -2.4  ±  2.1  -3.3  ± 6.4 
% Fat mass z-score < 2 SD (n;%) 
  5; 56%   5; 45%   10; 50% 
Fat free mass (kg) 
 26.7  ±  8.5  32  ±  8.4  29.6  ±  8.6 
Fat mass (kg) 
 6.6  ±  6.5  4.4  ±  2.1  5.4  ±  4.6 
Impedance (Ohms) 
 715  ±  70  665  ±  113  687  ±  97 
Total body water (kg) 
 19.6  ±  6.2  23.5  ±  6.6  21.8  ±  6.6 
MAC (cm) 
 20.4  ±  3.4  20.7  ±  3.1  20.6  ±  3.2 
TSF (mm) 
 12.3  ±  5.0  12.1  ±  4.8  12.2  ±  4.8 
TSF z-score (SD) 
 0.1  ±  1.6  1.8  ±  2.6  1.1  ±  2.3 
% TSF z-score < 2SD (n;%) 
  1; 11%   0; 0%   1; 5% 
MAMC (cm) 
 16.6  ±  2.1  16.9  ±  1.8  16.8  ±  1.9 
 
Compared to a cohort of healthy Glaswegian children (Table 5.4), CD children had 
significantly lower BMI and weight z-scores (p<0.0001). No significant difference was found 
between the two groups with regard to height z-score. Similar to BMI, %FM z-score was 
significantly lower in children with CD than in healthy controls (p=0.002). BMI and weight z-
scores were significantly lower in CD boys and girls compared with their same gender 
healthy peers. However CD boys but not girls had significantly lower mean %FM z-score 
(p<0.01) compared to their healthy peers (Table 5.4). No differences between genders were 
found for CD patients or healthy children regarding BMI, height and weight z-score.  
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Table 5.4: Basic anthropometric and body composition characteristics (mean±SD) with percent of underweight, short stature in paediatric patients 
with CD and healthy Glaswegian children  
 CD  Healthy 
Measurement F M Total  F M Total 
Patients (n) 
  11   14   25   63   57   117 
Age (y) 
 11.1  ±  2.9  12.5  ±  1.8  11.9  ±  2.4   12.6  ±  3.2  12.4  ±  3.7  12.5  ±  3.4 
Weight (kg) 
 32.8  ±  13.4  36.3  ±  9.9  34.6  ±  11.6   46.4  ±  17.7  47.8  ±  19.1  47  ±  18.3 
Weight z-score (SD) 
 -1.0  ±  1.4*  -1.1  ±  1.3*  -1.1  ±  1.3*   0.3  ±  1.2  0.5  ±  1.1  0.4  ±  1.1 
Height (cm) 
 142.5  ±  19.8  149.4  ±  11.1  146.1  ±  15.8  149.2 ±  14  152  ±  20 150.5  ±  17.0 
Height z-score (SD) 
 -0.1  ±  1.4  -0.5  ±  0.9  -0.3  ±  1.2   0.0  ±  1.0  0.1  ±  1.0  0.06  ±  1.0 
Height z-score < 2 SD (n;%) 
  1; 10%   1; 9%  2; 9%    2; 3%  1; 2%   3; 3% 
BMI (kg/m2) 
 15.5  ±  2.3  16.0  ±  2.3  15.7  ±  2.3   20.2  ±  4.8  19.7  ±  3.9  20.0  ±  4.4 
BMI z-score (SD) 
 -1.3  ±  1.1*  -1.3  ±  1.3*  -1.3  ±  1.2*   0.4  ±  1.2  0.6  ±  1.1  0.5  ±  1.1 
BMI z-score < 2SD (n;%) 
  30%   27%   29%    1; 2%   0; 0%   1; 1% 
% Body fat z-score < 2 SD 
 16.9  ±  9.2  11.7  ±  3.1  14.0  ±  6.9   22.7  ±  9.5  16.6  ±  7.4  19.9  ±  9.1 
% Body fat z-score (SD) 
 -4.5  ±  9.4  -2.4  ±  2.1*  -3.3  ±  6.4*   -1.1  ±  4.0  -0.7  ±  2.4  -0.9  ±  3.3 
% Body fat  z-score < 2 SD 
(n;%) 
  5; 56%   5; 45%  10;  50%   17; 27%   12; 22%   29; 25% 
Fat free mass (kg) 
 26.7  ±  8.5  32.0  ±  8.4  29.6  ±  8.6   34.0  ±  8.9  39.1  ±  15.5  36.4  ±  12.6 
Fat mass (kg) 
 6.6  ±  6.5  4.4  ±  2.1  5.4  ±  4.6   11.7  ±  10.1  8.1  ±  5.8  10.0  ±  8.5 
Impedance (Ohms) 
 715  ±  70  665  ±  113  687  ±  97*  601  ±  71  564  ±  72 584  ±  74 
Total body water (kg) 
 19.6  ±  6.2  23.5  ±  6.6  21.8  ±  6.6   24.9  ±  6.5  28.6  ±  11.4  26.6  ±  9.2 
* Mann Whitney test, different from healthy (for same gender or total) p<0.002 
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5.3.2.2. Mean circulating concentration of micronutrients in CD children 
Systemic levels of micronutrients are displayed in Table 5.5. Females had higher 
concentrations of vitamin A (p<0.04), vitamin E (p<0.01), vitamin E / cholesterol (p<0.03), 
vitamin B6 in erythrocytes and plasma than boys (p<0.003) (Table 5.5).  
 
Table 5.5: Concentration of circulating micronutrient of CD children (mean ± SD) 
Micronutrient Total Female Male 
Vitamin A (µmol/l) 
 1.1  ±  0.4  1.4  ±  0.5*  1.0  ±  0.3 
Lutein (µg/l) 
 69.7  ±  35.3  75.2  ±  35.9  65.4  ±  35.5 
Lycopene (µg/l) 
 85.4  ±  61.0  69.5  ±  55.2  98.0  ±  64.3 
A carotene (µg/l) 
 16.8  ±  12.8  15.6  ±  10.3  17.7  ±  14.8 
b-carotene (µg/l) 
 87.3  ±  84.3  93  ±  94.8  82.9  ±  78.5 
Vitamin E (µmol/l) 
 23.7  ±  5.7  27  ±  5.5*  21.1  ±  4.5 
Vitamin E/Chol (µmol/mmol) 
 7.2  ±  2.1  8.3  ±  2.3*  6.4  ±  1.5 
Vitamin D (nmol/l) 
 64.8  ±  38.7  54.5  ±  42.7  73.0  ±  34.6 
Vitamin B1 (wbl) (ng/g Hb)  576  ± 134   605  ±  95  552  ± 157 
Vitamin B2 (wbl) (nmol/l)  433  ±  49  448  ±  47  420  ±  49 
Vitamin B2 (rbc) (nmol/g Hb)  2.4  ±  0.5  2.6  ±  0.3  2.2  ±  0.6 
Vitamin B6 (nmol/l)   32.8  ±  39.3  53.3  ±  53.1*  16.6  ±  7.4 
Vitamin B6 (rbc) (pmol/g Hb)  560  ± 241  719  ± 220*  435  ± 178 
Vitamin B12 (pg/ml)  762  ± 482  915  ± 488  642  ± 459 
Folate (ng/ml) 
 4.2  ±  3.2  4.4  ±  2.9  4.1  ±  3.5 
Vitamin C (µmol/l) 
 35.4  ±  24.5  39.6  ±  29.9  31.8  ±  19.4 
Zn (µmol/l) 
 9.7  ±  2.5  10.4  ±  2.8  9.1  ±  2.1 
Cu (µmol/l) 
 21.7  ±  5.6  21.3  ±  3.8  22  ±  6.8 
Se (µmol/l) 
 0.6  ±  0.2  0.6  ±  0.2  0.6  ±  0.1 
Mg (mmol/l) 
 0.9  ±  0.1  0.9  ±  0.1  0.8  ±  0.1 
P (mmol/l) 
 1.3  ±  0.2  1.3  ±  0.1  1.3  ±  0.2 
Ca (mmol/l) 
 2.3  ±  0.1  2.3  ±  0.1  2.3  ±  0.1 
Ferritin (ng/ml)  
 48.4  ±  61  56.3  ±  84.7  42.1  ±  35.8 
Cholesterol (mmol/l) 
 3.4  ±  0.5  3.4  ±  0.7  3.4 ±  0.3 
* Different from male p< 0.05; whl: whole blood; rbc: red blood cells 
 
For a substantial number of children the circulating levels of micronutrients were 
below the lower threshold of the laboratory reference range (Appendix) (Figs 23-25). 
Approximately three quarters of the participants had suboptimal levels for lutein, Zn, and Se 
whereas two thirds had low levels for carotenoids, lycopene, α-carotene, and β-carotene 
(Table 5.6; Figs 23-25). Low circulating levels were found also for serum vitamin A, vitamin 
B6, folate, vitamin C, copper, ferritin and calcium. Although a few patients had low serum 
concentration of B6, none had suboptimal levels when the latter was measured in 
erythrocytes. No patient had suboptimal concentrations for vitamin D, thiamine, riboflavin, 
and B12. Suboptimal levels of serum B6 were seen more often in boys than girls (Table 5.6). 
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Table 5.6: CD children (n;%) with suboptimal concentrations of systemic micronutrients 
compared with the laboratory reference range 
Micronutrient F (n=11) M (n=14) Total (n=25) 
Vitamin A 1;  9 5;  36 6;  24 
Lutein 9;  82 11;  79 20;  80 
Lycopene 8;  73 9;  64 17;  68 
A carotene 7;  64 9;  64 16;  64 
b-carotene 7;  64 9;  64 16;  64 
Vitamin E 0;  0 1;  7 1;  4 
Vitamin E/Cholesterol 0;  0 1;  7 1;  4 
Vitamin D 0;  0 0;  0 0;  0 
Vitamin B1 (wbl) 0;  0 0;  0 0;  0 
Vitamin B2 (wbl) 0;  0 0;  0 0;  0 
Vitamin B2 (rbc) 0;  0 0;  0 0;  0 
Vitamin B6  2;  18 9;  64* 11;  44 
Vitamin B6 (rbc) 0;  0 0;  0 0;  0 
Vitamin B12 0;  0 0;  0 0;  0 
Folate 3;  27 6;  43 9;  36 
Vitamin C 3;  27 3;  23 6;  25 
Zn 8;  73 13;  93 21;  84 
Cu 0;  0 2;  14 2;  8 
Se 8;  73 10;  71 18;  72 
Mg 0;  0 0;  0 0;  0 
P 0;  0 0;  0 0;  0 
Ca 0;  0 4;  33 4;  21 
Ferritin 5;  45 3;  21 8;  32 
*Different between genders p<0.02 for chi square test; whl: whole blood; rbc: red blood cells 
 
 
 
Figure  23: : Percent of paediatric CD patients with suboptimal systemic levels of minerals & 
trace elements  
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Figure  24: Percent of paediatric CD patients with suboptimal levels of water soluble vitamins & 
ferritin 
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Figure  25: Percent of of paediatric CD patients with suboptimal levels of fat soluble vitamins 
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5.2.3. Correlation between disease activity markers, micronutrients 
and body composition in children with CD 
As the data were not normally distributed, values were ranked and Spearman rank 
correlations performed. The circulating levels of several micronutrients were strongly 
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associated with markers of disease activity (Table 5.7). Serum albumin and CRP were 
significantly associated with β-carotene (Fig 26), plasma B6, vitamin C, zinc, ferritin (Fig 26), 
magnesium, calcium and folate, whereas faecal calprotectin levels were not associated with 
any micronutrient (Fig 26).  
 
Table 5.7: Spearman correlation coefficients between systemic and gut disease activity 
markers and serum micronutrient concentrations in paediatric CD patients (r coefficient; p-
value) 
Micronutrient CRP ESR Albumin Calprotectin 
  R p-value  R p-value  R p-value R    p-value 
Lutein 
 -0.50 0.01    
A carotene 
   0.42  0.04  
Β-carotene 
 -0.55  0.01   0.40  0.05  
B6 plasma  -0.39 0.06   0.50  0.01  
Vitamin C 
 -0.47  0.02  -0.44  0.03  0.67 0.001  All p>0.05 
Zn 
 -0.44  0.03   0.58 0.002   
Ferritin 
 0.71  0.001    -0.42 0.04  
Mg 
 -0.46 0.03  -0.45 0.03  0.44 0.03  
P 
 -0.50 0.03     
Ca 
 -0.55 0.02   0.92 0.001  
Folate 
   0.62 0.001  
Haemoglobin 
   0.7 0.001  
 
Figure  26: Spearman correlation coefficients between disease activity markers and serum 
micronutrient concentrations in CD children 
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Faecal calprotectin and serum albumin concentrations were significantly associated with BMI 
and %FM z-scores (Table 5.8). With increasing gut inflammation, BMI and %FM were lower 
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suggesting that increased disease activity is strongly associated with thinness and 
underweight (Fig 27). A similar positive association was observed with serum albumin levels. 
Low albumin levels were associated with low BMI and body fat stores. 
 
Table 5.8: Spearman correlation between systemic and gut disease activity markers and body 
composition measurements in paediatric CD patients (r coefficient; p-value) 
Disease activity marker BMI z-score  %FM z-score 
  R p-value   R p-value 
Albumin 
 0.5  0.021   0.4  0.061 
CRP 
 -0.4   0.097   -0.2  0.315 
ESR 
 -0.5  0.037   -0.1  0.571 
Calprotectin 
 -0.6  0.021   -0.5  0.073 
 
Figure  27: Sprearman correlation between body composition measures and intestinal 
inflammation markers in paediatric CD patients 
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5.3.3. Changes in body composition and systemic micronutrient 
levels in CD children during treatment with EEN (prospective follow 
up data) 
 
5.3.3.1. Patients characteristics 
For thirteen children, follow up measurements of body composition and micronutrient levels 
were obtained (Table 5.9). Extensive disease with involvement of the upper GI tract and ileo-
colon was the predominant site of disease (Table 5.9). Five children had other concomitant 
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medical treatment during EEN (Table 5.9). For all but three this was their first course on 
EEN. Five children entered complete clinical remission at the end of treatment (PCDAI≤10).   
  
Table 5.9: Disease characteristics and concomitant medication of paediatric CD patients on 
treatment with EEN for eight weeks 
 F (n=7) M (n=6) All (n=13) 
Age 11.5 ± 3 12.9 ± 1.1 12.1 ± 2.3 
Disease location* (n) 
   
   Colitis ( L2) 1 0 1 
    Upper & colitis (L2L4) 1 2 3 
    Ileocolitis (L3) 1 0 1 
    Upper ileocolitis (L3L4) 4 4 8 
Concomitant treatment (n) 
   
     Aminosalicylates 3   
     Immunosuppresants 6   
     Corticosteroids 1   
     Antibiotics 1   
     None 5   
* Montreal classification 
5.3.3.2. Changes in systemic micronutrient status during EEN 
The serum levels of several micronutrients changed significantly during EEN (Table 5.10; 
Figs 28 & 29). Compared to baseline, vitamin C, folate, thiamine, B6 and selenium 
significantly increased at the end of treatment (Table 5.10, Fig 29). In particular a three-fold 
increase was observed for serum folate as opposed to a dramatic deterioration of all 
carotenoids levels at the end of EEN treatment (Table 5.10, Figs 28 & 29).  
As mean serum concentration changes do not reflect the adequacy of body store 
status, the percentage of patients with suboptimal levels was calculated at the different time 
points of follow up. At baseline the serum levels for several micronutrients were below the 
laboratory reference cut offs with the most pronounced being carotenoids, trace elements, 
vitamin C, serum B6 and folate (Table 10). Two thirds of the children had suboptimal levels 
for carotenoids whereas vitamin C, folate, and ferritin were at insufficient levels for more than 
25% of the patients (Figs 30-34).   
On treatment completion significantly fewer patients had suboptimal levels for most of 
the micronutrients apart from carotenoids, copper and ferritin which further deteriorated. 
Compared to 42% of the children at baseline, none of the children had suboptimal serum 
levels of folate at the end of treatment. Similar results were observed for selenium, which 
improved significantly over the treatment period, and 10 times fewer children had lower 
levels at the end of EEN. In contrast more than 90% of patients had carotenoid levels below 
the reference range on treatment cessation (Table 5.10). Indeed for many of the children, the 
latter were below the detection limits of the assay. 
Significant changes were observed when children returned to their normal diet. Those 
nutrients that had improved at the end of EEN reversed to pre-treatment levels whereas 
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serum carotenoid concentrations increased and as a result significantly fewer patients 
presented biochemically insufficient levels (Table 5.10 Fig 28).  
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Table 5.10: Micronutrient concentrations (median) and percentage of patients with suboptimal levels before, at the end, and after treatment with 
EEN in paediatric CD patients   
Before EEN After EEN On normal diet 
Micronutrient‡ Median 
N; (%) with low 
levels§ Median 
N; (%) with low 
levels§ Median 
N; (%) with low 
levels§ 
Vitamin A (µmol/l) 1.2  1; (7) 1.7 0; (0) 1.2† 1; (8) 
Vitamin E (µmol/l) 27  0; (0) 24 0; (0) 25 0; (0) 
Vitamin E:cholesterol (µmol/mmol) 7.7 0; (0) 6.6 0; (0) 5.8 0; (0) 
Lutein (µg/l) 64 11; (79) 29.5* 11; (92) 108† 3; (25) 
Lycopene (µg/l) 76 9; (64) 12* 12; (100) 165† 4; (33) 
α-Carotenoid (µg/l) 10 9; (64) 10 12; (100) 14† 5; (42) 
β-Carotenoid (µg/l) 53 9; (64) 41* 11; (92) 99† ;4 (33) 
Vitamin D (nmol/l) 64 0; (0) 102 0; (0) 59† 0; (0) 
Vitamin C (µmol/l) 29 3; (25) 51* 0; (0) 46 1; (8) 
Thiamin (whl; ng/g Hb) 559 0; (0) 669* 0; (0) 573 0; (0) 
Riboflavin (erythrocytes; nmol/g Hb )  2.5 0; (0) 2.5 0; (0) 2.1 0; (0) 
Riboflavin (whl; nmol/l) 461 0; (0) 477 0; (0) 435 0; (0) 
Vitamin B6 (nmol/l)  36 4; (29) 63* 0; (0) 21 5; (42) 
Vitamin B6 (erythrocytes; pmol/g Hb) 662 0; (0) 721 0; (0) 438 0; (0) 
Vitamin B12 (pg/ml) 662 0; (0) 843 0; (0) 505† 0; (0) 
Folate (ng/ml) 2.85 5; (42) 10.5* 0; (0) 7.3 2; (17) 
Zn (µmol/l) 8.5 9; (75) 11.5 7; (64) 10 11; (92) 
Cu (µmol/l) 21.2 1; (8) 26 2; (18) 24.5 1; (8) 
Se (µmol/l) 0.5 9; (69) 1* 1; (9) 0.7† 7; (58) 
Mg (mmol/l) 0.8 0; (0) 0.9 0; (0) 0.8 0; (0) 
Ferritin (ng/ml) 18.4 5; (42) 6.9* 7; (64) 15.7 2; (17) 
Haemoglobin (g/dl) 10.8  11.6  11.7  
Values were significantly different from those before EEN (Wilcoxon signed rank test): *P<0.05. Values were significantly different from those after EEN (Wilcoxon signed rank test): †P<0.05. 
‡Plasma, unless otherwise stated. §With reference to normal range; whole blood: wbl 
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Figure  28: Concentrations of carotenoids and Se before, at the end, and after treatment with EEN in paediatric patients with CD 
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Figure  29: Concentrations of vitamin B1, B6, and folic acid before, at the end, and after treatment with EEN in paediatric patients with CD 
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Figure  30: Percent of patients with suboptimal circulating levels of trace elements before, after 
EEN and on normal diet in paediatric CD 
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Figure  31: Percent of patients with suboptimal circulating levels of fat soluble vitamin before, after 
EEN and on normal diet in paediatric CD 
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Figure  32: Percent of patients with suboptimal circulating levels of carotenoids before, after EEN 
and on normal diet in paediatric CD 
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Figure  33: Percent of patients with suboptimal circulating levels of Β complex vitamins before, 
after EEN and on normal diet in paediatric CD  
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Figure  34: Percent of patients with suboptimal circulating levels of vitamins (C, B12, folate) & 
ferritin before, after EEN and on normal diet in paediatric CD 
0
10
20
30
40
50
60
70
80
90
100
Vit C B12 Folate Ferritin
(%
) S
u
bo
pt
im
al
 
le
v
el
s
Before EN After EN Normal Diet
 
 
5.3.3.3. Changes in body composition during EEN 
Body composition was assessed in 16 children whose measurements were available before 
treatment initiation, 30 days on treatment, at the end of EEN and on normal diet (Table 5.11). 
Weight (absolute mass and z-scores) and accordingly BMI and BMI z-score significantly 
increased within 30 days of treatment with an average increase of more than three kg. Weight 
increase plateaued and no further significant improvement was observed during the following 
month, and up till the end of treatment.  
Although body fat, expressed as absolute mass (kg) or expressed as percentage of body 
weight increased during EEN, the difference did not reach statistical significance. In contrast, 
FFM in absolute mass was significantly increased at follow up compared with baseline values 
and achieved its highest peak at the end of treatment (all p< 0.001). However, when expressed 
proportional to total body weight, no significant difference from baseline was observed.  
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Similar to total body composition, all surrogate measurements of body composition (i.e. 
TSF, MAC, MAMC) significantly increased during EEN with a maximum increase observed at 
the end of eight weeks EEN. Changes in height were not assessed during EEN, due to the 
imprecision of the height measurements in short observation periods. Although body weight 
increased in both the patients who entered into remission and those who failed treatment, the 
magnitude of change was smaller in the latter group. However, FFM increased significantly at all  
time points of follow up (p<0.006) only in those patients who had entered clinical remission at 
the end of treatment. On normal diet no significant changes in body composition were observed 
compared to the end of treatment.  
 
Table 5.11: Anthropometry and body composition changes during treatment with EEN and on 
normal diet in paediatric CD patients (mean ± SD) 
Measurement Before EEN 30 d on EEN End of EEN On normal diet 
Weight (kg) 
 33.6  ±  11.9  36.9  ±  10.1*  36.3  ±  9.7*  38.2  ±  12.2 
Weight z-score (SD) 
 -1.5  ±  1.6  -0.7  ±  1.2*  -0.9  ±  1.1*  -0.8  ±  1.3 
BMI (kg/m2)
 
 
 15.1  ±  2.8  16.7  ±  2.1*  16.7  ±  1.9*  16.8  ±  2.6 
BMI z-score (SD) 
 -2  ±  1.7  -0.7  ±  1.0*  -0.7  ±  1.0*  -0.8  ±  1.2 
FM (kg) 
 4.8  ±  5.5  5.8  ±  5.1  5.9 ± 4.7  6.9  ±  5.9 
FM (%) 
 12.0  ±  8.4  14.5 ±  8.4  15.1  ±  7.8  14.1  ±  7.6 
FM z-score (SD) 
 -5.5  ±  6.7  -2.5  ±  2.6  -2.6  ±  3.5  -2.5  ±  2.6 
FFM (kg) 
 29.1  ±  8.2  31.0  ±  7.0*  30.4  ±  6.7*  32.1  ±  8.0 
Impedance (Ohms) 
 719  ± 100  645.0  ±  99.0*  660.0  ± 105*  626.0  ±  57 
TBW (kg) 
 21.3  ±  6.0  21.1  ±  6.6  22.3  ±  4.9*  23.5  ±  5.8 
TSF (mm) 
 10.5  ±  5.6  13.3  ±  5.0*  13.8  ±  4.7*  12.7  ±  4.9 
TSF z-score 
 -0.32  ±  1.2  0.49  ±  0.9*  0.49  ±  0.25*  0.40  ±  0.95 
MAC (cm) 
 19.8  ±  3.3  21.3  ±  3.1*  21.3  ±  2.6*  21.4  ±  3.1 
MAMC (cm) 
 19.8  ±  3.3  21.3  ±  3.0*  21.3  ±  2.5*  21.3  ±  3.1 
 
    
* Statistical significant from “Before EEN” for a-nova of repeated measures and Bonferroni post-hoc test  All p<0.02 Mean + SEM 
 
5.4. Discussion 
Nutritional status is a composite term that grossly describes the state of energy/protein, and 
other micronutrient stores in the human body. Excessive consumption causes overnutrition and 
the risk of toxicity whereas poor intake increases the risk of undernutrition. Protein/energy 
undernutrition is important as it increases the risk of disease-associated complications, mortality, 
and impact negatively on length of hospital stay, and in children may impair linear growth and 
bone health.  
On the other hand micronutrients, including minerals, trace elements and vitamins are 
important nutrients in body homeostasis, function and metabolism. Suboptimal intake can cause 
nutrient-associated anaemia, osteoporosis, neurological disorders, altered taste, depression, 
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epithelial defects, and it is only when the body stores have been depleted that clinical 
manifestations occur.  
 Micronutrient deficiencies are uncommon in the general Westernised population, but their 
incidence can be high in chronic illness where an optimal balance is not achieved or maintained. 
With regard to IBD, poor dietary intake, malabsorption (190;199), and increased needs 
substantially increase the risk of micronutrient deficiency (87;173;189).  
Earlier paediatric studies in IBD were restricted to assessing the energy stores and body 
composition (84;102) with negligible evidence existing on micronutrient status. As extrapolation 
of results from adult studies is inappropriate, due to differences in requirements, this study 
aimed to assess the body composition and systemic micronutrient levels of CD children, and 
secondly to assess longitudinal changes under treatment with EEN.  
  This study confirmed the results from previous extensive research that underweight, and 
increased undernutrition risk is a common finding in CD children , and at the same time offered 
new evidence on the micronutrient status of CD children. Compared to the national reference 
range CD children were significantly thinner and had more store deficits with approximately 1/3 
of them having BMI values consistent with the definition of underweight and risk of 
undernutrition. Likewise compared to a cohort of Glaswegian children, recruited at the same 
time, the CD children’s BMI was lower by a mean of approximately 2 SD.  
Body composition is a dynamic process in childhood, which varies considerably with age 
and gender, and this should be considered when attempting to compare groups with different 
demographic characteristics. As national reference range is now available (579) this study 
compared differences in body composition between groups, by expressing %FM in respective z-
scores. In contrast to the nutritional status classification by BMI, 50% of the children had %FM 
less than 2 SD of the reference population, with a mean %FM z-score of –3.3. However 25% of 
the healthy children had depleted fat stores too despite the fact that only 1% of them were 
underweight based on BMI cut-offs. Lack of concordance between these two measurements of 
nutritional status may denote that BMI is not a suitable surrogate of body composition, and 
moreover that the healthy cohort recruited was significantly slimmer than the reference 
population. Alternatively these results should be interpreted bearing in mind differences in 
socioeconomic characteristics of the reference population and the healthy cohort as well as 
differences in the BIA equipment and the body composition prediction algorithm that the authors 
of the national reference data used to assess body composition.  
Weight loss, and underweight is among the major presenting symptoms of the newly 
diagnosed CD (33), which explains the increased prevalence of underweight in this sample, 
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which consisted of approximately 50% of newly diagnosed children. None of the participants 
were on concomitant treatment EEN, which may have biased the results.  
Growth faltering is common in children with CD (109) and although no mean height 
difference was found with the healthy Glaswegian children, four times more children with CD 
were classified as growth retarded than the healthy controls. Undernutrition, the action of pro-
inflammatory cytokines, delayed pubertal onset, and long-term use of steroids are all implicated 
in the slow linear development in CD (111).  
For sixteen CD children, serial measurements of body composition were obtained during 
their disease management course with EEN. Although previous studies assessed changes in 
fundamental anthropometric characteristics during EEN, (Table 1.5.1) only a few studies 
measured parallel changes in body composition. As BMI is best seen as an index of nutritional 
status rather than a true measure of body composition (104;272), more comprehensive methods 
are needed to distinguish between changes in body fat and lean mass stores during therapy with 
EEN. Foot to foot BIA is a quick, easy to use, cost effective, patient friendly method of body 
composition assessment, suitable for monitoring body composition in a clinical setting. Although 
there is good evidence to suggest that the validity of BIA equipment is poor compared to 
reference methods and that was also shown in a previous chapter of this thesis (Chapter 4), 
these studies have assessed only the ability of the manufacturer’s algorithm to predict body 
composition. As explained elsewhere in this thesis (Section 4.4), there are now new body 
composition norms which manipulate impedance measurements independently of the 
manufacturer’s prediction equations (587), and classify children at different nutritional status 
scores. As these norms have been established only recently, this study relied on the use of the 
BIA manufacturer’s equation and checked their validity against a reference method. On the other 
hand, use of BIA to longitudinally assess changes in body composition may be more useful than 
predicting accurate measurements of body composition.  
Faecal calprotectin a marker of gut inflammation correlated negatively with BMI z-scores, 
and may show that increased intestinal inflammation and hence disease activity can cause 
weight loss and increase underweight and malnutrition risk. On the contrary systemic markers of 
disease activity like CRP did not correlate strongly with BMI which indicates that in-situ intestinal 
inflammation is a more important determinant of nutritional status than the acute phase 
response. Serum albumin was equally associated with BMI and may represent both increased 
disease activity and undernutrition.  
In this study, serial measurements of anthropometry and body composition were 
assessed and showed that changes depended on the response of the patient to the treatment. 
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Although body weight increased in patients who achieved clinical remission and those who did 
not, the mean increase was higher in the former group. The mean BMI increase in the group of 
children who achieved complete clinical remission was 1.5 SD compared to 1.2 SD for patients 
with active disease at the end of EEN. It is worth mentioning that increased FFM was observed 
only in those patients who entered clinical remission by the end of treatment. Absolute FFM 
increased sharply by 2.7 kg within one month of treatment and continued so to a lower extent 
over the following month. The increase in FM was marginal and less than 1kg by the end of 
treatment. On the contrary, only TSF thickness changed significantly in the group of patients 
who either failed treatment or had ongoing active disease at the end of EEN. Whether clinical 
remission is achieved only in those patients who restore muscle body stores, or the latter is the 
result of disease remission should be studied further. This is supported by previous studies 
which observed lean mass accretion during EEN (104) and recent evidence suggesting an 
anabolic effect of EEN in children with CD with shift in the protein turnover (333). On the other 
hand these results should be considered with caution as the number of patients in each group 
was small and statistical results may be a random finding. 
An increase in body weight and favourable changes in body composition, better 
represent the energy and macronutrient adequacy of the prescribed EEN regime. However 
improvement in energy/protein status may not parallel improvement or even conservation of 
body micronutrient balance.       
Although clinical presentation of micronutrient deficiencies in IBD is very rare (175;180) 
and largely limited to case reports (176;594), suboptimal circulating levels for virtually every 
vitamin, mineral and trace element have been reported previously in adult IBD patients (99;157). 
In paediatric CD patients the few studies were limited to the assessment of a selective small 
number of antioxidant vitamins and minerals (Section 1.5.2.8.3) (145;177;181-183) and similar to 
adult studies, the serum levels of zinc, selenium, and antioxidant vitamins were significantly 
lower compared to healthy controls of the laboratory reference range.  
In this prospective observational study, a substantial number of CD children had 
circulating levels of a large number of micronutrients below the laboratory reference range. 
Approximately 50% of the participants had suboptimal levels for serum zinc, selenium, and 
carotenoids. Indeed the serum concentration of carotenoids was out of the detection limit of the 
assay for some children. Although suboptimal circulating levels of micronutrients may reflect 
depleted body stores, none of the subjects presented overt deficiency symptoms. On the other 
hand, low levels of antioxidants may represent suboptimal antioxidant defensive systems and 
increased risk of oxidative stress (80;146;173). Excessive production of reactive oxygen species 
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by the activated immune system, in conjunction with low dietary intake (87;190) may 
compromise the body’s antioxidant status. Unfortunately this study did not measure markers of 
biological molecules oxidation (eg malondialdehyde) to confirm this hypothesis.  
Acute phase response in inflammatory conditions, infection and cancer can alter serum 
levels of many nutrients and biomolecules irrespective of actual body stores (178;595;596). Thus 
assessing them in serum may not represent body adequacy and results can be fallacious and 
misleading. There are proponents suggesting the measurement of the same nutrients in other 
body tissues or blood cell types (597). In this study erythrocyte levels of some B complex 
vitamins were measured and different results were found compared with serum levels. 
Approximately 50% of the participants were deemed to have insufficient serum concentrations of 
B6 but none had suboptimal levels in their erythrocytes which could more correctly reflect the 
adequacy in the tissues. Likewise artefactual changes from the acute phase response may 
explain the suboptimal levels observed for some vitamins and trace elements in a significant 
proportion of the subjects. Among them serum carotenoids, selenium, zinc, vitamin C, and B6 
are negative acute phase respondents, whereas Cu, and ferritin are increased during 
inflammation (178). In this study, serum ferritin was strongly correlated with inflammatory 
markers as shown in Chapter 3. Measurement of ferritin levels in patients with active disease is 
incorrect and can be misleading. However one third of patients had ferritin levels lower than the 
reference range, which clearly represents depleted iron stores independently of an acute phase 
response artefact. Although haemoglobin levels did not change significantly during treatment 
with EEN, they were strongly associated with albumin levels, a marker of disease activity and 
malnutrition and this is in accordance with the findings of a retrospective study described in a 
previous chapter (Chapter 3).     
Changes during the acute phase response may also explain the strong association found 
between the serum levels of various micronutrients and systemic inflammatory markers like 
CRP. Previous studies explained this as a casual association between increase disease activity 
and suboptimal micronutrient status (99;175;177) but we believe that these results are 
misleading and are actually an epiphenomenon of the acute phase response that occurs in 
inflammation. Reduced serum levels of micronutrients are often used to define deficiency state, 
but these levels may correlate better with markers of disease activity and inflammation and do 
not always reflect body tissue stores or functional deficits (157;177;178). A prime example is that 
perturbation in trace elements and vitamin concentrations in patients with cancer of the colon 
can be partially reversed by anti-inflammatory treatment, without supplementation (179). In this 
study CRP was significantly correlated with serum (r=-0.39; p=0.06) but not erythrocyte (r=-0.21; 
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p=0.32) vitamin B6. To further support of this and challenging a causative association between 
micronutrients levels and disease activity, none of the micronutrients was significantly 
associated with faecal calprotectin concentration, a gut specific marker of disease activity that 
better represents intestinal inflammation. Nevertheless copper, a positive acute phase 
respondent was below the reference levels for 10% of the patients and this may indeed 
represent insufficient body stores.  
For half of the participants, measurements of micronutrients were available before 
treatment initiation and at the end of EEN. Serum levels for many micronutrients improved but 
carotenoids further deteriorated. Carotenoids are negative phase respondents and someone 
would expect them to improve at the end of treatment as the combined effect of nutritional 
hyperalimentation and improvement of disease activity. However, in contrast to expectations, 
these further deteriorated and more than 90% of the participants had depleted stores for all 
carotenoids on treatment completion. Indeed their concentrations were under the detection limit 
of the laboratory assay. These results provide strong evidence to suggest that carotenoids are 
severely depleted at the end of treatment with EEN. Increased consumption during the active 
course of the disease and inadequate replenishment through dietary intake (190) explains these 
findings. The nutritional supplement the participants used, is better characterised as an “artificial 
food” and is nutritionally complete and balanced for the basic nutrients for which recommended 
amounts have been established and therefore may lack the “non-nutrient compounds” 
micronutrients. Indeed Modulen® Nestle composition tables (Appendix) do not outline 
carotenoids as part of their constituents and none of their ingredients is a carrier of them. This in 
conjunction with the increased utilisation of antioxidants during the active phase of the disease, 
and small body reserves, may explain the depleted body stores in the patients of this study.  
Within a short period of time, following treatment cessation, the majority of the 
micronutrients reversed to pre-treatment levels. Carotenoids increased significantly whereas 
selenium and vitamin A decreased. Although none of the participants had suboptimal levels for 
vitamin D and B12 at any time point of follow up, their median concentration was significantly 
decreased compared to the end of EEN treatment reflecting a gradual deterioration of body 
stores. Sentogo et al (136;136) reported that 16% of CD children and young adults presented 
low levels of vitamin D, in line with the definition of hypovitaminosis, compared to none of the 
participants of this study. Different definitions of hypovitaminosis between the two studies 
explain this discrepancy. If like Sentogo, a threshold of 38nmol/L had been set for the definition 
of vitamin D hypovitaminosis in this study, 24% of participants would have been classified with 
suboptimal body stores.       
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Among the main limitations of this study are the small sample size, missing data, and the 
lack of a healthy control group. As this study is supplementary to the main study on the effect 
EEN on gut microbiota, the collection of stool samples discouraged many children to participate, 
and subsequently increased the recruitment period by 1,5 years (planned one year). Similarly 
paediatric CD is an uncommon disease with approximately 20 new cases per year in the biggest 
paediatric referral center in Scotland. This in conjunction to alternative treatment options 
(steroids, anti-TNFα agents) and the unpredictable course of the disease reduced substantially 
the eligible number of participants. Venupuncture for entirely research purposes was deemed 
unethical and this did not allow the recruitment of a healthy control group, or blood sampling 
when patient was not due to give monitoring clinical bloods.    
This study found that the protein/energy stores and micronutrient status of children with 
CD are suboptimal and significant changes occurred during treatment with EEN. The findings of 
this study advocate the use of EEN as a nutritional complete regime to support the 
protein/energy stores of CD with active disease but the formula may be insufficient to sustain 
carotenoid body stores. Suboptimal levels for many micronutrients were found but it is difficult to 
differentiate between true deficiencies or an artifact of the acute phase response. If these are 
true deficiencies these could be attributed to suboptimal dietary intake (87;190), increased 
consumption by the activated immune system, malabsorption or increased enteric losses (199). 
On the other hand if these are an epiphenomenon of the acute phase response, measurement 
of the same micronutrients in other blood cells, which are unaffected by acute phase response, 
might be required to correctly assess body balance, and their causal association with disease 
activity, and intestinal injury. This needs to be studied further. 
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CHAPTER SIX 
 
 
Changes in systemic and gut markers of 
inflammation during treatment with EEN in 
paediatric patients with CD 
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OUTLINE 
This study assessed changes in faecal markers of intestinal inflammation in paediatric patients 
with CD undergoing EEN treatment. Correlation between faecal calprotectin levels, systemic 
inflammatory markers and clinical activity indices are explored. 
 
6.1. Introduction 
Mucosal healing rather than gastrointestinal symptom resolution could be considered the 
definitive target of contemporary drug therapy in IBD. However routine monitoring of intestinal 
inflammation and the mucosa healing process is difficult due to the inaccessibility of the 
digestive tract. Assessing mucosal inflammation and healing routinely with endoscopy is 
impractical, expensive, not acceptable to patients and needs general anaesthesia in paediatric 
patients. On the other hand surrogate markers of systemic inflammation are not sensitive 
enough or sufficiently specific to reflect mucosal inflammation (598). 
The presence of active gut inflammation in patients with CD is associated with migration 
of leukocytes to the intestinal mucosa. This causes the production of several proteins, which can 
be detected in serum or stools (599).  Calprotectin, a 36K Da calcium and zinc binding protein, is 
a neutrophil derived protein present in faeces. It represents 60% of the cytosolic proteins in 
granulocytes (599) and its presence in faeces is directly proportional to the migration of 
neutrophils and therefore gut inflammation (600).  
There is good evidence that faecal calprotectin correlates with histological activity, and 
mucosal healing in patients with UC and colonic CD (601-604). Thus measurement of faecal 
calprotectin may have good potential as a non-invasive way of assessing disease activity and 
treatment response at the site of inflammation rather than relying on markers of systemic 
response.  
So far, one study of paediatric UC patients showed that faecal calprotectin remained high 
in children with UC despite clinical improvement after treatment with steroids (312;601).  
Considering previous evidence, which showed that mucosal healing is achieved after treatment 
with EEN (Section 1.5.2.2), significant reduction in the calprotectin concentration in those 
patients whose disease activity improved at the end of treatment would be expected.   
 The aim of this study was to assess any changes of faecal calprotectin concentration in 
CD children on treatment with EEN and how these correlate with clinical activity indices.   
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6.2. Subjects and Methods 
6.2.1 Subjects 
As this study was supplementary to the main study of the effect of EEN on gut microbiota, 
eligible participants and overall recruitment is presented elsewhere (Section 5.3.1). Faecal 
calprotectin levels were also measured in a first-degree relative of the CD children and in healthy 
children with no family history of IBD.  
  
6.2.2. Study design 
Stool samples were collected from children with CD during their eight weeks course on EEN. A 
baseline sample was collected close to the date of EEN initiation, two during their course of 
treatment (15 & 30 d), and one close to the end of treatment (60 d). A final sample was collected 
whilst patients were on normal diet within 1-4 months after EEN treatment cessation. The 
samples were collected within a maximum of four hours of defecation from the patient’s home, 
homogenized with mechanical kneading and stored at –70 oC until further analysis. 
 
6.2.3. Systemic markers of disease activity 
Systemic markers of disease activity (CRP, ESR, albumin) were measured in plasma at the 
beginning of EEN, at the end of treatment and whilst on normal diet. These were available from 
the routine clinical measurements of the patients and were assayed according to standard 
hospital protocols. A serum albumin concentration less than 35 g/l, and CRP and ESR more 
than 7 mg/l, and 20 mm/h respectively were deemed “abnormal” according to the local hospital 
reference range. 
 
6.2.4. Clinical activity index 
Disease activity was assessed with the Paediatric Crohn’s Disease Activity Index (PCDAI) 
(Appendix). The PCDAI is a well established and validated clinical activity index used 
extensively in research to assess disease activity in paediatric CD patients (332). An overall 
score is calculated taking into consideration a week history recall of symptoms, laboratory 
markers of disease and clinical examination. The index was completed by data collected by the 
paediatric gastrointestinal consultants at the beginning and the end of their treatment and on the 
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same day as the collection of the last stool sample. An overall score more than 10 is suggestive 
of active disease.  
6.2.5. Faecal calprotectin 
Calprotectin concentration in faecal samples was measured with a commercial ELISA kit 
(Phical®, Norway) according to the manufacture’s protocol. A sample is tested by an enzyme 
immunoassay specific for calprotectin. Samples and standards are incubated in separate 
microtitre wells coated with polyclonal antibodies against calprotectin. After incubation and 
washing of the wells, bound calprotectin is allowed to react with immunoaffinity purified enzyme 
labeled anti-calprotectin. The amount of enzyme bound is proportional to the amount of 
calprotectin in the sample or standard. Microtitre plates were coated with rabbit anticalprotectin 
for capture, and immunoaffinity-purified rabbit anti-calprotectin conjugated with alkaline 
phosphatase was used for development.  
Approximately 100 mg of thawed faeces were suspended in manufacturer’s “extract 
buffer” (w/v; 1:50) and homogenized for 30 sec on a vortex mixer (Fisher Scientific, FB 15024) 
and for 30 min on an orbital shaker (IKA VIBRAX VXR BASIC) at 1200 rpm. The homogenates 
(approximately 1.5 ml) were transferred into Eppendorf tubes and centrifuged for 20 min at 10 
000 g at 4 °C. The clear extract supernatant was di luted 1:50 in the manufacturer’s “dilution 
solution” and immediately analysed by ELISA.  
Fifty µl of each standard, control and diluted sample were added in duplicate in the wells 
of a 96 microtitre plate according to the manufacturer’s protocol. The plate was covered with 
sealing foil and incubated at room temperature on a horizontal shaker for 45+/- 5 min. At the end 
of incubation, the wells were washed out six times with ample washing buffer. Fifty µl of 
conjugate were added to each well with a multi-channel pipette and reverse technique. The plate 
was covered and incubated as above. Six further washings were performed as above. One 
hundred µl of “substrate solution” were added to each well using a multi-channel pipette and 
reverse pippeting technique. The plate was incubated at room temperature for approximately 15-
20 min in the dark until the O.D. value of the 1000ng/ml standard reached at 2.0 absorbance 
units. One-hundred µl of stop solution (NaOH 1N) was added to each well. The O.D. values 
were read by means of an ELISA reader at 405nm (ThermoLab Systems Multiskan Spectrum). 
The concentration of calprotectin in stool samples was calculated with reference to the standard 
curve and expressed as mg/kg of wet and dry faecal material. Values above 50mg/kg were 
regarded as positive calprotectin level according to the manufacturer’s protocol.  
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Samples were measured in duplicate. All serial samples from the same patient were 
measured in the same kit under the same conditions and calibration curve to avoid inter-assay 
variance.  
 
6.3. Results 
6.3.1. Participants 
Measurements of calprotectin measurements were carried out for 16 CD children with serial 
samples whilst on EEN (age 11.8±2.3 y, range 7.4-14.7 y) and their 14 first-degree relatives (13 
healthy parents, one sibling). Calprotectin concentration was also measured in stool samples of 
10 healthy children without family history of IBD. This assured the validity of the assay and also 
offered a group for comparison with the results of children with CD.   
Nine children were on no other medication apart from EEN. The rest had other parallel 
medical treatments (Table 6.1). All but one child finished at least six weeks on EEN. One child 
stopped treatment after a month on EEN due to symptoms exacerbation. All participants 
provided at least three serial stool samples whilst on EEN. A final stool sample was collected on 
normal diet in all apart from one patient who had surgical removal of part of the large bowel. 
Twelve children were newly diagnosed with CD and this was their first course of EEN while for 
the remaining four this was a subsequent course following disease relapse. Seven children were 
girls. Thirteen children had extensive disease involving parts of both the small intestine and large 
bowel (Table 6.1). 
 
Table 6.1: Disease location and concomitant medical treatment of CD children on EEN treatment 
Disease location N Concomitant medication N 
Colitis (L2) 2 None 9 
Ileocolitis (L3) 1 5-ASAs 4 
Upper GI & Ileocolitis (L3L4) 9 Immunomodulators 5 
Upper & Colitis (L2L4) 4 Steroids 2 
  Antibiotics 1 
 
6.3.2. Changes in disease activity markers 
All participants had active disease as depicted by the calculation of the clinical activity index and 
the systemic inflammatory markers (Table 6.2). As expected the median value of the disease 
activity markers decreased at the end of treatment (Table 6.2). Individually, the majority of the 
children experienced improvement in clinical activity and improvement of the systemic 
inflammatory markers (Fig 35). For all apart from one patient, CRP and PCDAI were reduced 
compared with baseline values (Fig 35). PCDAI remained the same (PCDAI=10) for one patient. 
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Although most of the children had improved PCDAI in only seven out of the 16 children was 
complete clinical remission (PCDAI<10) achieved. There was no statistical significant difference 
in the baseline markers of disease activity between patients who achieved remission and those 
who did not. 
 
Table 6.2: Mean changes in PCDAI and systemic markers of disease activity before, after EEN and 
on normal diet in paediatric patients with CD 
 Baseline 
(mean ± SD) 
End of EEN 
(mean ± SD) 
Normal Diet 
(mean ± SD) 
PCDAI 
 40  ±  17  16  ±  16$  18  ±  14 
CRP (mg/L) 
 47  ±  70  14  ±  17*  23  ±  36 
ESR (mm/h) 
 39  ±  27  22  ±  26*  28  ±  19 
Albumin (g/dl) 
 29  ±  7  35  ±  5$  34  ±  6 
* p< 0.05; $ p<0.01   Wilcoxon Singed Rank Test;  
 
6.3.3. Correlation between systemic and gut specific markers of 
disease activity 
Correlation between systemic and gut specific markers of inflammation was assessed after 
pooling the results of all CD patients who participated in the EEN study. As anticipated there 
were significant associations with all systemic markers of disease activity and faecal calprotectin 
(Fig 36). Albumin was negatively and strongly associated with calprotectin whereas ESR, CRP 
and PCDAI were positively (Table 6.3).  
 
6.3.4. Changes in faecal calprotectin concentrations 
All participants had faecal calprotectin concentrations significantly higher than the upper normal 
reference range of the manufacturer’s reference range (50 mg/kg) at most of the time points of 
the observational period (Table 6.4). Inter-individual calprotectin concentration changes varied 
considerably during treatment (Fig 37).  
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Figure  35: Individual changes of clinical activity and systemic markers of disease activity before and at the end of treatment with EEN in 
paediatric patients with CD   
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Figure  36: Spearman correlation (r coefficient and p-values) between systemic markers of 
disease activity, PCDAI and faecal calprotectin in paediatric patients with CD 
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Table 6.3: Spearman correlation between systemic markers of disease activity and PCDAI with 
faecal calprotectin in paediatric patients with CD (R coefficient, p-value) 
Disease marker R coefficient p-value 
ESR 0.56 0.001 
Albumin -0.62 0.001 
CRP 0.48 0.002 
PCDAI 0.49 0.001 
  
Table 6.4: Individual changes of faecal calprotectin (mg/kg) levels during EEN and on normal 
diet in paediatric patients with CD 
Subject Before EEN 15 d 30 d 60 d Normal diet 
A 1130.4 47.7 5.8 88.4 2054.6 
B 1701.4 1241.4 1846.6 1894.8 145.6 
C 2076.3 1704.8 1459.5 39.1 1712.1 
D 2585.3 2390.1 2324.6 2563.7 2431.8 
E 2262.3 1808 1797.6 2055.8 2470.2 
F 2102.2 1999.9 1535.8 718.1 1632.2 
G 1170.1 224.4 2191.6 2163.7 245.4 
H 2272.3 1841.6 1673.7 1685.8 2085.3 
I 2581.7 2341.1 2394.3 2460.9 2495 
J 2187.9 2056.2 2076.7 2298.3 2169.5 
K 2438.7 2221.6 2000.5 1723.5 2327.7 
L 2389.7 3148.7 2717  1681.5 
M 2086.8 2026.6 2338 2437.7 1511.9 
N 2088.51  296.39 77.12 2418.17 
O 2474 2347 1864.9   
P 3114.22 2216.35 1803.81 106.12 2355.18 
      
Mean ± SD 2166 ± 503 1841 ± 807 1770 ± 717 1451 ± 1009* 1849 ± 748 
* Significant different from “Before EEN” for ANOVA of repeated and Bonferroni post-hoc test 
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Only one of the fourteen children that completed the course of EEN had a calprotectin level 
within the normal range (<50mg/kg) at the end of EEN and three children had values of 
approximately 100mg/kg. The rest remained at much higher than normal levels and the 
extent of the change during treatment varied considerably (Fig 37) and (Table 6.4). Using 
analysis of variance of repeated measures and Bonferroni post-hoc adjustment, mean 
calprotectin was significantly reduced at the end of treatment compared to baseline 
measurements (p=0.01).  
 
Figure  37: Individual changes of faecal calprotectin in CD children during EEN (with red line 
patients who achieved clinical remission and with blue line patients with active disease at the 
end of EEN)  
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 The group of patients was divided into those children who entered in clinical 
remission (n=7) and those who did not or the treatment failed (n=9). In those patients who 
entered clinical remission (PCDAI <10) faecal calprotectin concentration reduced significantly 
(Fig 38). Faecal calprotectin was reduced during EEN treatment and was significantly lower 
than baseline at 30 (p<0.01) and 60 day of treatment (P<0.0001). Mean calprotectin 
concentration was reduced by 921 mg/kg (95%CI: -1568 to -274) and 1541 mg/kg (95%CI: -
2187 to -894) after 30 and 60 days of treatment respectively. Two of these children relapsed 
within six months of treatment cessation, judged by the introduction of a subsequent EEN, 
steroid course or anti-TNFα treatment.     
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Figure  38: Calprotectin levels in paediatric patients with CD who achieved clinical remission 
(PCDAI≤10) on treatment with EEN 
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*p<0.0001
*a-nova of repeated measures and Bonferroni pot-hoc test.
All follow up points significantly  different from "BeforeEEN"
 
In contrast, in those patients who presented clinical symptoms of disease activity disease at 
the end of treatment (PCDAI≥10) of discontinued treatment, calprotectin levels did not 
change significantly from baseline (Fig 39).  
     
Figure  39: Calprotectin levels in paediatric patients with CD who did not achieve clinical 
remission (PCDAI>10) on treatment with EEN 
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*a-nova of repeated measures and Bonferroni pot-hoc test
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6.3.5. Changes of faecal calprotectin on normal diet 
None of the patients had calprotectin levels within the normal reference range (<50 mg/kg) 
up to four months of EEN completion and whilst on normal diet. Calprotectin increased by 
approximately 10 times in those patients (n=4) who achieved calprotectin levels close to the 
normal range at the end of EEN (Table 6.4). Compared to the values at the end of EEN, 
faecal calprotectin dropped in five children and increased to nine children whilst on normal 
diet (Table 6.4).  
 
6.3.6. Comparison of faecal calprotectin levels of CD patients on 
normal diet, their first degree relatives and healthy children  
For ten healthy children, with no family history of IBD, and for 14 healthy first degree relatives 
of the CD children (13 parents, one sibling) faecal calprotectin was measured in a single 
stool sample. As expected none of the healthy children had calprotectin above the normal 
range (<50 mg/kg). On the contrary the majority of the healthy relatives of CD children (9/14) 
had abnormal calprotectin levels (Fig 40). 
Figure  40: Faecal calprotectin levels in CD patients, their healthy first degree relatives and 
healthy children with no familial history of IBD (with blue cross the median) 
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6.4. Discussion 
Calprotectin is a marker of intestinal inflammatory activity with increasing use in research and 
clinical gastroenterology. It has good diagnostic validity to discriminate between organic and 
functional disorders (605;606). In this study most of the patients (14/16) were newly 
diagnosed or had undergone recent repeat endoscopy that confirmed histological findings of 
active intestinal inflammation. In all of these patients faecal calprotectin concentration was 
significantly higher than the normal reference range, as opposed to 86%, 69%, and 73% of 
the same patients who presented with abnormal CRP, ESR and serum albumin respectively 
(data not shown). This is in accordance with substantial evidence, which suggests that 
calprotectin levels have excellent negative predictive value, better sensitivity and equal 
specificity compared to serological inflammatory markers to reflect gut inflammation 
(311;603;604;607;608). Moreover faecal calprotectin concentration correlates well with 
endoscopic and histological activity scores (311) that makes it a useful tool to monitor 
treatment efficacy at the site of the disease onset. So far only a few studies have assessed 
the effect of IBD treatments on faecal calprotectin levels (312;609), and to the best of our 
knowledge this is the first study in paediatric patients on treatment with EEN.  
Similar to previous research (604;606;610) this study found a strong association 
between clinical activity indices, CRP, ESR, serum albumin and faecal calprotectin and 
moreover showed that calprotectin levels are decreased only in those patients who achieved 
clinical remission at the end of EEN treatment.  Calprotectin did not change significantly in 
the patients where treatment failed or had ongoing clinically active disease (PCDAI>10) at 
the end of treatment. These results suggest that in only those patients who enter clinical 
remission is mucosal healing achieved. However it is noteworthy that for only one of the 
patients who achieved clinical remission, calprotectin levels decreased to within the normal 
reference range at the end of treatment. This may indicate that either there is still ongoing 
subclinical intestinal inflammation, despite apparent full clinical remission, or that 
improvement of clinical disease activity occurs more quickly than resolution of intestinal 
inflammation.  
It was not within the scope of this research to explore whether increased calprotectin 
levels at the end of EEN predict an earlier clinical relapse and this must be addressed in a 
future prospective study. Nevertheless there is evidence to suggest that calprotectin levels 
can predict disease relapse in IBD (311;611;612) and if this is the case then calprotectin 
levels should be monitored along with clinical activity.  
Apart from its growth promoting effects, the impact on the patient’s nutritional status 
and lack of side effects, EEN is superior to steroids due to its gut mucosal healing effects 
 240 
(90;261). This is in agreement with the findings of this study and a previous report in Finland, 
which failed to find any effect of oral steroid treatment on faecal calprotectin levels of IBD 
patients (312;604).  
Some patients were on concomitant medical treatment that may have confounded the 
net effect of EEN on faecal calprotectin levels. This was unavoidable as it is unethical to 
withhold medical treatment for research purposes when there are clinical indications for use. 
Nevertheless none of the patients on parallel medical treatment experienced statistically 
significant reduction of calprotectin levels or entered clinical remission, which may have 
confounded the results of this study. Indeed all apart from one of the patients whose faecal 
calprotectin was reduced at follow up, were solely on treatment with EEN or on stable 
treatment on 5-aminosalicylates (n=1) prior to EEN introduction. Moreover there was no 
difference in the baseline disease activity characteristics between those patients whose 
faecal calprotectin improved and those did not change or increased. 
Increased gut mucosal permeability and increased levels of calprotectin in CD 
relatives have been described before (489;490;613;614) and the findings of this study are in 
agreement. The majority of the healthy parents recruited had faecal calprotectin levels 
significantly higher than the normal reference range and this may denote that genetic and 
common environmental factors may predispose to intestinal inflammation. On the other hand 
this may be the result of lack of faecal calprotectin specificity or other unknown underlying 
gastrointestinal comorbidities that can affect calprotectin levels (606). Only a follow up of 
these subjects will address whether relatives of CD relatives with high faecal levels of 
calprotectin are more susceptible to develop IBD or other digestive inflammatory disorders.  
For ten healthy children with no family history of IBD, faecal calprotectin was 
measured. These were significantly lower compared to any time point of the follow up in CD 
children and within the normal reference range of the kit. This ensured the validity of the 
assay and precluded any methodological errors. In fact the study design and the method of 
sample analysis are among the strongest points of this study. All of the samples were 
collected within four hours of defaecation, were homogenized, and all the follow up samples 
of the same participant were assayed in duplicate, with the same ELISA kit using the same 
calibration curve. Homogenization of faecal samples prior to measurement, and intra and 
inter assay variance are methodological issues that can affect the validity of the current 
assay to measure accurately calprotectin levels particularly when changes between follow up 
measurements are to be considered. In this study faecal calprotectin levels were also 
converted to per dry kg faecal material to balance for differences in the water content of the 
stool samples particularly between the active and inactive phase of the disease. No different 
results were found (data not shown) compared to the “fresh” stool” samples.  
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In conclusion this study found that induction of clinical remission in paediatric CD 
undergoing treatment with EEN is accompanied by a reduction in faecal calprotectin levels. 
However most patients had still high levels of calprotectin at the end of treatment and future 
studies should address whether these predict an earlier relapse. If this is the case then, 
monitoring faecal calprotectin along with changes in clinical activity will be a more 
appropriate indication of treatment termination or prolongation.  
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CHAPTER SEVEN 
 
 
 
Nutritional therapy and gut microbiota in 
paediatric CD  
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7.1. Introduction 
There is now vast clinical experience supported by a substantial number of clinical studies to 
advocate the use of nutritional therapy in the management of active paediatric CD. Exclusive 
enteral nutrition attenuates disease activity and induces clinical remission in the majority of 
CD children with active disease and gut mucosal healing is achieved in the majority of the 
cases (90;261) (Section 1.5.1.2).  
 As with many popular medications, the mode of action and ideal formulation of EEN 
remain unknown (530;615). There is still much discussion and debate about putative 
mechanisms of action, mainly because the gut is a difficult organ to study directly. Gut rest, 
direct anti-inflammatory effects, and nutritional rehabilitation have all been implicated 
(327;533) (Section 1.5.2) but at present there is no robust evidence to consistently support 
any of them in particular.  
Substantial evidence over the last 10-15 years has suggested that the gut 
endogenous microbiota, rather than a specific microbial pathogen, plays an important role in 
the pathogenesis and propagation of intestinal inflammation and tissue injury, in CD (Section 
1.7.2) (30). Although it remains unclear whether perturbation of the intestinal microbiota 
balance is a trigger of inflammation rather than the result of IBD, an unstable gut microbiota 
consisting of uncommon bacterial species (512;513), with mucosa invasive and adherent 
properties has been described in several studies (504;523) (Section 1.7.2).  
Moreover studies in the early nineties described differences in the metabolic activity 
and production of bacterial metabolites between IBD patients and healthy controls (Section 
1.7.1) which subsequently triggered the experimental use of SCFA, mainly butyrate enemas, 
in a number of clinical trials (439;440) and animal models of colitis (428) (Section 1.7.1.1). 
Recently a number of clinical and animal studies (75;538) have tested food grade bacteria 
(probiotics) and prebiotics to induce, or maintain remission in both CD and UC by switching a 
putative “dysbiotic” gut microbiota (498) towards one more “normal”. 
Thus modulation of the intestinal microbiota could be an attractive potential 
mechanism for the action of EEN. Despite this being reported among the potential modes of 
EEN action in many relevant review articles (530;615) until recently no primary evidence had 
been cited. This was highlighted recently by an expert in paediatric CD and nutrition, Dr Anne 
Griffiths, who called for more research to be conducted on the effect of EEN on gut 
microbiota (327).  
Thus far, two recent studies have described changes in the diversity of the dominant 
microbiota of children with CD on treatment with EEN. In the first of these studies, Lionetti et 
al (531) analyzed stool samples of nine CD children with TGGE and compared them with five 
healthy controls. A greater stability of the gut microbiota diversity was observed in the 
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healthy group, compared with the CD patients on EEN treatment, although no analysis of the 
electrophoresis gels was undertaken by the authors, who evaluated the TGGE gels only 
visually. The authors concluded that EEN may exert its therapeutic properties through a 
prebiotic effect on the large bowel microbiota of children with CD. 
In the second study, Leach et al (532) collected serial stools samples from six CD 
children during EEN, and at four weeks and at four months after treatment, and compared 
their bacterial composition patterns and diversity with seven healthy children. The bacterial 
diversity was assessed with DGGE and changes in the global bacterial and group specific 
diversity and similarity patterns were measured. Although bacterial diversity (bacterial band 
count) did not differ significantly between healthy and CD children at treatment initiation, a 
lower diversity was found at the end of treatment in the CD group compared with the healthy 
controls. Bacteroides-prevotella and Clostridium coccoides bacteria were significantly less in 
the CD group compared with the healthy controls at the end of EEN treatment. Moreover the 
similarity index of the bacterial diversity was low during treatment for all bacterial groups 
studied, and significantly lower than in healthy subjects. However no comparison of changes 
in bacterial diversity and similarity patterns were reported during EEN to investigate changes 
during treatment.     
Both these studies assessed changes in the bacterial diversity and composition 
stability of CD children on EEN. To the best of our knowledge no previous study has 
explored whether EEN affects the metabolism of the microbiota in paediatric CD patients.  
To increase knowledge of the role of the microbiota in the action of EEN, the primary 
purpose of the study, described in this chapter, was to assess the effect of EEN on the gut 
microbiota metabolism and diversity in children with active CD. The secondary purpose was 
to compare the diversity of the gut microbiota and bacterial metabolism of the same children 
with their healthy first degree relatives and with healthy children with no family history of IBD.   
 
7.2. Subjects and methods 
 
7.2.1. Subjects 
For the purpose of this study three groups of subjects were recruited.  
i) Paediatric CD patients with active disease on EEN 
ii) First degree relatives of the above (CD) children 
iii) Healthy children with no family history of IBD 
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Crohn’s disease patients on EEN 
The characteristics of the eligible patients have been presented in Chapter 5. Briefly these 
included all the paediatric CD patients with active disease (<16 y old) who commenced an 
EEN course, as part of their standard medical management.  
 
First degree relatives of patients with CD on EEN 
A single stool sample was requested from one of the patients’ first degree relatives for 
comparison purposes. This should allow a comparison between the gut microbiota diversity 
and metabolism of CD patients and their healthy relatives controlling partially for factors, 
which are known modifiers of the composition and metabolic activity of human gut microbiota 
(i.e. genes, diet, and environment). 
 
Healthy children with no family history of CD 
Stool samples were collected from 21 healthy children with no family history of IBD. Two 
stool samples were collected with at least a month gap between collections, to assess the 
temporal stability of bacterial diversity, composition, and metabolic activity, and to compare 
with the gut microbiota of CD patients under treatment with EEN.  
 
Exclusion criteria 
All participants were asked to declare recent use of antibiotics (last three months) or 
systematic use of probiotic products or supplements. Healthy children or family members of 
CD patients that had been on a recent course of antibiotics were excluded. Although CD 
patients with recent use of antibiotics were not excluded their results are presented and 
discussed with caution and, where differences were found, separately.  
 
7.2.2. Study design 
Serial stool samples were collected from CD children during their course of treatment on 
EEN. In total, five faecal samples were collected over a period of three to six months. A first 
stool sample was collected before or within five days of therapy initiation. For those patients 
who started treatment on the same day as endoscopy, a two day wash out period was 
allowed to “balance” perturbation of bacterial population and metabolism owing to the bowel 
preparation procedure. For these patients bowel preparation was performed with sodium 
picosulfate (Picolax ®) and sennosides (Senna ®) liquid preparations. Collection of stool at 
this time was not ideal but unavoidable.  Serial stool samples were collected at 15, 30 days 
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on treatment and close to the last day of EEN (day 60). A final stool sample was collected at 
least one month after treatment cessation whilst patients were on normal diet.   
 
7.2.3. Exclusive enteral nutrition regime 
In all cases, the patients followed an eight weeks planned EEN course with a polymeric 
casein-based liquid supplement enriched with Transforming Growth Factor-β (Modulen®, 
Nestle). The details of the composition of the dietary regime is described elsewhere (Section 
5.2.2). 
 
7.2.4. Methods & materials 
7.2.4.1. Samples collection and initial manipulation 
Fresh stool samples were provided by all participants (CD, relatives, healthy) at home or 
during their routine visit to the hospital. To facilitate the collection of the stool samples a 
special kit was supplied to all participants. The patient passed the entire bowel movement 
into a plastic single use container supported on the toilet seat through a paper bedpan. 
Immediately after defecation the patients or their parents put the container inside a gas proof 
bag along with a special anaerobic kit (Anaerocult® A, Merck, Germany) to reduce the 
oxygen concentration in the sample and induce anaerobic conditions. A special indicator 
(Anaerotest®, Merck) was used to check the development of anaerobic conditions. The stool 
sample was kept inside an insulated bag along with frozen ice blocks to retard ongoing 
bacterial metabolism (Appendix).  
Typically stool samples were transferred to the laboratory within a maximum of four 
hours of defaecation and were processed within an hour. The protocol for the initial handling 
of the samples ensured that the biomarkers of interest most susceptible to the effect of time 
would be tested first. The initial handling of the sample included mechanical blending of the 
whole faecal sample with a domestic hand blender (Braun, MR4050HC, Germany). Samples 
were blended until complete homogenization (2-3 min, depending on consistency) inside a 
biological flow cabinet ((MSC 12, BS 5726, Juan).    
 
7.2.4.2. Determination of faecal pH 
Measurement of faecal pH was performed on 1:3 w/v aqueous faecal slurries.  Approximately 
0.8-1.2 g of homogenized faecal sample was measured accurately and suspended in 
threefold volume of distilled water. The slurry was agitated by vortex at full power for 1 min or 
until the sample was completely dispersed. In the case of hard samples, a thin stick or small 
glass beads were used to break the lumps. The measurement of the pH was performed with 
an autocalibrated portable digital pH meter (Hanna HI 98140, Portugal). 
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7.2.4.3. Determination of SCFA and BCFA  
Short chain fatty acids (C2-C8) and  branched chain acids isobutyrate, isopentanoic, and 
isocaproic were measured with gas chromatography in ether extracts and according to the 
method by Laurentin & Edwards (616). 
 
Stabilization of faecal specimens for SCFA analysis 
Short chain fatty acids are particularly volatile and susceptible to oxidation. Substitution of 
their free carboxylic hydroxyl group, by divalent ions and conversion to their salt form in 
strong alkaline milieu preserves them from oxidation and decreases volatility and prevents 
the ongoing metabolic activity of the bacteria. Depending on the stool sample size (small 
samples) and its consistency (diarrhoeal samples) 0.8-1.5 g of specimens were fully 
dispersed in a small (7 ml) bijoux tube with an equal volume of NaOH 1M. Each tube was 
agitated vigorously on a vortex mixer for approximately one min or until the sample was fully 
dispersed. In the case of hard samples pre-weighed small beads or magnetic stirrer were 
used for more efficient homogenization. The procedure was repeated in triplicate. The 
samples were subsequently stored in –20 oC until further use. 
 
Moisture and volatile matter determination 
Moisture content was determined the day before SCFA analysis based on the freeze drying 
method. The pre-weighted NaOH-stabilized stool samples, were freeze dried for 24 hours in 
a Edwards apparatus (Freezer Dryer Micro Modulyo). The sample dry weight was measured 
and the moisture content was expressed as percentage of water per mass of stool sample.  
 
Gas chromatographic determination of SCFA 
Short chain fatty acids were estimated by gas liquid chromatography using a TRACE 2000 
gas chromatograph (ThermoQuest Ltd, Manchester, UK) equipped with a flame ionisation 
detector (250 oC) and using a Zebron ZB-Wax capillary column (15 m x 0.53 mm id x 1 µm 
film thickness), made of polyethylene glycol (catalogue No. 7EK-G007, Phenomenex, 
Cheshire, UK). Nitrogen (30 ml/min) was used as the carrier gas.  
One hundred µl of internal standard solution (86.1 mmol/l 2-Ethylbutyric acid) and 100 
µls of concentrated orthophosphoric acid were added to 800 µls of distilled water containing 
50 µg freeze dried faeces previously stabilized with 1:1 NaOH 1 N. The mixture was 
homogenized by vortex for 15 sec and was extracted immediately three consecutive times 
with 3 ml of diethyl ether, vortexed for 1 min each time, recovering and pooling the ether 
phase (supernatant) each time in a clean tube. Pooled extract (1ul) was automatically 
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injected (injector temp 230 oC, splitless) onto the column. The column temp was held at 80 
oC for 1 min, increasing by 15 oC per min to a final oven temp of 210 oC. 
The chromatograph and the peak integrals were analysed using Chrom-Card 32-bit 
version 2.2 (April 2003) (Thermofinnigan, Milan, Italy). For the calibration an external 
standard of (166.5 µmol/l acetic, 135 µmol/l propionic, 113.5 µmol/l isobutyric, 113 µmol/l 
butyric, 97.9 µmol/l isovaleric, 97.9 µmol/l valeric, 86.1 µmol/l hexanoic, 76.8 µmol/l 
heptanoic and 69.3 µmol/l octanoic, pH 8) was used. The external standard was run five 
times at the start of each run and the response factor for each standard averaged and the 
coefficient of variance calculated. The external standard was run again and the coefficient of 
covariance calculated after every 12 samples. All reagents used were Analytical Reagent 
Grade and supplied by Sigma-Aldrich Company Ltd (Dorset, UK), except acetic acid (glacial) 
which was supplied by Fisher Scientific (Loughborough, UK). All serial samples from each 
patient were analyzed at the same run to minimize inter-assay error. Each sample was 
extracted and analysed in duplicate (two different extractions) and in reverse order, to 
account for any time effect (due to evaporation of the very volatile SCFA) on the accuracy of 
the results. The results from the two extracts were averaged unless their variance was wide. 
A quality control sample (well homogenized freeze dried stock faecal material) was included 
at the beginning and the end of each run to assure repeatability of the assay and intra-assay 
comparison of the results between different runs.  
 
7.2.4.4. Determination of faecal lactate 
D- and L- Lactate were measured in freeze dried faecal samples using a modified enzymatic 
spectrophotometric commercial assay (D, L Lactic Acid, UV Method, Boehringer Mannheim, 
Roche, Cat No; 11112821035). In the presence of lactate dehydrogenase, lactic acid is 
oxidized to pyruvate by NAD according to the reaction:  
Lactate + NAD ⇔ Pyruvate + NADH + H 
The equilibrium of these reactions lies on the side of lactate. By trapping pyruvate in a 
subsequent one-way reaction catalyzed by the enzyme glutamate-pyruvate transaminase 
(GPT) in the presence of L-glutamate, the equilibrium can be displaced in favour of pyruvate 
and NADH according to the reaction. 
Pyruvate + L-glutamate ⇒ L-alanine + 2-oxoglutarate 
The amount of NADH formed in the above reactions is stoichiometric to the amount of D-
lactic and L-lactic acid respectively. The concentration of NADH is determined by means of 
its ultraviolet absorbance at 340 nm and equals to the expended lactate. 
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Modification and optimization of the commercial Kit 
The initial protocol of the assay was based on a commercially available kit of measuring D 
and L lactate in foodstuffs (D, L Lactic Acid, UV Method, Boehringer Mannheim, Roche, Cat 
No; 11112821035). Several modification steps were applied to scale down the original 
method to a microtitre calibre, and additional steps were added for the purification and 
extraction of faecal lactate. In a two months optimization phase, different lactate extraction 
and enzymatic reaction conditions and protocols were tested and optimal conditions were 
selected. The description of the optimization steps is beyond scope of this thesis.  
The final optimized protocol for the measurement of faecal lactate in stool sample had 
two major stages.  
a. Lactate extraction and removal of impurities  
b. Spectrophotometric Determination of D and L lactate  
 
Table 7.1: Preparation method and reagents for the assay of the determination of faecal lactate 
NAD working solution 
(0.003097 mg/µl) 
Dissolve 232 mgs of NAD (Fluka 43407) in 5 ml of distilled water. 
The solution is stable at 4 oC for one week. 
 
GPT solution (0.0139 Unit/µl) Dilute 0.8 ml of well-shaken stock solution of GPT (Glutamic 
Pyruvic Transaminase from porcine heart 90 Unit / mg protein, 
14.4 mg / ml. SAFC G9980 15UN) suspension in 4.2 ml of 
distilled water. Shake well before use.  
 
D-lactase dehydrogenase 
(0.048 Unit/µl) 
Dissolve 4.63 mg of lyophilised enzyme (SAFC 59023, D Lactate 
from Lactobacillus species, 1165 U / mg) in 5 ml of distilled 
water. The solution is  stable at 4 oC for one week 
L-lactase dehydrogenase 
(0.048 Unit/µl) 
Dissolve 38 mg of lyophilised enzyme (Biochemika: L-lactate 
Dehydrogenase from rabbit muscles 142 U/mg 61305) in 5 ml 
distilled water. The solution is stable at 4 oC for one week. 
 
Carrez I and II clarification 
system 
Bioquant Carrez clarification 5-fold concentrated (Merck. 10537) 
(D, L Lactic Acid, UV Method, Boehringer Mannheim, Roche, Cat 
No; 11112821035) 
Quality standards Standard solutions of D and L lactate were available from the 
manufacturer’s kit. 
  
Buffer glycylglycine Dissolve 1.321 g of Glycylglycine (Argos Chemicals) in 100 ml of 
water. Add 1.4667 g L-glutamic acid (Fisher) in 100 ml. Stir with 
magnetic stirrer and adjust pH with concentrated KOH (5M). 
Bring solution to room temperature before use. 
 
Reagents 
All reagents (Table 7.1) were kept in dark bottles or in universal tubes wrapped with 
aluminium foil and brought to room temperature before use.  
 
Lactate extraction and removal of impurities  
Freeze-dried stool samples (30-50 mg; same sample as for SCFA determination; fixed with 
1:1 NaOH 1M) were suspended in 800 µl of distilled H2O in a 2 ml secure lock eppendorf 
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tube. The suspension was agitated vigorously by vortex (1 min) and incubated in a water 
bath at 65 oC for 20 min. The suspension was agitated for further 45 sec and faecal 
impurities removed with the Carrez clarification system (Merck, UN 3082). Typically 100 µl of 
Carrez I were added followed by short agitation and addition of 100 µl of Carrez II. The 
suspension was vortexed for further 10 sec before being spun at 14000 g for 8 min. 500 µl of 
the supernatant were transferred into a clean secure lock eppendorf tube and 50 µl of Carrez 
I and Carrez II were added as above. The suspension was centrifuged at 14000g for 6 min 
and the clear supernatant was transferred into a clean eppendorf tube. The extract was 
centrifuged for a further 4 min without addition of Carrez clarification system and the final 
supernatant analysed immediately for the determination of the D and L lactate.  
 
Spectrophotometric determination of D and L lactate  
Each sample was analyzed twice (two separate extractions) and each extract in duplicate. 
The values of the two replicates and extracts from the same sample were averaged unless 
variance was wide. Two standard samples of D and L lactate were run each time to check 
completion of the reaction. A quality control faecal sample identical that used for the 
determination of SCFA was analysed in each run to ensure intra-assay repeatability.  
In a 96 microtitre well plate (Costar 9017, US), the reactants and the under 
determination samples, quality controls and standards were added according to Table 7.2. 
The plate was covered with membrane sealer and mixed on an orbital shaker for 10 min to 
mix up the reagents. Absorbance was measured at 340 nm and corresponds to the 
background absorption. D-lactate dehydrogenase (10ul) was added, and the plate incubated 
on a shaker for 60 min followed by measurement of absorbance at 340 nm. Finally, 10 µl L-
lactate dehydrogenase was added and the plate incubated as above for two hours and 
absorbance measured at 340 nm.  
 
Table 7.2: Composition table of the faecal lactate assay 
 
GPT Buffer NAD Water Sample QC D-lactase L-lactase 
Blank (µl) 15 100 15 75 0 0 10 10 
Control (µl) 15 100 15 65 0 10 10 10 
Sample (µl) 15 100 15 45 30 0 10 10 
 
 
 
Calculation of lactate concentration 
The concentration of lactate is given by the general formula:  
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V= Total volume of reactants in the well, v= Sample volume, MW= Molecular weight of substance to 
be assayed (g/mol), d= Well effective light path (cm), ε= Extinction coefficient of NADH at 340 nm = 
6.3 (l x mmol-1 x cm-1), DA=the difference between absorbance: For D-lactate this was A1 – A0, and for 
L-lactate  A2 – A1 
 
A0: Background Absorbance 
A1: Background Absorbance plus Absorbance due to D-lactate conversion 
A2: Background Absorbance plus Absorbance due to D-lactate and L-lactate conversion 
 
Concentration of )/(
1000020.064.03.6
1.90215.0 lgDAlactateD ×





×××
×
=−  
 
 
Concentration of )/(
1000020.067.03.6
1.90225.0 lgDAlactateL ×
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



×××
×
=−  
 
Lactate concentration of initial slurry (g/l): 
9.0
teionoflactaConcentrat
 
 
 
Lactate concentration in dry stools (g/100g) = 100×
sampleeezeddriedWeightoffr
yioninslurrConcentrat
 
Lactate concentration was expressed per g of dry or wet stool sample.  
 
7.2.4.5. Determination of free and total sulphide in faecal samples 
Free and total sulphide were measured in stool samples with a spectrophotometric assay in 
accordance to an in-house modified method reported by Strocchi (617). This is based on the 
principle of the methylene blue reaction first described by Cline (618) measuring sulphide in 
environmental specimens. Typically sulphide reacts with a diamine reagent in an acidic 
environment under the oxidative effect of ferric chloride. The absorbance is measured at 670 
nm and its intensity is proportional to the concentration of sulphide.  
 
Optimization of previous assays 
Several methods have been reported in the literature for determination of faecal sulphide. 
Most are based on the principle of the methylene blue reaction (457;617;619) and one (620) 
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is based on microdistillation and ion chromatography. A number of spectrophotometric 
assays were tested to select the most appropriate for this research and optimized them 
where appropriate. The protocols described by Florin (619) and Moore (457) were initially 
chosen as they seemed easier and more practical but our results were not encouraging 
particularly regarding the recovery of the assays and the sensitivity of the methods. To select 
the best concentrations of reactants, samples, and reaction conditions (incubation times, 
temperatures and reaction pH) an optimization phase of four months was undertaken. The 
detailed experimental description of these optimization steps and their results are out of the 
scope of this thesis and will not be reported in detail.  
 
Interference of assay by formula feed ingredients and sulphate salts.  
In a short experiment the influence of the ingredients of a nutritional supplement (Modulen), 
and particularly sulphur containing compounds (eg sulphate salts) was tested on the assay 
performance and mainly specificity. The free and total sulphide concentration of Modulen 
feeds (20%), a commercial infant milk powder (Cow & Gate), and three inorganic sulphate 
salts (magnesium sulphate, sodium sulphate, ferrous sulphate) were measured.  
None of the inorganic salts tested presented substantial amounts of total or free 
sulphide and therefore interference from sulphate salts (not bacterial produced sulphide) 
should be negligible. Surprisingly in both Modulen and baby feed free sulphide was detected 
but not total sulphide.  In theory this could be attributed to release of sulphide during the free 
sulphide stabilization step with NaOH and a possible unspecific reaction between the latter 
and sulphur containing ingredients in Modulen (sulphur containing amino acids). 
The main assay protocol consists of two main stages:  
a. Trapping and stabilization of free and bound sulphide 
b. Spectrophotometric determination of sulphide 
 
Reagents  
All the reagents (Table 7.3) were of Analytical Reagents Grade and supplied from Sigma 
Aldrich and Fisher Scientific (Loughborough). 
 
Trapping and stabilization of free and bound sulphide step 
Sulphide occurs in stool samples in two chemical forms, typically as hydrogen sulphide or 
bound to divalent minerals like zinc and copper. Although bound sulphide is relatively stable, 
hydrogen sulphide is extremely volatile and susceptible to oxidation. Stabilization of free 
sulphide by converting it to the relevant salt is necessary for accurate measurements of 
sulphide in faecal material. A rule of thumb is to trap total (free and bound) sulphide in 
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insoluble zinc sulphide with zinc acetate or to increase solubility and decrease oxidation of 
free sulphide in an oxygen-free alkaline solution.  
 
Table 7.3: Preparation method and reagents for assay of the determination of faecal sulphide 
NaOH 1.25 M 
 
Oxygen free NaOH 1.25 M prepared to solubilise free H2S and to prevent 
oxidation. Aliquots of 1.25 N NaOH stored in 28 ml McCartney tubes 
(rubber sealed) and degassed by sonication (15 min) in warm water-bath 
(Sonomatic 375H, Jencons Scientific ltd, Bedfordshire, England).  
 
Zn-acetate 0.11 M 
 
Zinc acetate trapping solution prepared to preserve and stabilize both 
free and bound sulphide.  Zinc displaces the H atoms and other divalent 
minerals attached to sulphide forming stable insoluble zinc sulphide salt.  
Zinc acetate 0.11 M (Fisher 2/0700/50) prepared by mixing zinc acetate 
dihydrate with distilled water and degassing by sonication as above.  
 
Colour forming reagent 
(reaction reagent) 
 
Reaction reagent (concentrated) prepared by dissolving 2g of n,n-
dimethyl-p-phenylenediamine (DPD; Fluka 07750) and 3g of FeCl3 
(Sigma Aldrich, 23648) in 500 ml of ice cold HCl 6M. Solution prepared 
fresh (weekly) and kept in dark bottle at -20 oC. Diluted reagent prepared 
by mixing equal volumes of the concentrated reagent with ice cold HCl 
6N. Both dilute and concentrated reaction reagents used ice cold.  
 
Sulphide standard 
stock solution (2 mM): 
 
Sulphide standard stock solution prepared with sodium sulphide 
nonahydrate (Na2S • 9H2O) (Sigma Aldrich, 20804-3). A crystal of 
sodium sulphide nonahydrate (Na2S • 9H2O) washed out with distilled 
water discarding washings, wiped dry with cellulose tissue and weighed 
accurately.  2mmol/l solution made up with zinc-acetate 0.11 M in a gas 
proof glass container with rubber seal and flushed with nitrogen for 10 
min to displace oxygen. Slight nitrogen over-pressure applied. 
Concentration of sulphide calculated from amount of sulphide dissolved 
(after washings) or iodometrically. Stock solution kept in 4 oC for 15 d and 
working aliquots drawn prior to assay with syringe after shaking 
vigorously.  
 
Sulphide spike solution 
(0.5 mM) 
 
Spikes of standard sulphide (0.5 mM) prepared fresh prior to assay to 
measure the recovery of faecal sulphide in the assayed samples. 0.5 mM 
spike was prepared by mixing 200 µl of standard (2mM) solution with 600 
µl of zinc acetate 0.11 M.  
 
Typically 1-1.5 g of weighed faecal sample was dispersed in a 50 ml pre-weighed 
polypropylene centrifuge tube containing 10 ml oxygen free NaOH 1,25M (free sulphide) or 
oxygen free zinc acetate 0,11 M (total sulphide). The sample was dispersed completely in 
the liquid phase by vortex. The zinc acetate faecal slurry was kept at –20 oC until further 
handling whereas the alkaline slurry was centrifuged at 15000g for 30 min to precipitate 
insoluble sulphide salts and recover the supernatant that contained the soluble free sulphide. 
The supernatant was transferred carefully in new eppendorfs and was stored at –20 oC.  
 254 
 
Dilution step 
Prior to analysis, frozen faecal extracts (free sulphide) and slurries (total sulphide) were 
thawed and brought to room temperature. The determination of sulphide was performed 
immediately after thawing and the time of the assay was kept minimal to avoid loss of 
sulphide due to oxidation. The alkaline faecal extract (free sulphide) was centrifuged for five 
min at 14000 g whereas the faecal slurry (total sulphide) was resuspended thoroughly before 
use. 1.5 ml of faecal extract (free sulphide) was diluted with 6 ml of distilled water in a dilution 
ratio 1:5. Similarly 0.5 ml of well-dispersed total sulphide faecal slurry were diluted to 1:20 
with 9.5 ml of zinc acetate trapping solution.  
 
Spectrophotometric determination of free and total sulphide 
Samples (faecal extracts or slurries) were run in duplicate and their results averaged unless 
the variance between replicates was large. All serial samples from the same participant were 
run on the same assay using the same calibration curve to minimize intra-assay variance.  
Ice cold concentrated (80 µl; blank samples) or 160 µl of diluted reaction reagent 
(sample and spiked sample) were added in polypropylene eppendorfs containing 900 µl of 
faecal slurry or extract (Table 7.4). Tubes were capped immediately to trap released sulphide 
and inverted gently approximately 5-10 times. Tubes were vortexed for 5 sec and incubated 
in the dark for 15 min at room temperature and then for 30 min at 37 oC to allow full colour 
development. Eppendorfs were centrifuged (6 min, 14000 g) and the supernatant transferred 
into disposable cuvettes. Absorbance was measured at 670 nm in a conventional 
spectrophotometer (Biomate® 3,Thermo, UK).  
For each sample a blank replicate was prepared to correct for background 
absorbance of the faecal particulate and any interference due to a non specific reaction 
between the latter and the reaction reagent. The blank sample had identical composition to 
the unknown sample apart from all intrinsic sulphide being driven off, achieved by adding 80 
µl of HCl 6N (Table 7.4) before development of the methylene blue color and vigorously 
agitating the tube on an orbital shaker (VXR Basic IKA Vibrax® SHAKER) for 1 hour with the 
cap on.   
A spiked sample identical to the under determination sample, but spiked with 10 µl of 
sulphide standard (0.5 mM), was assayed to measure the recovery of the assay for each 
individual sample and to correct the measured absorbance of the unknown sample (Table 
7.4).  
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Standard Calibration Curve 
A standard calibration curve (Fig 41) was prepared at the beginning of each run. A working 
standard solution of 0.05M was prepared by mixing 200 µl of 2mM sulphide standard and 7.8 
µl of zinc-acetate 0.11 M. Seven serial dilutions (0 – 37.4µM) were assayed with the same 
protocol for the determination of sulphide in faecal samples (Table 7.5). Absorbance of the 
standards was plotted against their concentrations and a linear curve was plotted. 
 
Table 7.4: Composition of blank, sample, blank spike, spike and spiked sample in the 
determination of sulfide in faecal samples (all volumes in (µl) 
 Blank Sample Spiked Sample Spike Blank Spike 
Sample$ 900 900 900   
Zinc acetate 0.11N 10 10  900 900 
Sulphide standard 0.5mM 
  10 10 10 
Reaction reagent 80* 80* 
HCl 6N 80 
 
160 
 
160 80 
 
160 
Final volume 1070 1070 1070 1070 1070 
* Concentrated reaction reagent; $ Faecal slurry or  extract 
 
Table 7.5: Composition of calibration curve for the determination of sulphide in faecal samples 
Sulphide 
(µM) Blank 0 1.4 2.3 4.7 9.3 18.7 28 37.4 
Zn-Acetate 810 910 880 860 810 710 510 310 110 
Standard  100 0 30 50 100 200 400 600 800 
Reagent 80* 
HCl 80 
160 160 160 160 160 160 160 160 
*Concentrated reaction reagent 
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Figure  41: Calibration curve of spectrophotometric determination of sulphide 
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Calculation of sulphide concentration 
The concentration of sulphide in samples was calculated by reference to the 
calibration curve equation corrected for recovery. The recovery of the assay was 
calculated by the formula:  
100)]()([
)]()([)]()([)(covRe% ×
−
−−−
=
BSpAbsSpAbs
BSAbsSAbsBSAbsSSpAbsRery  
 
Where: Abs the absorbance of Spiked Sample (SSp), Sample Blank (BS), Sample (S), Spike (Sp), and 
Spike Blank (BSp). 
The corrected absorbance of the sample was calculated by the formula:  
100)()( ×=
R
SAbsCabsbsorbanceCorrectedA  
The concentrations of free and total sulphide per mass of stool sample are calculated by the formula:  
WB
ACabsgmoleFreeSulfid
××
−×
=
100
)(94.5)/(µ  
 
WB
ACabsgmoldeTotalSulfi
××
−×
=
100
)(78.23)/(µ  
 
Where: Cabs is the corrected absorbance, A and B the intercept and slope of the calibration curve, 
and W the weight of the stool sample.  
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7.2.4.6. Determination of faecal ammonia 
Faecal ammonia was measured in the same faecal slurry (1:3, w/v) used for pH 
determination. Faecal slurry (100-500 µl) was diluted to a final volume of 40 ml with distilled 
water in a conical polypropylene centrifuge tube. The suspension was vortexed and filtered 
(0.22 µm Millipore filter). Determination of ammonia in the clear supernatant was performed 
with an automated ammonia analyzer (Hanna, HI 93715). 
 
7.2.4.7. Analysis of bacterial diversity and composition with molecular 
bacteriology techniques 
The bacterial diversity of CD children and changes during EEN treatment were assessed 
with molecular microbiology methods. Temporal temperature gradient gel electrophoresis 
(TTGE) is a molecular fingerprinting method that separates polymerase chain reaction (PCR) 
generated DNA amplicons of the same size (340). During TTGE, PCR products encounter 
increasingly higher running buffer temperature as they migrate through a polyacrylamide gel. 
Upon reaching a threshold buffer temperature, the weaker melting domains of the double 
stranded PCR product will begin to denature at which time migration slows substantially. 
Different sequences of DNA (from different) bacteria will denature at different temperatures 
resulting in a pattern of bands. Each band theoretically represents a different bacterial 
species present in the community. TTGE uses a polyacrylamide gel containing a constant 
concentration of urea.  
DNA isolation from faecal samples 
Approximately 200-300 mg of homogenized faecal material were stored in 1.5 ml screw cap 
eppendorfs on sample collection and stored at –80 oC until further analysis. Total DNA was 
extracted with the bead beating method according to Sokol et al (512) as originally described 
by Godon et al. (621) 200 mg (wet weight) of stool were suspended in 250 µl buffer 4M 
guanidine thiocyanate (G-9277 Sigma), 0.1M Tris (pH 7.5)  and 40 µl of 10% N-lauroyl 
sarcosine. After addition of 500 µl 5% N-lauroyl sacrosine in 0.1 M buffer phosphate (pH 8) 
the eppendorf was incubated in 70 oC for 1 hour. 375 µl of 0.1 mm diameter zirconium beads 
(Cat. No 110791012, Biospec) previously sterilized by autoclaving were added, and the tube 
was shaken in a Fastprep® homogenizer (MP FastPrep 24, MP Biomedicals, California, 
USA) 5.5 speed twice for 5 min to lyse bacterial cells. Polyvinylpolypyrrolidone (P6755 
Sigma) (15 mg) was added to the tube, which was vortexed and centrifuged for 3 min at 
15,000 rpm. After recovery of the supernatant in a new eppendorf, the pellet was washed 
with 500 ml TENP (50 mM Tris [pH 8], 20 mM EDTA [pH 8], 100 mM NaCl, 1% 
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polyvinylpolypyrrolidone) and centrifuged for 3 min at 15,000 rpm. The new supernatant was 
added to the first supernatant. The washing step was repeated three times. The pooled 
supernatants (about 2 ml) were centrifuged briefly to remove particles and then split into two 
2-ml tubes. 
Precipitation and purification of nucleic acids 
Nucleic acids were precipitated by the addition of 1 ml of isopropanol for 10 min at room 
temperature and centrifuged for 5 min at 15000 rpm. The supernatant was discarded and 
pellets resuspended and pooled in 450 ml 100 mM phosphate buffer, pH 8, and 50 µl 5 M 
potassium acetate (P1190, Sigma). The tube was placed on ice for 90 min or left at 4 oC 
overnight. Following centrifugation at 15,000 rpm for 30 min, the supernatant was transferred 
to a new tube and 2 µl of RNAse (RNAase ONE, M426A, Promega) (1 unit/µl) added. The 
mixture was incubated in a dry bath at 37°C for 30 min. DNA was precipitated by the addition 
of 50 µl of 3 M sodium acetate (S2889, Sigma) and 1 ml of ice cold absolute ethanol. The 
tube was left for 30 min at room temperature or overnight at -20C.  DNA was recovered with 
a sterile stick after centrifugation at 15000 rpm for 15 min. The DNA pellet was finally washed 
with 70% ice cold ethanol, dried, and resuspended in 30-300 µl of TE buffer.  
Assessment of DNA concentration and integrity 
The amount and integrity of DNA were estimated visually by electrophoresis on agarose gel. 
Typically 2 µl of DNA template were mixed with 3 µl of loading buffer (Bromophenol 6 X 
(B0126, Sigma) and loaded onto the wells of an agarose gel (0.8% containing ethidium 
bromide 5 µl for 50 ml of agarose). The electrophoresis run in 1 X TBE (Tris Borate EDTA) 
for 30 min at 100 V. A 100 bp DNA ladder (G210A, 100 bp DNA Ladder, Promega) was run 
in parallel to quantify the base pair size of the DNA templates.   
Spectrophotometric determination of DNA concentration and purity 
The concentration of total DNA was determined by measuring the ratio of the absorbance of 
total DNA to protein. Typically 2 µl of DNA extract were dissolved to a final volume of 50 µl 
with distilled water and the absorbance measured in UV at 260 (DNA) and 280 (proteins) nm 
corrected for the background absorbance at 320 nm. A ratio greater than 1.8 represented 
DNA fraction of high purity. The initial concentration of the DNA template was calculated by 
multiplying with the dilution factor.  
Ribosomal DNA amplification 
Primers with GCclamp-U968 (5’ GCclamp- GAA CGC GAA GAA CCT TAC) and L1401 (5’ 
GCG TGT GTA CAA GAC CC) were used to amplify the V6 to V8 regions of bacterial 16S 
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rDNA. Polymerase chain reaction (PCR) was performed using HotStar Taq Master Mix 
(Qiagen). The PCR mix (50 ml) contained 25 µl of the Hotstar mixture (HotStar Taq Master 
Mix Kit Cart. No 203443 QIAGEN) (1 x PCR buffer, 15 mM MgCl2, 200mM each dNTP, 2.5 
units of HotStar Taq DNA polymerase), 20 pmol of primers U968-GC and L1401, and 
approximately 20 ng of DNA. Samples were amplified in a thermocycler (PT C-200, Peltier 
thermal Cycler, Massachusetts, USA) using the following programme: 95°C for 15 min, 35 
cycles of 97°C for 1 min, 58°C for 1 min, 72°C for I.5min, and finally 72°C for 15 min. PCR 
products were identified by electrophoresis on 1% agarose gel (BPE 1356, Fisher) containing 
ethidium bromide to check their size (500 base pairs) and estimate their concentration.  
Temporal temperature gel electrophoresis (TTGE) 
The DCode Universal Mutation Detection System (Bio-Rad, Paris, France) was used for 
sequence specific separation of PCR products. Electrophoresis was performed through a 
1mm thick, 16x16 cm polyacrylamide gel (8% wt/vol acrylamide/Bis (A7168, Sigma), 7M 
urea, 1.25XTAE, and, respectively, 60µl and 600µl of N,N,N',N'-Tetramethylethylenediamine 
(T9281, Sigma) and 10% ammonium persulfate (A3678, Sigma) using 7l of 1.25 XTAE as the 
electrophoresis buffer. Electrophoresis was run at a fixed voltage of 64 V for 16 hrs with an 
initial temperature of 66°C and a ramp rate of 0.3° C/h. For better resolution, the voltage was 
fixed at 20V for 20 min at the beginning of electrophoresis. Each well was loaded with 300–
400 ng of amplified DNA plus an equal volume of 2X gel loading dye (0.05% bromophenol 
blue, 0.05% xylene cyanol, and 70% glycerol). A DNA ladder and a mixture of PCR 
amplicons of known bacteria were used for each gel. Gels were stained in the dark by 
immersion for 30 min in a solution of SYBR Green I Nucleic Acid Gel Stain (Roche 
Diagnostics, GmbH, Mannheim, Germany) and read under UV light (Gel Doc EQ 170-8060, 
Paris, France). 
Calprotectin assay 
Faecal calprotectin, a marker of mucosal inflammation, was measured in the stool samples 
of children with CD and their relatives. The assay description is outlined in Section 6.2.5 . 
 
7.2.4.8. Statistical analysis 
The results of faecal metabolites were expressed both per g ‘dry’ and per g ‘wet’ faecal 
material to account for overall production (‘dry’ matter) and to demonstrate their approximate 
luminal concentration in the large bowel lumen that is ready available to the colonocytes 
(‘wet’). The relative ratio of each SCFA to the total amount of SCFA (% of total SCFA) was 
calculated to assess changes in the pattern of SCFA production. Likewise the ratio of D to L 
isomer lactate concentration was computed to assess changes in the production pattern.  
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 Data are presented with means and SD or with medians and range for parametric 
and nonparametric variables respectively. To assess changes of faecal biomarkers during 
EEN one way analysis of variance (ANOVA) with repeated measures and Bonferroni post-
hoc test was applied. For between two group comparisons the Mann-Whitney test was used 
and for intra-individual changes one sample Wilcoxon signed rank was applied. Fisher exact 
test and chi-square test were applied for differences in categorical variables between groups. 
Correlations between faecal calprotectin levels and faecal metabolites were assessed with 
Spearman rank r correlation.  
TTGE gel images were captured with UV camera (Gel Doc 170-8060, Biorad, Paris, 
France) and analyzed with the Quantity One software version 4.5.0 (Biorad). A TTGE profile 
with more bands generally indicates a greater degree of bacterial species diversity compared 
with a TTGE profile with few bands. Therefore the number of bands that appeared on the 
TTGE was quantitated and used to estimate bacterial diversity in each sample. Comparison 
of the TTGE band patterns of individual samples was performed by Sorensen's pairwise 
similarity coefficient (Cs) using the similarity matrix function of the software. Cs is defined as 
(2j/a+b)*100, where a is the number of bands in lane one, b is the number of bands in lane 
two, and j is the number of common bands in both lanes. Two identical profiles result in a Cs 
value of 100%, whereas completely different profiles (no common band) result in a Cs value 
of 0%.  
 
7.2.4.9. Power calculation 
The statistical power of the study was calculated for an 80% probability of detecting a 5.5 
mM increase or decrease in the faecal concentration of butyrate at a 5% significance level. 
For a faecal butyrate concentration of 13.4 mM with a standard deviation of 12.7 (417) and 
for a minimum clinical significant increase or decrease of 5.5 mM concentration the required 
sample size is 44 subjects. 
 
7.3. Results 
7.3.1. Recruitment 
Between October 2005 and August 2007 approximately 60 children started on EEN as part 
of their standard clinical management. Thirty children were invited to participate in the “EEN 
and gut microbiota study” and three patients in clinical remission were approached as a 
control group. In total, six children refused participation, and two withdrew the day after 
recruitment. Two collected less than two stool samples but did not formally withdraw from the 
study. One patient’s participation was terminated deliberately after a final biopsy histology 
report was consistent with UC diagnosis. One patient experienced a cerebral vascular 
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accident while on treatment with EEN and stopped treatment within a week of recruitment. 
For two patients, disease activity further deteriorated and both had to stop EEN and initiate a 
regime of steroids. Two other patients were recruited 15 days and 21 days after EEN 
initiation and their results are not included in the arm of the study on the effect of EEN on gut 
microbiota diversity and metabolism. Fourteen children completed between six to eight 
weeks of EEN course. Approximately 100 stool samples were collected from children with 
CD. Only eight stool samples were provided at hospital despite the expectations of the single 
researcher. The rest were collected from patients’ home by the researcher within four hours 
of defecation.  
Fresh stool samples were collected from eighteen CD children (11 boys) at the 
different time points of the follow on EEN (Table 7.6). Two patients provided only two 
samples (one discontinued treatment and the other withdrew within 2 weeks of treatment) 
and therefore were excluded from analysis. Three children gave in total three serial samples 
during treatment (one could not provide a sample-was on holiday, two stopped at week 5 and 
4 respectively due to symptoms deterioration). These patients were included in the analysis.  
A final stool sample was collected whilst patients were on normal diet. For one child a 
final sample was not collected due to subsequent operation and resection of a significant part 
of the ileocolon.  
From the 16 children whose data is presented (mean age: 11.8 ± 2.3 y) nine were 
boys, twelve were newly diagnosed and this was their first course on EEN. The remaining 
four patients were receiving their second course to manage a subsequent disease relapse. 
Nine children were on no other medication apart from EEN. The rest were on other 
concomitant treatments (Table 7.6). For the patients with longstanding disease, the type and 
dose of concurrent treatment did not change during EEN course. Thirteen children had 
extensive disease involving the upper and lower part of the GI tract (Table 7.6). 
 
Table 7.6: Disease location and medical treatment of CD children on EEN treatment 
Disease location (Montreal 
classification) 
N Concomitant medication N 
Colitis (L2) 2 None 9 
Ileocolitis (L3) 1 5-ASAs 4 
Upper GI & ileocolitis (L3L4) 9 Immunomodulators 5 
Upper & colitis (L2L4) 4 Steroids 2 
  Antibiotics 1 
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7.3.2. Changes of disease activity markers during EEN  
Changes in disease activity markers are described in detail in Chapter 6. All participants 
were undergoing the active phase of their disease as evident by the increased score of the 
clinical activity index (PCDAI) and elevated systemic inflammatory markers (Table 6.2).  
All disease activity markers improved significantly at the end of treatment as a group 
and individually in the majority of the children (Chapter 6, Fig 35). Regardless of any 
improvement in disease activity during treatment, seven out of the 16 children achieved 
complete clinical remission (PCDAI≤10). There was no statistically significant difference in 
the baseline markers of disease activity between patients who achieved remission and those 
who did not.  
 
7.3.3. Changes in bacterial metabolic activity during EEN  
7.3.3.1. Changes in faecal water content, pH and ammonia  
No significant changes in faecal water content were observed during treatment with EEN. In 
contrast, faecal pH rose significantly (p<0.0001) (Fig 42). Compared to baseline values, a 
mean increase of 0.5 pH units was observed within 15 days of treatment initiation (p<0.01). 
Faecal pH remained significantly elevated at all time points of follow up (p<0.02) (Fig 42) but 
returned to pre-treatment levels when children were eating their normal diet.  
 Different patterns of faecal pH change were observed between those patients who 
achieved complete clinical remission and those who discontinued treatment or presented 
with still active disease at the end of treatment. In those patients who achieved clinical 
remission (PCDAI≤10) faecal pH was significantly increased at all follow up points compared 
to baseline values (p<0.0001; Fig 43) whereas, no significant changes were observed in 
those patients who did not achieve clinical remission or discontinued treatment (Fig 44).  
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Figure  42: Boxplots showing changes in faecal pH during EEN and on normal diet in 
children with CD (all patients) 
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Figure  43: Boxplots showing changes in faecal pH during EEN and on normal diet in children 
with CD (remission) 
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Figure  44: Boxplots showing changes in faecal pH during EEN and on normal diet in children 
with CD (No remission) 
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Treatment with EEN had no effect on faecal ammonia (expressed per litre of stool sample or 
per kg dry faecal material). No difference in pattern of change was found between patients 
who achieved clinical remission at the end of EEN treatment and those did not (Fig 45).  
 
Figure  45: Boxplots showing changes in faecal ammonia during EEN and on normal diet in 
children with CD  
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7.3.3.2. Changes in faecal SFCA and BCFA concentration  
Overall there were no major changes in the concentration of the main SCFA and BCFA 
during EEN treatment. Faecal butyrate concentration and its proportional fraction (% of total 
SCFA) were reduced during EEN treatment but this did not reach statistical significance.  
However, similar to the patterns of faecal pH change, significant SCFA alterations 
were observed for the patients who achieved clinical remission at the end of treatment (Table 
7.7). Butyrate concentration and its relative ratio (% of total SCFA) were significantly reduced 
within 15d of treatment initiation and continued to decrease during follow up with the 
maximum mean reduction observed at the end of treatment (60 d) (Table 7.7). At the end of 
EEN, faecal butyrate concentration was half that of baseline values, and its proportional ratio 
was reduced to one third of pre-treatment levels (Table 7.7). Whilst on normal diet, butyrate 
levels reverted to pre-treatment levels.  None of the SCFA or BCFA measured changed 
during treatment in those patients who did not achieve clinical remission or discontinued 
treatment (Table 7.8).  
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Table 7.7: Changes in faecal concentration and % of SCFA and BCFA in paediatric CD patients who achieved clinical remission with EEN treatment   
Subjects (n=7) Before EEN 15 d 30 d 60 d Normal diet 
 Mean SD Mean SD Mean SD Mean SD Mean SD 
Dry faecal material 
          
Acetate (µmol/g) 237.9 138.9 222.5 63.6 199.8 99.6 187.3 82.3 238.9 124.5 
Propionate (µmol/g) 37.0 23.4 41.2 23.6 34.4 21.5 29.7 15.1 53.2 19.6 
Butyrate (µmol/g) 63.0 38.9 31.7 19.0 26.3* 10.5 23.8* 11.7 59.8 32.3 
Valeric (µmol/g) 5.9 6.7 4.9 6.6 4.2 5.0 4.8 4.5 5.6 5.6 
Caproic (µmol/g) 0.8 0.5 2.0 1.4 1.3 0.9 0.8 0.5 1.7 0.7 
Heptanoic (µmol/g) 0.2 0.6 1.1 0.7 0.4 0.7 0.0 0.0 0.7 1.3 
Octanoic (µmol/g) 0.8 1.0 2.0 1.7 1.3 1.0 1.1 0.6 1.2 1.1 
Isobutyrate (µmol/g) 12.2 7.0 12.2 4.5 10.0 4.3 7.9 2.1 7.0 1.3 
Isovaleric (µmol/g) 17.4 8.9 17.4 7.3 14.6 6.5 11.4 2.5 11.7 3.0 
Isocaproic (µmol/g) 4.2 9.4 0.7 1.0 0.4 0.7 0.1 0.4 0.0 0.0 
Total SCFA (µmol/g) 379.4 160.8 335.7 91.3 292.6 119.8 266.9 98.4 379.9 174.5 
Stool sample 
          
Acetate (µmol/g) 57.3 21.3 61.2 17.9 54.5 14.8 50.1 16.5 59.6 17.5 
Propionate (µmol/g) 9.4 5.4 11.6 7.7 9.5 5.0 7.9 3.5 13.8 3.5 
Butyrate (µmol/g) 15.4 7.4 9.1 6.3 7.8* 3.4 6.7** 2.9 14.8 5.6 
Valeric (µmol/g) 1.6 2.1 1.2 1.6 1.3 1.5 1.4 1.3 1.5 1.5 
Caproic (µmol/g) 0.2 0.1 0.5 0.3 0.4 0.3 0.2 0.1 0.5 0.2 
Heptanoic (µmol/g) 0.1 0.2 0.3 0.2 0.1 0.3 0.0 0.0 0.2 0.5 
Octanoic (µmol/g) 0.3 0.4 0.6 0.5 0.4 0.3 0.3 0.2 0.4 0.4 
Isobutyrate (µmol/g) 3.2 1.9 3.5 1.6 2.9 1.1 2.2 0.4 1.9 0.7 
Isovaleric (µmol/g) 4.9 3.7 5.0 2.6 4.3 1.8 3.1 0.6 3.2 1.2 
Isocaproic (µmol/g) 0.8 1.5 0.2 0.2 0.1 0.2 0.0 0.1 0.0 0.0 
Total SCFA (µmol/g) 93.1 27.6 93.2 30.5 81.3 18.3 72.0 18.3 96.0 25.9 
Proportional ratio 
          
% Acetate 61.7 14.5 66.1 8.4 66.7 9.1 68.7 6.7 61.8 3.1 
% Propionate 9.4 4.3 12.3 5.6 11.4 4.8 11.5 5.6 14.7* 2.9 
% Butyrate 16.9 8.8 9.3* 3.8 9.8* 3.6 9.3** 3.5 15.2 3.1 
% Valeric 1.6 1.9 1.4 1.8 1.7 2.0 1.9 1.8 1.5 1.4 
% Caproic 0.3 0.2 0.6 0.4 0.4 0.4 0.3 0.2 0.5 0.3 
% Heptanoic 0.1 0.2 0.3 0.2 0.1 0.3 0.0 0.0 0.2 0.4 
% Octanoic 0.3 0.4 0.7 0.7 0.5 0.4 0.5 0.2 0.4 0.3 
% Isobutyrate 3.5 1.8 3.7 1.2 3.7 1.1 3.2 0.9 2.1** 0.8 
% Isovaleric 5.2 2.8 5.4 2.1 5.4 1.9 4.6 1.3 3.6 1.5 
% Isocaproic 1.1 2.3 0.2 0.3 0.2 0.3 0.0 0.1 0.0 0.0 
Values were significantly different from those “Before EEN” (repeated measures ANOVA and Bonferroni post-hoc test):  *P<0.05, **P<0.02. 
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Table 7.8: Changes in faecal concentration and % total SCFA and BCFA in paeiatric CD patients who did not achieve clinical remission with EEN 
treatment   
Subjects (n=9) Before EEN 15 d 30 d 60 d Normal diet 
 Mean SD Mean SD Mean SD Mean SD Mean SD 
Dry faecal material 
          
Acetate (µmol/g) 230.5 126.9 240.7 126.6 254.9 130.1 271.1 149.3 276.8 183.4 
Propionate (µmol/g) 37.8 24.5 29.9 23.6 33.7 17.4 39.8 12.6 41.6 30.3 
Butyrate (µmol/g) 26.3 25.6 20.0 16.7 20.6 15.3 25.4 15.4 39.6 42.9 
Valeric (µmol/g) 5.0 7.8 3.3 4.3 4.4 5.5 4.3 4.2 3.3 4.5 
Caproic (µmol/g) 1.4 1.9 1.0 1.2 1.3 0.9 1.3 0.3 1.0 0.7 
Heptanoic (µmol/g) 0.5 0.6 0.4 0.7 0.7 1.1 0.1 0.4 0.3 0.5 
Octanoic (µmol/g) 1.1 1.3 0.6 0.9 0.7 1.2 0.5 0.7 1.0 1.3 
Isobutyrate (µmol/g) 7.8 6.9 6.1 3.9 6.0 4.3 9.3 9.0 5.7 2.1 
Isovaleric (µmol/g) 10.6 7.8 6.7 3.6 7.8 6.2 10.3 6.2 9.1 4.3 
Isocaproic (µmol/g) 1.1 1.4 1.8 3.0 1.3 2.1 3.9 7.0 0.0 0.1 
Total SCFA (µmol/g) 322.1 130.0 310.5 135.2 331.5 123.2 366.0 159.0 378.5 203.7 
Stool sample 
          
Acetate (µmol/g) 44.5 17.6 43.5 14.6 44.9 20.7 46.8 11.3 63.4 32.5 
Propionate (µmol/g) 9.5 7.6 6.3 5.7 6.9 4.3 7.4 1.1 10.9 7.2 
Butyrate (µmol/g) 7.2 7.0 4.0 2.9 4.7 5.1 5.1 2.8 10.5 9.8 
Valeric (µmol/g) 1.4 2.1 0.7 0.8 1.2 1.6 1.0 1.0 0.9 1.4 
Caproic (µmol/g) 0.4 0.6 0.2 0.3 0.3 0.2 0.3 0.1 0.2 0.2 
Heptanoic (µmol/g) 0.1 0.2 0.1 0.2 0.2 0.2 0.0 0.1 0.1 0.1 
Octanoic (µmol/g) 0.3 0.3 0.1 0.2 0.2 0.4 0.1 0.2 0.3 0.4 
Isobutyrate (µmol/g) 2.1 1.9 1.3 0.7 1.4 1.2 1.8 1.4 1.6 0.9 
Isovaleric (µmol/g) 2.8 2.3 1.5 1.0 1.9 2.0 2.1 1.2 2.7 1.7 
Isocaproic (µmol/g) 0.3 0.3 0.3 0.4 0.2 0.3 0.6 1.1 0.0 0.0 
Total SCFA (µmol/g) 68.5 34.3 58.0 18.9 62.0 28.3 65.3 9.8 90.7 39.1 
Proportional ratio 
          
% Acetate 70.9 18.2 75.5 12.1 73.5 13.9 71.3 10.2 69.6 15.2 
% Propionate 11.9 6.7 10.2 6.1 11.1 5.0 11.7 3.0 12.1 7.2 
% Butyrate 8.3 6.8 6.8 4.9 7.1 4.9 7.8 3.8 10.9 7.7 
% Valeric 1.6 2.3 1.3 1.6 2.0 2.8 1.6 1.6 1.2 1.8 
% Caproic 0.5 0.5 0.3 0.4 0.4 0.3 0.4 0.2 0.3 0.2 
% Heptanoic 0.2 0.4 0.2 0.3 0.3 0.4 0.0 0.1 0.1 0.2 
% Octanoic 0.4 0.4 0.2 0.3 0.3 0.4 0.2 0.3 0.4 0.5 
% Isobutyrate 2.4 1.8 2.2 1.3 2.1 1.5 2.7 1.9 2.0 1.2 
% Isovaleric 3.4 2.2 2.6 1.8 2.8 2.2 3.3 1.9 3.3 2.2 
% Isocaproic 0.3 0.4 0.6 0.9 0.4 0.6 0.9 1.5 0.0 0.1 
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7.3.3.3. Changes in faecal sulphide concentration  
Total but not free faecal sulphide concentration increased significantly during EEN 
(p<0.0001) (Fig 46). A three-fold increase in total sulphide was observed within 15 d of 
treatment initiation (p=0.02). This plateaued at 30 d of treatment (p<0.02). At 60 d the mean 
total sulphide concentration was higher than at baseline but this did not reach statistical 
significance. Total sulphide reverted to pre-treatment levels on normal diet. 
  
Figure  46: Boxplots showing changes in faecal free & total sulphide during EEN and on normal 
diet in children with CD 
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When sub-analysis was conducted separately for patients who achieved clinical 
remission at the end of treatment, and those did not or who discontinued treatment, different 
patterns of change were observed (Fig 47 & 48). A seven-fold increase for total sulphide was 
observed after 15 days of treatment introduction in the patients who entered clinical 
remission. From a pre-treatment concentration of 0.64 µmol/g, total sulphide increased to 
4.74 µmol/g after two weeks on EEN treatment introduction (p<0.001). At 30 and 60 d follow 
up measurements, total sulphide remained at the same high levels (p<0.03). Concentration 
of total sulphide returned to pre-treatment levels when patients went back to their normal diet 
(Fig 48). No significant changes were seen for total sulphide concentration in patients with 
active disease at end of treatment or those who discontinued treatment (Fig 48).   
Faecal free sulphide concentration did not change from baseline levels during EEN 
(Fig 47). No different patterns of change were seen between patients who achieved clinical 
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remission and those did not (Fig 47 & 48). Same change patterns were found when sulphide 
concentrations expressed per g dry sample (data not presented). 
 
Figure  47: Boxplots showing changes in free faecal sulphide during EEN in CD children. 
Comparison between patients with active disease and in remission at the end of EEN 
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Figure  48: Boxplots showing changes in total faecal sulphide during EEN in children with CD. 
Comparison between patients with active disease and in remission at the end of EEN 
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7.3.3.4. Changes in faecal lactate concentration  
Neither D nor its isomer L-Lactate changed significantly during treatment with EEN. In sub-
group analysis D but not L-Lactate decreased after 15 and 30 d of treatment initiation in the 
group of children who achieved clinical remission (p<0.04; Table 7.9). At 60 d the mean 
decrease did not reach statistical significance (p=0.08). No change was found in the ratio of 
D and L lactate isomer concentration during the course of treatment. However children who 
achieved clinical remission had a higher D/L Lactate ratio on normal diet than pre-treatment. 
No significant changes in concentrations of D-Lactate, L-Lactate nor their ratio were 
found in children who did not achieve clinical remission or discontinued treatment (Table 
7.10).  
 
7.3.4. Gut inflammation and bacterial metabolic activity 
Patients were categorized into two groups based on the direction of calprotectin change at 
the end of treatment.  The first group included those patients (n=11) whose calprotectin 
levels was reduced at the end of treatment, and the second group (n=5) those patients with 
calprotectin concentrations, at treatment cessation higher than at baseline. Four patients in 
the first group did not achieve complete clinical remission at the end of EEN (PCDAI>10) 
compared to all patients in the group in which calprotectin increased.  
 
7.3.4.1. Changes in water content, faecal pH and ammonia 
For both groups no significant changes in the faecal water content or ammonia were found 
during EEN (data not presented). Faecal pH increased only in the group of patients that 
calprotectin decreased at the end of treatment (Figs 49 & 50). In this group pH reversed to 
pre-treatment when patients were on normal diet. 
 
7.3.4.2. Changes in faecal sulphide concentration 
Similar to the pattern of change observed in the patients who achieved clinical remission at 
the end of EEN, faecal levels of total but not free sulphide increased significantly at 15 and 
30 d, only in the patients with lower than pre-treatment levels of calprotectin, at the end of 
EEN (Fig 51). Total sulphide returned to pre-treatment levels when patients returned to 
normal diet. No change in total or free sulphide was found in the group of patients with higher 
than baseline levels of calprotectin at the end of treatment (Fig 52).   
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Table 7.9: Changes in faecal lactate concentration during treatment with EEN and on normal in patients who achieved clinical remission 
N=7 Before EEN 15 d 30 d 60 d Normal diet 
 
Mean SD Mean SD Mean SD Mean SD Mean SD 
Dry faecal material           
D-lactate (mg/100g) 51.9 47.4 18.4* 6.5 18.9* 8.9 22.4 10.8 40.3 24.8 
L-lactate (mg/100g) 160.4 262.6 29.8 10.6 29.7 11.5 32.5 15.6 49.9 31.0 
Total lactate (mg/100g) 213.0 294.0 49.2 17.3 49.2 19.3 55.7 25.8 91.2 53.3 
Stool sample 
          
D-lactate (mg/100g) 10.3 6.2 4.9$ 1.1 5.2$ 1.3 6.0 2.2 10.0 4.0 
L-lactate (mg/100g) 28.9 41.0 8.1 2.2 8.4 2.3 8.6 3.2 12.2 4.8 
Total lactate (mg/100g) 39.4 44.6 13.3 3.4 13.9 3.0 14.9 5.1 22.5 7.1 
D/L-lactate 0.6 0.3 0.6 0.1 0.7 0.2 0.8 0.3 0.9* 0.7 
ANOVA of repeated measures and Bonferroni post-hoc test *P<0.04 $  P<0.03 from “Before EEN” 
 
Table 7.10: Changes in faecal lactate concentration i during treatment with EEN and on normal in patients who did not achieve clinical remission 
after EEN 
N=9 Before EEN 15 d 30 d 60 d Normal diet 
 
Mean SD Mean SD Mean SD Mean SD Mean SD 
Dry faecal material           
D-lactate (mg/100g) 39.4 35.7 76.8 87.5 78 75.7 72.3 62.2 77.3 129.0 
L-lactate (mg/100g) 76.2 77.7 187.4 214.8 173.7 168.9 151.5 192.6 106.9 170.5 
Total lactate (mg/100g) 115.7 111.2 264.3 285 251.7 231.6 223.8 246.4 184.0 299.0 
Stool sample 
          
D-lactate (mg/100g) 6.8 3.2 11.7 8.7 11.2 7.3 11.7 6.4 13.9 15.0 
L-lactate (mg/100g) 12.5 8.3 29.2 28.9 23.9 17.7 22.9 22.2 19.7 19.5 
Total lactate (mg/100g) 19.3 11.2 40.9 34.6 35.1 23.2 34.6 27.4 33.6 34.5 
D/L-lactate 0.6 0.2 0.5 0.2 0.6 0.2 0.6 0.2 0.7 0.1 
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Figure  49: Boxplots showing changes in faecal pH during EEN and on normal diet in children 
with CD (calprotectin decreased) 
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Figure  50: Boxplots showing changes in faecal pH during EEN and on normal diet in children 
with CD  (calprotectin increased) 
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Figure  51: Boxplots showing changes in faecal free & total sulphide during EEN in children 
with CD (calprotectin decreased at the end of EEN) 
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Figure  52: Boxplots showing changes in faecal free & total sulphide during EEN in children 
with CD (calprotectin increased at the end of treatment) 
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7.3.4.3. Changes in faecal SFCA and BCFA concentration 
Butyrate concentration decreased by 50% within 15d on EEN only in patients whose 
calprotectin decreased at the end of treatment (Table 7.11). From a baseline mean 
concentration of 47.9 µmol/g, butyrate dropped to 24.6 µmol/g at 15 d and continued to 
decline further during follow up reaching the nadir mean concentration of 20.5 µmol/g at the 
end of treatment. No significant changes were observed for the other SCFA or BCFA (Table 
7.11). None these metabolites changed in the group of patients with increased levels of 
calprotectin at the end of treatment (Table 7.12). On normal diet butyrate concentration 
returned to pre-treatment concentrations and BCFA proportional ratio were significantly lower 
than on treatment initiation.     
 
7.3.4.4. Changes in lactate 
Neither D or the L isomer of lactate changed significantly during EEN in any group of patients 
(Tables 7.13 & 7.14). On normal diet the D/L lactate concentration ratio was higher than pre-
treatment in patients with a calprotectin decrease at the end of EEN treatment (p<0.001).  
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Table 7.11: Changes in faecal concentration and % of SCFA & BCFA in paediatric CD patients with decreased levels of calprotectin at end of EEN 
treatment   
Subjects (n=11) Before EEN 15 d 30 d 60 d Normal diet 
 Mean SD Mean SD Mean SD Mean SD Mean SD 
Dry faecal material 
          
Acetate (µmol/g) 245.6 150.7 224.5 125.8 227.7 137.7 219.4 133.4 285.9 175.5 
Propionate (µmol/g) 38.5 22.9 39.1 27.0 34.4 21.2 32.5 14 53.3 27.4 
Butyrate (µmol/g) 47.9 38.7 24.6 17.3 21.6* 11.3 20.5* 11.0 47.8 33.7 
Valeric (µmol/g) 5.8 6.7 3.9 5.4 4.5 5.1 4.0 4.2 5.0 5.5 
Caproic (µmol/g) 0.8 0.5 1.5 1.2 1.4 1.0 0.9 0.5 1.7 0.6 
Heptanoic (µmol/g) 0.4 0.7 0.8 0.7 0.7 1.0 0.1 0.3 0.7 1.1 
Octanoic (µmol/g) 1.0 1.2 1.4 1.5 1.0 0.9 0.8 0.7 0.9 1.0 
Isobutyrate (µmol/g) 10.4 6.9 9.7 5.0 8.4 4.7 7.9 1.8 6.3$ 2.1 
Isovaleric (µmol/g) 15.2 8.4 13.6 7.6 12 6.7 11.2 2.4 10.4 4.2 
Isocaproic (µmol/g) 2.9 7.6 0.4 0.8 0.2 0.6 0.7 1.3 0.0 0.0 
Total SCFA (µmol/g) 368.5 158.4 319.6 143.8 311.9 141.7 297.9 140.9 411.9 196.5 
Stool sample 
          
Acetate (µmol/g) 53.8 20.1 55.2 18.1 53.4 19.2 49.4 15.9 64.7 28.7 
Propionate (µmol/g) 10.0 6.2 10.6 7.5 9 5 7.7 2.9 13.7 5.9 
Butyrate (µmol/g) 12.0 8.0 6.9 5.6 6.2** 3.7 5.5** 3.1 12.1 6.8 
Valeric (µmol/g) 1.6 1.9 1.0 1.3 1.3 1.5 1.2 1.2 1.4 1.6 
Caproic (µmol/g) 0.2 0.2 0.4 0.3 0.4 0.3 0.2 0.1 0.4 0.2 
Heptanoic (µmol/g) 0.1 0.2 0.2 0.2 0.2 0.3 0 0.1 0.2 0.4 
Octanoic (µmol/g) 0.3 0.4 0.4 0.4 0.3 0.3 0.2 0.2 0.3 0.4 
Isobutyrate (µmol/g) 2.8 1.8 2.7 1.6 2.4 1.3 2 0.5 1.7 0.8 
Isovaleric (µmol/g) 4.2 3.2 3.9 2.4 3.4 2.0 2.8 0.8 2.9 1.5 
Isocaproic (µmol/g) 0.5 1.2 0.1 0.2 0.1 0.2 0.1 0.2 0.0 0.0 
Total SCFA (µmol/g) 85.6 30.0 81.4 29.4 76.8 23 69.2 16.7 97.5 33.8 
Proportional ratio 
          
% Acetate 64.1 15.6 68.5 10.3 69.1 12.7 70.4 8.5 65.9 13.6 
% Propionate 11 5.8 12.6 6.1 11.6 5.2 11.7 5.0 14.0 5.3 
% Butyrate 13.5 8.9 8* 3.9 8.2** 4.2 7.9** 4.0 12.4 6.2 
% Valeric 1.8 2.1 1.4 1.8 2.1 2.7 1.7 1.8 1.5 1.8 
% Caproic 0.3 0.3 0.5 0.4 0.5 0.4 0.3 0.2 0.5 0.3 
% Heptanoic 0.2 0.4 0.3 0.2 0.3 0.4 0.0 0.1 0.2 0.3 
% Octanoic 0.4 0.4 0.5 0.6 0.4 0.4 0.3 0.3 0.3 0.3 
% Isobutyrate 3.1 1.7 3.3 1.3 3.1 1.4 3.0 1.0 1.9** 1.1 
% Isovaleric 4.7 2.6 4.7 2.1 4.5 2.3 4.3 1.5 3.2** 1.9 
% Isocaproic 0.7 1.8 0.1 0.2 0.1 0.2 0.2 0.3 0.0 0.0 
Values were significantly different from those before EEN (repeated measures ANOVA and Bonferroni post-hoc test): $P<0.07, *P<0.05, **P<0.02. 
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Table 7.12: Changes in faecal concentration and % of SCFA and BCFA in paediatric CD patients with increased levels of calprotectin at end of EEN 
treatment   
Subjects (n=5) Before EEN 15 d 30 d 60 d Normal diet 
 Mean SD Mean SD Mean SD Mean SD Mean SD 
Dry faecal material 
          
Acetate (µmol/g) 207.6 56.4 251.3 35.0 237.8 65.3 253.7 108.8 205.6 93.4 
Propionate (µmol/g) 35.1 26.5 25.1 10.7 33.1 13.2 40.3 15.6 34.5 17.8 
Butyrate (µmol/g) 30.1 30.0 24.7 21.4 26.4 18.2 35.0 13.4 51.5 51.0 
Valeric (µmol/g) 4.4 8.8 4.1 5.3 3.9 5.6 6.0 4.3 3.1 4.1 
Caproic (µmol/g) 1.9 2.6 1.1 1.5 1.0 0.7 1.5 0.1 0.7 0.8 
Heptanoic (µmol/g) 0.3 0.4 0.6 0.9 0.3 0.7 0.0 0.0 0.1 0.2 
Octanoic (µmol/g) 0.9 1.1 0.6 1.1 0.8 1.6 0.8 0.8 1.5 1.5 
Isobutyrate (µmol/g) 8.1 7.9 6.2 4.8 6.4 4.9 10.4 12.4 6.3 1.6 
Isovaleric (µmol/g) 10.1 9.3 5.7 3.5 8.0 7.9 9.9 8.5 10.3 3.6 
Isocaproic (µmol/g) 1.7 1.7 3.2 3.4 2.4 2.4 5.2 9.4 0.1 0.2 
Total SCFA (µmol/g) 300.2 95.6 322.6 31.9 320.2 55.8 362.9 133.3 313.6 152.8 
Stool sample 
          
Acetate (µmol/g) 42.0 18.4 41.3 14.7 39.6 13.9 46.0 6.4 55.5 19.8 
Propionate (µmol/g) 8.2 7.6 4.2 2.2 5.9 3.2 7.5 1.1 9.4 4.7 
Butyrate (µmol/g) 8.2 8.5 4.4 3.8 5.7 6.8 6.8 2.0 13.5 11.2 
Valeric (µmol/g) 1.2 2.5 0.6 0.7 1.1 1.6 1.4 1.0 0.7 1.0 
Caproic (µmol/g) 0.5 0.7 0.2 0.3 0.2 0.1 0.3 0.1 0.2 0.2 
Heptanoic (µmol/g) 0.1 0.1 0.1 0.2 0.0 0.1 0.0 0.0 0.0 0.1 
Octanoic (µmol/g) 0.2 0.3 0.1 0.2 0.2 0.5 0.2 0.3 0.4 0.5 
Isobutyrate (µmol/g) 2.1 2.3 1.0 0.6 1.4 1.5 2.0 1.9 1.8 0.7 
Isovaleric (µmol/g) 2.6 2.7 1.0 0.6 2.0 2.6 2.1 1.5 3.0 1.5 
Isocaproic (µmol/g) 0.3 0.4 0.5 0.5 0.4 0.3 0.9 1.4 0.0 0.1 
Total SCFA (µmol/g) 65.4 38.5 53.4 19.6 56.5 28.2 67.2 8.4 84.6 31.6 
Proportional ratio 
          
% Acetate 73.0 19.5 78.3 11.8 73.6 11.6 68.8 9.3 66.1 7.8 
% Propionate 10.3 6.1 7.9 3.6 10.4 3.9 11.3 2.5 12.0 6.4 
% Butyrate 8.9 8.1 7.3 6.0 8.5 5.4 9.9 2.1 13.9 7.0 
% Valeric 1.1 2.1 1.2 1.5 1.3 1.8 2.0 1.5 1.0 1.4 
% Caproic 0.6 0.6 0.3 0.4 0.3 0.2 0.5 0.2 0.2 0.2 
% Heptanoic 0.1 0.1 0.2 0.3 0.1 0.2 0.0 0.0 0.0 0.1 
% Octanoic 0.3 0.3 0.2 0.3 0.2 0.5 0.3 0.4 0.6 0.6 
% Isobutyrate 2.3 2.0 1.9 1.4 2.1 1.7 2.9 2.6 2.4 1.0 
% Isovaleric 2.9 2.4 1.8 1.1 2.6 2.5 3.0 2.1 3.8 1.7 
% Isocaproic 0.5 0.4 1.0 1.1 0.8 0.7 1.2 1.9 0.0 0.1 
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Table 7.13: Changes in faecal lactate concentration in paediatric CD patients whose calprotectin concentration decreased at the end of EEN 
N=11 Before EEN 15 d 30 d 60 d Normal diet 
 
Mean SD Mean SD Mean SD Mean SD Mean SD 
Dry faecal material           
D-lactate (mg.100g) 39.9 40.4 40.5 66.9 43.5 68.3 39.5 44.5 74.1 114.9 
L-lactate (mg/100g) 117.1 212.3 73.9 129.5 70.8 119.8 91.5 168.4 95.7 154.1 
Total lactate (mg/100g) 157.3 240.4 115.0 196.2 114.6 187.8 131.6 211.7 170.5 268.5 
Stool sample 
          
D-lactate (mg/100g) 8.3 5.7 8.0 7.2 8.1 7.0 7.9 4.9 13.8 13.4 
L-lactate (mg/100g) 21.7 33.4 14.3 14.1 12.9 12.3 15.7 19.9 17.5 18.1 
Total lactate (mg/100g) 30.0 37.0 22.3 21.3 21.1 19.1 23.6 24.6 31.2 31.1 
D/L-lactate 0.6 0.3 0.6 0.1 0.7 0.2 0.7 0.3 0.9* 0.5 
* p<0.001 from “Before EEN "for ANOVA of repeated measures and Bonferroni post-hoc test 
 
 
Table 7.14: Changes in faecal lactate concentration in paediatric CD patients whose calprotectin concentration increased at the end of EEN 
N=5 Before EEN 15 d 30 d 60 d Normal diet 
 
Mean SD Mean SD Mean SD Mean SD Mean SD 
Dry faecal material           
D-lactate (mg/100g) 55.9 42.1 79.4 84.3 71.3 51.9 66.8 65.0 31.9 9.5 
L-lactate (mg/100g) 104.2 98.7 225.0 241.0 198.5 166.8 93.3 78.4 49.5 10.4 
Total lactate (mg/100g) 160.1 138.1 305.0 296.0 269.7 198.4 160.2 143.1 81.4 19.6 
Stool sample 
          
D-lactate (mg/100g) 8.4 2.9 11.0 8.3 9.7 4.6 11.3 6.8 8.6 2.2 
L-lactate (mg/100g) 15.3 10.4 33.7 36.2 26.3 18.5 16.0 7.1 13.6 2.5 
Total lactate (mg/100g) 23.7 13.1 44.6 40.9 36.0 20.8 27.3 13.8 22.2 4.6 
D/L-lactate 0.6 0.2 0.5 0.2 0.5 0.2 0.7 0.2 0.6 0.1 
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7.3.5. Changes in bacterial metabolic activity of healthy children 
without family history of IBD  
The stability of the gut bacterial metabolic activity of healthy children was evaluated by 
comparing the concentration of faecal biomarkers between two serial stool samples of 
healthy children with no family history of IBD. 
 
7.3.5.1. Recruitment 
20 healthy children controls (12 boys; 9.6 y [4.5-16.9]) without known family history of IBD 
were recruited via advertisement and word of mouth. Eighteen children gave two serial 
samples at least one month apart. For two children follow up samples were not obtained 
(both withdrew) and these were excluded from this analysis.  
 
7.3.5.2. Changes in faecal water content, pH and ammonia  
Faecal pH did not differ significantly between the two faecal samples. The average water 
content was higher in the second sample but the difference did not reach statistical 
significance (p=0.061). Faecal ammonia concentration was not different between the two 
samples when this was calculated per volume of stool sample but it was marginally 
significant when it was expressed per kg of dry faecal material (Table 7.15). 
 
Table 7.15: Comparison of water content, faecal pH and ammonia concentration in two serial 
stool samples of healthy children (n=20) 
 First sample 
Median          Range 
Second sample 
Median       Range 
p-value* 
Water content (%) 
 66.3 59.6 - 84.8  69.8 65.2 - 76.4  0.061 
Faecal pH 
 6.8 6.0 - 8.0  6.8 5.7 - 7.4  0.538 
Ammonia (mg/lit stool) 
 1151 641 -5060  1073 447 -1806  0.050 
Ammonia (mg/kg dry stool) 
 3580 2526 -13130  3755 1797 -5569  0.276 
* One sample Wilcoxon signed rank 
 
7.3.5.3. Changes in faecal SFCA and BCFA concentration  
There were no major differences in the concentration of the individual or total SCFA, 
between the two serial stool samples. Mean propionate concentration was slightly (p=0.05) 
higher in the second sample. Similarly the molar proportion of isopentanoic and octanoic 
acids were significantly lower in the second sample (Table 7.16).  
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Table 7.16: Comparison of faecal SCFA concentration and proportional ratio in two serial stool samples of healthy children 
 Dry faecal material (µmol/g) 
 
Relative ratio (%) “Wet” stool sample (µmol/g) 
Subjects 
(n=18) 
First sample Second sample p First sample Second sample p First sample Second sample p 
 Median range Median range  Median range Median range  Median range Median range  
Acetate  2312 68.4 - 464.3 248.8 90.3 - 451.7 0.163 65.2 54.2 -73.0 63.5 52.6 -76.9 0.459  73.1 26.9 -103.2  73.3 28.8 -110.4 0.542 
Propionate  41 11.8 - 86.4  58.4 8.7 - 116.5 0.050 11.6  9.3 -18.7 12.7 7.4 -23.0 0.055  14.8 4.6 - 24.3  16.7 2.8 - 36.4 0.055 
Isobutyrate   5.6 0.0 - 13.3  5.2 1.9 - 15.4 0.695  1.9 0.0 - 2.7  1.6 0.4 - 2.6 0.089  1.9 0.0 - 4.7  1.6 0.6 - 5.0 0.258 
Butyrate   51.3 10.9 - 135.5  59.6 8.6 - 130.8 0.223 15.0 7.4 -20.3 14.3 7.3 -27.6 0.862  16.6 3.8 - 30.6  16.6 2.7 - 37.6 0.360 
Isopentanoic   9.2 0.0 - 23.3  8.3 2.7 - 26.7 0.486  3.1 0.0 - 4.8  2.6 0.4 - 4.6 0.033  3.2 0.0- 8.2  2.6 0.6 - 8.6 0.139 
Pentanoic   7.6 0.0 - 17.0  7.7 0.0 - 19.2 0.636  2.4 0.0 - 3.8  2.1 0.0 - 3.3 0.130  2.5 0.0 - 5.9  2.3 0.0 - 6.2 1.000 
Isocaproic   0.0 0.0 - 0.56  0.0 0.0 - 3.4 1.000  0.0 0.0 - 0.2  0.0 0.0 - 0.7 1.000  0.0 0.0 - 0.2  0.0 0.0 - 0.9 1.000 
Caproic   1.6 0.0 - 12.9  1.5 0.5 - 14.8 0.760  0.6 0.0 - 2.4  0.44 0.1 - 2.5 0.794  0.5 0.0 - 3.8  0.5 0.1 - 4.1 0.931 
Eptanoic   0.1 0.0 - 1.6  0.0 0.0 - 2.4 0.563  0.03 0.0 - 0.7  0.0 0.0 - 7.0 0.351  0.04 0.0 - 0.58 0.0  0.0 - 0.8 0.398 
Octanoic   1.8 0.0 - 7.4  1.4 0.0 - 3.6 0.098  0.6 0.0 - 2.0  0.39 0.0 - 1.14 0.045  0.6 0.0 - 2.1  0.4 0.0 - 1.2 0.050 
Total SCFA  353.5 104.0 - 691.5 407.5 117.4 - 651.3 0.177 - -  114.9 40.8 -171.0 116.3 37.5 -189.1 0.384 
* One sample Wilcoxon signed rank 
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7.3.5.4. Changes in faecal sulphide and lactate concentration 
Free sulphide and the dextrorotatory isomer of lactate differed significantly between the two 
serial samples (Table 7.17). Free sulphide was significantly higher and D-Lactate significant 
lower in the second sample.   
 
Table 7.17: Comparison of total and free faecal sulphide and lactate concentration in two serial 
stool samples of healthy children 
Subjects (n=18) First sample Second sample p-value* 
 
Median Range Median Range  
Dry faecal material 
 
 
 
Free sulphide (µmol/g)  0.38 0.11 - 1.91  0.62 0.19 - 2.3 0.005 
Total sulphide (µmol/g)  1.28 0.0 - 2.91  1.13 0.34 - 2.9 0.794 
D-lactate (mg/100g)  25.1 15.6 -393.6  26.2 14.9 - 54.3 0.965 
L-lactate (mg/100g)  25.2 17.6 -423.8  26.9 11.7 - 44.4 0.695 
Total lactate (mg/100g)  52.7 33.2 -817.4  56.0 32.5 - 80.2 0.794 
D/L-lactate  0.88 [0.8 - 2.6  0.84 0.7 - 2.1 0.055 
Stool sample 
  
 
D-lactate (mg/100g)  7.8 5.5 - 59.7  7.7 4.8 - 17.3 0.033 
L-lactate (mg/100g)  8.3 6.2 - 64.2  8.6 3.5 - 12.6 0.794 
Total lactate (mg/100g)  16.8 11.7 -123.9  16.7 10.5 - 25.5 0.207 
Free sulphide (µmol/g)  0.11 0.04 - 0.62  0.17 0.06 - 0.54 0.029 
Total sulphide (µmol/g)  0.46 0.0 - 0.98  0.36 0.11 - 0.92 0.408 
 * One sample Wilcoxon signed rank 
 
7.3.6. Comparison of metabolic activity between healthy children 
and CD children on normal diet 
Faecal metabolites of gut microbiota activity were compared between CD children and 
healthy children with no family history of IBD. Due to the substantial effect of EEN on the gut 
microbiota which was observed in the previous section of this thesis (Section 7.3.3), the 
following study chose to compare only the gut microbiota of CD children whilst on normal diet 
to avoid any confounding effect from the concomitant use of EEN.  
 
7.3.6.1. Recruitment 
For this arm of the study 19 children with CD (13 boys/ 6 girls) and 20 healthy controls (12 
boys / 8 girls) were recruited. The healthy children (9.6; range [4.5-16.9]) were significantly 
younger than the patients with CD (13; range [7.6-15]). The majority of the CD children were 
also participated in the study of the effect of EEN on gut microbiota. Only those children who 
provided a stool sample whilst on normal diet were included. For healthy children the values 
of the faecal bacterial metabolites of two serial samples were averaged. All, apart from three 
 281 
children, were on concomitant treatment (Table 7.18). No patient was on antibiotics or EEN. 
The majority of the children had elevated systemic and gut inflammatory markers of 
inflammation (Table 7.18). Nevertheless six out of 19 were in clinical remission (PCDAI ≤10). 
 
Table 7.18: Disease activity markers and medical treatment in CD children on normal diet 
Disease markers Median   Range Medical treatment N (%) 
PCDAI  15.0 0.0 - 55.0 Steroids 4 (21%) 
ESR (mm/h)  20.5 3.0 - 55.0 Azathioprine 11 (58%) 
CRP (mg/l)  7.0 7.0 - 69.0 5-ASAs 7 (37%) 
Albumin (g/l)  36.0 20.0 - 41.0 Infiximab 1 (5%) 
Calprotectin (mg/l) 2070 146 -2495 Nutrition supplements 2 (11%) 
  Omeprazole 3 (16%) 
  Methotrexate 2 (11%) 
  Vitamins/Minerals 4 (21%) 
  No Treatment 3 (16%) 
 
7.3.6.2. Differences in water content, faecal pH and ammonia 
No difference in faecal pH was found between CD children and their healthy peers. Faecal 
water and ammonia concentration were significantly lower in CD children (Table 7.19).  
 
Table 7.19: Comparison of water content, faecal pH and ammonia concentration between CD 
and healthy children 
 CD (n=19) 
Median Range 
Healthy (n=20) 
Median; Range 
p-value* 
Water content (%)  73.0 64.2 - 87.2  68.2 58.1 - 77.8 0.041 
Faecal pH  6.8 5.5 - 7.9  6.9 5.9 - 7.6 0.683 
Ammonia (mg/lit stool)   844.9 427.0 -1882.0] 1073.0 544.0 -3200 0.044 
Ammonia (mg/kg dry stool) 3169 1907 -14703 3336 2388 -8509 0.098 
* Mann-Whitney test 
 
7.3.6.3. Differences in faecal SFCA and BCFA concentration 
Compared to the healthy group, total SCFA concentration was significantly lower in the stool 
samples of CD patients. At the individual level butyrate, valeric, caproic and octanoic acid 
were at significantly higher concentrations in the stool samples of healthy children (Table 
7.20). Valeric and octanoic were proportionally higher in the faeces of healthy children but 
this difference did not receive statistical significance. In particular valeric and octanoic acid 
were detected in the stool samples of more healthy children than CD. Thirty seven and 47% 
of the CD children had undetectable amounts of octanoic and pentanoic respectively as 
opposed to 5% and 0% of the healthy children (p=0.003).  
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Table 7.20: Comparison of faecal SCFA concentration and proportional ratio between CD children and healthy children 
 Dry faecal material (µmol/g) 
 
Relative ratio (%) “Wet” stool sample (µmol/g) 
Subjects CD (n=20) Healthy (n=20) p CD (n=20) Healthy (n=20) p CD (n=20) Healthy (n=20) p 
 Median    Range Median   Range  Median  Range Median   Range  Median   Range Median    range  
Acetate   210.7 106.9 -602.9  227.4 99.4 -458.0 0.789  62.6 48.8 -97.1  64.3 53.4 - 74.1 0.944 56 30.2-132.5 70.4 32.6-101.6 0.106 
Propionate  45.0 9.3 -103.3  49.2 11.5 - 90.8 0.423  13.4 1.9 -23.8  12.0 8.4 - 20.9 0.565 12.9 1.2 - 22.7  15.0 3.8 - 30.4 0.267 
Isobutyrate   5.9 1.6 - 8.6  4.7 2.9 - 14.4 0.148  1.93 0.0 - 3.3  1.75 0.43- 2.69 0.232  1.7 0.0 - 2.95 1.62 0.6 - 4.8 0.944 
Butyrate   29.8 0.0 -138.4  54.2 9.9 -125.3 0.182  11.7 0.0 -24  14.3 7.3 - 21.1 0.222 10.6 0.0 - 30.8  16.4 3.2 - 32.6 0.054 
Isopentanoic   9.1 1.6 - 15.9  8.4 3.4 - 25.0 0.292  2.9 0.0 - 5.9  2.9 0.5 - 4.7 0.279  2.7 0.2 - 5.0 2.7 0.74 - 8.41 0.855 
Pentanoic   0.3 0.6 - 13.9  7.7 0.0 - 18.1 0.023  0.1 0.0 - 4.8  2.41 0.0 - 3.39 0.068  0.16 0.0 - 4.0 2.5 0.0 - 6.1 0.009 
Isocaproic   0.0 0.0 - 0.35  0.0 0.0 - 1.7 0.811  0.0 0.0 - 0.19  0.0 0.0 - 0.38 0.811  0.0 0.0 - 0.1 0.0 0.0 - 0.4 0.789 
Caproic   1.2 0.0 - 2.6  1.6 0.36- 10.3 0.211  0.32 0.0 - 0.78  0.58 0.05- 2.18 0.089  0.32 0.0 - 0.76  0.47 0.09-3.02 0.062 
Eptanoic   0.09 0.0 - 3.56  0.3 0.0 - 1.9 0.684  0.04 0.0 - 0.99  0.06 0.0 - 0.61 0.877  0.02 0.0 - 1.27 0.09 0.0 - 0.67 0.684 
Octanoic   0.7 0.0 - 3.9  1.6 0.4 - 3.7 0.024  0.13 0.0 - 1.53  0.51 0.15-1.07 0.058  0.16 0.0 - 1.27  0.46 0.14 - 1.06 0.015 
Total SCFA   307.0 184.5. -749.8  365.0 134.8 -671.4 0.527 - -  83.1 50.4-164.8  109.044.2 - 180.0 0.054 
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7.3.6.4. Difference in sulphide and lactate concentration 
Both D and particularly L-lactate in stool samples or dry faecal material of CD children were 
significantly higher than healthy children. Significant differences were found for the fractional 
production of the lactate isomers (Table 7.21). The D to L lactate ratio was significantly lower 
in stool samples of CD children denoting differences in the pattern of isomer production 
between the two groups. No difference was found for free or total faecal sulphide between 
healthy and CD children (Table 7.21).     
Table 7.21: Comparison of total and free faecal sulphide and lactate concentration between CD 
children and healthy children 
 
CD (n=20) 
Median Range 
Healthy (n=20) 
Median Range p-value* 
Stool sample 
  
 
Free sulphide (µmol/g)  0.08 0.02 - 0.64  0.14 0.03 - 0.58 0.099 
Total sulphide (µmol/g)  0.46 0.0 - 1.82  0.43 0.11 - 0.95 0.922 
D-lactate (mg/100g)  9.1 5.1 - 50.7  7.6 5.2 - 33.8 0.090 
L-lactate (mg/100g)  12.5 6.2 - 67.6  8.4 5.5 - 37.2 0.001 
Total lactate (mg/100g)  21.4 11.7 -118.3   16.2 11.1 - 98.0 0.003 
Dry faecal material 
  
 
Free sulphide (µmol/g)  0.33 0.0 - 1.78  0.46 0.08 - 2.11 0.182 
Total sulphide (µmol/g)  1.45 0.0 - 5.6   1.22 0.4 - 2.9 0.684 
D-lactate (mg/100g)  35.1 16.5 -395.9  24.6 15.2 -210.2 0.044 
L-lactate (mg/100g)  44.8 17.4 -528.3  27.5 17.6 -229.0 0.001 
Total lactate (mg/100g)  77.8 46.1 -924.2  51.9 32.9 -439.3 0.001 
D/L lactate  0.72 0.4 - 2.4  0.86 0.6 - 2.3 0.002 
* Mann and Whitney test 
7.3.6.5. Correlation of faecal bacterial metabolites with disease activity 
markers 
Significant correlations were found between systemic markers of disease activity and the 
faecal metabolites checked (Table 7.22). The BCFA, isobutyrate and isovaleric acid were 
positively associated with CRP and ESR but no association was found with faecal 
calprotectin (Table 7.22). A strong negative association was found for ESR with faecal 
acetate and a positive with propionate (Table 7.22). D and L lactate were negatively 
associated with CRP levels and ESR positively with free and total sulphide.  
 Faecal calprotectin expressed per weight of dry faecal material was associated with 
acetate concentration as well as with D but not L Lactate (Table 7.22). A strong positive 
association was found between calprotectin in dry faecal material and faecal water content 
(Table 7.22).  
Only the percentage butyrate and heptanoic differed significantly between the 
patients with active disease (PCDAI>10) and those in clinical remission (PCDAI≤10). Median 
butyrate in dry faecal material was significantly higher (63 vs 28.3 µmol/g; p=0.048) and 
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heptanoic significantly lower (0 vs 0.473 µmol/g; p=0.032) in the group of patients with 
quiescent disease compared with the children with clinically active disease.   
 
 
 
 
 
 
 
Table 7.22: Spearman rank correlation between gut and systemic inflammatory markers and 
faecal metabolites in dry faecal material in CD children 
Faecal 
metabolites 
CRP ESR Calprotectin* 
 R P value R P value R P value 
Free sulphide 
(dry faecal  
material) 
0.45 0.081 0.57 0.027   
Total sulphide 
(dry faecal  
material) 
  0.56 0.029   
Acetate (dry 
faecal  
material)  
    0.56 0.020 
% Acetate 
  -0.71 0.006   
Propionate 
(dry faecal 
material) 
  0.63 0.014   
% Propionate 
  0.60 0.020   
Isobutyrate 
(dry faecal 
material)  
0.52 0.042 0.54 0.037   
% Isobutyrate  
  0.50 0.055   
Isovaleric (dry 
faecal  
material)  
0.56 0.031 0.52 0.046   
% Isovaleric 
  0.49 0.058   
D-Lactate (dry 
faecal 
material)  
-0.49 0.059   0.51 0.037 
L-Lactate (dry 
faecal 
material)  
-0.57 0.028     
Faecal water  
    0.62 0.010 
* Expressed per kg of dried faecal material 
 
7.3.7. Comparison of faecal metabolic activity between CD children 
and their healthy first degree relatives  
Stool samples were collected from the first-degree relatives of children with CD and were 
compared with samples of CD children on normal diet.   
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7.3.7.1. Recruitment  
For 14 CD children stool samples were collected from their respective first-degree relatives. 
For the remaining CD children no samples were provided by their relatives and for two 
children their parents were also sufferers of IBD. One child with CD was excluded due to 
parallel use of antibiotics.  
 
7.3.7.2. Comparison in faecal water content, Faecal pH and ammonia 
Similar to the results observed in healthy control children, the water content in the relatives of 
CD children was significantly lower. Faecal ammonia was significantly higher in the relatives 
of CD children. Faecal pH was significantly higher in the relatives of CD children (Table 
7.23).     
 
Table 7.23: Comparison of water content, faecal pH and ammonia concentration between CD 
children and their first degree relatives 
Variable CD (n=14) 
Median         range 
Relatives (n=14) 
Median          range 
p-value* 
Water content (%) 
 72.0 64.2 - 87.2  63.6 51.0 - 74.1 0.001 
Faecal pH 
 7.0 6.0 - 7.9  7.3 6.6 - 7.7 0.046 
Ammonia (mg/lit stool)  864 427 -1882 1607 1063 -3807 0.001 
Ammonia (mg/kg dry stool) 2989 2179 -14703 4636 2181 -10111 0.016 
* Mann and Whitney test 
 
7.3.7.3. Difference in faecal SFCA and BCFA concentration 
No substantial difference was found between CD children and their healthy relatives for 
butyrate concentration (Table 7.24). In contrast acetate, propionate and isobutyrate and the 
total amount of SCFA, were significantly higher in the dry faecal material of CD children 
compared to their healthy relatives (Table 7.24). Although valeric and caproic acid in “fresh” 
stool samples or dry faecal material did not differ significantly between the groups (CD 
children & healthy relatives), these were significantly higher in the healthy group when the 
results were expressed as the relative ratio to total quantity of SCFA (Table 7.24). Similar to 
the patterns observed in healthy children, valeric and octanoic acid were detected more 
frequently in the stool samples of the healthy relatives than CD children. Forty-three and 36% 
of the CD children had undetectable pentanoic and octanoic acid respectively as opposed to 
7% of their healthy relatives (relatives p=0.08 for octanoic and p=0.03 for pentanoic).  
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Table 7.24: Comparison of faecal SCFA concentration and proportional ratio between CD children and their healthy first degree relatives 
 Dry faecal material (µmol/g) 
 
Relative ratio (%) “Wet” stool sample (µmol/g) 
Subjects  CD (n=14) Relatives (n=14) p CD (n=14) Relatives (n=14) p CD (n=14) Relatives (n=14) p 
 Median        Range  Median       Range  Median    Range Median      Range  Median   Range Median    Range   
Acetate  212.6 110.6 -491.6  124 74.4 - 352.2 0.006 61.2 57.7 - 97.1 66.4 53.7 - 79.3 0.800 58.5 30.2 - 82.3 49.3 27 - 91.4 0.175 
Propionate 43.4 9.3 - 94.8  27.7 6.3 -52.3 0.02 13.9 1.9 - 23.8 12.1 6.0 -17.1 0.260 13.6 1.2 - 22.5 10.4 2.38 - 18.76 0.113 
Isobutyrate   6.0 1.6 - 8.3  4.6 2.0 - 8.1 0.051  2.13 0 - 3.34  2.42 0.8 - 3.38 0.395  1.74 0.0 - 2.95  1.72 0.72 - 2.9 0.836 
Butyrate  38.7 0.0 -138.4  31.1 2.6 -92.3 0.206 12.7 0.0 - 24.0] 11.6 2.8 - 20.2 0.629 11.6 0.0 - 30.8 10.3 0.95 - 23.96 0.323 
Isopentanoic   9.7 1.6 - 14.6  8.0 4.2 -13.1 0.135  3.4 0.3 - 5.7  4.41 1.11- 6.0 0.280  2.7 0.2 - 5.0  2.9 1.45 - 4.9 0.765 
Pentanoic   0.64 0.0 - 13.9  6.3 0.0 -10.2 0.260  0.2 0.0 - 4.13  2.77 0.0 - 3.72 0.026  0.16 0.0 - 4.0  2.0 0.0 - 3.7 0.093 
Isocaproic   0.0 0.0 - 0.35  0.0 0.0  -0.0 1.000  0.0 0.0 - 0.19  0.0 0.0 - 0.0 1.000  0.0 0.0 - 0.1  0.0 0.0 - 0.0 1.000 
Caproic   1.18 0.0 - 2.65  1.64 0.0 - 5.2 0.206  0.31 0.0 - 0.76  1.1 0.0 - 2.77 0.032  0.30 0.0 - 0.76  0.69 0.0 - 1.98 0.103 
Eptanoic   0.0 0.0 - 3.6  0.0 0.0 - 0.68 0.765  0.0 0.0 - 0.99  0.0 0.0 - 0.53 0.800  0.0 0.0 - 1.27  0.0 0.0 - 0.19 0.765 
Octanoic   0.92 0.0 - 3.9  1.52 0.0 - 3.72 0.251  0.3 0.0 - 1.53  0.9 0.0 - 1.53 0.066  0.25 0.0 - 1.28  0.51 0.0 - 1.23 0.141 
Total SCFA  332.6 184.5 -728.3  208.1 94.7-  503.6 0.007 - - 0.800 91.7 50.4 -128.3 79.4 34.0 -130.7 0.301 
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7.3.7.4. Difference in sulphide and lactate concentration 
No difference between groups was found for free sulphide concentration expressed either 
per g of “fresh” stool sample or “dry” faecal material. Total sulphide in the stool samples of 
the relatives of CD patients was significantly higher than their offsprings. However the 
difference disappeared when results were expressed per g of dry faecal material (Table 
7.25).  
Total and L- lactate but not D-lactate was statistically higher in dry faecal material CD 
children compared with their healthy relatives. No difference was found when the same 
bacterial metabolites were expressed per g of “fresh” stool sample (Table 7.25).   
 
 
 
Table 7.25: Comparison of total and free faecal sulphide and lactate concentration between CD 
children and their healthy first-degree relatives 
Variable CD (n=15) 
Median         Range 
Relatives (n=15) 
Median        Range 
p-value 
Dry faecal material 
   
Free sulphide (µmol/g)  0.46 0.0 - 1.8  0.33 0.0 - 0.71 0.408 
Total sulphide (µmol/g)  1.54 0.0 - 5.6  1.91 0.0 - 9.0 0.260 
D-lactate (mg/100g)  34.1 16.5 -395.9  22.5 8.5 - 41.7 0.077 
       L-lactate (mg/100g)  45.1* 17.4 -528.3  32.8 18.0 - 61.7 0.051 
Total lactate (mg/100g)  76.5* 46.1 -924.2  55.7 34.6 -103.4 0.020 
D/L lactate  0.69 0.4 - 2.4  0.68 0.3 - 2.1 0.597 
Stool sample 
  
 
Free sulphide (µmol/g)  0.16 0.02 - 0.64  0.11 0.02 - 0.32 0.918 
Total sulphide (µmol/g)  0.49 0.0 - 1.8  0.85 0.19 - 3.35 0.049 
D-lactate (mg/100g)  9.3 5.1 - 50.7  8.5 4.2 - 13.9 0.301 
L-lactate (mg/100g)  13.1 6.2 - 67.6  12.1 6.5 - 20.1 0.535 
Total lactate (mg/100g)  22.3 11.7 -118.3  19.7 14.3 - 33.7 0.241 
*P<0.02 Mann-Whitney compared to relatives 
 
 
7.3.8. Bacterial diversity and composition in children with CD on 
EEN and healthy controls 
All stools collected from children with CD and control children and parents were subjected to 
DNA extraction and PCR-TGGE (Fig 53 & 54). Although a decreasing trend was observed 
there was no statistical significant difference in the total number of bacterial bands between 
samples collected on treatment initiation and those at any time point of the follow up (Fig 55). 
No different patterns were observed between those patients who achieved clinical remission 
and those who did not, nor when patients on antibiotic treatment were excluded. Similar to 
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the CD children, no statistical significant difference was found in the faecal bacterial diversity 
between two samples collected with at least one-month gap in healthy children. However the 
total number of bacterial bands in the samples of CD children was significantly lower than 
healthy children at all times of follow up (Fig 55). Likewise stool samples from healthy 
relatives of CD children had significantly less bacterial bands compared with healthy children. 
No such difference was found with their CD offsprings at any time point of the follow up. 
A higher degree of microbiota pattern similarity was observed between the two serial 
stool samples in the healthy children compared with the samples of CD children on EEN. 
Indeed compared with any time point of the observational period, the similarity index of the 
bacterial pattern of the faecal microbiota in CD children was significantly lower than the 
healthy controls (Fig 56). The similarity index dropped by more than 40% within 15 days of 
start of treatment and remained low during follow up. In contrast, the similarity remained high 
and more than 70% in the healthy children (Fig 56). 
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Figure  53:TTGE bacterial profiles of serial stool samples of CD patients during EEN, on normal diet, and their healthy first degree relatives 
 
 
 
 
A-D: samples during EEN at  0, 15, 30, 60 d; E: 
sample on normal diet; R: relative’s sample; S: 
sibling’s sample; Black R: reference bacterial 
scale; L: DNA ladder; Same color samples from 
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        Figure  54: TTGE bacterial profiles of two serial stool samples of healthy children 
 
 
 
 
A & B: serial samples from the same 
subject; R: reference bacterial scale; 
L: DNA ladder; Neighbouring samples 
with same color: samples from same 
patient 
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Figure  55: Number of gut bacterial bands of healthy children, healthy relatives of CD children. 
and CD children on EEN and normal diet (mean with 95% CI) 
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Figure  56: Percent similarity of gut bacterial composition of healthy children and CD children 
on EEN and on normal diet (mean with 95% CI) 
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7.4. Discussion 
The exact mechanism of the therapeutic action of EEN in paediatric CD remains unknown. 
This in conjunction with robust evidence suggesting an important role of the commensal gut 
microbiota in IBD pathogenesis prompted the researcher to undertake this study. 
Since the initiation of this work in 2004 there have been two studies which looked at 
changes in the bacterial microbiota diversity (531;532).  The study presented here in addition 
to studying micorbiota diversity explored changes in the bacterial metabolic activity of CD 
children during treatment with EEN.  
Taken as a whole the findings of this study are in contrast to the statement by 
Lionnetti and his colleagues (531) for a therapeutic mechanism of EEN action mediated by a 
“prebiotic” effect of the nutritional supplement on the gut microbiota of children with active 
CD. On the contrary, this study reported significant deterioration of the colonic micro-
environment and a substantial increase in the faecal concentration of potentially “harmful”, 
for the colonic health, bacterial metabolites. Indeed these effects were seen solely in those 
patients whose intestinal markers of gut inflammation decreased and achieved complete 
clinical remission at the end of the treatment course.  
Changes in the metabolic dynamics of the gut microbiota, and mainly fermentation, 
are grossly reflected and assessed by changes in the colonic pH. In the current study faecal 
pH was significantly increased to the alkaline range within 15 days of EEN initiation and 
remained elevated during the entire course of treatment. This first observation pre-predicted 
the significant changes observed in the concentration of acidic, like SCFA, and alkaline, like 
ammonia and sulphide, bacterial metabolites.  
Within 15 days of treatment initiation, butyrate, the colonocytes’ preferred metabolic 
fuel decreased dramatically by 100% and further continued to decrease until the end of the 
treatment course. This was not unexpected, as the nutritional supplement that all  
participants received, Modulen IBD, is of low residue content and hence lacks fermentable 
fibre or prebiotic substrates that colonic bacteria would ferment to SCFA. This lack of 
fermentable substrate in the feeds may have reduced the metabolic activity of the butyrate 
producing bacteria and consequent production of butyric acid. This was also represented by 
the significant reduction in the relative molar concentration of butyrate to the total SCFA pool. 
On the other hand, reduced faecal concentration of butyrate may be an indication of a more 
efficient absorption and utilization of butyrate by the colonic epithelium following disease 
improvement. Although the evidence is controversial (622) some studies have proposed that 
butyrate metabolism (426), oxidation (422), and uptake (427) is impaired in the colonocytes 
of IBD patients particularly during the active phase of the disease (425). Thus a better 
absorption and utilization of butyrate by the colonocytes may explain the reduction in 
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butyrate concentration during treatment only in those patients who achieved clinical 
remission.  
Sulphide in its free form as hydrogen sulphide has been implicated in the 
pathogenesis of IBD primarily due to its toxic effect to the colonocytes and inhibition of 
butyrate oxidation (452). Previous research in this area reported a high number of sulphate 
reducing bacteria, increased faecal concentration and rate of hydrogen sulphide production 
in UC patients (458) but overall the results are contradictory (406;457). In contrast to that and 
expectations for a reduction in the faecal sulphide levels during treatment with EEN, this 
current study reports a remarkable increase in the faecal concentration of total sulphide. 
Although the free fraction of faecal sulphide, hydrogen sulphide, did not change during the 
course of treatment, bound sulphide in the form of salts with divalent metals significantly 
increased within two weeks of treatment. A seven-fold increase was observed despite 
improvement in the disease activity and colonic inflammation. This could be attributed to the 
increased metabolic activity of sulphate reducing bacteria in the presence of abundant 
sulphur containing substrate (623) and an increase in the gut transit time (468). Modulen IBD 
is a nutritional supplement rich in protein and fortified with divalent metals in the form of 
sulphate salts (Appendix). Ferrous sulphate, manganese sulphate, zinc sulphate, copper 
sulphate, are added in order to increase the nutritional value of the feeds and may actually 
offer abundant fermentative substrate for the sulphide reducing bacteria (468). Sulphate 
reducing bacteria may utilize sulphate anions and subsequently increase faecal sulphide 
concentration. 
It was a paradoxical finding that disease improvement coincided with the increase of 
total sulphide. This may imply that either sulphide is not implicated in the tissue injury in CD, 
as proposed by others (406;457) or that the biological importance of the bound compared to 
free sulphide is different. Moreover recent studies have now revised the role of sulphide in 
gut physiology (408) and current evidence suggests that it can be a potent, endogenous anti-
inflammatory substance, modulating leukocyte-endothelial adhesion and leukocyte migration 
in the gut (466). Fiorucci et al (466) recently found that a sulphide reducing derivative of 
mesalamine was more effective than standard mesalamine in reducing the severity of colitis 
in an animal model by reducing granulocyte infiltration into the colonic tissue as well as 
reducing the expression of mRNA for several key proinflammatory cytokines. A new era for 
the role of sulphide in IBD may be emerging. 
No significant changes were observed for the bacterial metabolites of protein 
metabolism like BCFA, ammonia and C5:C8 SCFA. We anticipated seeing an increased 
bacterial proteolytic activity in the absence of non-digestible carbohydrates in the feeds, and 
fermentation of amino acids that escaped absorption in the upper digestive tract. However no 
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such change was observed and the results may indicate that absorption of amino acids is 
efficient in the upper digestive tract and no significant residual protein reaches the colon.  
Faecal lactate was relatively high on treatment initiation and significantly decreased 
during treatment in the group of patients who clinically improved. D and L lactate are 
metabolic products of bacterial fermentation that are further metabolized to butyrate and 
acetate (400) and they occur only in low concentration in the healthy colon. High 
concentration of lactate may denote malabsorption in the small intestine and increased 
availability of carbohydrates in the ileum, which are further fermented to lactate by the lactic 
producing bacteria. Increased L-lactate levels have been observed in inflamed colonic 
mucosal (421;434) and have been implicated in disease activity previously (421;434) but we 
suggest that this is not of causative association but an epiphenomenon of malabsorption, 
reduced gut transit time and diarrhoea (434;624). Indeed in the current study faecal water 
content was strongly associated with lactate concentration (data not shown) and was 
significantly higher in the patients with watery diarrhoea.  
The use of molecular biology fingerprinting techniques in this study, allowed 
characterization of changes of the intestinal microbiota during treatment with EEN, which 
was independent of the drawbacks of the traditional microbiology culture media. No 
significant changes were observed in the diversity of the gut microbiota of CD children during 
treatment on EEN. An unstable faecal microbiota was found during treatment and the 
average similarity between any time points of the follow up was significantly lower than the 
similarity index in the healthy children. These findings are in accordance with the findings by 
Leach et al (532) and agree with adult IBD studies which found that commensal microbiota in 
IBD is unstable over time and is characterized by low bacterial diversity (504;523). 
Comparison of these findings with those by Leach et al (532) is difficult as the authors did not 
report pairwise changes in bacterial similarity and diversity changes during EEN treatment. 
This is surprising in a follow up study. On the other hand this study did not replicate the 
results by Leach et al (532) of a similar bacterial diversity with healthy controls at the 
beginning of treatment. In fact it was observed that bacterial diversity was consistently lower 
than healthy controls at all time points of the observational period. This different result may 
be due to differences in methodology (DGGE vs TTGE, extraction DNA with spin column vs 
beat beater) or the small sample size and lack of statistical power. 
The molecular biology used to characterize the intestinal microbiota, although robust, 
can only assess changes in the composition and diversity of the intestinal microbiota without 
allowing for identification of changes in specific species. For this, other molecular techniques, 
such as cloning and sequencing, are required for group specific bacteria (532). This 
technique is laborious, expensive and no resources were available to conduct this during this 
PhD. Alternatively changes in selective bacteria can be assessed using other molecular 
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biology techniques, such as FISH which identify bacteria by using species specific 
fluorescence probes (340). Although it was among the aims of this study to assess changes 
using FISH analysis, and hence samples were prepared for such analysis, lack of resources, 
and shortage of time did not allow it.  
On the other hand although significant changes in the diversity of microbiota were not 
observed during treatment with EEN, the method used in this study can characterize only the 
dominant microbiota of the digestive tract, which essentially occurs in more than 106-107 
bacterial per g of faecal material. Therefore our knowledge for changes in the diversity of 
subdominant species remains unknown. Moreover faecal microbiota is at the best an 
abstract of the mucosal associated microbiota (346) and different changes may have 
occurred at the bacteria adherent to the gut lining. However a study with multiple serial 
mucosal biopsies within a short period of two months might be unfeasible and unethical.  
Although it was not a primary outcome, part of this project studied differences in the 
gut microbiota diversity and metabolic activity between CD children, their healthy first-degree 
relatives, and healthy children with no family history of IBD. Prior to the current study the 
faecal concentration of SCFA in CD children had been reported in a single study 15 years 
ago (417). In contrast to this previous report, which reported increased levels of butyrate in 
children with CD, this current study found that total faecal SCFA and butyric acid were 
significantly lower in CD children compared to their healthy peers. Nevertheless this 
difference disappeared when results were expressed per mass of dry faecal material. This 
suggests that high faecal water content and diarrhoea in patients with CD may explain the 
different results with Treem et al (417). Alternatively, adherence to a diet low in fibre, which is 
commonly followed by IBD patients (545) and as in the IBD population this study recruited 
(625), in order to avoid symptom exacerbation, might explain the lower concentration of 
SCFA in CD patients.  
CD children had significantly lower levels of faecal pentanoic and octanoic acids than 
healthy controls and in fact a substantial proportion of them had undetectable levels. Little is 
known about the biological significance of SCFA longer length than butyrate such as valerate 
(C5) and caprylic (C8) acid, although antimicrobial properties against enteropathogenic E. 
coli bacteria have been described for some of them (626). On the other hand, increased 
production of these metabolites may be a random finding or in conjunction with the increased 
levels of ammonia observed in healthy children may denote increased proteolytic 
fermentation due to excessive consumption of dietary protein in modern healthy children. 
This, in parallel with an inadequate dietary intake in children with IBD, may explain these 
findings. Moreover carbohydrate fermentation and SCFA production tend to occur at the 
ascending colon whereas protein fermentation and production of iso-carbonic acids and C5-
C8 carbon SCFA occurs in the descending colon (367). Fast transit time and diarrhoea in 
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active CD may limit protein fermentation in the distal colon (367), and perhaps explain the 
significantly low levels of these bacterial metabolites compared with the healthy controls. 
Fast intestinal transit time and malabsorption may also explain the higher concentration of 
faecal lactate in CD children compared to the healthy cohort.  
In accordance to the findings by Treem (417) this study did not observe any major 
differences in SCFA with disease activity. The higher concentration of butyrate and a lower 
concentration of heptanoic found in patients with quiescent, compared with those with 
clinically active disease, may be related to differences in water content and gut transit time 
between groups (627).  
To the best of our knowledge this is the first study that compared the intestinal 
microbiota of CD patients with that of their healthy first-degree relatives. Environment, diet 
and genes are strong determinants of the bacterial composition and metabolic activity and 
this study enrolled healthy relatives of CD children to control for that. Total acetate, 
propionate, isobutyrate and hence total SCFA were significantly higher in the dry faecal 
matter of CD patients. Malabsorption of macronutrients in the small bowel may have 
increased the availability of fermentable substrate in the large bowel and consequently 
increased the production of SCFA. On the other hand, age dependent differences in the 
bacterial metabolic activity (628) may explain some of the differences observed between CD 
children and their healthy relatives although these have been reported for subjects older than 
70 years old (628). To the best of our knowledge none of the healthy relatives were over 70 
years of age. Similar to healthy children a higher proportion of CD children had undetectable 
levels of pentanoic and octanoic. These may indicate differences in the metabolic activity of 
the bacterial microbiota or rapid transit time in CD patients which limits the fermentation of 
proteins at the distal colon (367).  
Another interesting finding of the current study was the low diversity of the faecal 
microbiota observed in the relatives of CD patients. Although no difference was found with 
the CD patients, the bacterial diversity was significantly lower than healthy children. 
Differences in age between groups may not allow a straightforward comparison with healthy 
children. However there is very limited data on the effect of age on bacterial metabolic 
activity and diversity, and mostly relates to very young infants or toddlers. A comparison with 
a cohort of healthy adults will show whether bacterial diversity is reduced in family members 
of patients with CD.    
Although this study was initially powered to detect a 40% change in butyrate (417) a 
more than a 120% decrease was observed and therefore the study achieved significance 
even with a smaller number of patients. However it may lack power to detect significant 
differences in other parameters this study assessed, like changes in the diversity and 
composition of the dominant microbiota. Lack of power is common in this type of research 
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where long and large recruitment are required. With an intended recruitment sample size of 
40 children within 1½ years 21 children on CD were enrolled within approximately two years. 
Although more than 60 children started on treatment in the same period only half of them 
were approached. Recruitment on the day of disease diagnosis, the restrictive type of 
treatment and in particular the type of collected sample significantly decreased out 
recruitment success, and increased significantly recruitment period. On the other hand due to 
the unpredictable course of the disease, many participants had either to stop treatment, or to 
introduce other treatments. This reduced the number of patients used in the final analysis.  
The type of the analysis conducted and the effect of the time on the metabolites 
measured did not allow to use ‘old’ samples. According to the protocol of this study it was 
expected that most of the samples would be collected during the routine hospital visits of the 
patients. However just eight out of the approximately 187 samples were brought to or 
collected in the clinic. The remaining samples were collected within four hours of defaecation 
at any time (3 am earliest to 11:30 pm latest) and any place convenient to the participants 
(maximum distance 60 miles), 24 hours, seven days a week. Despite these difficulties and 
the discomfort this caused this study managed to recruit twice as many subjects than any 
similar previous report (531;532). Moreover using vigorous methods of sample collection and 
preservation samples were processed soon after collection ensuring rigorous and reliable 
findings. 
As this study recruited new patients along with children in clinical relapse, many 
patients had received recent bowel preparation. That was inevitable and although it may 
have imposed an important confounding factor in study results, no differences were observed 
between children who had a recent colonoscopy and those who did not. The exclusive nature 
of the treatment on the other hand is an advantage of this study as it assessed only the effect 
of the treatment and results were not confounded by other dietary intake.  
In conclusion the findings of this study oppose the speculation by Lionetti et al (531) 
for a mechanism of EEN action in paediatric CD mediated by a prebiotic effect of the 
nutritional supplement. Indeed results show that in those patients achieved remission, EEN 
induced an “unfriendly” for the colon, luminal microenvironment, with reduced availability of 
metabolic fuels for the colonocytes, and increased production of potent harmful substances 
for the colonic health. Moreover in light of the remarkable effect on EEN on gut metabolism, 
future studies of bacterial metabolic activity in IBD, should consider carefully the recruitment 
of patients on oral artificial nutritional support, in the same way as with the usage of 
antibiotics.  
Relating the effects of changes in the concentration of faecal metabolites to events in 
the colon is not straightforward. It is difficult to know whether these effects have a causative 
association or they are simply epiphenomenon. Many factors can affect the luminal 
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concentrations of faecal metabolites that are difficult to distinguish. Changes in production 
rate (458), gut mobility (468;627), malabsorption, luminal conditions (401) or impairment in 
metabolism and absorption  make interpretation of the results a difficult task.  
On the other hand it is not possible to be sure whether the changes observed were 
disease specific and do not happen in healthy children too. Comparison with a parallel cohort 
of healthy children on treatment with the same dietary regime will better answer this. 
However such a study is unethical to conduct in healthy children. Previous studies 
summarized by Whelan et al (529) found a significant decrease in the concentration of total 
SCFA and butyrate in healthy human subjects.  
The current study offers substantial insight on the effect of EEN on the metabolic 
activity and gut microbiota of CD children. The initial scope of this project was to use this 
baseline data to conduct a RCT on the use of a prebiotic or synbiotic supplement in parallel 
with EEN. The findings of this study encourage such a trial although the anticipated outcome 
is ambiguous. If the observed effects are the inevitable result of a lack of non-digestible 
carbohydrate in the EEN feeds, improvement of colonic health with synbiotic (pre and 
probiotic) therapy (324) may improve the clinical efficacy of the treatment. On the other hand 
if reduction of butyrate and a high colonic pH mediates the therapeutic effect of EEN, 
addition of a synbiotic supplement could potentially be harmful. This has to be addressed 
with a clinical trial or in-vitro studies with colonic biopsies.    
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CHAPTER 8 
 
General discussion 
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8.1. General discussion and conclusions 
Since I finished my first degree in nutrition and dietetics in 1999, I have always been 
interested in the importance of nutrition in diseases of the alimentary tract. Then it was the 
important role of the dietitian in the clinical management of the paediatric patient with IBD 
that motivated me to undertake this PhD. This is because nutrition is implicated in all aspects 
of the disease:  
a) Disease pathogenesis with dietary risk factors predisposing disease onset. 
b) Management of active disease with nutritional therapies; EEN being the primary 
treatment for paediatric CD patients. 
c) Overall health, nutritional status, and growth of the patient.  
Although the primary aim of this thesis was to study the effect of EEN on the commensal 
microbiota composition and metabolic activity, for several reasons outlined below I had the 
opportunity to explore other aspects of the nutrition in paediatric IBD. Thus this thesis would 
be better presented as a compilation of research on nutritional aspects in paediatric IBD.  
Although the prevalence of juvenile onset of CD is high in Scotland (16), it still 
remains an uncommon GI disorder with a frequency of 20-25 new cases per year in a busy 
paediatric tertiary hospital like the one in which this PhD took place. This did not allow easy 
recruitment of a large number of patients and inevitably prolonged recruitment duration much 
beyond the initial expectations of this study. Moreover due to ethical constraints this study 
did not recruit newly presented patients before their disease diagnosis had been medically 
confirmed. As a result the majority of patients were approached on the same day of 
diagnosis, soon after the end of their endoscopy, and before the patients were discharged! 
This resulted in many patients being missed or not being appropriate for recruitment. In 
addition, the incurable and chronic nature of the disease and the restrictive dietary regime 
was upsetting for the majority of families and patients, and resulted in many children refusing 
to participate. Finally the collection of stool samples was not pleasant. For all these reasons 
recruitment had to be extended from one year to 2 ½ years. This in conjunction with the 
uncertainly of recruitment and possible patient dropout gave time for the researcher to 
develop parallel projects. Four of these six projects were presented in this thesis. Two other 
projects, which were conducted at the same time, were not included. 
In summary the aims of the studies that comprise this PhD were: 
1. To assess the prevalence and predictors of use of dietary modifications, nutritional 
supplements and alternative medicine in paediatric patients with IBD. 
2. To investigate the prevalence and predictors of anaemia in paediatric IBD patients. 
3. To investigate the effect of EEN on  
a. Gut specific and systemic markers of disease activity 
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b. Gut microbiota diversity and metabolic activity 
c. Body composition, and circulating micronutrients in children with CD 
4. To compare  
a. The validity of the body composition method used in some of the studies 
described in this thesis against a reference method 
b. The body composition of CD children with a cohort of healthy Scottish 
children. 
 
Prevalence and predictors of use of dietary modifications, nutritional supplements 
and alternative medicine in paediatric patients with IBD 
In agreement with previous studies in adult populations with IBD (63;68;70;536), this study 
described a high use of dietary modifications, nutritional supplements and alternative 
medicine in paediatric patients with IBD. Probiotic use was the most predominant form of 
unconventional treatment by both the current and past users.  
Although the majority of the nutritional therapies that the respondents of the 
questionnaire used have good safety records, this study shows that patients supported and 
used alternative treatment options, which they did not declare to their doctors. This has 
important clinical applications as some of them may present adverse effects (77), may 
interfere with the action of conventional treatment and the avoidance of specific food groups 
or adherence on special diets can compromise the long-term health and nutritional status of 
the patients. A prime example is the use of dairy free diets, which can negatively affect the 
already vulnerable bone health of IBD children. Similarly exclusion of high fibre/residue foods 
in order to avoid exacerbation of GI symptoms can reduce the production of butyrate from 
the colonic microbiota and simultaneously increase the action of proteolytic bacteria. This 
could possibly induce an unhealthy luminal environment and lack of energy substrate to the 
colonocytes. This may also explain the low faecal butyrate concentrations observed in this 
and other studies (419).  
Therefore medical and health professional staff responsible for the care of these 
patients should ask and record the use of unconventional therapies and this must be 
integrated in the standard clinical review of the patient.  
Although the sample size was relatively small this study managed to recruit the 
majority of patients of a representative IBD population and to achieve an excellent 
compliance rate. The stringent recruitment process this study followed ensured anonymity 
and perhaps undistorted responses. Although a limitation of this study would be the lack of a 
cohort of healthy children to compare with the results of the IBD children this was overcome 
this by asking parents of IBD children for details of their use of unconventional treatment 
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prior to disease onset, and the questionnaire was specific to the use of remedies exclusively 
for the management of IBD.  
Among the main reasons this study was carried out was to assess the use of 
probiotic supplements. It was the intention of the researcher to use this information to 
support the design of a clinical trial on the use of probiotic/prebiotic supplements in the same 
paediatric population. The findings of this study can now justify an intervention study with the 
systematic use of probiotic supplements in a population that is already receiving them and 
supports their use.  
Several studies have been conducted on the composition and diversity of the colonic 
microbiota in IBD patients (Section 1.7.2.3.4). Although most of these considered patients’ 
use of antibiotics, they rarely described or commented on the use of probiotic supplements. 
In light of these results, and the established effects of probiotic organisms on the gut 
microbiota and metabolism, future studies in this field should question eligible patients about 
probiotic use.  
It is difficult to compare the results of this study with previous reports and to assess 
temporal changes in the use of unconventional treatments as the definition unconventional 
medicine and the types of therapies used varies considerably among the studies. Only a 
study using the same questionnaire in the same population will allow assessment of temporal 
changes in the use of unconventional medicine by children with IBD.   
Moreover, with the increasing use of CAM reported in this and previous studies (see 
Section 1.2.2), and the positive attitude of parents and patients to them, more high quality 
and clinical trials are needed to establish their efficacy and to better inform parents, patients 
and medical staff.  
 
Prevalence and predictors of anaemia in paediatric IBD patients 
Anaemia is an extraintestinal manifestation in IBD. Although its prevalence is well described 
in adult IBD studies, in paediatrics the evidence comes from a limited number of reports with 
significant methodological flaws (see Section 1.4.4). 
Using age and gender appropriate cut offs to define anaemia, it was found that its 
occurrence was high in a large population of paediatric patients with IBD and higher than 
previous adult reports (229). Disease severity and underweight were the strongest predictors 
of anaemia incidence at diagnosis and their improvement at follow up, correlated with parallel 
improvement in the concentration of haemoglobin. Knowledge of predictors of anaemia 
incidence at diagnosis and at follow up may avert early onset and accelerate its resolution at 
follow up.  
This study failed to find a treatment that was associated with improvement or 
deterioration of haemoglobin levels at one year of follow up. In particular it was postulated 
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that nutritional replenishment on treatment with EEN would be associated with improvement 
of haemoglobin levels at follow up but the results of this study failed to confirm this. It is 
possible that the retrospective design of the study, that correlated the use of EEN at any time 
point over a 12-month period with changes of haemoglobin levels at 12 months, was not an 
appropriate method to detect any potential short-term effects of EEN on the patient’s 
haematology profile. Nevertheless neither did haemoglobin levels improve significantly in the 
prospective longitudinal study in this thesis (Chapter 5), which assessed the effect of EEN on 
circulating micronutrient status. Unfortunately this study had a small number of participants 
and therefore may be underpowered. A larger prospective study is needed.  
A strong positive correlation was found between CRP and serum a ferritin level, which is 
consistent with the evidence that suggests that serum ferritin is a positive acute phase 
respondent. This implies that the diagnostic value of serum ferritin to assess body iron stores 
can be misleading in the presence of a systemic inflammatory response and this should be 
considered by the medical staff responsible for the care of these patients. In particular, 
discrimination between the different types of anaemia, and mainly between IDA and ACD, 
cannot rely solely on these markers, and other serological indices with better predictive value 
should be used.  
Despite the retrospective design of this study, it was found that iron therapy is indeed a 
valuable option in the treatment of anaemia in paediatric IBD, although it can exacerbate GI 
symptoms in patients and animal studies (236) and may increase the risk for colonic 
carcinogenesis. For those patients who do not improve on treatment with oral iron, the use of 
alternative treatment options such as intravenous iron sucrose and erythropoetin are needed. 
As ACD pathogenesis is attributed to the action of inflammatory cytokines (231), future 
studies should address whether the use of anti-inflammatory agents, which avert the 
activation or propagation of the pro-inflammatory cytokine cascade, can improve 
haematological profiles. 
Although a proportion of the patients improved at follow up, some deteriorated and 
became anaemic. Future research should be focused on this patient group to find predictors 
and modifiable factors that could prevent anaemia onset with early intervention.  
Anaemia in IBD can be attributed to many factors with the most important being GI 
bleeding. Although a diet poor in iron should be considered too, there is not good evidence to 
support that in paediatric IBD patients. Future studies in an IBD population should assess the 
dietary iron intake of these patients. An iron balance study could be designed where the 
equilibrium of iron will be monitored to accurately assess intake, use, and GI losses. A study 
which assesses the dietary intake of IBD patients and patients with other GI disorders has 
been designed by the researcher of this PhD and is ongoing.  
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The effect of EEN on gut specific and systemic markers of disease activity 
Improvement in the clinical activity and systemic inflammatory markers occur within a few 
days on treatment initiation on EEN although they may not both be sensitive or specific 
enough to reflect intestinal inflammation and mucosal healing. New faecal markers of 
intestinal inflammation are now available with good diagnostic value to discriminate between 
organic and functional GI disorders. Faecal calprotectin levels was measured in the majority 
of patients at the time of their colonoscopy and the results showed that this correlated well 
with serologic markers of inflammation and presented a 100% sensitivity to identify patients 
with mucosal inflammation. On the contrary CRP and ESR were within the normal range for 
a substantial proportion of patients despite evident endoscopic and histological inflammation. 
This study for first time measured changes in faecal calprotectin levels during treatment 
with EEN and correlated changes with clinical response to the treatment. Although the 
majority of the patients improved clinically and their systemic inflammatory markers 
decreased, only in those patients who achieved complete clinical remission, did faecal 
calprotectin levels decrease. This may indicate that improvement in clinical activity does not 
parallel changes in intestinal inflammation unless full clinical remission is achieved. This may 
also imply that complete clinical remission is achieved only in those patients whose intestinal 
inflammation attenuated. Nevertheless even in the patients who entered clinical remission, 
calprotectin decreased to within the manufacturer’s normal reference values in only one 
patient. This may indicate that there is still subclinical intestinal inflammation despite 
induction of clinical remission or that improvement in clinical symptoms preceded 
improvement of intestinal inflammation. Perhaps there is a faecal calprotectin concentration 
cut off below which clinical symptoms of inflammation are quiescent. This should be explored 
in a future study.  
Although recent studies (612) have shown that calprotectin levels can predict disease 
exacerbation this study did not explore that, and in particular whether calprotectin levels at 
the end of treatment on EEN can predict a subsequent flare up. This has to be addressed in 
a future study. If this is the case then the decision to terminate or prolong EEN treatment 
duration may depend also on changes in markers of GI inflammation beyond improvement in 
clinical activity.  
A secondary outcome of this study was that a high number of healthy first-degree 
relatives with CD have considerably high levels of calprotectin. This has been reported 
previously in the literature (614) and further studies should monitor these individuals to 
confirm whether they are at a high risk of developing GI inflammatory conditions.  
Strength of this study was the methodology followed to obtain stool samples and analyze 
faecal calprotectin. All samples were collected within four hours of defaecation, the whole 
bowel movement was homogenized, and all specimens from the same patient were analyzed 
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in duplicate on the same ELISA plate to avoid inter-assay variability. A limitation was the 
small number of participants and thus the results should be interpreted cautiously.  
 
The effect of EEN on body composition and circulating micronutrient levels. 
Reduced dietary intake, malabsorption, increased energy requirements, and the action of 
pro-inflammatory cytokines have all been implicated in the undernutrition and growth 
retardation seen in paediatric IBD patients (Table 1.3.1).  
This study assessed the nutritional status of CD children, using body composition 
assessment and circulating micronutrient levels and explored how these changed on 
treatment with EEN. The results of this study agreed with previously published evidence that 
anthropometry is negatively affected in paediatric patients with CD (33;82). Underweight and 
growth failure were proportionally higher in CD patients compared with a cohort of healthy 
children. An interesting outcome of this study, which highlights the importance of using body 
composition assessment, is that FFM but not FM increased during EEN treatment only in the 
group of patients who achieved clinical remission. In those patients who did not enter clinical 
remission no significant changes in total body composition were observed. Use of BIA as a 
body composition assessment method may lack of validity as was found in another study of 
this thesis (Chapter 4) and therefore the results of this study should be confirmed by more 
accurate body composition reference methods such as the four compartment model (556). If 
these results are replicated then FFM replenishment should be further explored as a 
potential mechanism mediating induction of clinical remission. This is also supported by 
recent evidence that suggested suppressed proteolysis and increasing protein synthesis with 
nutritional therapy in children with inactive CD (333). 
Suboptimal levels of circulating micronutrients have been described in adult patients with 
IBD (100;180), and this paediatric study is in accordance with that. Most of the antioxidant 
vitamins and trace elements measured were lower than the laboratory reference range. 
However none of the patients developed clinical symptoms of deficiency although this study 
did not specifically look at that. Some authors linked suboptimal antioxidant system with the 
aetiology of intestinal injury (141), but we suggest that this is an epiphenomenon of the acute 
phase response. Upon increase of CRP, in inflammatory conditions and infection, 
redistribution of many micronutrients takes place in the human body compartments, and 
therefore serum measurements are not reflective of the actual body stores. A lack of a 
causative association between inflammation and micronutrient status is further supported by 
the lack of association found between the serum micronutrient levels and gut specific 
markers of inflammation (calprotectin). We suggest that other indices of body micronutrient 
status should be used in patients with acute phase response in order to assess the actual 
body stores. Measurements in red blood cells are a potential surrogate index, as they are not 
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influenced by the acute phase response. Such a study, measuring micronutrients in 
erythrocytes, is required to reliably answer the question whether body micronutrient stores 
are low in children with CD and whether this is associated with intestinal inflammation.  
An interesting finding of the second part of this study is that nutritional therapy with EEN 
improved the circulating levels of several micronutrients but the serum carotenoid 
concentrations deteriorated with more than 90% of the patients being biochemically depleted 
at the end of treatment. This is a surprising result contrary to expectations. Carotenoid 
concentration was predicted to increase firstly due to nutritional replenishment, and secondly 
because of the resolution of the inflammation and reversal of the serum levels of carotenoids 
(which are negative phase respondents) to higher levels. Instead carotenoids further 
deteriorated at the end of treatment, which may indicate increased metabolism, due to the 
increased oxidative stress in patients with IBD, and/or poor replenishment from the nutritional 
supplement. Indeed the nutritional supplements that the patients received in all cases lacks 
of carotenoids. Considering the importance of an effective antioxidant system in health and in 
mucosal injury in IBD, these results may have implications in the industrial production of 
artificial feeds. Depletion of antioxidant micronutrients may compromise the body’s defensive 
mechanisms and increase oxidative stress and damage of biological macromolecules. 
Unfortunately this study did not measure the serum levels of oxidative stress markers like 
malondialdehyde, and therefore it is not possible to comment whether treatment with EEN 
impaired the antioxidant defensive mechanisms. If this is the case supplementation or the 
feeds with antioxidants may be required and perhaps increase the clinical efficacy of the 
treatment given the important role of antioxidants in IBD.  
Similar to the cross-sectional data on the circulating micronutrient status of children with 
CD, the changes in the level of some of the micronutrients observed are difficult to interpret. 
Improvement in the levels of some of the micronutrients may be a combined effect of the 
nutritional replenishment, resolution of the acute phase response, and less consumption with 
improvement of disease activity. The use of other markers of micronutrient body stores may 
facilitate the interpretation of these results. The results of this study triggered the researcher 
to continue this study and explore changes in the levels of the same micronutrient in 
erythrocytes. 
A limitation of this study was the small number of participants, which is frequently seen in 
investigations in uncommon diseases. Moreover collection of blood samples for research 
purposes were only allowed as an extra amount collected during routine blood samples of 
the patient. It was deemed unethical to venupuncture children for research purposes only 
and therefore, some blood samples were missed from patients who were not due to give 
routine clinical bloods. As this study was supplementary to the main project of the effect of 
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EEN on gut microbiota, recruitment was hampered by the fact that many patients did not 
want to participate in the arm of study, which involved the collection of stool samples. 
 
Comparison of body composition assessment in healthy children with leg to leg 
bioelectrical impedance and DXA analysis 
An additional experimental chapter of this work compared two methods of body composition 
in healthy children (Chapter 4). One of them is a common reference method to assess bone 
mineral content and body composition and the other one a novel bedside body composition 
analyzer suitable for routine measurements. The overall results of this part of the thesis do 
not suggest that the validity of the new bedside equipment, using the manufacturer’s 
equation is as good as the reference method at individual level, and thus the results in the 
studies this used should be interpreted bearing that in mind. Manipulation of body impedance 
values in a way that would be independent of the manufacturer prediction equations may be 
better and the most reliable way to use BIA. Recently lean and fat index norms have been 
developed that use bioimpedance measurements and classify children as having relatively 
high, average or low fatness and leanness independently (587). On the other hand although 
BIA may not be accurate to precisely assess body composition its use to assess longitudinal 
changes in follow up studies, like those presented in this thesis, may be more reliable. Its 
sensitivity to detect changes in body composition should be addressed with follow up studies 
measuring body composition with BIA at different intervals and comparing it with other 
reference methods. 
Although this chapter seems to be unlinked from the rest of the thesis, it gave 
important information on the accuracy of a quick method to assess body composition in 
healthy children. A subsequent study should be planned to check the accuracy of the same 
method in a paediatric cohort of IBD children. The results of a respective study will be useful 
in clinical practice and may help the transition from recordings of anthropometric 
measurements to the actual evaluation of body composition stores. Furthermore this study 
offered the opportunity to compare the body composition of CD children with a large sample 
of contemporary healthy children of the same socio-demographic background.  
 
The effect of EEN on gut microbiota diversity and metabolic activity 
A substantial number of studies have compared EEN with other mainstream treatments in 
the induction of clinical remission in active paediatric CD (Section 1.5.1), but there is lack of 
evidence to suggest the actual mechanisms of action. On the other hand the strong evidence 
implicating commensal microbiota in disease pathogenesis challenged the researcher to 
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undertake a study on the effect of EEN on the gut microbiota metabolism and diversity of 
these patients.  
 To the best of our knowledge this is the first study that explored the effect of EEN on 
intestinal microbiota metabolic activity in patients with CD, and one of the few that explored 
changes in gut bacterial diversity. A prebiotic effect of EEN proposed by the first Italian 
research on the topic (531) is not supported by the findings of this study which observed an 
increase in the faecal pH, reduced concentration of butyrate, and significant increase in the 
total sulphide concentration. These conditions should be better described as an “unhealthy” 
colonic microenvironment where colonocytes are deprived by significant energy substrates. 
This is a paradox finding, as the patients who presented these findings were those who 
clinically improved and their gut inflammation ameliorated. Similar findings were not 
observed in the patients who did not achieve full clinical remission. It is very difficult to 
interpret this discrepancy and whether this is a random finding resulting from differences in 
gut motility between the two patient groups or an actual phenomenon mediating the efficacy 
of EEN. Perhaps an impaired metabolism of butyrate, which has been described previously 
and in recent studies, is resolved on treatment with EEN although most of the evidence on 
an abnormal metabolism of butyrate in IBD, comes from studies on UC but not CD patients. 
Likewise the role of total sulphide should be further explored in the light of evidence that 
sulphide-releasing derivatives have better efficacy than standard mesalazine in animal model 
of colitis (466). An alternative explanation of these findings is that while on treatment with 
EEN, the growth, metabolic activity and microbial products of bacterial species, which may 
be involved in the pathogenesis or perpetuation of intestinal injury in IBD, are decreased, and 
the findings of this study are in fact a secondary epiphenomenon of these changes with the 
reduction of some as yet unidentified bacterial product which exacerbates the inflammation in 
the GI tract.  
Although this study compared the changes of intestinal microbiota diversity and 
metabolic activity in CD on treatment with EEN against the changes observed in serial 
samples of healthy children on normal diet, a study on healthy children on EEN treatment 
would be more appropriate and would answer whether changes in bacterial metabolism and 
diversity are disease specific.  
 Apart from the effect of EEN on the bacterial metabolic activity this study explored 
parallel changes in the diversity of the commensal microbiota. Although the commensal 
microbiota diversity was significantly lower than in healthy controls, no significant changes in 
the bacterial diversity were observed during treatment. Unfortunately the molecular biology 
method used does not allow to comment on strain specific changes or changes in the 
bacterial counts. Other methods like FISH should be used to explore that. That was among 
the original aims of this study and samples were prepared for analysis with the FISH 
 309 
technique combined with flow cytometry. However due to the lack of time, resources and 
essential equipment this analysis was not performed. The changes in bacterial metabolic 
activity observed, with significant increase in sulphide concentrations and reductions in 
butyrate strongly suggest the use of SRB specific probes and probes specific for major 
butyrate producing species for FISH analysis. Further funding and collaboration is required to 
allow to analyze these samples and explore the changes in bacterial diversity, composition, 
and metabolic activity during treatment with EEN. On the other hand both the TTGE and 
FISH analysis can only assess the dominant microbiota that occur in a concentration of > 
106/g of colonic content. Thus any changes in the subdominant microbiota remain unknown 
and are difficult to study with current techniques. Changes in the mucosal bacterial 
microbiota may not coincide with changes in faecal material and this should be explored, 
although serial biopsies over a short period of time may be judged unethical and 
inappropriate. 
 A limitation of this study is the small number of patients and the heterogeneity in 
disease characteristics between patients. Lack of statistical power is a common problem in 
these studies due to the feasibility of large numbers given the rarity of the disease. The need 
to measure metabolic products in fresh stool samples, within four hours of defaecation 
reduced recruitment rates, imposed a significant personal burden to the researcher who had 
to travel in a radius of 60 miles, at any time and day to collect the samples. However the 
rigorous methodology followed in this study ensured reliable results. Multicentre studies are 
essential to achieve better recruitment and acquire adequate sample sizes. However this 
study is by far the biggest study carried out so far having recruited at least a double number 
of participants than previous report. 
 
Conclusion 
The results of this work offer new insight into several aspects of the nutrition of paediatric 
IBD patients and comprise the foundation for further ongoing work. Although the efficacy of 
EEN to induce clinical remission in active paediatric CD was well described before the 
initiation of this PhD, the mechanisms of action remained unknown. This PhD tried to assess 
potential modes of action, which involve changes in the gut microbiota and nutritional status 
of the patients.  
Considering the results of this study, the importance of the commensal microbiota in 
IBD pathogenesis, and other studies showing clinical and experimental evidence on the 
therapeutic effect of probiotics, prebiotics and butyrate in IBD, future studies should look at 
the effect of dual nutritional therapies or improvement of the composition of the existing ones. 
Prebiotics or fibre can easily be added in nutritional feeds, whereas new vehicles of oral 
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butyrate derivatives which could act along the large bowel are now available. Probiotic 
supplements could also be used and their use is supported by a few studies.  
Using a dual nutritional therapy may improve the colonic microenvironment and 
improve the efficacy of EEN. Such a speculation would be best addressed with well-designed 
clinical trials, animal models and in vitro studies using intestinal biopsies.  
In this study although treatment with EEN corrected the anthropometry and nutritional 
status, the circulating levels of certain micronutrients deteriorated due to lack of carotenoids 
in the feeds. As carotenoids are important micronutrients in the human antioxidant system, 
and the latter have been implicated in tissue injury in IBD, future studies should compare the 
efficacy of standard EEN with feeds supplemented with carotenoid antioxidants. A potential 
superior effect of the fortified supplement may have important implications for the producers 
of feed companies. On the other hand, measurement of systemic micronutrients in red blood 
cells will better assess the actual micronutrient body stores and would better address 
whether there is an actual aetiological association with inflammation, intestinal injury in IBD.  
 
“This is the END of a long journey to reach “My Ithaca”. Although I avoided the rage of 
Poseidon and did not fight with Cyclops, and Lestrygonians, like Ulysses in Homer Odyssey, 
I run my journey of over four years, where I fought patience, and persistence to reach “My 
Ithaca”. Unfortunately my Penelope was not still waiting for me…. and I had to be deceived 
by some Sirens!!!” 
 
As an overall review of these last four years 
 
• 6 studies were designed, and run of which four were presented in this thesis 
• 4 full ethical ethic applications (3 for clinical studies) and two substantial amendments were 
prepared 
• Over 400 patients were actively recruited 
• Over 180 stool samples were collected from the four points of the compass within four hours of 
defaecation, within a 2 ½ years of 24-hour daily recruitment. 
• Four laboratory assays developed and established in the department 
• Over 600 stool samples were analysed for SCFA 
• Over 250 stool samples were analysed for calprotectin,  
• Over 2500 stool samples were analysed for sulphide concentration 
• Over 200 stool samples were analysed for TTGE analysis 
• Over 200 stool were analyzed for ammonia and pH 
• Over 400 stool samples were analysed for lactate 
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• Over 300 measurements of body composition were conducted 
• Over 300 patient medical notes were scrutinized 
• Hundred of hours of data analysis 
• 6 posters, 3 oral presentations and two full papers (one under review) 
• 2 prizes for best presentations won 
ALL by the same and only crazy Greek!!!! 
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Micronutrient reference range from the Trace Element unit, Glasgow Royal Infirmary 
- copper 10-22 µmol/L (adults) 
 
1.5 to 7.0 (0 to 3 mth) 
 
4.0 to 17.0 (4 to 6 mth) 
 
8.0 to 20.5 (7 to 12 mth) 
 
12.5 to 23.5 (1 to 5 y) 
 
13.0 to 21.5 (6 to 9 y) 
 
12.5 to 19.0 (10 to 13 y) 
- selenium 0.8 - 2.0 µmol/L (adult)  
 
0.2 - 0.9 µmol/L (0 to 2 y) 
 
0.5 - 1.3 µmol/L (2 to 4 y) 
 
0.7 - 1.7 µmol/L (4 to 16 y) 
- magnesium 0.7 to 1.0 mmol/L 
- zinc 12-18 µmol/L  
- vitamin A 1.0 to 3.0 µmol/L (adults) 
 
0.5 to 1.5 µmol/L (< 1 y) 
 
0.7 to 1.5 µmol/L (1 to 6 y) 
 
0.9 to 1.7 µmol/L (7 to 12 y) 
 
0.9 to 2.5 µmol/L (13 to 18 y) 
Carotenoids α-carotene: 14 to 60 µg/L 
 
β-carotene: 90 to 310 µg/L  
 
Lutein: 80 to 200 µg/L  
 
Lycopene: 100 to 300 µg/L 
- vitamin B1 275 to 675 ng/g Hb 
- vitamin B2 Whole blood: 220 to 410 nmol/L 
Red cell: 1.0 to 3.4 nmol/g Hb 
- vitamin B6 20 to 140 nmol/L 
234 to 815 pmol/g Hb 
- vitamin C 15 to 90 nmol/L 
- vitamin E 15 to 45 nmol/L 
- vitamin D 25 to 170 nmol/L 
- folate 2.7 to 34 ng/mL 
- ferritin 10 to 275 ng/mL 
- vitamin B12 180 to 883 pg/mL 
- ferritin > 10 µg/l 
- Calcium 2.25 to 2.70 mmol/L 
- Phosphate 0.9 to 1.8 mmol/L 
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